UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	PATENT NUMBER	GROUP ART UNIT	REQUEST ID
15/589,615	10610125	1797	167357

PAIR Correspondence Address/Fee Address Change

The following fields have been changed to Customer Number 51414 on 06/03/2022 via Private PAIR in view of the certification copied below that authorized the change.

- Maintenance Fee Address

The address for Customer Number 51414 is:
51414
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 NORTHERN AVENUE
BOSTON, MA 02210

I certify, in accordance with 37 CFR 1.4(d)(4) that I am:

An attorney or Agent of Record registered to practice before the Patent and Trademark Office who has been given power of attorney in this application

Signature:	/Ioana Davies/
Name:	Ioana Davies
Registration Number:	75817

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	PATENT NUMBER	GROUP ART UNIT	REQUEST ID
15/589,615	10610125	1797	167357

PAIR Correspondence Address/Fee Address Change

The following fields have been changed to Customer Number 51414 on 06/03/2022 via Private PAIR in view of the certification copied below that authorized the change.

- Correspondence Address

The address for Customer Number 51414 is:
51414
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 NORTHERN AVENUE
BOSTON, MA 02210

I certify, in accordance with 37 CFR 1.4(d)(4) that I am:

An attorney or Agent of Record registered to practice before the Patent and Trademark Office who has been given power of attorney in this application

Signature:	/Ioana Davies/
Name:	Ioana Davies
Registration Number:	75817

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/589,615	04/07/2020	10610125	AGS-013USC2	7017

148106 7590 03/18/2020

GOODWIN PROCTER LLP/AGIOS
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 101 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Lenny Dang, Boston, MA;
Agios Pharmaceuticals, Inc., Cambridge, MA;
Valeria Fantin, Burlingame, CA;
Stefan Gross, Brookline, MA;
Hyun Gyung Jang, Waltham, MA;
Shengfang Jin, Newton, MA;
Francesco G. Salituro, Marlborough, MA;
Jeffrey O. Saunders, Lincoln, MA;
Shin-San Michael Su, Boston, MA;
Katharine Yen, Wellesley, MA;

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

148106 7590 11/15/2019
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2	7017

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1000	$0.00	$0.00	$1000	02/18/2020

EXAMINER	ART UNIT	CLASS-SUBCLASS
HIXSON, CHRISTOPHER	1797	436-173000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Goodwin Procter LLP
2
3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE: Agios Pharmaceuticals, Inc.

(B) RESIDENCE: (CITY and STATE OR COUNTRY): Cambridge, MA

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☒ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment: *(Please first reapply any previously paid fee shown above)*

☒ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. 07-1700

5. **Change in Entity Status** (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature /Ioana Davies/ Date February 14, 2020

Typed or printed name Ioana Davies Registration No. 75,817

Electronic Patent Application Fee Transmittal

Application Number:	15589615
Filing Date:	08-May-2017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Filer:	Ioana Davies
Attorney Docket Number:	AGS-013USC2

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
UTILITY APPL ISSUE FEE	1501	1	1000	1000

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**1000**

Electronic Acknowledgement Receipt	
EFS ID:	38580374
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies
Filer Authorized By:	
Attorney Docket Number:	AGS-013USC2
Receipt Date:	14-FEB-2020
Filing Date:	08-MAY-2017
Time Stamp:	10:11:25
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$1000
RAM confirmation Number	E20202DA11508612
Deposit Account	
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Issue Fee Payment (PTO-85B)	Issue_Fee_Transmittal.PDF	127953 ce180e13d5fb491c8998b8ca919abbf969b6a8dd	no	1
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	29903 1bcb590d629dc298e356241609623b6ed3202616	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	157856		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
15/589,615	05/08/2017	1797	2540	AGS-013USC2	18	1

CONFIRMATION NO. 7017

CORRECTED FILING RECEIPT

148106
GOODWIN PROCTER LLP/AGIOS
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

OC000000114122611

Date Mailed: 01/23/2020

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Lenny Dang, Boston, MA;
Valeria Fantin, Burlingame, CA;
Stefan Gross, Brookline, MA;
Hyun Gyung Jang, Waltham, MA;
Shengfang Jin, Newton, MA;
Francesco G. Salituro, Marlborough, MA;
Jeffrey O. Saunders, Lincoln, MA;
Shin-San Michael Su, Boston, MA;
Katharine Yen, Wellesley, MA;

Applicant(s)

Agios Pharmaceuticals, Inc., Cambridge, MA;

Assignment For Published Patent Application

Agios Pharmaceuticals, Inc., Cambridge, MA

Power of Attorney: The patent practitioners associated with Customer Number 148106

Domestic Priority data as claimed by applicant

This application is a CON of 13/939,519 07/11/2013 ABN
which is a CON of 13/256,396 11/29/2011 ABN
which is a 371 of PCT/US10/27253 03/12/2010
which claims benefit of 61/266,929 12/04/2009
and claims benefit of 61/253,820 10/21/2009
and claims benefit of 61/229,689 07/29/2009

and claims benefit of 61/227,649 07/22/2009
and claims benefit of 61/220,543 06/25/2009
and claims benefit of 61/180,609 05/22/2009
and claims benefit of 61/173,518 04/28/2009
and claims benefit of 61/160,664 03/16/2009
and claims benefit of 61/160,253 03/13/2009

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 08/08/2017

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 15/589,615**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

Preliminary Class

436

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed

from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

Application Number	Application/Control No.	Applicant(s)/Patent under Reexamination	
* 15/589,615 *	15/589,615	Dang et al.	
	Examiner	Art Unit	
	HIXSON, CHRISTOPHER	1797	

Document Code - DISQ	Internal Document - DO NOT MAIL

TERMINAL DISCLAIMER	☑ APPROVED	☐ DISAPPROVED
Date Filed: **14 November 2019**	**This patent is subject to a Terminal Disclaimer**	

Approved/Disapproved by:

/LAWANA R HIXON/

Technology Center: OPLC

Telephone: (571)272-6074

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
15/589,615	05/08/2017	1797	2540	AGS-013USC2	18	1

CONFIRMATION NO. 7017

CORRECTED FILING RECEIPT

148106
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

OC000000112706993

Date Mailed: 11/19/2019

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Lenny Dang, Boston, MA;
Valeria Fantin, Burlingame, CA;
Stefan Gross, Brookline, MA;
Hyun G. Jang, Waltham, MA;
Shengfang Jin, Newton, MA;
Francesco G. Salituro, Marlborough, MA;
Jeffrey O. Saunders, Lincoln, MA;
Shin-San Michael Su, Boston, MA;
Katharine Yen, Wellesley, MA;

Applicant(s)

Agios Pharmaceuticals, Inc., Cambridge, MA;

Assignment For Published Patent Application

Agios Pharmaceuticals, Inc., Cambridge, MA

Power of Attorney: The patent practitioners associated with Customer Number 148106

Domestic Priority data as claimed by applicant

This application is a CON of 13/939,519 07/11/2013 ABN
which is a CON of 13/256,396 11/29/2011 ABN
which is a 371 of PCT/US10/27253 03/12/2010
which claims benefit of 61/266,929 12/04/2009
and claims benefit of 61/253,820 10/21/2009
and claims benefit of 61/229,689 07/29/2009

and claims benefit of 61/227,649 07/22/2009
and claims benefit of 61/220,543 06/25/2009
and claims benefit of 61/180,609 05/22/2009
and claims benefit of 61/173,518 04/28/2009
and claims benefit of 61/160,664 03/16/2009
and claims benefit of 61/160,253 03/13/2009

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 08/08/2017

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 15/589,615**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

Preliminary Class

436

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed

from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2

CONFIRMATION NO. 7017

148106
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

POA ACCEPTANCE LETTER

OC000000112706952

Date Mailed: 11/19/2019

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 11/14/2019.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/dtdinh/

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

148106 7590 11/15/2019
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

EXAMINER	
HIXSON, CHRISTOPHER	
ART UNIT	PAPER NUMBER
1797	

DATE MAILED: 11/15/2019

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2	7017

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1000	$0.00	$0.00	$1000	02/18/2020

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

148106 7590 11/15/2019
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2	7017

TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1000	$0.00	$0.00	$1000	02/18/2020

EXAMINER	ART UNIT	CLASS-SUBCLASS
HIXSON, CHRISTOPHER	1797	436-173000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. Fees submitted: ❑ Issue Fee ❑ Publication Fee (if required) ❑ Advance Order - # of Copies _____

4b. Method of Payment: *(Please first reapply any previously paid fee shown above)*

❑ Electronic Payment via EFS-Web ❑ Enclosed check ❑ Non-electronic payment by credit card (Attach form PTO-2038)

❑ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. **Change in Entity Status** (from status indicated above)

❑ Applicant certifying micro entity status. See 37 CFR 1.29

❑ Applicant asserting small entity status. See 37 CFR 1.27

❑ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2	7017

148106 7590 11/15/2019

GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

EXAMINER	
HIXSON, CHRISTOPHER	
ART UNIT	**PAPER NUMBER**
1797	

DATE MAILED: 11/15/2019

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

PTOL-85 (Rev. 02/11)

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 15/589,615	Applicant(s) Dang et al.	
	Examiner CHRISTOPHER A HIXSON	Art Unit 1797	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☑ This communication is responsive to the after final amendment dated 1 November 2019.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

3. ☑ The allowed claim(s) is/are 1-12 . As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see **http://www.uspto.gov/patents/init_events/pph/index.jsp** or send an inquiry to **PPHfeedback@uspto.gov.**

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:

   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____ .

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____ .

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____.
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____.
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date. _____.
5. ☐ Examiner's Amendment/Comment
6. ☑ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/Christopher Adam Hixson/
Primary Examiner, Art Unit 1797

DETAILED ACTION

Notice of Pre-AIA or AIA Status

The present application is being examined under the pre-AIA first to invent provisions.

Allowable Subject Matter

Claim(s) 1-12 are allowed.

The following is an examiner's statement of reasons for allowance: in a previous action the examiner withdrew all rejections aside from a rejection over double patenting. In view of the approved terminal disclaimed filed 1 November 2019, the examiner allows the claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER A. HIXSON whose telephone number is (571)270-5027. The examiner can normally be reached on M-F 10am-6pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an

interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lyle Alexander can be reached on 571-272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Christopher Adam Hixson/
Primary Examiner, Art Unit 1797

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	Art Unit
	CHRISTOPHER A HIXSON	1797

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	10/13/2018	03/26/2019	08/28/2019	11/06/2019					
	1	✓	✓	✓	=					
	2	✓	✓	O	=					
	3	✓	✓	O	=					
	4	✓	✓	O	=					
	5	✓	✓	O	=					
	6	✓	✓	✓	=					
	7	✓	✓	O	=					
	8	✓	✓	O	=					
	9	✓	✓	✓	=					
	10	✓	✓	✓	=					
	11	✓	✓	✓	=					
	12	✓	✓	✓	=					
	13	✓	-	-	-					
	14	✓	✓	-	-					
	15	✓	✓	-	-					
	16	✓	✓	-	-					
	17	✓	✓	-	-					
	18	✓	✓	-	-					

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	**Art Unit**
	CHRISTOPHER A HIXSON	1797

CPC						
Symbol					**Type**	**Version**
A61B	/	5	/	055	F	2013-01-01
A61K	/	31	/	41	I	2013-01-01
A61K	/	31	/	426	I	2013-01-01
A61K	/	45	/	06	I	2013-01-01
C12N	/	15	/	1137	I	2013-01-01
C12Y	/	101	/	01042	I	2013-01-01
G01N	/	33	/	574	I	2013-01-01
C12Q	/	1	/	32	I	2013-01-01
C12Q	/	1	/	6886	I	2013-01-01
G06F	/	19	/	328	I	2013-01-01
C12N	/	2310	/	14	A	2013-01-01
Y02A	/	90	/	24	A	2018-01-01
Y02A	/	90	/	26	A	2018-01-01

CPC Combination Sets							
Symbol					**Type**	**Set**	**Ranking**	**Version**
A61K	/	31	/	41	I	1	1	2013-01-01
A61K	/	2300	/	00	I	1	2	2013-01-01
A61K	/	31	/	426	I	2	1	2013-01-01
A61K	/	2300	/	00	I	2	2	2013-01-01

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	12	
/Christopher Adam Hixson/ Primary Examiner, Art Unit 1797	06 November 2019	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	-

U.S. Patent and Trademark Office — Part of Paper No.: 20191104-2

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	**Art Unit**
	CHRISTOPHER A HIXSON	1797

INTERNATIONAL CLASSIFICATION				
CLAIMED				
G01N	/	33	/	574

NON-CLAIMED				
	/		/	

US ORIGINAL CLASSIFICATION	
CLASS	**SUBCLASS**

CROSS REFERENCES(S)						
CLASS	**SUBCLASS (ONE SUBCLASS PER BLOCK)**					

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	12	
/Christopher Adam Hixson/ Primary Examiner, Art Unit 1797	06 November 2019	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	-

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	**Art Unit**
	CHRISTOPHER A HIXSON	1797

☑ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIMS

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	12	
/Christopher Adam Hixson/ Primary Examiner, Art Unit 1797	06 November 2019	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	-

U.S. Patent and Trademark Office — Part of Paper No.: 20191104-2

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	Art Unit
	CHRISTOPHER A HIXSON	1797

CPC - Searched*		
Symbol	Date	Examiner
g01n2800/52,7028	11/06/2019	cah
a61p43/00	11/06/2019	cah
a61p35/00	11/06/2019	cah

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
search in EAST as attached, inventor name search, google.com as attached	10/12/2018	cah
search in EAST as attached, inventor name search	03/26/2019	cah
search in EAST as attached, inventor name search	08/26/2019	cah
search in EAST as attached, inventor name search	11/06/2019	cah

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner
	same as classified search	11/06/2019	cah

OK TO ENTER: /CAH/

Docket No.: AGS-013USC2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Lenny Dang et al.

Application No.: 15/589,615 | Confirmation No.: 7017

Filed: May 8, 2017 | Art Unit: 1797

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Examiner: C. Hixson

AMENDMENT AFTER FINAL ACTION UNDER 37 C.F.R. § 1.116

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Final Office Action dated September 3, 2019, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

Bibliographic Data

Application No: 15/589,615

Foreign Priority claimed: ○ Yes ◉ No

35 USC 119 (a-d) conditions met: ☐ Yes ☑ No ☐ Met After Allowance

Verified and Acknowledged: /Christopher Adam Hixson/ Examiner's Signature | Initials

Title: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
05/08/2017	436	1797	AGS-013USC2
RULE			

APPLICANTS

INVENTORS

Lenny Dang Boston, MA, UNITED STATES

Valeria Fantin Burlingame, CA, UNITED STATES

Stefan Gross Brookline, MA, UNITED STATES

Hyun G. Jang Waltham, MA, UNITED STATES

Shengfang Jin Newton, MA, UNITED STATES

Francesco G. Salituro Marlborough, MA, UNITED STATES

Jeffrey O. Saunders Lincoln, MA, UNITED STATES

Shin-San Michael Su Boston, MA, UNITED STATES

Katharine Yen Wellesley, MA, UNITED STATES

CONTINUING DATA

This application is a CON of 13939519 07/11/2013ABN

13939519 is a CON of 13256396 11/29/2011ABN

13256396 is a 371 of PCT/US10/27253 03/12/2010

PCT/US10/27253 has PRO of 61266929 12/04/2009

PCT/US10/27253 has PRO of 61253820 10/21/2009

PCT/US10/27253 has PRO of 61229689 07/29/2009

PCT/US10/27253 has PRO of 61227649 07/22/2009

PCT/US10/27253 has PRO of 61220543 06/25/2009

PCT/US10/27253 has PRO of 61180609 05/22/2009

PCT/US10/27253 has PRO of 61173518 04/28/2009

PCT/US10/27253 has PRO of 61160664 03/16/2009

PCT/US10/27253 has PRO of 61160253 03/13/2009

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

08/08/2017

STATE OR COUNTRY

UNITED STATES

ADDRESS

GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210
UNITED STATES

FILING FEE RECEIVED

$0

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	162172	@pd>="20190826"	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:13
L2	6214	idh1 or idh2 or (isocitrate with dehydrogenase)	US-PGPUB; USPAT; USOCR	OR	ON	2019/11/06 15:13
L3	1528	L2 and ((acute with leukemia) or AML or ALL)	US-PGPUB; USPAT; USOCR	OR	ON	2019/11/06 15:13
L4	677	((("DANG") near3 ("Lenny")) OR (("FANTIN") near3 ("Valeria")) OR (("GROSS") near3 ("Stefan")) OR (("JANG") near3 ("Hyun")) OR (("JIN") near3 ("Shengfang")) OR (("SALITURO") near3 ("Francesco")) OR (("SAUNDERS") near3 ("Jeffrey")) OR (("SU") near3 ("Shin-San")) OR (("YEN") near3 ("Katharine"))).INV.	USPAT	OR	OFF	2019/11/06 15:13
L5	19	L3 and L4	USPAT	OR	OFF	2019/11/06 15:13
L6	0	L5 and 1	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:13
L7	498397	@pd>="20190326"	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:14
L8	821654	@pd>="20181012"	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:14
L9	6214	idh1 or idh2 or (isocitrate with dehydrogenase)	US-PGPUB; USPAT; USOCR	OR	ON	2019/11/06 15:14
L10	9312	g01n2800/52,7028.cpc.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:14
L11	51	L10 and L8 and L9	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:14
L12	7029	a61p35/00.cpc.	US-PGPUB; USPAT;	OR	OFF	2019/11/06 15:14

			USOCR			
L13	448	a61p43/00.cpc.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:14
L14	209	(L12 or L13) and L9	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:14
L15	117	(L11 or L14) and L7	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:14
L16	256	(L11 or L14 or L15)	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:14
L17	38	16 and 1	US-PGPUB; USPAT; USOCR	OR	OFF	2019/11/06 15:14

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L18	3950	g01n2800/52,7028.cpc. or a61p43/00.cpc. or a61p35/00.cpc.	USPAT	OR	OFF	2019/11/06 15:15
L19	2246	idh1 or idh2 or (isocitrate with dehydrogenase)	USPAT	OR	ON	2019/11/06 15:15
L20	72	19 and 18	USPAT	OR	ON	2019/11/06 15:15
L21	34263	((acute with leukemia) or AML or ALL)	USPAT	OR	ON	2019/11/06 15:16
L22	47	20 and 21	USPAT	OR	ON	2019/11/06 15:16
L23	47	inhibitor and 22	USPAT	OR	ON	2019/11/06 15:17
L24	23	(small with molecule with inhibitor) and 22	USPAT	OR	ON	2019/11/06 15:18
L25	6	2HG and 24	USPAT	OR	ON	2019/11/06 15:18

11/ 6/ 2019 3:18:50 PM
C:\ Users\ chixson\ Documents\ EAST\ Workspaces\ 15589615.wsp

PTO/AIA/26 (04-14)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) AGS-013USC2

In re Application of: Lenny Dang et al.

Application No.: 15/589,615-Conf. #7017

Filed: May 8, 2017

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

The applicant, Agios Pharmaceuticals, Inc., owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. 9,982,309 as the term of said **prior patent** is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

expires for failure to pay a maintenance fee;
is held unenforceable;
is found invalid by a court of competent jurisdiction;
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
has all claims canceled by a reexamination certificate;
is reissued; or
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 75,817

/Ioana Davies/ — Signature
November 14, 2019 — Date

Ioana Davies — Typed or printed name

Agent for Applicant — Title
(617) 570-3920 — Telephone Number

☒ Terminal disclaimer fee under 37 CFR 1.20(d) paid November 1, 2019.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Electronic Acknowledgement Receipt

EFS ID:	37747477
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies
Filer Authorized By:	
Attorney Docket Number:	AGS-013USC2
Receipt Date:	14-NOV-2019
Filing Date:	08-MAY-2017
Time Stamp:	09:22:41
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Power of Attorney	Executed_POA.pdf	1184661 4389c20d60556ec7c5583d3faea77e62b5e29962	no	2

Warnings:

Information:					
2	Application Data Sheet	Application_Data_Sheet.pdf	48333 b21e83769183e26856ffb812108d1b4a7bef86c3	no	1
Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
3	Assignee showing of ownership per 37 CFR 3.73	Statement_Under_37_CFR_373c_PTO_AIA-96.PDF	5930715 64e4b71872084fe6ce90359da9ebd2a9a15bd47b	no	8
Warnings:					
Information:					
4	Terminal Disclaimer Filed	Terminal_Disclaimer.pdf	21228 29e58b9d3005a488f5faf40ffb49c2813d39a71a	no	1
Warnings:					
Information:					
		Total Files Size (in bytes):	7184937		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82A (07-13)
Approved for use through 01/31/2018. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	15/589,615
Filing Date	May 8, 2017
First Named Inventor	Lenny Dang
Title	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

SIGNATURE of Applicant or Patent Practitioner

Signature	/Ioana Davies/	Date (Optional)	
Name	Ioana Davies	Registration Number	75,817
Title (if Applicant is a juristic entity)	**Agent for Applicant**		
Applicant Name (if Applicant is a juristic entity)	**Agios Pharmaceuticals, Inc.**		

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ *Total of 1 forms are submitted.

101349079
IPTS/101349079.1

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82B (07-13)
Approved for use through 01/31/2018. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date
15/589,615	May 8, 2017

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

[x] I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 148106

OR

[ ] I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

[ ] The address associated with the above-mentioned Customer Number

OR

[ ] The address associated with Customer Number:

OR

[ ] Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone		Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

Agios Pharmaceuticals, Inc.

[ ] Inventor or Joint Inventor (title not required below)

[ ] Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

[x] Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

[ ] Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature	/JWB/	Date (Optional)	11/7/19
Name	James W. Burns		
Title	Vice President, Commercial Healthcare Law & Chief Compliance Officer		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

[ ] Total of 1 forms are submitted.

IPTS/101349079.1

Corrected Application Data Sheet

Applicant Information

Applicant Number::	1
Applicant Type::	Assignee
Organization Name::	Agios Pharmaceuticals, Inc.
Street of mailing address::	88 Sidney Street
City of mailing address::	Cambridge
State or Province of mailing address::	MA
Country of mailing address::	US
Postal or Zip Code of mailing address::	02139
E-Mail Address::	ip@agios.com

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2019-11-14
Name	Ioana Davies	Registration Number	75,817

PTO/AIA/96 (08-12)
Approved for use through 01/31/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

STATEMENT UNDER 37 CFR 3.73(c)

Applicant/Patent Owner: Agios Pharmaceuticals, Inc.

Application No./Patent No.: 15/589,615 Filed/Issue Date: May 8, 2017

Titled: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

Agios Pharmaceuticals, Inc. , a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that, for the patent application/patent identified above, it is (choose **one** of options 1, 2, 3 or 4 below):

1. [X] The assignee of the entire right, title, and interest.

2. [ ] An assignee of less than the entire right, title, and interest (check applicable box):

   [ ] The extent (by percentage) of its ownership interest is _____ %). Additional Statement(s) by the owners holding the balance of the interest must be submitted to account for 100% of the ownership interest.

   [ ] There are unspecified percentages of ownership. The other parties, including inventors, who together own the entire right, title and interest are:

   Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

3. [ ] The assignee of an undivided interest in the entirety (a complete assignment from one of the joint inventors was made). The other parties, including inventors, who together own the entire right, title, and interest are:

   Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

4. [ ] The recipient, via a court proceeding or the like (*e.g.*, bankruptcy, probate), of an undivided interest in the entirety (a complete transfer of ownership interest was made). The certified document(s) showing the transfer is attached.

The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose **one** of options A or B below):

A. [X] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____ , Frame _____ , or for which a copy thereof is attached.

B. [ ] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
   The document was recorded in the United States Patent and Trademark Office at
   Reel _____ , Frame _____ , or for which a copy thereof is attached.

2. From: _____ To: _____
   The document was recorded in the United States Patent and Trademark Office at
   Reel _____ , Frame _____ , or for which a copy thereof is attached.

PTO/AIA/96 (08-12)
Approved for use through 01/31/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

STATEMENT UNDER 37 CFR 3.73(c)

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____ , Frame _____ , or for which a copy thereof is attached.

4. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____ , Frame _____ , or for which a copy thereof is attached.

5. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____ , Frame _____ , or for which a copy thereof is attached.

6. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____ , Frame _____ , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

☒ As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

/Ioana Davies/	November 14, 2019
Signature	Date
Ioana Davies	75,817
Printed or Typed Name	Title or Registration Number

ASSIGNMENT

For valuable consideration, we, LENNY DANG of Boston, MA, VALERIA FANTIN of Cambridge, MA, STEFAN GROSS of Brookline, MA, HYUN GYUNG JANG of Arlington, MA, SHENGFANG JIN of Newton, MA, FRANCESCO G. SALITURO of Marlborough, MA, JEFFREY O. SAUNDERS of Concord, MA, SHINSAN SU of Newton, MA and KATHARINE YEN of Wellesley, MA ; hereby assign to AGIOS PHARMACEUTICALS, INC., a corporation of Delaware, having a place of business at 38 Sidney Street, Cambridge, MA 02139, and its successors and assigns (collectively hereinafter called "the Assignee"), our entire right, title and interest throughout the world in the inventions and improvements which are subject of an application for United States Patent entitled METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS, filed September 13, 2011, and assigned U.S. Serial Number 13/256,396, this assignment, including said application, and any and all continuations, continuations-in-part, and divisional applications, and any and all United States and foreign patents (including reissues, reexaminations, extensions), utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventor's certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment, the effectiveness of this assignment including as of the filing date of the above-identified application and any applications from which the above-identified application claims benefit of.

IN TESTIMONY WHEREOF, I LENNY DANG have executed this document on the date indicated below.

Signature of Inventor — 10/28/11 (Date)

BOSTON, MA
Inventor's City, State of residence

Witnessed by:

(1) Signature of Witness — 10/28/2011 (Date)

Karen Arcyzaga
Print Witness Name — Newton MA (Witness' City, State of residence)

(2) Signature of Witness — 10/28/11 (Date)

Tess Bohn
Print Witness Name — Somerville, MA (Witness' City, State of residence)

IN TESTIMONY WHEREOF, I VALERIA FANTIN have executed this document on the date indicated below.

Signature of Inventor — 10/27/11 (Date)

LA JOLLA, CA
Inventor's City, State of residence

Witnessed by:

(1) Signature of Witness — 10/27/11 (Date)

SANDRA SEDANO
Print Witness Name — SAN DIEGO, CA (Witness' City, State of residence)

(2) Signature of Witness — 27 Oct 2011 (Date)

Leslie Sharp
Print Witness Name — San Diego, CA (Witness' City, State of residence)

IN TESTIMONY WHEREOF, I STEFAN GROSS have executed this document on the date indicated below.

Signature of Inventor — 28 Oct 2011 — Date

Brookline MA
Inventor's City, State of residence

Witnessed by:

(1) Signature of Witness — 10/28/2011 — Date

Karen Arreyzaga — Newton, MA
Print Witness Name — Witness' City, State of residence

(2) Signature of Witness — 10/28/11 — Date

Tess Bohn — Somerville, MA
Print Witness Name — Witness' City, State of residence

IN TESTIMONY WHEREOF, I HYUN GYUNG have executed this document on the date indicated below.

Signature of Inventor — 10/31/2011 — Date

Arlington, MA
Inventor's City, State of residence

Witnessed by:

(1) Signature of Witness — 10/31/2011 — Date

Karen Arreyzaga — Newton, MA
Print Witness Name — Witness' City, State of residence

(2) Signature of Witness — 10/31/11 — Date

Tess Bohn — Somerville MA
Print Witness Name — Witness' City, State of residence

IN TESTIMONY WHEREOF, I SHENGFANG JIN have executed this document on the date indicated below.

Shengfang Jin
Signature of Inventor

10-31-2011
Date

Newton MA
Inventor's City, State of residence

Witnessed by:

(1) Khanh Nguyen
Signature of Witness

10/31/2011
Date

Karen Arreyzaga
Print Witness Name

Newton, MA
Witness' City, State of residence

(2) Brianna Nelson
Signature of Witness

10/31/11
Date

Brianna Nelson
Print Witness Name

Charlestown, MA
Witness' City, State of residence952129

IN TESTIMONY WHEREOF, I FRANCESCO G. SALITURO have executed this document on the date indicated below.

Francesco G Saliturro
Signature of Inventor

10-27-2011
Date

Marlborough, MA
Inventor's City, State of residence

Witnessed by:

(1) Khanh Nguyen
Signature of Witness

10/27/2011
Date

Karen Arreyzaga
Print Witness Name

Newton, MA
Witness' City, State of residence

(2) Tess Bohn
Signature of Witness

10/27/11
Date

Tess Bohn
Print Witness Name

Somerville, MA
Witness' City, State of residence

IN TESTIMONY WHEREOF, I JEFFREY O. SAUNDERS have executed this document on the date indicated below.

Signature of Inventor — Date: 27.0.1.2011

Lincoln, MA
Inventor's City, State of residence

Witnessed by:

(1) Signature of Witness — Date: 10/27/2011

Karen Arreyaga
Print Witness Name — Newton, MA
Witness' City, State of residence

(2) Signature of Witness — Date: 10/27/11

Tess Bohn
Print Witness Name — Somerville, MA
Witness' City, State of residence

IN TESTIMONY WHEREOF, I SHINSAN SU have executed this document on the date indicated below.

Signature of Inventor — Date: 10/27/2011

Newton, MA
Inventor's City, State of residence

Witnessed by:

(1) Signature of Witness — Date: 10/28/2011

Karen Arreyaga
Print Witness Name — Newton, MA
Witness' City, State of residence

(2) Signature of Witness — Date: 10/25/11

Tess Bohn
Print Witness Name — Somerville, MA
Witness' City, State of residence

IN TESTIMONY WHEREOF, I ~~KATHERINE~~ Katharine YEN have executed this document on the date indicated below.

KEY

Signature of Inventor — Date: 10/31/11

Wellesley, MA
Inventor's City, State of residence

Witnessed by:

(1) Signature of Witness — Date: 10/31/2011

Print Witness Name: Karen Areyzaga — Witness' City, State of residence: Newton, MA

(2) Signature of Witness — Date: 10/31/11

Print Witness Name: Tess Bohn — Witness' City, State of residence: Somerville MA

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2

CONFIRMATION NO. 7017

148106
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

IMPROPER CFR REQUEST

OC000000112560374

Date Mailed: 11/13/2019

RESPONSE TO REQUEST FOR CORRECTED FILING RECEIPT

Power of Attorney, Claims, Fees, System Limitations, and Miscellaneous

In response to your request for a corrected Filing Receipt, the Office is unable to comply with your request because:

- Any request to correct or update the name of the applicant must include an application data sheet (ADS) in compliance with 37 CFR 1.76 specifying the correct or updated name of the applicant in the applicant information section. Any request to change the applicant after an original applicant has been specified under 37 CFR 1.46(b) must include a new ADS in compliance with 37 CFR 1.76 specifying the applicant in the applicant information section and comply with 37 CFR 3.71 and 3.73. See 37 CFR 1.46(c).

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/zabraha/

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2

CONFIRMATION NO. 7017

IMPROPER CPOA LETTER

148106
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

OC000000112560301

Date Mailed: 11/13/2019

NOTICE REGARDING POWER OF ATTORNEY

This is in response to the power of attorney filed 11/07/2019. The power of attorney in this application is not accepted for the reason(s) listed below:

- The power of attorney has not been accepted because the party who is giving power has not been identified. Power of attorney may only be signed by the applicant for patent (37 CFR 1.42) or the patent owner. A party who is not the applicant must become the applicant in accordance with 37 CFR 1.46(c) and appoint any power of attorney in compliance with 37 CFR 3.71 and 3.73. For a reissue application, reexamination proceeding, or supplemental examination proceeding, a patent owner who was not the applicant under 37 CFR 1.46 must appoint any power of attorney in compliance with 37 CFR 3.71 and 3.73. See 37 CFR 1.32(b)(4).

/zabraha/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

Application Number * 15/589,615 *	Application/Control No. 15/589,615	Applicant(s)/Patent under Reexamination Dang et al.	
	Examiner HIXSON, CHRISTOPHER	Art Unit 1797	

Document Code - DISQ	Internal Document - DO NOT MAIL

TERMINAL DISCLAIMER	☐ APPROVED	☑ DISAPPROVED
Date Filed: 07 November 2019	**This patent is subject to a Terminal Disclaimer**	

Approved/Disapproved by:

/CHARRISSA S BROWN/

Technology Center: PLRC

Telephone: (571)272-1558

The terminal disclaimer identifies a party who is not the applicant (only for applications filed on or after September 16, 2012; See FP 14.26.10):

For cases filed on/after 9/16/12, 37 CFR 1.321 specifies that only the applicant can disclaim, and the terminal disclaimer must specify the extent of the applicant's ownership.

Below is what needs to be done to correct the defects:

A request under 37 CFR 1.46(c) to change the applicant needs to be filed, which is (1) a request, signed by a 1.33 (b) party, (2) a corrected ADS (37 CFR 1.76(c)) that identifies the "new" applicant in the applicant information, and is underlined since it is new, and (3) a 3.73(c) statement showing chain of title to the new applicant. Along with the § 1.46(c) request we need a POA that gives power to the attorney who is signing the TD, along with another copy of the TD, or a TD that is signed by the applicant.

PTO/AIA/26 (04-14)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) AGS-013USC2

In re Application of: Lenny Dang et al.

Application No.: 15/589,615-Conf. #7017

Filed: May 8, 2017

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

The applicant, Agios Pharmaceuticals, Inc., owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. 9,982,309 as the term of said **prior patent** is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

expires for failure to pay a maintenance fee;
is held unenforceable;
is found invalid by a court of competent jurisdiction;
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
has all claims canceled by a reexamination certificate;
is reissued; or
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 75,817

/Ioana Davies/ — Signature
November 7, 2019 — Date

Ioana Davies — Typed or printed name

Agent for Applicant — Title
(617) 570-3920 — Telephone Number

☒ Terminal disclaimer fee under 37 CFR 1.20(d) paid November 1, 2019.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82A (07-13)
Approved for use through 01/31/2018. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	15/589,615
Filing Date	May 8, 2017
First Named Inventor	Lenny Dang
Title	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

SIGNATURE of Applicant or Patent Practitioner

Signature	/Ioana Davies/	Date (Optional)	
Name	Ioana Davies	Registration Number	75,817
Title (if Applicant is a juristic entity)	**Agent for Applicant**		
Applicant Name (if Applicant is a juristic entity)	**Agios Pharmaceuticals, Inc.**		

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ *Total of 1 forms are submitted.

101349079
IPTS/101349079.1

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82B (07-13)
Approved for use through 01/31/2018. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date
15/589,615	May 8, 2017

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

[x] I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 148106

OR

[ ] I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

[ ] The address associated with the above-mentioned Customer Number

OR

[ ] The address associated with Customer Number:

OR

[ ] Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone		Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

Agios Pharmaceuticals, Inc.

[ ] Inventor or Joint Inventor (title not required below)

[ ] Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

[x] Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

[ ] Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature	/JWB/	Date (Optional)	11/7/19
Name	James W. Burns		
Title	Vice President, Commercial Healthcare Law & Chief Compliance Officer		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

[ ] Total of 1 forms are submitted.

IPTS/101349079.1

Electronic Acknowledgement Receipt

EFS ID:	37688489
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies
Filer Authorized By:	
Attorney Docket Number:	AGS-013USC2
Receipt Date:	07-NOV-2019
Filing Date:	08-MAY-2017
Time Stamp:	15:57:19
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Terminal Disclaimer Filed	Terminal_Disclaimer_Double_Patenting_Rejection_--_Prior_Patent_PTO_AIA-26.PDF	170715 0b91c84aa18d171ef1ffd02e4601bcc8f6e9fb25	no	1

Warnings:

Information:					
2	Power of Attorney	Executed_POA.pdf	1184661 4389c20d60556ec7c5583d3faea77e62b5e29962	no	2
Warnings:					
Information:					
			Total Files Size (in bytes):	1355376	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Application Number * 15/589,615 *	Application/Control No. 15/589,615	Applicant(s)/Patent under Reexamination Dang et al.	
	Examiner HIXSON, CHRISTOPHER	Art Unit 1797	

Document Code - DISQ	Internal Document - DO NOT MAIL

TERMINAL DISCLAIMER	☐ APPROVED	☑ DISAPPROVED
Date Filed: 01 November 2019	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:

/JEAN PROCTOR/

Technology Center: OPLC

Telephone: (571)272-1040

The person who signed the terminal disclaimer (only for applicatins filed on or after September 16,2012 is not the applicant, patentee or an attorney or agent of record. 37 CFR 1.321 (a) and (b). (See FP 14.26.08) failed to state his/her capacity to sign for the juristic entity, and he/she has not been established as being authorized to act on behalf of the applicant. (See FP 14.26.09).
(Note: PoA can be given to a customer number, wherein all practitioners listed under the customer number have PoA. given to a list of practitioners by registration number, the list may not comprise more than 10 practitioners or a separate paper signed by a 37 CFR l.33(b) party must be in the record identifying which of the practitioners, up to 10, are recognized as having PoA. If the applicant is a juristic entity (e.g., corporation), a representative of the applicant cannot sign the TD unless it is established that the representative is a party authorized to act on behalf of the applicant.)

PTO/AIA/26 (04-14)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) AGS-013USC2

In re Application of: Lenny Dang et al.

Application No.: 15/589,615-Conf. #7017

Filed: May 8, 2017

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

The applicant, Agios Pharmaceuticals, Inc., owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. 9,982,309 as the term of said **prior patent** is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

expires for failure to pay a maintenance fee;
is held unenforceable;
is found invalid by a court of competent jurisdiction;
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
has all claims canceled by a reexamination certificate;
is reissued; or
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 75,817

/Ioana Davies/ — Signature
November 1, 2019 — Date

Ioana Davies — Typed or printed name

Agent for Applicant — Title
(617) 570-3920 — Telephone Number

☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Electronic Patent Application Fee Transmittal

Application Number:	15589615
Filing Date:	08-May-2017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Filer:	Ioana Davies
Attorney Docket Number:	AGS-013USC2

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
STATUTORY OR TERMINAL DISCLAIMER	1814	1	160	160
		Total in USD ($)		**160**

Electronic Acknowledgement Receipt

EFS ID:	37629635
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies
Filer Authorized By:	
Attorney Docket Number:	AGS-013USC2
Receipt Date:	01-NOV-2019
Filing Date:	08-MAY-2017
Time Stamp:	13:12:24
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$160
RAM confirmation Number	E2019A1D12386634
Deposit Account	
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Amendment_After_Final_Action_Under_37CFR1.pdf	37931 bd46f6c2e5ca055f849f386a084619abd1acd063	yes	5

Multipart Description/PDF files in .zip description

Document Description	Start	End
Response After Final Action	1	1
Claims	2	3
Applicant Arguments/Remarks Made in an Amendment	4	5

Warnings:

Information:

2	Terminal Disclaimer Filed	Terminal_Disclaimer.pdf	71868 7fff6c12cdc00da2f236554b6f43895ca0aa7a0f	no	1

Warnings:

Information:

3	Fee Worksheet (SB06)	fee-info.pdf	30077 fd35c3885b6c04239d89b1d816231fc282942bb9	no	2

Warnings:

Information:

Total Files Size (in bytes):	139876

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Docket No.: AGS-013USC2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Lenny Dang et al.

Application No.: 15/589,615 | Confirmation No.: 7017

Filed: May 8, 2017 | Art Unit: 1797

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Examiner: C. Hixson

AMENDMENT AFTER FINAL ACTION UNDER 37 C.F.R. § 1.116

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Final Office Action dated September 3, 2019, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Previously presented) A method of treating a subject having acute myelogenous leukemia (AML) characterized by the presence of a mutant isocitrate dehydrogenase 1 enzyme (IDH1) or a mutant isocitrate dehydrogenase 2 enzyme (IDH2), wherein the mutant IDH1 or mutant IDH2 has the ability to convert alpha-ketoglutarate to 2-hydroxyglutarate (2HG), the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of said mutant IDH1 or mutant IDH2.

2. (Original) The method of claim 1, wherein the inhibitor binds to IDH1R132X or IDH2R172X and inhibits the ability to convert alpha-ketoglutarate to 2-HG.

3. (Original) The method of claim 1, wherein the cancer is characterized by an IDH1 mutation.

4. (Original) The method of claim 3, wherein the IDH1 mutation is an IDH1R132X mutation.

5. (Original) The method of claim 3, wherein the IDH1 mutation is selected from R132H, R132C, R132S, R132G, R132L, and R132V.

6. (Original) The method of claim 1, wherein the cancer is characterized by an IDH2 mutation.

7. (Original) The method of claim 6, wherein the IDH2 mutation is an IDH1R172X mutation.

8. (Original) The method of claim 6, wherein the IDH2 mutation is selected from R172K, R172M, R172S, R172G, and R172W.

9. (Original) The method of claim 1, wherein the mutant IDH1 or mutant IDH2 is detected in a sample obtained from the subject.

10. (Original) The method of claim 9, wherein the sample comprises tissue or bodily fluid.

11. (Original) The method of claim 1, wherein the mutant IDH1 or mutant IDH2 is detected by sequencing a nucleic acid from an affected cell that encodes the relevant amino acid(s) from the mutant IDH1 or mutant IDH2.

12. (Original) The method of claim 11, wherein the sequencing is performed by polymerase chain reaction (PCR).

13-18. (Cancelled)

REMARKS

In response to the Final Office Action dated September 3, 2019, Applicant respectfully requests reconsideration in view of the following remarks. Claims 1-12 are pending for examination with claim 1 being an independent claim. No new matter has been added.

Double Patenting

Claims 1, 6, and 9-12 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6 and 11-13 of U.S. Patent No. 9,982,309 (hereinafter the '309 Patent). Without appearing to agree with the Examiner and solely to facilitate prosecution of the present Application, Applicant submits herewith a Terminal Disclaimer to disclaim any patent term that would extend beyond the term of the '309 Patent. Accordingly, this rejection should be withdrawn.

Allowable Subject Matter

Claims 2-5, 7, and 8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Applicant submits that the Terminal Disclaimer concurrently submitted overcomes all remaining rejections of the base claims 1 and 6, rendering the objection moot.

CONCLUSION

In view of the foregoing amendments and remarks, reconsideration is respectfully requested. This application should now be in condition for allowance; a notice to this effect is respectfully requested. If the Examiner believes, after this amendment, that the application is not in condition for allowance, the Examiner is requested to call the Applicant's agent at the telephone number listed below.

The Director is hereby authorized to charge any additional fees which may be required with respect to this communication, or credit any overpayment, to Deposit Account No. 07-1700, under Order No. AGS-013USC2.

Dated: November 1, 2019

Respectfully submitted,

Electronic signature: /Ioana Davies/
Ioana Davies
Registration No.: 75,817
Catherine M. McCarty
Registration No.: 54,301
GOODWIN PROCTER LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Agent/Attorney for Applicant

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 15/589,615	Filing Date 05/08/2017	☐ To be Mailed

ENTITY: ☑ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $80 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $420 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

AMENDMENT	11/01/2019	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 12	Minus	** 20	= 0		x $100 =	0
	Independent (37 CFR 1.16(h))	* 1	Minus	*** 3	= 0		x $460 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

AMENDMENT		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	LIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/PAMELA V THERATT/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2	7017

148106 7590 09/03/2019

GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

EXAMINER	
HIXSON, CHRISTOPHER	

ART UNIT	PAPER NUMBER
1797	

NOTIFICATION DATE	DELIVERY MODE
09/03/2019	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATENTBOS@GOODWINLAW.COM
glenn.williams@goodwinlaw.com
pair_agios@firsttofile.com

Office Action Summary	**Application No.** 15/589,615	**Applicant(s)** Dang et al.	
	Examiner CHRISTOPHER A HIXSON	**Art Unit** 1797	**AIA (FITF) Status** No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 25 June 2019.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☑ This action is **FINAL.** 2b) ☐ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 1-12 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 1,6 and 9-12 is/are rejected.

8) ☑ Claim(s) 2-5 and 7-8 is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

The present application is being examined under the pre-AIA first to invent provisions.

Status of Application

The amendment dated 25 June 2019 is acknowledged. Claims 13-18 were cancelled. Claims 1-12 are pending and are considered on the merits below.

In response to the present amendment, the examiner withdraws the rejection over prior art, but maintains the rejection over double patenting with slight modification.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*,

686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

Claim(s) 1, 6, and 9-12 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6 and 11-13 of U.S. Patent No.

9,982,309. Although the claims at issue are not identical, they are not patentably distinct from each other.

Claim 1 is taught in claims 1-2 and 12 of the '309 patent.

Claim 6 is taught in claims 1 of the '309 patent.

Claim 9-12 is taught in claims 3-6 of the '309 patent.

Allowable Subject Matter

Claims 2-5, 7, and 8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The following is a statement of reasons for the indication of allowable subject matter: As the examiner withdrew the previous rejection over prior art, all that remains is the rejection over double patenting. As no further rejection appears possible for these claims, they are indicated as allowable subject matter.

Response to Arguments

Applicant's arguments filed 25 June **2019** have been fully considered but they are not persuasive. The rejection over prior art is withdrawn in view of the amendment and argument. However, the rejection over double patenting cannot be withdrawn. Applicants requested it be held in abeyance, though a telephone call asking that it be resolved went unanswered. This action is therefore issued.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER A. HIXSON whose telephone number is (571)270-5027. The examiner can normally be reached on M-F 10am-6pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lyle Alexander can be reached on 571-272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Christopher Adam Hixson/
Primary Examiner, Art Unit 1797

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	Art Unit
	CHRISTOPHER A HIXSON	1797

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	10/13/2018	03/26/2019	08/28/2019						
	1	✓	✓	✓						
	2	✓	✓	O						
	3	✓	✓	O						
	4	✓	✓	O						
	5	✓	✓	O						
	6	✓	✓	✓						
	7	✓	✓	O						
	8	✓	✓	O						
	9	✓	✓	✓						
	10	✓	✓	✓						
	11	✓	✓	✓						
	12	✓	✓	✓						
	13	✓	-	-						
	14	✓	✓	-						
	15	✓	✓	-						
	16	✓	✓	-						
	17	✓	✓	-						
	18	✓	✓	-						

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	Art Unit
	CHRISTOPHER A HIXSON	1797

CPC - Searched*		
Symbol	Date	Examiner
g01n2800/52,7028	08/26/2019	cah
a61p43/00	08/26/2019	cah
a61p35/00	08/26/2019	cah

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
search in EAST as attached, inventor name search, google.com as attached	10/12/2018	cah
search in EAST as attached, inventor name search	03/26/2019	cah
search in EAST as attached, inventor name search	08/26/2019	cah

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("9,982,309").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/28 15:47
S53	1	("9732062").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/27 07:42
S52	1	("10294215").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/27 07:41
S51	1	("10274215").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/27 07:40
S50	1	("9732062").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:40
S49	1	S48 and S36	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:37
S48	43	S46 and S47	US-PGPUB; USPAT; USOCR	OR	ON	2019/08/26 12:37
S47	2011	((("DANG") near3 ("Lenny")) OR (("FANTIN") near3 ("Valeria")) OR (("GROSS") near3 ("Stefan")) OR (("JANG") near3 ("Hyun")) OR (("JIN") near3 ("Shengfang")) OR (("SALITURO") near3 ("Francesco")) OR (("SAUNDERS") near3 ("Jeffrey")) OR (("SU") near3 ("Shin-San")) OR (("YEN") near3 ("Katharine"))).INV.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2019/08/26 12:37
S46	1447	S45 and ((acute with leukemia) or AML or ALL)	US-PGPUB; USPAT; USOCR	OR	ON	2019/08/26 12:37
S45	6051	idh1 or idh2 or (isocitrate with dehydrogenase)	US-PGPUB; USPAT; USOCR	OR	ON	2019/08/26 12:37
S44	79	(S40 or S43) and S36	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:34

S43	178	(S41 or S42) and S38	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:34
S42	384	a61p43/00.cpc.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:34
S41	6033	a61p35/00.cpc.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:34
S40	43	S39 and S37 and S38	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:34
S39	9113	g01n2800/52,7028.cpc.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:34
S38	6051	idh1 or idh2 or (isocitrate with dehydrogenase)	US-PGPUB; USPAT; USOCR	OR	ON	2019/08/26 12:34
S37	659528	@pd>="20181012"	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:34
S36	336271	@pd>="20190326"	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 12:33
S35	1	("9982309").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 10:59
S34	0	S33 and hixson.xp.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 10:12
S33	6051	idh1 or idh2 or (isocitrate with dehydrogenase)	US-PGPUB; USPAT; USOCR	OR	ON	2019/08/26 10:12
S32	1	("20110229479").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/08/26 10:04

EAST Search History (Interference)

< This search history is empty>

8/28/2019 3:52:46 PM
C:\Users\chixson\Documents\EAST\Workspaces\15589615.wsp

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 15/589,615	Filing Date 05/08/2017	☐ To be Mailed

ENTITY: ☑ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $80 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $420 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

AMENDMENT	06/25/2019	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 12	Minus	** 20	= 0		x $100 =	0
	Independent (37 CFR 1.16(h))	* 1	Minus	*** 3	= 0		x $460 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

AMENDMENT		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	SLIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/PARTHENIA D MERRILL/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

Docket No.: AGS-013USC2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Lenny Dang et al.

Application No.: 15/589,615 | Confirmation No.: 7017

Filed: May 8, 2017 | Art Unit: 1797

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Examiner: C. Hixson

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION UNDER 37 C.F.R. § 1.111

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated March 29, 2019, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A method of treating a subject having ~~a cancer~~acute myelogenous leukemia (AML) characterized by the presence of a mutant isocitrate dehydrogenase 1 enzyme (IDH1) or a mutant isocitrate dehydrogenase 2 enzyme (IDH2), wherein the mutant IDH1 or mutant IDH2 has the ability to convert alpha-ketoglutarate to 2-hydroxyglutarate (2HG), the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of said mutant IDH1 or mutant IDH2.

2. (Original) The method of claim 1, wherein the inhibitor binds to IDH1R132X or IDH2R172X and inhibits the ability to convert alpha-ketoglutarate to 2-HG.

3. (Original) The method of claim 1, wherein the cancer is characterized by an IDH1 mutation.

4. (Original) The method of claim 3, wherein the IDH1 mutation is an IDH1R132X mutation.

5. (Original) The method of claim 3, wherein the IDH1 mutation is selected from R132H, R132C, R132S, R132G, R132L, and R132V.

6. (Original) The method of claim 1, wherein the cancer is characterized by an IDH2 mutation.

7. (Original) The method of claim 6, wherein the IDH2 mutation is an IDH1R172X mutation.

8. (Original) The method of claim 6, wherein the IDH2 mutation is selected from R172K, R172M, R172S, R172G, and R172W.

9. (Original) The method of claim 1, wherein the mutant IDH1 or mutant IDH2 is detected in a sample obtained from the subject.

10. (Original) The method of claim 9, wherein the sample comprises tissue or bodily fluid.

11. (Original) The method of claim 1, wherein the mutant IDH1 or mutant IDH2 is detected by sequencing a nucleic acid from an affected cell that encodes the relevant amino acid(s) from the mutant IDH1 or mutant IDH2.

12. (Original) The method of claim 11, wherein the sequencing is performed by polymerase chain reaction (PCR).

13-18. (Cancelled)

REMARKS

In response to the Office Action dated March 29, 2019, Applicant respectfully requests reconsideration in view of the amendments and the following remarks. Claims 1-12 and 14-18 were previously pending in this application. By this amendment, Applicant is canceling claims 14-18 without prejudice or disclaimer. Claim 1 is amended. As a result claims 1-12 are pending for examination with claim 1 being independent. No new matter has been added.

Rejections under 35 U.S.C. § 102

Claim(s) 1-16 is/are rejected under pre-AIA 35 U.S.C. 102(e) as being allegedly anticipated by Vogelstein et al. (US 2011/0229479 or US 8,685,660). Without acquiescing to the propriety of the rejection and solely for the purpose of expediting prosecution of the instant application, Claim 1 has been amended to incorporate the limitations of claim 17, which was found to possess novelty over Vogelstein.

Rejections under 35 U.S.C. § 103

Claim(s) 17 and 18 is/are rejected under pre-AIA 35 U.S.C. 103(a) as being obvious in view of Vogelstein et al. (US 2011/0229479 or US 8,685,660) in further view of Kang et al. (International Journal of Cancer 2009).

Vogelstein discloses IDH1 and IDH2 mutations in CNS tumors such as astrocytomas, oligodendrogliomas and glioblastomas. There is nothing in Vogelstein to suggest that these mutations would be present in non-CNS cancers. To the contrary, Vogelstein discloses that no IDH1 mutations were found in any of the 494 non-CNS cancer samples, including 45 AML samples (*see, e.g.*, Fig 4B and Example 5: " In contrast, no R132 mutations were observed in 21 pilocytic astrocytomas (WHO Grade I), two subependymal giant cell astrocytomas (WHO Grade I), 30 ependymomas (WHO Grade II), 55 medulloblastomas, *or in any of the 494 non-CNS tumor samples.* Sequence analysis of the remaining IDH1 exons revealed no other somatic mutations of IDH1 in the R132-negative tumors." (emphasis added))

Kang does not cure the deficiencies of Vogelstein, and similarly states that no IDH1 mutations were found in cancers other than GBM, prostate carcinoma and B-ALL (*see, e.g.*, abstract) and specifically that no IDH1 mutations were found in AML samples (*see, e.g.* Table 1, showing 0/100 AML samples with IDH1 mutations).

Taken individually and together, Vogelstein and Kang suggest that IDH mutations are not present in AML. Consequently, at the time of the filing of the instant application, a person of skill in the art would find no motivation in either Vogelstein or Kang, alone or in combination to use a small molecule inhibitor of mutant IDH1 or mutant IDH2 in a method for treating acute myelogenous leukemia (AML) characterized by the presence of a mutant isocitrate dehydrogenase 1 enzyme (IDH1) or a mutant isocitrate dehydrogenase 2 enzyme (IDH2), wherein the mutant IDH1 or mutant IDH2 has the ability to convert alpha-ketoglutarate to 2-hydroxyglutarate (2HG).

Applicant submits that the claims as amended are non-obvious in view of Vogelstein and in further view of Kang, and respectfully requests withdrawal of the rejection under pre-AIA 35 U.S.C. 103(a).

Double Patenting

Claim(s) 1, 6, 9-12, 14, 17, and 18 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6 and 11-13 of U.S. Patent No. 9,982,309. Although the claims at issue are not identical, they are not patentably distinct from each other.

Applicant respectfully requests that the nonstatutory double-patenting rejection be held in abeyance until otherwise allowable matter has been identified in the instant application.

CONCLUSION

In view of the foregoing amendments and remarks, reconsideration is respectfully requested. This application should now be in condition for allowance; a notice to this effect is respectfully requested. If the Examiner believes, after this amendment, that the application is

not in condition for allowance, the Examiner is requested to call the Applicant's agent at the telephone number listed below.

The Director is hereby authorized to charge any additional fees which may be required with respect to this communication, or credit any overpayment, to Deposit Account No. 07-1700, under Order No. AGS-013USC2.

Dated: June 25, 2019

Respectfully submitted,

Electronic signature: /Ioana Davies/
Ioana Davies
Registration No.: 75,817
Catherine M. McCarty
Registration No.: 54,301
GOODWIN PROCTER LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Agent/Attorney for Applicant

Electronic Acknowledgement Receipt

EFS ID:	36398487
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies
Filer Authorized By:	
Attorney Docket Number:	AGS-013USC2
Receipt Date:	25-JUN-2019
Filing Date:	08-MAY-2017
Time Stamp:	11:51:36
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Amendment_in_Response_to_Non-Final_Office_Action_Under_37 CFR1.pdf	45533 bce46a38d14a980ac37eed1e007d011c820e7b55	yes	6

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment/Req. Reconsideration-After Non-Final Reject	1	1
	Claims	2	3
	Applicant Arguments/Remarks Made in an Amendment	4	6
Warnings:			
Information:			
	Total Files Size (in bytes):	45533	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2	7017

148106 7590 03/29/2019

GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

EXAMINER	
HIXSON, CHRISTOPHER	

ART UNIT	PAPER NUMBER
1797	

NOTIFICATION DATE	DELIVERY MODE
03/29/2019	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATENTBOS@GOODWINLAW.COM
glenn.williams@goodwinlaw.com
pair_agios@firsttofile.com

Office Action Summary	**Application No.** 15/589,615	**Applicant(s)** Dang et al.	
	Examiner CHRISTOPHER A HIXSON	**Art Unit** 1797	**AIA (FITF) Status** No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 09 January 2019.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☑ This action is **FINAL.** 2b)☐ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☑ Claim(s) 1-12 and 14-18 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☑ Claim(s) 1-12 and 14-18 is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☑ Notice of References Cited (PTO-892)

2) ☑ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

The present application is being examined under the pre-AIA first to invent provisions.

Status of Application

The amendment dated 9 January 2019 is acknowledged. Claims 13 were cancelled. Claims 1-12 and 14-18 are pending and are considered on the merits below.

In response to the present amendment, the examiner enters a new rejection over prior art. Though the examiner does not understand that his previous rejection was in error, when updating his search, a superior reference was found. The previous rejection is replaced by a rejection over that reference. Furthermore, a rejection over double patenting is made in view of the IDS submission.

Claim Rejections - 35 USC § 102

In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claim(s) 1-16 is/are rejected under pre-AIA 35 U.S.C. 102(e) as being anticipated by Vogelstein et al. (US 2011/0229479 or US 8,685,660).

Regarding claim 1, Vogelstein teaches one can treat a subject having a cancer characterized by the presence of a mutant isocitrate dehydrogenase 1 enzyme (IDH1) or a mutant isocitrate dehydrogenase 2 enzyme (IDH2) (see provisional support – 61/110,397 at [25]-[36]; 61/093,739 at [25]-[29]), wherein the mutant IDH1 or mutant IDH2 has the ability to convert alpha-ketoglutarate to 2-hydroxyglutarate (2HG), the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of said mutant IDH1 or mutant IDH2 (‘397 provisional application at [36]; ‘739 provisional application at [29]).

Regarding claim 2, the inhibitor binds to IDH1R132X or IDH2R172X (‘397 provisional application at [36]; ‘739 provisional application at [29]) and inhibits the ability to convert alpha-ketoglutarate to 2-HG (implicit, as inhibiting the action of a protein is the expected behavior of an inhibitor).

Regarding claim 3, the cancer is characterized by an IDH1 mutation (‘397 provisional application at [36]; ‘739 provisional application at [29]).

Regarding claim 4, the IDH1 mutation is an IDH1R132X mutation ('397 provisional application at [36]; '739 provisional application at [29]; also see the '739 at [27] and the '397 at [34]).

Regarding claim 5, the IDH1 mutation is selected from R132H, R132C, R132S, R132G, R132L, and R132V (Id).

Regarding claim 6, the cancer is characterized by an IDH2 mutation (Id).

Regarding claim 7, the IDH2 mutation is an IDH2R172X mutation (Id).

Regarding claim 8, the IDH2 mutation is selected from R172K, R172M, R172S, R172G, and R172W (Id).

Regarding claim 9, the mutant IDH1 or mutant IDH2 is detected in a sample obtained from the subject (see provisional support – 61/110,397 at [25]-[36]; 61/093,739 at [25]-[29]).

Regarding claim 10, the sample comprises tissue or bodily fluid ('397 application, [28], tumor tissue).

Regarding claim 11, the mutant IDH1 or mutant IDH2 is detected by sequencing a nucleic acid from an affected cell that encodes the relevant amino acid(s) from the mutant IDH1 or mutant IDH2 ('397 - [26], [28], [45], [46] "sequence analysis").

Regarding claim 12, the sequencing is performed by polymerase chain reaction (Id).

Regarding claim 14-16, the cancer is selected from an astrocytic tumor, an oligodendroglial tumor, an oligoastrocytic tumor, an anaplastic astrocytoma, fibrosarcoma, paraganglioma, prostate cancer, acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia (AML) ('397 application – [25], [26], [29], [36]).

Claim Rejections - 35 USC § 103

In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.

2. Ascertaining the differences between the prior art and the claims at issue.

3. Resolving the level of ordinary skill in the pertinent art.

4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under pre-AIA 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein

were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of pre-AIA 35 U.S.C. 103(c) and potential pre-AIA 35 U.S.C. 102(e), (f) or (g) prior art under pre-AIA 35 U.S.C. 103(a).

Claim(s) 17 and 18 is/are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Vogelstein et al. (US 2011/0229479 or US 8,685,660) in view of Kang et al. (International Journal of Cancer 2009).

Regarding claims 17 and 18, the previously applied reference does not appear to teach that the mutation is found in AML or ALL cancers.

Kang teaches that because near the time of invention the mutation was newly discovered as being relevant in glial cancer, there was interest in determining whether it could be found in other cancers as well (abstract; Table 1), including in acute leukemias. In his preliminary search, he did find evidence that it could be found in B-ALL cancers (Id – "We found … one [IDH1 codon 132 mutation] in the B-acute lymphoblastic leukemias").

It would have been obvious to one of ordinary skill in the art at the time of invention to have used the treatment for any cancer which included the mutation of the claim, including for B-cell ALL cancers, as was found by Kang, or for AML cancers, once any to be discovered to include the mutation, because matching the therapy with the specific pathology would lead to a more effective treatment.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

Claim(s) 1, 6, 9-12, 14, 17, and 18 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6 and 11-13 of U.S. Patent No. **9,982,309**. Although the claims at issue are not identical, they are not patentably distinct from each other.

Claim 1 is taught in claims 1-2 of the '309 patent.

Claim 6 is taught in claim 1 of the '309 patent.

Claim 9-12 is taught in claims 3-6 of the '309 patent.

Claim 14, 17, and 18 are taught in claims 11-13 of the '309 patent.

Response to Arguments

Applicant's arguments filed **9 January 2019** have been fully considered but they are not persuasive. Arguments concerning the Zernicka-Goetz and Yan references are mooted in view of the new rejection. Applicants argue against the rejection of claims 17 and 18 by stating that "Kang discloses that no IDH1 mutations were detected in the" AML and T-ALL samples, by citing to table 1 of the reference. The examiner does not

disagree. However, claim 18 also recites B-ALL, where such a mutation was detected. Furthermore, the examiner's rejection depended on the fact that the mutation was newly discovered, and that the understanding of the mutation was evolving. He cites one study that did not find a mutation that he found (p.355, col. 1 – referring to the Bleeker study). The mutations at issue are apparently of low frequency, and would be expected to have required a large sample size to establish that they were important or to rule out that they occur. That he included these cancers in the list to be studied implies that there was reason to have considered them, and is concrete evidence of obviousness by itself. The reference is therefore not found to teach away.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER A. HIXSON whose telephone number is (571)270-5027. The examiner can normally be reached on M-F 10am-6pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lyle Alexander can be reached on 571-272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Christopher Adam Hixson/
Primary Examiner, Art Unit 1797

Notice of References Cited	Application/Control No. 15/589,615	Applicant(s)/Patent Under Reexamination Dang et al.	
	Examiner CHRISTOPHER A HIXSON	Art Unit 1797	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-20110229479-A1	09-2011	Vogelstein; Bert	C12Q1/6886	424/138.1
*	B	US-8685660-B2	04-2014	Vogelstein; Bert	C12Q1/6886	435/7.23
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	Art Unit
	CHRISTOPHER A HIXSON	1797

CPC - Searched*		
Symbol	Date	Examiner
g01n2800/52,7028	03/26/2019	cah
a61p43/00	03/26/2019	cah
a61p35/00	03/26/2019	cah

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
search in EAST as attached, inventor name search, google.com as attached	10/12/2018	cah
search in EAST as attached, inventor name search	03/26/2019	cah

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	**Art Unit**
	CHRISTOPHER A HIXSON	1797

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	10/13/2018	03/26/2019							
	1	✓	✓							
	2	✓	✓							
	3	✓	✓							
	4	✓	✓							
	5	✓	✓							
	6	✓	✓							
	7	✓	✓							
	8	✓	✓							
	9	✓	✓							
	10	✓	✓							
	11	✓	✓							
	12	✓	✓							
	13	✓	-							
	14	✓	✓							
	15	✓	✓							
	16	✓	✓							
	17	✓	✓							
	18	✓	✓							

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	1	STN Tokyo, Registry Number 9200679-46-5, Entered STN on February 13, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(4-pyridinyl)-1-piperazinyl]carbonyl]phenyl]-"	
	2	STN Tokyo, Registry Number 920822-52-2, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, N-[4- [[4-(4-fluoropheyl)-1-piperazinyl]carbonyl]phenyl] - 2,3dihydro-"	
	3	STN Tokyo, Registry Number 920824-56-2, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(3-thienylmethyl)-1-piperazinyl]carbonyl]phenyl]-"	
	4	STN Tokyo, Registry Number 920847-34-3, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-methylphenyl)-1-piperazinyl]carbonyl]phenyl]-"	
	5	STN Tokyo, Registry Number 920875-39-4, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-hydroxyphenyl)-1-piperazinyl]carbonyl]phenyl]-"	
	6	STN Tokyo, Registry Number 920902-88-1, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-thienylmethyl)-l-piperazinyl]carbonyl]phenyl]-"	
	7	STN Tokyo, Registry Number 920921-09-1 Entered STN on February 14, 2007, Chemical Abstracts Index Name "2H-1, 5-Benzodioxepin-7-sulfonamide, 3,4-dihydro-N-[4-[[4-(2pyridinyl)-1-piperazinyl]carbonyl]phenyl]-"	
	8	STN Tokyo, Registry Number 920924-42-1, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-pyridinylmethyl)-1-piperazinyl]carbonyl]phenyl]-"	
	9	STN Tokyo, Registry Number 941220-77-5, Entered STN on July 4, 2007, Chemical Abstracts Index Name "2H-1, 5-Benzodioxepin-7-sulfonamide, 3,4-dihydro-N-[4-[(4-methyl-l-piperazinyl)carbonyl]phenyl]-"	
	10	STNREGISTRY. L23 ANSWER 1 OF 3 (CAS NUMBER: 1038821-72-5),Database: ChemDB (University of California Irvine), Entered STN: 05 Aug. 2008 (05. 08. 2008)	
	11	STRUYS et al, Investigations by mass isotopomer analysis of the formation of D-2-hydroxyglutarate by cultured lymphoblasts from two patients with D-2-hydroxyglutaric aciduria, FEBS letters 92004 volume 557, pages 115-120	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	12	STRUYS et al. "Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria" American Journal of Human Genetics, 2005. 76:358-360	
	13	Supplementary European Search Report for EP Application No. 10825707.2 dated June 28, 2013	
	14	Supplementary Search Report for EP10794668 Mailed 10/18/12.	
	15	Supplimentary European Search Report for EP 10751525 Mailed December 14, 2012.	
	16	The radiation fact sheet published by the National Cancer Institute, http://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/radiation-fact-sheet, reviewed June 30, 2010	
	17	THOMPSON, "Metabolic Enzymes as Oncogenes or Tumor Suppressors." The New England 18-22 Journal of Medicine, 19 February 2009, Vol 360, No 8, pp 813-815; pg 813, pg 815, col 1; Fig 1.	
	18	WANG et al. "A novel ligand N,N?-di(2-pyridyl)-2,4-diamino-6-phenyl-1,3,5-triazine (dpdapt) and its complexes: [Cu(dpdapt)Cl2] and [Cu(dpdapt)(NO3)(H2O)] Â· NO3 Â· H2O" Polyhedron, 2006. Vol 25, Issue 1. pp 195-202	
	19	Ward, Patrick S, "The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting [alpha]-Ketoglutarate to 2-Hydroxyglutarate" Cancer cell, Vol:17,Nr:3,Page(s):225 - 234, 2010.	
	20	WATANABE et al., "IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas". American Journal of Pathology, April 2009 (published online 26 February (2009), Vol 174, No 4, pp 1149-1153; Abstract, pg 1150, col 1.	
	21	Written Opinion for PCT/US2010/027253 mailed 08/19/10.	
	22	Written Opinion of International Search Authority for PCT/CN2013/000009 dated April 18, 2013	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	23	Written Opinion of Search Authority for PCT/US2010/53623 dated January 18, 2011	
	24	Written Opinion of the International Searching Authority for PCT/US2011/067752 dated March 5, 2012	
	25	YAN et al., "IDH1 and IDH2 Mutations in Gliomas." The New England Journal of Medicine, 19 18-22 February 2009, Vol 360, No. 8, pp 765-73.	
	26	ZHAO ET AL: "Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha", SCIENCE, vol. 324, no. 5924, 10 April2009 (2009-04-10), pages 261-265	
	27	ZHENG et al. "Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives" Bioorganic & Medicinal Chemistry (2007) Vol 15, pp 1815-1827	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/Christopher Adam Hixson/	Date Considered	03/26/2019

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2017-10-03
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	3755322		1973-08-28	Winter et al.	
	2	3867383		1975-02-18	Winter	
	3	5021421		1991-06-04	Hino et al.	
	4	5807876		1998-09-15	Armistead et al.	
	5	5834485		1998-11-10	Dyke et al.	
	6	5965559		1999-10-12	Faull et al.	
	7	5965569		1999-10-12	Camps Garcia et al.	
	8	5984882		1999-11-16	Rosenschein et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	9	6262113		2001-07-17	Widdowson et al.	
	10	6313127		2001-11-06	Waterson et al.	
	11	6399358		2002-06-04	Williams et al.	
	12	6723730		2004-04-20	Bakthavatchalam et al.	
	13	6979675		2005-12-27	Tidmarsh	
	14	7173025		2007-02-06	Stocker et al.	
	15	8133900		2012-03-13	Hood et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020188027	A1	2002-12-12	Robinson et al.	
	2	20030095958	A1	2003-05-22	Bhisetti et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

	3	20030109527	A1	2003-06-12	Jin et al.	
	4	20030207882	A1	2003-11-06	Stocker et al.	
	5	20040067234	A1	2004-04-08	Einat et al.	
	6	20040248221	A1	2004-12-09	Stockwell	
	7	20060281122	A1	2006-12-14	Bryant et al.	
	8	20080300208	A1	2008-12-04	Einat et al.	
	9	20090093526	A1	2009-04-09	Miller et al.	
	10	20090163508	A1	2009-06-25	KORI et al.	
	11	20100129350	A1	2010-05-27	Zacharie et al.	
	12	20100273808	A1	2010-10-28	Armitage et al.	
	13	20100331307	A1	2010-12-30	Salituro et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

	14	20110086088	A1	2011-04-14	Berry	
	15	20120121515	A1	2012-05-17	Dang et al.	
	16	20120129865	A1	2012-05-24	WANG et al.	
	17	20120164143	A1	2012-06-28	TEELING et al.	
	18	20120202818	A1	2012-08-09	Tao et al.	
	19	20120238576	A1	2012-09-20	Tao et al.	
	20	20120277233	A1	2012-11-01	Tao et al.	
	21	20130035329	A1	2013-02-07	Saunders et al.	
	22	20130109643	A1	2013-05-02	Riggins et al.	
	23	20130184222	A1	2013-07-18	Popovici-Muller et al.	
	24	20130190249	A1	2013-07-25	Lemieux et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	25	20130190287	A1	2013-07-25	Cianchetta et al.	
	26	20140187435	A1	2014-07-03	Dang et al.	
	27	20150018328	A1	2015-01-15	Konteatis et al.	
	28	20150031627	A1	2015-01-29	Lemieux et al.	
	29	20150044716	A1	2015-02-12	Balss et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	101296909	CN	A	2008-10-29	Serono Lab		
	2	0022958	EP	A1	1981-01-28	Bayer Ag		X
	3	0384228	EP	A1	1990-08-29	Dainippon Pharmaceutical Co., Ltd		☐
	4	0385237	EP	A2	1990-09-05	Dainippon Pharmaceutical Co., Ltd		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

	5	2735127	FR	A1	1996-12-13	Pf Medicament		☐
	6	11158073	JP		1999-06-15	Takeda Chemical Industries LTD		☐
	7	4099768	JP	B2	2008-06-11			☐
	8	9291034	JP	A	1997-11-11	Yoshitomi Pharmaceuticals Industries, Ltd.		☐
	9	1996030343	WO	A1	1996-10-03	Merck & Co., Inc		☐
	10	1997044322	WO	A1	1997-11-27	Chiroscience Ltd		☐
	11	2001016097	WO	A1	2001-03-08	Sugen, Inc		☐
	12	2001019788	WO	A2	2001-03-22	Cor Therapeutics, Inc		☐
	13	2001019798	WO	A2	2001-03-22	Cor Therapeutics Inc		☐
	14	2001064642	WO	A2	2001-09-07	Cor Therapeutics, Inc		☐
	15	2001064643	WO	A2	2001-09-07	Cor Therapeutics, Inc		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

	16	2002100822	WO	A1	2002-12-19	Biovitrum Ab		☐
	17	2004050033	WO	A2	2004-06-17	Arqule, Inc		☐
	18	2004073619	WO	A2	2004-09-02	Smithkline Beecham Corp		☐
	19	2004074438	WO	A2	2004-09-02	Smithkline Beecham Corp		☐
	20	2004089470	WO	A2	2004-10-21	Novo Nordisk As		☐
	21	2005060956	WO	A1	2005-07-07	University Of Maryland, Baltimore		☐
	22	2005120474	WO	A2	2005-12-22	Leuven K U Res & Dev		☐
	23	2006034341	WO	A2	2006-03-30	Xenon Pharmaceuticals Inc		☐
	24	2006038594	WO	A1	2006-04-13	Ono Pharmaceutical Co., Ltd		☐
	25	2006070198	WO	A1	2006-07-06	Astex Therapeutics Ltd		☐
	26	2007003934	WO	A2	2007-01-11	Sterix Ltd		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

	27	2007023186	WO	A1	2007-03-01	Applied Research Systems		☐
	28	2008050168	WO	A1	2008-05-02	Ritcher Gedeon Nyrt		☐
	29	2008052190	WO	A2	2008-05-02	Flynn, Gary		☐
	30	2008073670	WO	A2	2008-06-19	Millennium Pharmaceuticals, Inc		☐
	31	2008131547	WO	A1	2008-11-06	Prometic Biosciences Inc		☐
	32	2009013126	WO	A1	2009-01-29	Nerviano Medical Sciences Srl		☐
	33	2009016410	WO	A2	2009-02-05	Astrazeneca Ab		☐
	34	2009126863	WO	A2	2009-10-15	Genentech, Inc		☐
	35	2009150248	WO	A1	2009-12-17	Cytomics Systems		☐
	36	2010007756	WO	A1	2010-01-21	Shionogi & Co., Ltd		☐
	37	2010028099	WO	A1	2010-03-11	Univ Johns Hopkins		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

	38	2010105243	WO	A1	2010-09-16	Agios Pharmaceuticals, Inc		☐
	39	2010129596	WO	A1	2010-11-11	Agios Pharmaceuticals, Inc		☐
	40	2010130638	WO	A1	2010-11-18	Evotec Ag		☐
	41	2010144338	WO	A1	2010-12-16	Abraxis Bioscience, Llc		☐
	42	2010144404	WO	A1	2010-12-16	Abraxis Bioscience, Llc		☐
	43	2011002817	WO	A1	2011-01-06	Agios Pharmaceuticals, Inc		☐
	44	2011032169	WO	A2	2011-03-17	Phusis Therapeutics Inc		☐
	45	2011047432	WO	A1	2011-04-28	Fibrotech Therapeutics Pty Ltd		☐
	46	201105210	WO	A1	2011-01-13	Milux Holding Sa		☐
	47	2011072174	WO	A1	2011-06-16	Agios Pharmaceuticals, Inc		☐
	48	2012009678	WO	A1	2012-01-19	Agios Pharmaceuticals, Inc		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	49	2012092442	WO	A1	2012-07-05	Agios Pharmaceuticals, Inc		☐
	50	2012151452	WO	A1	2012-11-08	Agios Pharmaceuticals, Inc		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	AGHILI et al. "Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review", Journal of Neuroncology, 2008. 91:233-236	
	2	BALSS, "Analysis of the IDH1 codon 132 mutation in brain tumors", Acata Neuropathol (2008) volume 116, pages 597-602.	
	3	BENNER et al, "Evolution, language and analogy in functional genomics", Trends in Genetics (2001) volume 17, pages 414-418.	
	4	BLEEKER et al., "IDH1 mutations at residue p.R132 (IDH1 (R132)) occur frequently in high-grade 18-22 gliomas but not in other solid tumors." Hum Muta1., January 2009, Vol 30, No 1, pp 7-11;	
	5	CAIRNS et al. "Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities" Cancer Discovery (2013) Vol 3, Iss 7, pp 730-741	
	6	Cecil Text Book of Medicine, edited by BENNET and PLUM, (1997) 20th edition, Volume 1, pp 1004-1010	
	7	COCCO et al. "Synthesis of Triflouromethylated Pyridinecarbonitriles" Journal of Heterocyclic Chemistry, 1995. Volume 32 pp 543-545	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	8	DANG et al., "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate." Nature, 10 29-32 December 2009, Vol 462, No 7274, pp 739-744.	
	9	Dang, Lenny, " Cancer-associated IDH1 mutations produce 2-hydroxyglutarate", Nature, Vol:462,Nr:7274,Page(s):739 - 744, 2009.	
	10	DAVIS et al. "Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1" The Journal of Biological Chemistry (2014) vol 289, No 20, pp 13717-13725	
	11	DERMER "another Anniversary for the War on Cancer" Bio/Technology (1994) Vol 12, p 320	
	12	Docoslis et al., "Characterization of the Distribution, Polymorphism, and Stability of Nimodipine in Its Solid Dispersions in Polyethylene Glycol by Micro-Raman Spectroscopy and Powder X-Ray Diffraction". The AAPS Journal 2007; 9 (3) Article 43, E361-E370.	
	13	EP Search Report & Written Opinion for EP 10825706 Dated 03/20/13	
	14	European Search Report for Application No. 10751525.6 dated 12/14/2012	
	15	Eurpoean Search Report for EP Application No. 11763425.3 dated September 23, 2013	
	16	Extended European Search Report for European application no. 16152308.9 dated July 18, 2016	
	17	FRESHNEY et al. "Culture of Animal Cells, A Manual of Basic Techniques" Alan R. Liss, Inc. (1983) pp 1-6	
	18	Genetics Home Reference. "L2HGDH." accessed at <http://ghr.nlm.nih.gov/gene/L2HGDH> on 4 September 2015	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	19	GOLUB et al. "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring" Science (1999) Vol 286, pp 531-537	
	20	HARTMANN et al. "Type and Frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas" Acta Neuropathologica (2009) 118: 469-474	
	21	HOLMES et al, 750 MHz 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2-hydroxyglutaric aciduria and maple syrup urine disease., Journal of Pharmaceutical and Biomedical Analysis (1997) volume 15, pages 1647-1659	
	22	International Preliminary Report for related application No. PCT/US2010/059778 dated June 12, 2012	
	23	International Preliminary Report on Patentability for International Application No. PCT/CN2012/000841 dated September 10, 2012	
	24	International Preliminary Report on Patentability for International Application No. PCT/CN2012/077096 dated September 17, 2012	
	25	International Preliminary Report on Patentability for PCT/CN2012/000841 dated December 17, 2013	
	26	International Preliminary Report on Patentability for PCT/CN2012/077096 dated December 17, 2013	
	27	International Preliminary Report on Patentability for PCT/US2010/027253 mailed 09/13/11.	
	28	International Preliminary Report on Patentability for PCT/US2010/040486 dated 1/12/12	
	29	International Preliminary Report on Patentability for PCT/US2010/053623 dated April 24, 2012	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	30	International Preliminary Report on Patentability for PCT/US2010/053624 dated 4/7/2011	
	31	International Preliminary Report on Patentability for PCT/US2011/030692 dated October 2, 2012	
	32	International Preliminary Report on Patentability for PCT/US2011/067752 dated April 11, 2013	
	33	International Search Report & Written Opinion for PCT/CN2013/070755 dated April 25, 2013	
	34	International Search Report and Written Opinion for Internatinal Application No. PCT/US2013/064601 dated February 24, 2014	
	35	International Search Report and Written Opinion for International Application No. PCT/US15/020349 dated June 15, 2015	
	36	International Search Report and Written Opinion for International Application No. PCT/US2014/049469 dated January 22, 2015	
	37	International Search Report and Written Opinion for International Application No. PCT/US2015/020346 dated June 18, 2015	
	38	International Search Report dated March 5, 2012 for related international application no. PCT/US2011/067752.	
	39	International Search Report for PCT/2011/030692 dated 7/27/2011	
	40	International Search Report for PCT/CN2012/000841 dated September 27, 2012	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

	41	International Search Report for PCT/CN2012/077096 dated 10/4/2012	
	42	International Search Report for PCT/CN2013/000009 dated April 18, 2013	
	43	International Search Report for PCT/CN2013/000068 dated 04/25/13.	
	44	International Search Report for PCT/US10/040486 dated September 1, 2010.	
	45	International Search Report for PCT/US2010/027253 mailed 08/19/10.	
	46	International Search Report for PCT/US2010/059778 dated 03/17/11.	
	47	International Search Report for PCT/US2010/53623 dated January 18, 2011	
	48	International Search Report for PCT/US2010053624 dated 4/7/2011	
	49	International Search Report for PCT/US2011/067752 dated February 22, 2012	
	50	International Search Report for PCT/US2011044254 dated 5/10/2011	

If you wish to add additional non-patent literature document citation information please click the Add button Add

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

EXAMINER SIGNATURE			
Examiner Signature	/Christopher Adam Hixson/	Date Considered	03/26/2019

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2017-10-03
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L3	2	"13060191".apnr.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 14:41
L1	1	"15714349".apnr.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 13:46
S31	0	("15129759.apnr.").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 10:03
S30	0	("15129759.apnr.").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 10:03
S29	0	("15129759.app.").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 10:03
S28	44	("20020188027" | "20030095958" | "20030109527" | "20030207882" | "20040067234" | "20040248221" | "20060281122" | "20080300208" | "20090093526" | "20090163508" | "20100129350" | "20100273808" | "20100331307" | "20110086088" | "20120121515" | "20120129865" | "20120164143" | "20120202818" | "20120238576" | "20120277233" | "20130035329" | "20130109643" | "20130184222" | "20130190249" | "20130190287" | "20140187435" | "20150018328" | "20150031627" | "20150044716" | "3755322" | "3867383" | "5021421" | "5807876" | "5834485" | "5965559" | "5965569" | "5984882" | "6262113" | "6313127" | "6399358" | "6723730" | "6979675" | "7173025" | "8133900").PN.	US-PGPUB; USPAT	OR	OFF	2019/03/26 09:33
S27	1	("9982309").PN.	US-PGPUB; USPAT	OR	OFF	2019/03/26 09:26
S26	476	(idh1 or idh2 or (isocitrate with dehydrogenase)) with inhibit$4	FPRS; EPO; JPO; DERWENT	OR	ON	2019/03/26 08:31
S25	117	(S23 or S24) and S18	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 08:19

S24	219	a61p43/00.cpc.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 08:16
S23	3718	a61p35/00.cpc.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 08:16
S22	19	S21 and S17 and S18	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 07:58
S21	8664	g01n2800/52,7028.cpc.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 07:58
S20	1	S19 and S17 and S18	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 07:40
S19	629	((("DANG") near3 ("Lenny")) OR (("FANTIN") near3 ("Valeria")) OR (("GROSS") near3 ("Stefan")) OR (("JANG") near3 ("Hyun")) OR (("JIN") near3 ("Shengfang")) OR (("SALITURO") near3 ("Francesco")) OR (("SAUNDERS") near3 ("Jeffrey")) OR (("SU") near3 ("Shin-San")) OR (("YEN") near3 ("Katharine"))).INV.	USPAT	OR	OFF	2019/03/26 07:40
S18	5735	idh1 or idh2 or (isocitrate with dehydrogenase)	US-PGPUB; USPAT; USOCR	OR	ON	2019/03/26 07:40
S17	330473	@pd>="20181012"	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/26 07:24
S16	1	"15599419".apnr.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/25 10:31
S15	1	("20110229479").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/03/25 07:44
S14	1	"15129759".apnr.	US-PGPUB; USPAT; USOCR	OR	ON	2019/03/25 07:40
S13	1101	(idh1 or idh2 or (isocitrate with dehydrogenase)) with inhibit$4	US-PGPUB; USPAT; USOCR	OR	ON	2019/03/22 13:44

EAST Search History (Interference)

< This search history is empty>

3/26/2019 3:48:03 PM
C:\Users\chixson\Documents\EAST\Workspaces\15589615.wsp

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2012160034	WO	A1	2012-11-29	Bayer Ip Gmbh		
	2	2014015422	WO	A1	2014-01-30	Ontario Inst For Cancer Res		
	3	9728128	WO	A1	1997-08-07	Zeneca Ltd		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	4	9728129	WO	A1	1997-08-07	Zeneca Ltd		
	5	9932463	WO	A1	1999-07-01	Bayer Ag		

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	International Search Report for PCT/US2013/064601 dated February 24, 2014	
	2	JENNINGS et al, Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase, Biochemistry (1997)volume 36, pages 13743-13747	
	3	KIM et al " Ser95, Asn97, and Thr78 are important for the catalytic function of porcine NADP-dependent isocitrate dehydrogenase" Protein Science (2005) 14: pp140-147	
	4	KIM et al. "Identification and Functional Characterization of a Novel, Tissue-specific NAD1-dependent Isocitrate Dehydrogenase b Subunit Isoform" JBC. 24 December 1999, Vol 274 No. 52 pages 36866-36875	
	5	Kranendijk, Martijn, "IDH2 Mutations in Patients with D-2-Hydroxyglutaric Aciduria" Sciences, Vol:330,Page(s):336, 2010.	
	6	KRELL et al., "IDH mutations in tumorigenesis and their potential role as novel therapeutic targets" Future Oncology (2013) Vol 9, Iss 12, pp 1923-1935	
	7	KUSAKABE et al. Chemical Abstracts vol. 152, No. 191956, Abstract for WO2010007756 (2010)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

	8	LIU et al. "Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure - Activity Relationship, and Selective Antitumor Activity" Journal of Medicinal Chemistry (2014) vol 57, pp 8307-8318	
	9	LOU. "IDH1: function follows form." SciBX, 2009, 1-2	
	10	Lutker et al, "Crystal Polymorphism in a Carbamazepine Derivative: Oxcarbazepine". NIH Public Access. J Pharm Sci. 2010 February ; 99(2): 794-803. doi: 10.1002/jps.21873	
	11	MAY et al, How many species are there on earth, Science (1988) volume 241, page 1441	
	12	MCROBBIE et al. "MRI from picture to proton." Cambridge Univ. Press, 2007, 307-308	
	13	PARONIKYAN et al. "Synthesis and biological activity of 3-piperazinylpyrano [3,4-C] pyridines" Armyanskii Khimicheskii Zhurnal (1990) Vol. 43, No. 8, pp 518-523	
	14	PARSONS et al. "An Integrated Genomic Analysis of Human Glioblastoma Multiforme" Science Vol 321 (2008) pp 1807-1812 and Supplemental Data	
	15	POLLARD et al, "Cancer. Puzzling patterns of predisposition." Science. 10 April 2009, Vol 324, 1-5,15-16, 18-22,35-38 No 5924, pp 192-194.	
	16	POPOVICI-MULLER, Janeta et al. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor2-HG in Vivo. ACS Medicinal Chemistry Letters. 17 Sep. 2012 (17. 09. 2012), vol. 3, no. 10, 850-855	
	17	PUBCHEM CID 4078245 [online]; September 13, 2005 [retrieved on February 4, 2012]; retrieved from http://pubchem.ncbi.nim.nih.gov/; 2d-structure	
	18	PUBCHEM CID 4854170 [online]; September 17, 2005 [retrieved on February 4, 2012]; retrieved from http://pubchem.ncbi.nim.nih.gov/; 2d-structure	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	19	Rao et al., "Polymorphism in Drugs and its Significance in Therapeutics". Journal of Scientific & Industrial Research Vol. 46 October 1987 pp 450-455.	
	20	REGISTRY (STN) [online], 2006.08.23 [Retrieved on 2016.01.29] CAS Registration No. 903862-76-0	
	21	REGISTRY (STN) [online], 2006.08.23 [Retrieved on 2016.01.29] CAS Registration No. 903869-26-1	
	22	REGISTRY (STN) [online], 2007.04.13 [Retrieved on 2016.01.29] CAS Registration No. 929819-92-1	
	23	REGISTRY (STN) [online], 2007.04.13 [Retrieved on 2016.01.29] CAS Registration No. 929971-43-7	
	24	REGISTRY (STN) [online], 2009.04.19 [Retrieved on 2016.01.29] CAS Registration No. 1136498-70-8	
	25	REGISTRY (STN) [online], 2009.08.27 [Retrieved on 2016.01.29] CAS Registration No. 1176756-98-1	
	26	REITMAN et al. "Isocitrate Sehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism" Journal of the National Cancer Institute, Vol. 102, No. 13, pp 932-941 (2010).	
	27	ROHLE et al. "An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells" Science, Vol. 340, No. 6132 pp 626-630 (2013)	
	28	SIRKANYAN, S.N. et al "Synthesis of new derivatives of piperazine-substituted pyrano[3,4-c]pyridines. Hayastani Kimiakan Handes 2009, Vol. 62, No 3-4 pp 378-385. English Abstract Only.	
	29	Sonoda, Yukihiko, " Analysis of IDH1 and IDH2 mutations in Japanese glioma patients" Cancer Science, Vol:100,Nr:10,Page(s):1996 - 1998, 2009.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

	30	SOSNOVIK et al. "Emerging concepts in molecular MRI." Curr. Op. Biotech., 2007, 18, 4-10	
	31	STN file CA, Registry Number 1023444-33-8, entered STN on May 29, 2008, Chemical Abstracts Index Name "Benzenesulfonamide, 3-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]-N-(4-butylphenyl)-4-methyl-"	
	32	STN File CA, Registry Number 1090629-29-0, entered STN on December 28, 2008, Chemical Abstracts Index Name "Benzenesulfonamide, 3-[[4-[(2,5-dimethoxyphenyl)methyl]-1-piperazinyl]carbonyl]-N-(4-methoxyphenyl)-4-methyl-"	
	33	STN File CA, Registry Number 134538-28-6, entered STN on June 28, 1991, Chemical Abstracts Index Name "1H-Pyrano[3,4-c]pyridine-5-carbonitrile,3,4-dihydro-3,3-dimethyl-6-[4-(1-oxobutyl)-1-piperazinyl]-8-phenyl-", disclosed in Paronikyan et al. Armyanskii Khimicheskii Zhurnal, 1990, Vol 43, No.8	
	34	STN File CA, Registry Number 134538-29-7, entered STN on June 28, 1991, Chemical Abstracts Index Name "1H-Pyrano[3,4-c]pyridine-5-carbonitrile,3,4-dihydro-3,3-dimethyl-6-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-8-phenyl-", disclosed in Paronikyan et al. Armyanskii Khimicheskii Zhurnal, 1990, Vol 43, No.8	
	35	STN File CA, Registry Number 134538-30-0, entered STN on June 28, 1991, Chemical Abstracts Index Name "1H-Pyrano[3,4-c]pyridine-5-carbonitrile,6-(4-benzoyl-1-piperazinyl)-3,4-dihydro-3,3-dimethyl-8-phenyl-", disclosed in Paronikyan et al. Armyanskii Khimicheskii Zhurnal, 1990, Vol 43, No.8	
	36	STN File CA, Registry Number 134538-31-1, entered STN on June 28, 1991, Chemical Abstracts Index Name "1H-Pyrano[3,4-c]pyridine-5-carbonitrile,6-[4-(2-furanylcarbonyl)-1-piperazinyl]-3,4-dihydro-3,3-dimethyl-8-phenyl-", disclosed in Paronikyan et al. Armyanskii Khimicheskii Zhurnal, 1990, Vol 43, No.8	
	37	STN file CA, Registry Number 713505-78-3, entered STN on July 21, 2004, Chemical Abstracts Index Name "1-Piperazinecarboxylic acid, 4-[4-methyl-3-[(phenylamino)sulfonyl]benzoyl]-, ethyl ester"	
	38	STN File CA, Registry Number 847757-57-7, entered STN on April 1, 2005, Chemical Abstracts Index Name "Benzenesulfonamide, 3-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]-N-(4-ethoxyphenyl)-N,4-dimethyl-" or "Piperazine, 1-(1,3-benzodioxol-5-ylmethyl)-4-[5-[[(4-ethoxyphenyl)methylamino]sulfonyl]-2-methylbenzoyl]-"	
	39	STN REGISTRY, L23 ANSWER 2 OF 3 (CAS NUMBER: 1032450-21-7), Database: ASINEX Ltd.,Entered STN: 03 Jul2008 (03. 07. 2008)	
	40	STN Tokyo, Registry Number 1001833-18-6, Entered STN on February 6, 2008, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [(4-methyl-l-piperazinyl)carbonyl]phenyl]–"	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	41	STN Tokyo, Registry Number 1030142-35-8, Entered STN on June 24, 2008, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-[(5-methyl-3-isoxazolyl)methyl]-l-piperazinyl]carbonyl]phenyl]-"	
	42	STN Tokyo, Registry Number 1031531-78-8, Entered STN on June 29, 2008 Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, N-4[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]-2,3-dihydro-"	
	43	STN Tokyo, Registry Number 1057928-35-4, Entered STN on October 7, 2008, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-pyridinyl)-l-piperazinyl]carbonyl]phenyl]-"	
	44	STN Tokyo, Registry Number 1240875-006, entered STN on September 14, 2010, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4-[[4-(2-thiazolyl)-1-piperazinyl]carbonyl]phenyl]-"	
	45	STN Tokyo, Registry Number 748791-86-8, Entered STN on September 21, 2004, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, N-[4- [[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]phenyl]-2,3-dihydro-"	
	46	STN Tokyo, Registry Number 878469-24-0, Entered STN on March 29, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]phenyl]-"	
	47	STN Tokyo, Registry Number 878474-39-6, Entered STN on March 29, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4[(4-phenyl-1-piperazinyl)carbonyl]phenyl]-"	
	48	STN Tokyo, Registry Number 878590-33-1, Entered STN on March 30, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4-{[4-(tetrahydro-2-furanyl)methyl]-1-piperazinyl]carbonyl]phenyl]-"	
	49	STN Tokyo, Registry Number 878943-66-9 Entered STN on April 2, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 3,4-dihydro-N-[[4-(2-pyrimidinyl)-1-piperazinyl)carbonyl]phenyl]-"	
	50	STN Tokyo, Registry Number 878956-06-0, Entered STN on April 2, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, N-[4- [[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]phenyl]-2,3-dihydro-"	

If you wish to add additional non-patent literature document citation information please click the Add button Add

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (**Not for submission under 37 CFR 1.99**)	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

EXAMINER SIGNATURE			
Examiner Signature	/Christopher Adam Hixson/	Date Considered	03/26/2019

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2017-10-03
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	9982309		2018-05-29	Dang et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	1	"Glossary of Biosimilar Terms," http://www.pfizerbiosimilars.com/glossary, accessed on 12/30/2018	
	2	CADENA-NAVA et al. "Self-assembly of viral capsid protein and RNA molecules of different sizes: Requirement for a specific high protein/RNA mass ratio," Journal of Virology, 2012, 86(6):3318-3326	
	3	MAKOWSKI et al. "Genome-wide characterisation of the binding repertoire of small molecule drugs," Human Genomics, 2003, 1(1):41-51	
	4	MILO et al. "Cell Biology by the Numbers," draft, July 2015	
	5	REITMAN et al. "IDH1 and IDH2: Not your typical oncogenes," Cancer Cell, 2010, 17(3):215-216	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/Christopher Adam Hixson/	Date Considered	03/26/2019

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2019-01-09
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	9982309		2018-05-29	Dang et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	1	"Glossary of Biosimilar Terms," http://www.pfizerbiosimilars.com/glossary, accessed on 12/30/2018	
	2	CADENA-NAVA et al. "Self-assembly of viral capsid protein and RNA molecules of different sizes: Requirement for a specific high protein/RNA mass ratio," Journal of Virology, 2012, 86(6):3318-3326	
	3	MAKOWSKI et al. "Genome-wide characterisation of the binding repertoire of small molecule drugs," Human Genomics, 2003, 1(1):41-51	
	4	MILO et al. "Cell Biology by the Numbers," draft, July 2015	
	5	REITMAN et al. "IDH1 and IDH2: Not your typical oncogenes," Cancer Cell, 2010, 17(3):215-216	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2019-01-09
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Docket No.: AGS-013USC2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Lenny Dang et al.

Application No.: 15/589,615 | Confirmation No.: 7017

Filed: May 8, 2017 | Art Unit: 1797

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Examiner: C. Hixson

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, the attention of the United States Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of the above-identified application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the filing date of this application, OR more than three months after the date of entry of the national stage in the international application, AND after the mailing date of a first Office Action on the merits, but before the mailing date of any of a Final Action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311 or an action that otherwise closes prosecution in this application (37 C.F.R. § 1.97(c)).

In accordance with 37 C.F.R. § 1.98(a)(2)(ii), a copy of the U.S. patent is not submitted. Submitted herewith are copies of f non-patent literature in accordance with 37 C.F.R. § 1.98(a)(2).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in this Information Disclosure Statement is, or is considered to be, material to the patentability as defined in 37 C.F.R. § 1.56(b).

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98, and the Examiner is respectfully requested to consider the listed references.

Please charge our Credit Card in the amount of $240.00 covering the fee set forth in 37 C.F.R. § 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 07-1700, under Order No. AGS-013USC2.

Dated: January 9, 2019

Respectfully submitted,

Electronic signature: /Ioana Davies/
Ioana Davies
Registration No.: 75,817
Catherine M. McCarty
Registration No.: 54,301
GOODWIN PROCTER LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Agent/Attorney for Applicant

Electronic Patent Application Fee Transmittal

Application Number:	15589615
Filing Date:	08-May-2017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Filer:	Ioana Davies/Jeannie Le
Attorney Docket Number:	AGS-013USC2

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
SUBMISSION- INFORMATION DISCLOSURE STMT	1806	1	240	240
		Total in USD ($)		**240**

Electronic Acknowledgement Receipt	
EFS ID:	34800269
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies
Filer Authorized By:	
Attorney Docket Number:	AGS-013USC2
Receipt Date:	09-JAN-2019
Filing Date:	08-MAY-2017
Time Stamp:	11:29:40
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$240
RAM confirmation Number	010919INTEFSW11301501
Deposit Account	
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Amendment_in_Response_to_Non-Final_Office_Action_Under_37 CFR1.pdf	44592 0c7b0411774e13f891f5515d21c154d2741313f6	yes	6
	Multipart Description/PDF files in .zip description				
	Document Description		**Start**	**End**	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Claims		2	3	
	Applicant Arguments/Remarks Made in an Amendment		4	6	
Warnings:					
Information:					
2	Non Patent Literature	AGS-013USC2_-_NPL_-_Pfizer_Biosimilar_Glossary.pdf	410527 3c89b0879c2a435db0abe45e5d4f582b8099334c	no	5
Warnings:					
Information:					
3	Non Patent Literature	AGS-013USC2_-_NPL_-_CADENA-NAVA_Self-assembly_of_viral_capsid_protein_and_RNA_molecules_of.pdf	1673284 b50468448a1d57cfbc74988a2162fc3fd07e5126	no	9
Warnings:					
Information:					
4	Non Patent Literature	AGS-013USC2_-_NPL_-_MAKOWSKI_Genome-wide_characterisation_of_the_binding_repertoire_of_sma.pdf	668874 6eca2473d793e3af420c87672080a1bdb8051f10	no	11
Warnings:					
Information:					
5	Non Patent Literature	AGS-013USC2_-_NPL_-_MILO_Cell_Biology_by_the_Numbers.pdf	131643 21d2414ba8c360f6d1dda98dcf074f56dcfdec45	no	4

Warnings:					
Information:					
6	Non Patent Literature	NPL_-_REITMAN_IDH1_and_IDH2_Not_your_typical_oncogenes.pdf	246908 3690038d67455130821b1e22d02ad4de2d86284b	no	5
Warnings:					
Information:					
7	Information Disclosure Statement (IDS) Form (SB08)	AGS-013USC2_-_Information_Disclosure_Statement_Fillable_PDF.pdf	1034525 7754d6cfab665323280af53eb12dc4690d8a264f	no	4
Warnings:					
Information:					
8	Transmittal Letter	Information_Disclosure_Statement.pdf	21790 67b7056012e15cbae6011526f9da834511ece963	no	2
Warnings:					
Information:					
9	Fee Worksheet (SB06)	fee-info.pdf	30245 1cf3b5bad59875d0ca490c96b979334bb82dec8e	no	2
Warnings:					
Information:					
			Total Files Size (in bytes):	4262388	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Docket No.: AGS-013USC2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Lenny Dang et al.

Application No.: 15/589,615 | Confirmation No.: 7017

Filed: May 8, 2017 | Art Unit: 1797

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Examiner: C. Hixson

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION UNDER 37 C.F.R. § 1.111

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated October 17, 2018, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method of treating a subject having a cancer characterized by the presence of a mutant isocitrate dehydrogenase 1 enzyme (IDH1) or a mutant isocitrate dehydrogenase 2 enzyme (IDH2), wherein the mutant IDH1 or mutant IDH2 has the ability to convert alpha-ketoglutarate to 2-hydroxyglutarate (2HG), the method comprising administering to the subject a therapeutically effective amount of [[an]] a small molecule inhibitor of said mutant IDH1 or mutant IDH2.

2. (Original) The method of claim 1, wherein the inhibitor binds to IDH1R132X or IDH2R172X and inhibits the ability to convert alpha-ketoglutarate to 2-HG.

3. (Original) The method of claim 1, wherein the cancer is characterized by an IDH1 mutation.

4. (Original) The method of claim 3, wherein the IDH1 mutation is an IDH1R132X mutation.

5. (Original) The method of claim 3, wherein the IDH1 mutation is selected from R132H, R132C, R132S, R132G, R132L, and R132V.

6. (Original) The method of claim 1, wherein the cancer is characterized by an IDH2 mutation.

7. (Original) The method of claim 6, wherein the IDH2 mutation is an IDH1R172X mutation.

8. (Original) The method of claim 6, wherein the IDH2 mutation is selected from R172K, R172M, R172S, R172G, and R172W.

9. (Original) The method of claim 1, wherein the mutant IDH1 or mutant IDH2 is detected in a sample obtained from the subject.

10. (Original) The method of claim 9, wherein the sample comprises tissue or bodily fluid.

11. (Original) The method of claim 1, wherein the mutant IDH1 or mutant IDH2 is detected by sequencing a nucleic acid from an affected cell that encodes the relevant amino acid(s) from the mutant IDH1 or mutant IDH2.

12. (Original) The method of claim 11, wherein the sequencing is performed by polymerase chain reaction (PCR).

13. (Cancelled)

14. (Original) The method of claim 1, wherein the cancer is selected from an astrocytic tumor, an oligodendroglial tumor, an oligoastrocytic tumor, an anaplastic astrocytoma, fibrosarcoma, paraganglioma, prostate cancer, acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia (AML).

15. (Original) The method of claim 1, wherein the cancer is a glioblastoma.

16. (Original) The method of claim 1, wherein the cancer is a glioma.

17. (Original) The method of claim 14, wherein the cancer is AML.

18. (Original) The method of claim 14, wherein the ALL is B-cell ALL or T-cell ALL.

REMARKS

In response to the Office Action dated October 17, 2018, Applicant respectfully requests reconsideration in view of the amendments and the following remarks. Claims 1-18 were previously pending in this application. By this amendment, Applicant is canceling claim 13 without prejudice or disclaimer. No new claims are added. Claim 1 is amended. As a result claims 1-12 and 14-18 are pending for examination with claim 1 being an independent claim. No new matter has been added.

Rejections under 35 U.S.C. § 103

Claims 1-16 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Zernicka-Goetz (US 2003/0027783) in view of Yan et al. (The New England Journal of Medicine 2009), and with respect to certain claims evidenced by Dykxhoorn et al. (Gene Therapy 2006).

Current claim 1 is directed to a method of treating cancer characterized by neoactive IDH1 or 1DH2 mutations, comprising administering to a subject a therapeutically effective amount of a small molecule inhibitor of mutant IDH1 or IDH2. Zernika-Goetz discloses a method of treating cancers, comprising administering double stranded RNA (dsRNA) to inhibit the expression of a mutated gene associated with cancer. Yan teaches that in certain cancers, the subject's cancer cells are characterized by the presence of a mutant IDH1 or a mutant IDH2 enzyme, wherein the mutant IDH1 or mutant IDH2 has the ability to convert alpha-ketoglutarate to 2-hydroxyglutarate (2HG). The Examiner asserts that Dykxhoorn discloses "siRNAs [short interfering RNAs]" as "small molecule drugs".

One of skill in the art reading Zernika-Goetz in combination with Yan and in further view of Dykxhoorn would not arrive at the claimed method, at least for the reason that cited art of record does not include every element of the claimed invention. The specification as filed discloses that a small molecule has a molecular weight below 1000 daltons. This definition is widely recognized and accepted in the art (see for example Pfizer Biosimilars glossary, 2017, 4; and Makowski, Hum. Genomics, 2003, 1, 41). In contrast, Zernika-Goetz teaches that the duplex region of the RNA may be at least 25 bases long. The average molecular weight of a RNA nucleotide is ~330 daltons (Cadena-Nava, J. Virol., 2011, 3321; and Phillips, Cell Biology by the Numbers, 2015, 76). Thus, dsRNA is much larger than a small molecule (with a molecular

weight of >8000 daltons), and one of skill in the art would readily recognize that dsRNA is not a small molecule as defined by the instant specification. Therefore, the cited art of record fails to teach or suggest that a small molecule can be used to treat cancers characterized by IDH1 or IDH2 mutations.

Additionally, the cited art and the pending claims are directed to completely different targets. Zernika-Goetz discloses a method of inhibiting gene expression. In contrast, the claimed method is directed to the inhibition of mutant IDH1 (isocitrate dehydrogenase 1), or IDH2 (isocitrate dehydrogenase 2), which are enzymes. One of skill in the art would not expect that the method of inhibiting gene expression taught by Zernika-Goetz would have any similarity with a method of inhibiting the activity of an enzyme such as IDH1 or IDH2. Applicants respectfully requests that the rejection of claim 1 and claims 2-16, which depend upon claim 1 be withdrawn.

Claims 17 and 18 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Zernicka-Goetz (US 2003/0027783) in view of Yan et al. (The New England Journal of Medicine 2009) as applied to claim 1 above, and further in view of Kang et al. (International Journal of Cancer 2009). Zernika-Goetz and Yan teach as described above. Kang is cited for disclosing IDH1 mutations in B-acute lymphoblastic leukemias (B-ALL).

Kang discloses that no IDH1 mutations were detected in the acute myelogenous leukemia (AML) and T-acute lymphoblastic leukemia (T-ALL) samples from Kang's patient population (page 354, table 1). Thus, Kang teaches away from a method of treating AML and T-ALL containing IDH1 or IDH2 mutations. Furthermore, Kang does not cure the deficiencies of Zernika-Goetz and Yan of providing a small molecule inhibitor of mutant IDH1 or IDH2 to treat cancers such as B-ALL, T-ALL, and AML characterized by the presence of the aforementioned mutations. Applicants respectfully requests that the rejection of claims 17 and 18, which depend upon claim 1 be withdrawn.

CONCLUSION

In view of the foregoing amendments and remarks, reconsideration is respectfully requested. This application should now be in condition for allowance; a notice to this effect is respectfully requested. If the Examiner believes, after this amendment, that the application is

not in condition for allowance, the Examiner is requested to call the Applicant's agent at the telephone number listed below.

The Director is hereby authorized to charge any additional fees which may be required with respect to this communication, or credit any overpayment, to Deposit Account No. 07-1700, under Order No. AGS-013USC2.

Dated: January 9, 2019

Respectfully submitted,

Electronic signature: /Ioana Davies/
Ioana Davies
Registration No.: 75,817
Catherine M. McCarty
Registration No.: 54,301
GOODWIN PROCTER LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Agent/Attorney for Applicant

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 15/589,615	Filing Date 05/08/2017	☐ To be Mailed

ENTITY: ☒ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT	01/09/2019	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 17	Minus	** 20	= 0	X $100 =	0
	Independent (37 CFR 1.16(h))	* 1	Minus	***3	= 0	X $460 =	0
	☐ Application Size Fee (37 CFR 1.16(s))						
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
						TOTAL ADD'L FEE	**0**

AMENDMENT		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
	☐ Application Size Fee (37 CFR 1.16(s))						
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
						TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
VERONICA DAY EVERETT

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/589,615	05/08/2017	Lenny Dang	AGS-013USC2	7017

148106 7590 10/17/2018

GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

EXAMINER
HIXSON, CHRISTOPHER

ART UNIT	PAPER NUMBER
1797	

NOTIFICATION DATE	DELIVERY MODE
10/17/2018	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATENTBOS@GOODWINLAW.COM
glenn.williams@goodwinlaw.com
pair_agios@firsttofile.com

Office Action Summary	**Application No.** 15/589,615	**Applicant(s)** Dang et al.	
	Examiner CHRISTOPHER A HIXSON	**Art Unit** 1797	**AIA Status** No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL.** 2b)☑ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☑ Claim(s) 1-18 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☑ Claim(s) 1-18 is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☑ Notice of References Cited (PTO-892)

2) ☑ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

The present application is being examined under the pre-AIA first to invent provisions.

Status of Application

Under examination are the claims amended on 20 July 2017. Claim(s) 1-18 is/are pending and considered on the merits below.

Claim Rejections - 35 USC § 103

In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.

2. Ascertaining the differences between the prior art and the claims at issue.

3. Resolving the level of ordinary skill in the pertinent art.

4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under pre-AIA 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of pre-AIA 35 U.S.C. 103(c) and potential pre-AIA 35 U.S.C. 102(e), (f) or (g) prior art under pre-AIA 35 U.S.C. 103(a).

Claim(s) 1-16 is/are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Zernicka-Goetz (US 2003/0027783) in view of Yan et al. (The New England Journal of Medicine 2009), and with respect to certain claims evidenced by Dykxhoorn et al. (Gene Therapy 2006).

Regarding claims 1, 3, and 6, Zernicka-Goetz describes treating a subject having cancer, characterized by the expression of a particular gene ([0030], [0032], [0034]), by administering to the subject a therapeutically effective amount of an inhibitor of the gene (abstract, [0034]).

However, Zernicka does not particularly describe that the mutated gene is one of those subject to the present claim.

Yan teaches that in certain cancers, the subject's cancer cells are characterized by the presence of a mutant isocitrate dehydrogenase 1 enzyme (IDH1) or a mutant isocitrate dehydrogenase 2 enzyme (IDH2), wherein the mutant IDH1 or mutant IDH2 has the ability to convert alpha-ketoglutarate to 2-hydroxyglutarate (2HG) (abstract, Table 1, where enzymatic activity is implicitly present because the mutation is the same).

It would have been obvious to one of ordinary skill in the art at the time of invention to have treated the patients described by Yan with an appropriate dsDNA treatment advocated by Zernicka in order to provide an effective treatment for the illness which targets only the mutant enzymes leaving other cells without the mutation unaffected.

Regarding claims 2, 4, and 5, Zernicka-Goetz teaches that in use, the dsRNA treatment's effects can be observed by noting a decrease in the level of the protein targeted, or by a decrease in a phenotype associated with expression of the gene (where conversion of alpha-ketoglutarate to 2-hydroxyglutarate (2HG) is one such phenotype).

Yan describes that common mutations include IDH1R132X mutations including, for example, R132C (p.668, col. 2, final two paragraphs).

It would have been obvious to one of ordinary skill in the art at the time of invention to have targeted the specific mutation the patient possessed, such as the R132C mutation, by treating him with the dsRNA treatment described by Zernicka-Goetz tailored to that particular mutation, which would have allowed the inhibitor to bind

to the recited gene and which would have inhibited the cell's ability to convert alpha-ketoglutarate to 2-HG, in order to provide an effective treatment.

Regarding claims 7 and 8, Zernicka-Goetz teaches that in use, the dsRNA treatment's effects can be observed by noting a decrease in the level of the protein targeted, or by a decrease in a phenotype associated with expression of the gene (where conversion of alpha-ketoglutarate to 2-hydroxyglutarate (2HG) is one such phenotype).

Yan describes that common mutations include IDH1R172X mutations including, for example, R172G (p.669, col. 1, final two paragraphs).

It would have been obvious to one of ordinary skill in the art at the time of invention to have targeted the specific mutation the patient possessed, such as the R172G mutation, by treating him with the dsRNA treatment described by Zernicka-Goetz tailored to that particular mutation, which would have allowed the inhibitor to bind to the recited gene and which would have inhibited the cell's ability to convert alpha-ketoglutarate to 2-HG, in order to provide an effective treatment.

Regarding claims 9 and 10, Yan, to confirm that a patient suffers from the mutations described above, detects the mutation using a sample of tissue obtained from the subject (p.766, col. 1, final paragraph, bridging into col. 2).

It would have been obvious to one of ordinary skill in the art at the time of invention to have performed these steps, as accurate analysis of the mutation present in the patient's cancer is critical to determining the effective treatment.

Regarding claims 11 and 12, in Yan, the mutant IDH1 or mutant IDH2 is detected by sequencing a nucleic acid from an affected cell that encodes the relevant amino

acid(s) from the mutant IDH1 or mutant IDH2, wherein the sequencing is performed by polymerase chain reaction (PCR) (p.766, col 2., second full paragraph).

It would have been obvious to one of ordinary skill in the art at the time of invention to have performed these steps, as accurate analysis of the mutation present in the patient's cancer is critical to determining the effective treatment.

Regarding claim 13, in Zernicka-Goetz, the inhibitor is a small molecule compound (as a matter of claim construction – applicant's specification provides a non-limiting example by way of explanation of the term, but does not appear to define it, saying that it is "e.g., a molecule of less than 1,000 daltons"; however, in the art, dsRNA treatments are described as "small molecule drugs – see Dykxhoorn, title, abstract).

Regarding claims 14-16, Yan describes that the mutation which is part of the combination above can be found, for example, in astrocytic tumors, and in glioblastoma and glioma cancers (Table 1).

Claim(s) 17 and 18 is/are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Zernicka-Goetz (US 2003/0027783) in view of Yan et al. (The New England Journal of Medicine 2009) as applied to claim 1 above, and further in view of Kang et al. (International Journal of Cancer 2009).

Regarding claims 17 and 18, neither of the previously applied references appears to teach that the mutation is found in AML or ALL cancers.

Kang teaches that because near the time of invention the mutation was newly discovered as being relevant in glial cancer, there was interest in determining whether it

could be found in other cancers as well (abstract), including in acute leukemias. In his preliminary search, he did find evidence that it could be found in B-ALL cancers (Id).

It would have been obvious to one of ordinary skill in the art at the time of invention to have used the treatment for any cancer which included the mutation of the claim, including for B-cell ALL cancers, as was found by Kang, or for AML cancers, once any to be discovered to include the mutation, because matching the therapy with the specific pathology would lead to a more effective treatment.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER A. HIXSON whose telephone number is (571)270-5027. The examiner can normally be reached on M-F 10am-6pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lyle Alexander can be reached on 571-272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Christopher Adam Hixson/
Primary Examiner, Art Unit 1797

Notice of References Cited	Application/Control No. 15/589,615	Applicant(s)/Patent Under Reexamination Dang et al.	
	Examiner CHRISTOPHER A HIXSON	Art Unit 1797	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-20030027783-A1	02-2003	Zernicka-Goetz, Magdalena	A01K67/0275	514/44A
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Dykxhoorn, D. M. et al. "The silent treatment: siRNAs as small molecular drugs." Gene Therapy (2006) 13 541-552. (Year: 2006)
	V	Kang, Mi Ran et al. "Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers." International Journal of Cancer (2009) 125 353-355. (Year: 2009)
	W	Yan, Hai et al. "IDH1 and IDH2 mutations in gliomas." The New England Journal of Medicine (2009) 360 765-773. (Year: 2009)
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	Art Unit
	CHRISTOPHER A HIXSON	1797

CPC - Searched*		
Symbol	Date	Examiner
g01n2800/52,7028	10/12/2018	cah

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
search in EAST as attached, inventor name search, google.com as attached	10/12/2018	cah

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	15/589,615	Dang et al.
	Examiner	Art Unit
	CHRISTOPHER A HIXSON	1797

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	10/13/2018								
	1	✓								
	2	✓								
	3	✓								
	4	✓								
	5	✓								
	6	✓								
	7	✓								
	8	✓								
	9	✓								
	10	✓								
	11	✓								
	12	✓								
	13	✓								
	14	✓								
	15	✓								
	16	✓								
	17	✓								
	18	✓								

Google idh1 idh2 mutation

Sign in

All Images News Videos Shopping More Settings Tools

About 118,000 results (0.38 seconds)

Scholarly articles for **idh1 idh2 mutation**

... 1p19q codeleted gliomas are **mutated** on **IDH1** or **IDH2** - Labussiere - Cited by 210
IDH1 and **IDH2 mutation** studies in 1473 patients with ... - Tefferi - Cited by 274
... of leukemia-associated **IDH1** and **IDH2 mutations** is a ... - Ward - Cited by 1256

IDH1 and IDH2 mutations in tumorigenesis: mechanistic ... - NCBI - NIH

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897211/

by H Yang - 2012 - Cited by 154 - Related articles

Genes encoding for isocitrate dehydrogenases 1 and 2, IDH1 and IDH2, are frequently mutated in multiple types of human cancer. Mutations targeting IDH1 and ...

Abstract · Introduction · IDH1 and IDH2 genes are ... · Mutant IDH1 and IDH2 lose ...

IDH1 and IDH2 Mutations in Gliomas - NCBI - NIH

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109985/

by A Cohen - 2013 - Cited by 206 - Related articles

The mutations also drive increased methylation in gliomas. Gliomas with mutated IDH1 and IDH2 have improved prognosis compared to gliomas with wild-type ...

Abstract · Introduction · IDH Mutations and the ... · IDH mutation distribution ...

IDH1 and IDH2 mutations as novel therapeutic targets: current ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015873/

by J Mondesir - 2016 - Cited by 48 - Related articles

Sep 2, 2016 - Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. IDH1/2 mutations

IDH mutants produce D ... · Spectrum of cancer types ... · D-2HG as a predictive ...

IDH1 and IDH2 Mutations in Gliomas | NEJM

https://www.nejm.org/doi/full/10.1056/NEJMoa0808710

by H Yan - 2009 - Cited by 3357 - Related articles

Feb 19, 2009 - The enzymatic activity of the proteins that were produced from normal and mutant IDH1 and IDH2 genes was determined in cultured glioma ...

People also search for

idh mutation glioma prognosis	what does idh1 positive mean
idh1 overexpression	idh1 wild type prognosis
nct02454634	idh1 r132h

Prognostic Significance of IDH1 and IDH2 mutations in Older Patients ...

www.bloodjournal.org/content/128/22/5058

by J Wang - 2016

Jinghan Wang, Zhixin Ma, Qinrong Wang, Mengxia Yu, Xufeng Yin, Xia Li, Shanshan Suo, Dan Shen, Yungui Wang, Xin Huang, Hanzhang Pan, Huanping ...

Epigenetic Effects of IDH1/IDH2 Mutations | Blood Journal

www.bloodjournal.org/content/118/21/SCI-33

by AM Melnick - 2011

Heterozygous somatic mutations in the loci encoding isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in ~20% of AMLs and are accompanied by global DNA ...

The prognostic significance of IDH2 mutations in AML depends on the ...

www.bloodjournal.org/content/118/2/409

by CL Green - 2011 - Cited by 173 - Related articles

Recurrent mutations in the genes coding for isocitrate dehydrogenase isoforms 1 and 2 (IDH1 and IDH2) have recently been described in acute myeloid ...

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and ...

clincancerres.aacrjournals.org/content/18/20/5562

by H Yang - 2012 - Cited by 154 - Related articles

Oct 15, 2012 - Abnormal histone and DNA methylation are emerging as a common feature of tumors with IDH1 and IDH2 mutations and may cause altered ...

481484: IDH1/IDH2 Mutation Analysis | LabCorp
https://www.labcorp.com/test-menu/39706/idh1-idh2-i-mutation-analysis ▾
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes in human cancer. They encode cytosolic and mitochondrial ...

People also ask

What is idh1 mutation? ⌄
What is IDH wild type? ⌄
What is IDH? ⌄
Is glioblastoma a cancer? ⌄

Feedback

Searches related to idh1 idh2 mutation

idh1 mutation **treatment**
idh1 mutation **cholangiocarcinoma**
difference between idh1 **and** idh2
idh1 **wild type prognosis**
idh1 mutation **aml**
idh1 **and** idh2 **mutations in aml**
idh1 **and** idh2 **mutations in gliomas**
idh1 **cancer**

Did you mean:

Inhibiting DNA methylation causes an interferon response in **cancer** via **dsRNA** including endogenous retroviruses

KB Chiappinelli, PL Strissel, A Desrichard, H Li... - Cell, 2015 - Elsevier

... if Aza can indeed prime patients for sensitization to checkpoint **inhibition** (Brahmer, 2015 ... Aza-triggered immune response is induction of a cytosolic **double-stranded RNA** (**dsRNA**) sensing pathway ... DNA methyltransferases, but Aza also incorporates into RNA, **inhibiting** the RNA ...

☆ 99 Cited by 377 Related articles All 17 versions

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

DD Sarbassov, DA Guertin, SM Ali, DM Sabatini - Science, 2005 - science.sciencemag.org

... (B) **dsRNAs** corresponding to ... genes for the indicated proteins were transfected into Kc 167 Drosophila cells with (+) or without (–) a **dsRNA** for dPTEN ... 3C), and LY294002 acted at concentrations that **inhibit** S473 phosphorylation in cells (3). Staurosporine, an **inhibitor** of Akt ...

☆ 99 Cited by 5720 Related articles All 17 versions »

Inhibiting gene expression with **dsRNA**

M Zernicka-Goetz, F Wianny, M Evans... - US Patent App. 10 ..., 2003 - Google Patents

... 5: **Inhibition** of gene expression following injection of **double stranded RNA** is restricted to the clonal ... examples of the genes which the present invention may used to **inhibit**: developmental genes ... components are the **dsRNA** and a vehicle that promotes introduction of the **dsRNA** ...

☆ 99 Cited by 142 Related articles All 2 versions »

Utilizing RNA interference to enhance **cancer drug** discovery

E Ioms, CJ Lord, N Turner, A Ashworth - Nature reviews Drug discovery, 2007 - nature.com

... viruses and rogue genetic elements such as transposons that utilize **double-stranded RNA** (**dsRNA**) for self ... In mammalian cells, the experimental introduction of long **dsRNAs** induces an interferon ... the global shutdown of protein synthesis, which abrogates RNAi by long **dsRNA** ...

☆ 99 Cited by 281 Related articles All 12 versions

Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by **inhibition** of translation initiation

SS Palakurthi, H Aktas, LM Grubissich, RM Mortensen... - Cancer Research, 2001 - AACR

Skip to main content. AACR Publications: **Cancer** Discovery; **Cancer** Epidemiology, Biomarkers & Prevention; **Cancer** Immunology Research; **Cancer** Prevention Research; **Cancer** Research; Clinical **Cancer** Research; Molecular **Cancer** Research; Molecular **Cancer** Therapeutics ...

☆ 99 Cited by 368 Related articles All 6 versions

MicroRNA dysregulation in **cancer**: diagnostics, monitoring and therapeutics. A comprehensive review

MV Iorio, CM Croce - EMBO molecular **medicine**, 2012 - embomolmed.embopress.org

☆ 99 Cited by 1087 Related articles All 21 versions »

Survivin: a new target for anti-**cancer** therapy

BM Ryan, N O'Donovan, MJ Duffy - Cancer treatment reviews, 2009 - Elsevier

... animal model systems, downregulation of survivin or inactivation of its function has been shown to **inhibit** tumor growth ... of proteins, of which eight members are known to exit, ie, XIAP (X-linked **inhibitor** of apoptosis), NAIP (NLR family, apoptosis **inhibitory** protein), c ...

☆ 99 Cited by 454 Related articles All 7 versions

Rho GDP dissociation **inhibitor** protects **cancer** cells against **drug**-induced apoptosis

B Zhang, Y Zhang, MC Dagher, E Shacter - Cancer Research, 2005 - AACR

Skip to main content. AACR Publications: **Cancer** Discovery; **Cancer** Epidemiology, Biomarkers & Prevention; **Cancer** Immunology Research; **Cancer** Prevention Research; **Cancer** Research; Clinical **Cancer** Research; Molecular **Cancer** Research; Molecular **Cancer** Therapeutics ...

☆ 99 Cited by 134 Related articles All 9 versions

Translational control in **cancer**

D Silvera, SC Formenti, RJ Schneider - Nature Reviews Cancer, 2010 - nature.com

... Treatment of these tumours with the indirect allosteric mTOR **inhibitor** rapamycin reduces tumour ... Malignant transformation by a mutant of the IFN-inducible **dsRNA**-dependent protein ... with targeted disruption of the catalytic domain of the **double-stranded RNA**-dependent protein ...

☆ 99 Cited by 619 Related articles All 10 versions

Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an **anticancer drug**

G Shim, SE Han, YH Yu, S Lee, HY Lee, K Kim... - Journal of controlled ..., 2011 - Elsevier

... administration of siMcl1 and SAHA using pSTLOL could significantly **inhibit** the growth ... Fluorescent **double-stranded RNA** (**dsRNA**) was used to evaluate liposome delivery efficiency, employing both ... KB cells were treated with fluorescent **dsRNA** complexed with L2K (B), TLCL (C ...

☆ 99 Cited by 81 Related articles All 12 versions

Did you mean to search for:

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	8143	g01n2800/52,7028.cpc.	US-PGPUB; USPAT; USOCR	OR	OFF	2018/10/12 13:48
L3	5386	idh1 or idh2 or (isocitrate with dehydrogenase)	US-PGPUB; USPAT; USOCR	OR	ON	2018/10/12 13:48
L4	158	2 and 3	US-PGPUB; USPAT; USOCR	OR	ON	2018/10/12 13:48
L5	1145	3 and ((acute with leukemia) or AML or ALL)	US-PGPUB; USPAT; USOCR	OR	ON	2018/10/12 14:01
L6	5823862	@py>="2010"	US-PGPUB; USPAT; USOCR	OR	ON	2018/10/12 14:01
L7	179	5 not 6	US-PGPUB; USPAT; USOCR	OR	ON	2018/10/12 14:01
L8	1870	((("DANG") near3 ("Lenny")) OR (("FANTIN") near3 ("Valeria")) OR (("GROSS") near3 ("Stefan")) OR (("JANG") near3 ("Hyun")) OR (("JIN") near3 ("Shengfang")) OR (("SALITURO") near3 ("Francesco")) OR (("SAUNDERS") near3 ("Jeffrey")) OR (("SU") near3 ("Shin-San")) OR (("YEN") near3 ("Katharine"))).INV.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2018/10/12 14:22
L9	41	5 and 8	US-PGPUB; USPAT; USOCR	OR	ON	2018/10/12 14:22
L10	601	((("DANG") near3 ("Lenny")) OR (("FANTIN") near3 ("Valeria")) OR (("GROSS") near3 ("Stefan")) OR (("JANG") near3 ("Hyun")) OR (("JIN") near3 ("Shengfang")) OR (("SALITURO") near3 ("Francesco")) OR (("SAUNDERS") near3 ("Jeffrey")) OR (("SU") near3 ("Shin-San")) OR (("YEN") near3 ("Katharine"))).INV.	USPAT	OR	OFF	2018/10/12 14:23
L11	17	5 and 10	USPAT	OR	OFF	2018/10/12 14:23
S1	1	"15589615".apnr.	US-	OR	OFF	2018/10/11

			PGPUB; USPAT; USOCR			14:59
S2	1	("20030027783").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2018/10/11 15:11

EAST Search History (Interference)

< This search history is empty>

10/ 12/ 2018 2:25:14 PM
C:\ Users\ chixson\ Documents\ EAST\ Workspaces\ 15589615.wsp

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	2390529		1945-12-11	Friedheim	
	2	4084053		1978-04-11	Desai et al.	
	3	5489591		1996-02-06	Kobayashi et al.	
	4	6274620		2001-08-14	Labrecque et al.	
	5	7858782		2010-12-28	Tao et al.	
	6	8465673		2013-06-18	Yasuda et al.	
	7	8883438		2014-11-11	Cantley et al.	
	8	9434979		2016-09-06	Su et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

EFS Web 2.1.17

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030213405	A1	2003-11-20	Harada et al.	
	2	20060084645	A1	2006-04-20	Pal et al.	
	3	20070244088	A1	2007-10-18	Brickmann et al.	
	4	20090163545	A1	2009-06-25	Goldfarb	
	5	20100144722	A1	2010-06-10	Alexander et al.	
	6	20110073007	A1	2011-03-31	Yasuda et al.	
	7	20110288065	A1	2011-11-24	Fujihara et al.	
	8	20130183281	A1	2013-07-18	Su et al.	
	9	20130197106	A1	2013-08-01	Fantin et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	10	20130288284	A1	2013-10-31	Dang et al.	
	11	20150240286	A1	2015-08-27	Dang et al.	
	12	20170044620	A1	2017-02-16	Dang et al.	
	13	20170157132	A1	2017-06-08	Wu et al.	
	14	20170174658	A1	2017-06-22	LIN et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	101575408	CN	A	2009-11-11	Mca Technologies Gmbh		☒
	2	102659765	CN	A	2012-09-12	Univ Shenyang Pharmaceutical		☒
	3	103097340	CN	A	2013-05-08	Agios Pharmaceuticals Inc		☒
	4	3314663	DE	A1	1983-10-27	Nippon Kayaku Kk		☒

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

	5	3512630	DE	A1	1986-10-23	Hoechst Ag		☒
	6	0945446	EP	A1	1999-09-29	Nissan Chemical Industries, Limited		☐
	7	2004107220	JP	A	2004-04-08	Mitsubishi Pharma Corp		☒
	8	2009237115	JP	A	2009-10-15	Fuji Xerox Co Ltd		☒
	9	2010079130	JP	A	2010-04-08	Fuji Xerox Co Ltd		☒
	10	2010181540	JP	A	2010-08-19	Fuji Xerox Co Ltd		☒
	11	4753336	JP	B2	2011-08-24			☒
	12	030016289	WO	A1	2003-02-27	Ciba Sc Holding Ag		☐
	13	2002102313	WO	A2	2002-12-27	Squibb Bristol Myers Co		☐
	14	2004009562	WO	A1	2004-01-29	Janssen Pharmaceutica, Nv		☐
	15	2004046120	WO	A2	2004-06-03	Vertex Pharma		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

	16	2005035507	WO	A2	2005-04-21	Bayer Pharmaceuticals Corp		☐
	17	2005065691	WO	A1	2005-07-21	Scios, Inc		☐
	18	2006079791	WO	A1	2006-08-03	Astrazeneca Ab		☐
	19	2008070661	WO	A1	2008-06-12	Neurocrine Biosciences, Inc		☐
	20	2008076883	WO	A2	2008-06-26	Abraxis Bioscience, Inc		☐
	21	2008154026	WO	A1	2008-12-18	Miikana Therapeutics, Inc		☐
	22	2009118567	WO	A2	2009-10-01	Univ Nottingham		☐
	23	2011050210	WO	A1	2011-04-28	Agios Pharmaceuticals, Inc		☐
	24	2012074999	WO	A1	2012-06-07	Galleon Pharmaceuticals, Inc		☐
	25	2012171506	WO	A1	2012-12-20	Agios Pharmaceuticals, Inc		☐
	26	2013102431	WO	A1	2013-07-11	Agios Pharmaceuticals, Inc		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	27	2013107291	WO	A1	2013-07-25	Agios Pharmaceuticals, Inc		☐
	28	2013107405	WO	A1	2013-07-25	Agios Pharmaceuticals, Inc		☐
	29	2013133367	WO	A1	2013-09-12	Carna Biosciences, Inc		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	ANSELL et al. "The interactions of artificial coenzymes with alcohol dehydrogenase and other NAD(P)(H) dependent enzymes" Journal of Molecular Catalysis B: Enzymatic (1999) Vol 6, No 1-2, pp 111-123	
	2	BHUSHAN et al. "Reversed-phase liquid chromatographic resolution of diastereomers of protein and non-protein amino acids prepared with newly synthesized chiral derivatizing reagents based on cyanuric chloride" Amino Acids (2011) Vol 40, pp 403-409	
	3	BRAUN et al. "Triazine-based polymers: 4. MALDI-MS of triazine-based polyamines" Polymer (1996) Vol 37, No 5, pp 777-783	
	4	CHAN et al. "Multi-domain hydrogen-bond forming metal chelates: X-ray crystal structuresof dicyclopalladated 2,3-bis [6-(2-amino-4-phenylamino-1 ,3,5-triazinyl)]pyrazine(H2L) [Pd2Br2L] and 2,6-bis[6-(2-amino-4-phenylamino-1,3,5-triazinylium)] -pyridine dichloride" Chemical Communications (1996) No. 1, pp. 81-83	
	5	CHAPMAN et al. "Substituted aminopyrimidine protein kinase B (PknB) inhibitorsshow activity against Mycobacterium tuberculosis" Bioorganic & Medicinal Chemistry Letters (2012) Vol 22, pp 3349 - 3353	
	6	CHEN et al. " Cytotoxicity, Hemolysis, and Acute in Vivo Toxicity of Dendrimers Based on Melamine, Candidate Vehicles for Delivery" J. Am. Chem. Soc. (2004) Vol 126, No 32, pp 10044-10048	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	7	DANG et al. "IDH mutations in cancer and progress toward development of targeted therapeutics," Annals of Oncology, 2016, 27(4):599-608	
	8	DANG et al. "IDH Mutations in Glioma and Acute Myeloid Leukemia" Trends in Molecular Medicine (2010) Vol 16, No. 9, pp. 387-397	
	9	DANG et al. "Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: From basic discovery to therapeutics development," Annual Review of Biochemistry, 2017, 86:305-331	
	10	DOHNER et al. "Impact of Genetic Features on Treatment Decisions in AML" American Society of Hematology (2011) pp. 36-42	
	11	DUANMU et al. "Dendron-Functionalized Superparamagnetic Nanoparticles with Switchable Solubility in Organic and Aqueous Media: Matriced for Homogeneous Catalysis and Potential MRI Contrast Agents" Chem. Mater. (2006) Vol 18, No 25, pp 5973-5981	
	12	GEWALD et al. "Discovery of triazines as potent, selective and orally active PDE4 inhibitors" Bioorganic & medicinal Chemistry Letters (2013) Vol 23, pp 4308-4314	
	13	IRIKURA et al. "New s-Triazine Derivatives as Depressants for Reticuloendothelial Hyperfunction Induced by Bacterial Endotoxin" Journal of Medicinal Chemistry (2000) Vol 31, pp 1081-1089	
	14	KAILA et al. "A convenient one-pot synthesis of trisubstituted 1,3,5-triazines through intermediary amidinothioureas" Tetrahedron Letters (2010) Vol 51, pp 1486-1489	
	15	KELAREV et al. "Synthesis and properties of sym-triazines. 10 Synthesis of 2,4-diamino-sym-triazines containing a sterically hindered phenol substituent" Chemistry of Heterocyclic Compounds (1992) Vol 28, No 10, pp 1189-1193	
	16	KOSHELEV et al. " Synthesis of 1-3,7 N-substituted 2,4-diamino-1,3,5-triazines containing pyridyl groups" Russian Journal of Organic Chemistry (1995) Vol. 31, No. 2, pp 260-263	
	17	LEE et al. "Combinatorial Solid-Phase Synthesis of 6-Aryl-1,3,4-triazines via Suzuki Coupling" Aust. J. Chem. (2011) Vol 64, pp 540-544	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	18	MADSEN-DUGGAN et al. "Lead optimization of 5.6-diarylpyridines as CB1 receptor inverse agonists" Bioorganic & Medicinal Chemistry Letters (2007) Vol 17, pp 2031-2035
	19	MORENO et al. "Identification of diamine linkers with differing reactivity and their applicationin the synthesis of melamine dendrimers" Tetrahedron Letters (2008) Vol 49, pp 1152 - 1154
	20	MORENO et al. "Molecular recognition in dendrimers based on melamine" Polymer Preprints (2005) Vol 46, No 2, pp 1127
	21	RAYNAUD et al. "Absence of R140Q Mutation of Isocitrate Dehydrogenase 2 in Gliomas and Breast Cancers" Oncology Letters (2010) Vol 1, No 5, pp 883-884
	22	SCHARN et al. "Spatially Addressed Synthesis of Amino- and Amino-Oxy-Substituted 1,3,5-Triazine Arrays on Polymeric Membranes" Journal of Combinatorial Chemistry (2000) Vol 2, No 4, pp 361-369
	23	SHIH et al. "The Role of Mutations in Epigenetic Regulators in Myeloid Malignancies" Nature Reviews Cancer (2012) Vol 12, No 9, pp. 599-612
	24	STN File CA, Registry Number 380466-24-0 entered STN on January 4, 2002, Chemical Abstracts Index Name "Benzenesulfonamide, N-methyl-N-phenyl-3-[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]"
	25	STN File CA, Registry Number 736168-79-9 entered STN on August 31, 2004, Chemical Abstracts Index Name "Benzenesulfonamide, 3,4-difluoro-N-[3-334-(phenylmethyl0-1-piperazinyl]carbonyl]phenyl"
	26	STRUYS, EA. et al. "Measurement of Urinary D- and L-2-Hydroxyglutarate Enantiomers by Stable-Isotope-Dilution LiquidChromatography-Tandem Mass Spectrometry after Derivatization with Diacetyi-L-Tartaric Anhydride." Clinical Chemistry (2004)501391-1395.
	27	TAKAGI et al. "Synthesis of poly(triazinylstyrene) containing nitrogen-bawed ligand and function as metal ion adsorbent and oxidation catalyst" Reactive & Functional Polymers (2006) Vol 31, pp 1718-1724
	28	VAN SCHAFTINGEN et al. "L-2-Hydroglutaric aciduria, a disorder of metabolite repair" J Inherit. Metab. Dis. (2009) Vol 32, pp 135-142

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	29	WANG et al "Facile Synthesis of 2,4-Dianiino-6-alkyi- or 6-Aryl-PyrimidineDerivatives" Journal of Heterocyclic Chemistry (2010) Vol 47 pp 1056-1061
	30	YEN et al. "AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations," Cancer Discovery, 2017, 7(5):478-493

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/Christopher Adam Hixson/	Date Considered	10/12/2018

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2018-01-30
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CAH/

Bibliographic Data

Application No: 15/589,615

Foreign Priority claimed: ○ Yes ◉ No

35 USC 119 (a-d) conditions met: ☐ Yes ☐ No ☐ Met After Allowance

Verified and Acknowledged: /Christopher Adam Hixson/ Examiner's Signature | Initials

Title: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
05/08/2017	436	1797	AGS-013USC2
RULE			

APPLICANTS

INVENTORS

Lenny Dang Boston, MA, UNITED STATES

Valeria Fantin Burlingame, CA, UNITED STATES

Stefan Gross Brookline, MA, UNITED STATES

Hyun G. Jang Waltham, MA, UNITED STATES

Shengfang Jin Newton, MA, UNITED STATES

Francesco G. Salituro Marlborough, MA, UNITED STATES

Jeffrey O. Saunders Lincoln, MA, UNITED STATES

Shin-San Michael Su Boston, MA, UNITED STATES

Katharine Yen Wellesley, MA, UNITED STATES

CONTINUING DATA

This application is a CON of 13939519 07/11/2013

13939519 is a CON of 13256396 11/29/2011

13256396 is a 371 of PCT/US10/27253 03/12/2010

PCT/US10/27253 has PRO of 61266929 12/04/2009

PCT/US10/27253 has PRO of 61253820 10/21/2009

PCT/US10/27253 has PRO of 61229689 07/29/2009

PCT/US10/27253 has PRO of 61227649 07/22/2009

PCT/US10/27253 has PRO of 61220543 06/25/2009

PCT/US10/27253 has PRO of 61180609 05/22/2009

PCT/US10/27253 has PRO of 61173518 04/28/2009

PCT/US10/27253 has PRO of 61160664 03/16/2009

PCT/US10/27253 has PRO of 61160253 03/13/2009

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

08/08/2017

STATE OR COUNTRY

UNITED STATES

ADDRESS

GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210
UNITED STATES

FILING FEE RECEIVED

$1,600

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013USC2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	2390529		1945-12-11	Friedheim	
	2	4084053		1978-04-11	Desai et al.	
	3	5489591		1996-02-06	Kobayashi et al.	
	4	6274620		2001-08-14	Labrecque et al.	
	5	7858782		2010-12-28	Tao et al.	
	6	8465673		2013-06-18	Yasuda et al.	
	7	8883438		2014-11-11	Cantley et al.	
	8	9434979		2016-09-06	Su et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

EFS Web 2.1.17

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030213405	A1	2003-11-20	Harada et al.	
	2	20060084645	A1	2006-04-20	Pal et al.	
	3	20070244088	A1	2007-10-18	Brickmann et al.	
	4	20090163545	A1	2009-06-25	Goldfarb	
	5	20100144722	A1	2010-06-10	Alexander et al.	
	6	20110073007	A1	2011-03-31	Yasuda et al.	
	7	20110288065	A1	2011-11-24	Fujihara et al.	
	8	20130183281	A1	2013-07-18	Su et al.	
	9	20130197106	A1	2013-08-01	Fantin et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	10	20130288284	A1	2013-10-31	Dang et al.		
	11	20150240286	A1	2015-08-27	Dang et al.		
	12	20170044620	A1	2017-02-16	Dang et al.		
	13	20170157132	A1	2017-06-08	Wu et al.		
	14	20170174658	A1	2017-06-22	LIN et al.		

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	101575408	CN	A	2009-11-11	Mca Technologies Gmbh		☓
	2	102659765	CN	A	2012-09-12	Univ Shenyang Pharmaceutical		☒
	3	103097340	CN	A	2013-05-08	Agios Pharmaceuticals Inc		☒
	4	3314663	DE	A1	1983-10-27	Nippon Kayaku Kk		☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	5	3512630	DE	A1	1986-10-23	Hoechst Ag		☒
	6	0945446	EP	A1	1999-09-29	Nissan Chemical Industries, Limited		☐
	7	2004107220	JP	A	2004-04-08	Mitsubishi Pharma Corp		☒
	8	2009237115	JP	A	2009-10-15	Fuji Xerox Co Ltd		☒
	9	2010079130	JP	A	2010-04-08	Fuji Xerox Co Ltd		☒
	10	2010181540	JP	A	2010-08-19	Fuji Xerox Co Ltd		☒
	11	4753336	JP	B2	2011-08-24			☒
	12	030016289	WO	A1	2003-02-27	Ciba Sc Holding Ag		☐
	13	2002102313	WO	A2	2002-12-27	Squibb Bristol Myers Co		☐
	14	2004009562	WO	A1	2004-01-29	Janssen Pharmaceutica, Nv		☐
	15	2004046120	WO	A2	2004-06-03	Vertex Pharma		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	16	2005035507	WO	A2	2005-04-21	Bayer Pharmaceuticals Corp		☐
	17	2005065691	WO	A1	2005-07-21	Scios, Inc		☐
	18	2006079791	WO	A1	2006-08-03	Astrazeneca Ab		☐
	19	2008070661	WO	A1	2008-06-12	Neurocrine Biosciences, Inc		☐
	20	2008076883	WO	A2	2008-06-26	Abraxis Bioscience, Inc		☐
	21	2008154026	WO	A1	2008-12-18	Miikana Therapeutics, Inc		☐
	22	2009118567	WO	A2	2009-10-01	Univ Nottingham		☐
	23	2011050210	WO	A1	2011-04-28	Agios Pharmaceuticals, Inc		☐
	24	2012074999	WO	A1	2012-06-07	Galleon Pharmaceuticals, Inc		☐
	25	2012171506	WO	A1	2012-12-20	Agios Pharmaceuticals, Inc		☐
	26	2013102431	WO	A1	2013-07-11	Agios Pharmaceuticals, Inc		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	27	2013107291	WO	A1	2013-07-25	Agios Pharmaceuticals, Inc		☐
	28	2013107405	WO	A1	2013-07-25	Agios Pharmaceuticals, Inc		☐
	29	2013133367	WO	A1	2013-09-12	Carna Biosciences, Inc		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	ANSELL et al. "The interactions of artificial coenzymes with alcohol dehydrogenase and other NAD(P)(H) dependent enzymes" Journal of Molecular Catalysis B: Enzymatic (1999) Vol 6, No 1-2, pp 111-123	
	2	BHUSHAN et al. "Reversed-phase liquid chromatographic resolution of diastereomers of protein and non-protein amino acids prepared with newly synthesized chiral derivatizing reagents based on cyanuric chloride" Amino Acids (2011) Vol 40, pp 403-409	
	3	BRAUN et al. "Triazine-based polymers: 4. MALDI-MS of triazine-based polyamines" Polymer (1996) Vol 37, No 5, pp 777-783	
	4	CHAN et al. "Multi-domain hydrogen-bond forming metal chelates: X-ray crystal structuresof dicyclopalladated 2,3-bis [6-(2-amino-4-phenylamino-1 ,3,5-triazinyl)]pyrazine(H2L) [Pd2Br2L] and 2,6-bis[6-(2-amino-4-phenylamino-1,3,5-triazinylium)] -pyridine dichloride" Chemical Communications (1996) No. 1, pp. 81-83	
	5	CHAPMAN et al. "Substituted aminopyrimidine protein kinase B (PknB) inhibitorsshow activity against Mycobacterium tuberculosis" Bioorganic & Medicinal Chemistry Letters (2012) Vol 22, pp 3349 - 3353	
	6	CHEN et al. " Cytotoxicity, Hemolysis, and Acute in Vivo Toxicity of Dendrimers Based on Melamine, Candidate Vehicles for Delivery" J. Am. Chem. Soc. (2004) Vol 126, No 32, pp 10044-10048	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	7	DANG et al. "IDH mutations in cancer and progress toward development of targeted therapeutics," Annals of Oncology, 2016, 27(4):599-608
	8	DANG et al. "IDH Mutations in Glioma and Acute Myeloid Leukemia" Trends in Molecular Medicine (2010) Vol 16, No. 9, pp. 387-397
	9	DANG et al. "Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: From basic discovery to therapeutics development," Annual Review of Biochemistry, 2017, 86:305-331
	10	DOHNER et al. "Impact of Genetic Features on Treatment Decisions in AML" American Society of Hematology (2011) pp. 36-42
	11	DUANMU et al. "Dendron-Functionalized Superparamagnetic Nanoparticles with Switchable Solubility in Organic and Aqueous Media: Matriced for Homogeneous Catalysis and Potential MRI Contrast Agents" Chem. Mater. (2006) Vol 18, No 25, pp 5973-5981
	12	GEWALD et al. "Discovery of triazines as potent, selective and orally active PDE4 inhibitors" Bioorganic & medicinal Chemistry Letters (2013) Vol 23, pp 4308-4314
	13	IRIKURA et al. "New s-Triazine Derivatives as Depressants for Reticuloendothelial Hyperfunction Induced by Bacterial Endotoxin" Journal of Medicinal Chemistry (2000) Vol 31, pp 1081-1089
	14	KAILA et al. "A convenient one-pot synthesis of trisubstituted 1,3,5-triazines through intermediary amidinothioureas" Tetrahedron Letters (2010) Vol 51, pp 1486-1489
	15	KELAREV et al. "Synthesis and properties of sym-triazines. 10 Synthesis of 2,4-diamino-sym-triazines containing a sterically hindered phenol substituent" Chemistry of Heterocyclic Compounds (1992) Vol 28, No 10, pp 1189-1193
	16	KOSHELEV et al. " Synthesis of 1-3,7 N-substituted 2,4-diamino-1,3,5-triazines containing pyridyl groups" Russian Journal of Organic Chemistry (1995) Vol. 31, No. 2, pp 260-263
	17	LEE et al. "Combinatorial Solid-Phase Synthesis of 6-Aryl-1,3,4-triazines via Suzuki Coupling" Aust. J. Chem. (2011) Vol 64, pp 540-544

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	18	MADSEN-DUGGAN et al. "Lead optimization of 5.6-diarylpyridines as CB1 receptor inverse agonists" Bioorganic & Medicinal Chemistry Letters (2007) Vol 17, pp 2031-2035
	19	MORENO et al. "Identification of diamine linkers with differing reactivity and their applicationin the synthesis of melamine dendrimers" Tetrahedron Letters (2008) Vol 49, pp 1152 - 1154
	20	MORENO et al. "Molecular recognition in dendrimers based on melamine" Polymer Preprints (2005) Vol 46, No 2, pp 1127
	21	RAYNAUD et al. "Absence of R140Q Mutation of Isocitrate Dehydrogenase 2 in Gliomas and Breast Cancers" Oncology Letters (2010) Vol 1, No 5, pp 883-884
	22	SCHARN et al. "Spatially Addressed Synthesis of Amino- and Amino-Oxy-Substituted 1,3,5-Triazine Arrays on Polymeric Membranes" Journal of Combinatorial Chemistry (2000) Vol 2, No 4, pp 361-369
	23	SHIH et al. "The Role of Mutations in Epigenetic Regulators in Myeloid Malignancies" Nature Reviews Cancer (2012) Vol 12, No 9, pp. 599-612
	24	STN File CA, Registry Number 380466-24-0 entered STN on January 4, 2002, Chemical Abstracts Index Name "Benzenesulfonamide, N-methyl-N-phenyl-3-[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]"
	25	STN File CA, Registry Number 736168-79-9 entered STN on August 31, 2004, Chemical Abstracts Index Name "Benzenesulfonamide, 3,4-difluoro-N-[3-334-(phenylmethyl0-1-piperazinyl]carbonyl]phenyl"
	26	STRUYS, EA. et al. "Measurement of Urinary D- and L-2-Hydroxyglutarate Enantiomers by Stable-Isotope-Dilution LiquidChromatography-Tandem Mass Spectrometry after Derivatization with Diacetyi-L-Tartaric Anhydride." Clinical Chemistry (2004)501391-1395.
	27	TAKAGI et al. "Synthesis of poly(triazinylstyrene) containing nitrogen-bawed ligand and function as metal ion adsorbent and oxidation catalyst" Reactive & Functional Polymers (2006) Vol 31, pp 1718-1724
	28	VAN SCHAFTINGEN et al. "L-2-Hydroglutaric aciduria, a disorder of metabolite repair" J Inherit. Metab. Dis. (2009) Vol 32, pp 135-142

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

	29	WANG et al "Facile Synthesis of 2,4-Dianiino-6-alkyi- or 6-Aryl-PyrimidineDerivatives" Journal of Heterocyclic Chemistry (2010) Vol 47 pp 1056-1061
	30	YEN et al. "AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations," Cancer Discovery, 2017, 7(5):478-493

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013USC2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2018-01-30
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Docket No.: AGS-013USC2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Lenny Dang et al.

Application No.: 15/589,615 | Confirmation No.: 7017

Filed: May 8, 2017 | Art Unit: 1797

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Examiner: C. Hixson

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, the attention of the United States Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of the above-identified application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits (37 C.F.R. § 1.97(b)(3)).

In accordance with 37 C.F.R. § 1.98(a)(2)(ii), copies of U.S. patents and U.S. patent application publications are not submitted. Submitted herewith are copies of foreign patents and non-patent literature in accordance with 37 C.F.R. § 1.98(a)(2). A translation of the non-English language references is attached.

94017278

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in this Information Disclosure Statement is, or is considered to be, material to the patentability as defined in 37 C.F.R. § 1.56(b).

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98, and the Examiner is respectfully requested to consider the listed references.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 07-1700, under Order No. AGS-013USC2 from which the undersigned is authorized to draw.

Dated: January 30, 2018

Respectfully submitted,

Electronic signature: /Ioana Davies/
Ioana Davies
Registration No.: 75,817
GOODWIN PROCTER LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-3920

Electronic Acknowledgement Receipt

EFS ID:	31646429
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies/Jeannie Le
Filer Authorized By:	Ioana Davies
Attorney Docket Number:	AGS-013C2
Receipt Date:	30-JAN-2018
Filing Date:	08-MAY-2017
Time Stamp:	14:32:01
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Non Patent Literature	NPL_-_GEWALD_-_Discovery_of_triazines_as_a_potent.pdf	242255 31ca184ec68037361e27bef8c8709686d271b5db	no	7

Warnings:

Information:					
2	Non Patent Literature	NPL_-_IRIKURA_new_s-triazine_derivatives_as_depressants.pdf	1581982 094e2833d9469ff8338f9d633d4064ed3cc6d017	no	9
Warnings:					
Information:					
3	Non Patent Literature	NPL_-_KAILA_-_A_convenient_one-pot_synthesis_of_trisubstituted.pdf	156382 94a60be9636389ba88cd56db3cdd78f05e6eb0bb	no	4
Warnings:					
Information:					
4	Non Patent Literature	NPL_-_KELAREV_-_Synthesis_and_properties_of_sym-triazines.pdf	330937 8eb070f228a7d26ce497633340eebce333a920c1	no	5
Warnings:					
Information:					
5	Non Patent Literature	NPL_-_KOSHELEV_-_Synthesis_of_N-substituted.pdf	463896 c9d187ba929f4ca78d6e2345779e6e1f1f2da471	no	4
Warnings:					
Information:					
6	Non Patent Literature	NPL_-_LEE_-_Combinatorial_solid-phase_synthesis_of_6-aryl-.pdf	117809 349fbb7dd69351247ced6fed4b3ed30d1616dd54	no	5
Warnings:					
Information:					
7	Non Patent Literature	NPL_-_MADSEN-DUGGAN_lead_optimization_of_56-diarylpyridines.pdf	597315 a5998af925be6ec1ca69dd5c7d0fa1027b9bf021	no	5
Warnings:					
Information:					
8	Non Patent Literature	NPL_-_MORENO_-_Identification_of_diamine_linkers_with_differing_reactivity.pdf	181207 99537a04f3d7f5bd1611dbd1046bc867fa464f32	no	3
Warnings:					
Information:					

9	Non Patent Literature	NPL_-_MORENO_-_Molecular_recognition_in_dendrimers_based_on_melamine.pdf	106395 ff648e7451a77e7951fbfd822d1b7a24f69dc06b	no	1
Warnings:					
Information:					
10	Non Patent Literature	NPL_-_RAYNAUD_-_Absence_of_R140Q_mutation_of_isocitrate_dehydrogenase_2.pdf	378911 faa74cdd963b94ed0a48aece1bfded49298e6fa6	no	2
Warnings:					
Information:					
11	Non Patent Literature	NPL_-_SCHARN_Spatially_addressed_synthesis.pdf	574178 0593eddf15d1d2c02d9af7565fa6fd3b5c47b7f9	no	9
Warnings:					
Information:					
12	Non Patent Literature	NPL_-_SHIH_-_The_role_of_mutations_in_epigenetic_regulators_in_myeloid_malignancies.pdf	3213373 2789d5a7627514b800faf7bde421617373f8afdb	no	14
Warnings:					
Information:					
13	Non Patent Literature	NPL_-_STN_380466-24-0.pdf	113780 ad92c2e1c8ddd52c94ca927eee012d6bd6721e9c	no	1
Warnings:					
Information:					
14	Non Patent Literature	NPL_-_STN_736168-79-9.pdf	113346 9b6ba8c16bda167309a1ba8cb1e96b2dcbeee53c	no	1
Warnings:					
Information:					
15	Non Patent Literature	NPL_-_STRUYS_measurement_of_urinary.pdf	894314 20fa5181b3e11b662c9fa983dfeab6bb260d88d1	no	5
Warnings:					
Information:					

16	Non Patent Literature	NPL_-_TAKAGI_-_Synthesis_of_polytriazinylstyrene.pdf	190823 6d80ae87ca7bb7ca81362a1f6acfd8dae7d151f2	no	7
Warnings:					
Information:					
17	Non Patent Literature	NPL_-_VAN_SHAFTINGEN_-_L-2-Hydroxyglutaric_aciduria.pdf	1168596 f2713b27e0e86ed0d5dfdf29d4d8bf9b2d6222a7	no	8
Warnings:					
Information:					
18	Non Patent Literature	NPL_-_WANG_-_Facile_synthesis.pdf	1333476 2db6f5f12ec79b8880b65a6fbb562223d33e7572	no	7
Warnings:					
Information:					
19	Non Patent Literature	NPL_-_YEN_AG-221_a_first-in-class_therapy.pdf	3363426 0ff1fe58397047d115d4d7eb14434041c9c89c80	no	17
Warnings:					
Information:					
20	Information Disclosure Statement (IDS) Form (SB08)	Information_Disclosure_Statement_Fillable_PDF.pdf	1039503 6f2cb84f0dc45c68e122d78d8944d53da6cbf258	no	11
Warnings:					
Information:					
21	Transmittal Letter	Information_Disclosure_Statement.pdf	21526 1386c78752e7233171890c22021cc4eccb0ec14b	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	16183430		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt

EFS ID:	31646277
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies/Jeannie Le
Filer Authorized By:	Ioana Davies
Attorney Docket Number:	AGS-013C2
Receipt Date:	30-JAN-2018
Filing Date:	08-MAY-2017
Time Stamp:	14:26:01
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	CN101575408A.pdf	563683 50ac7b8baa7de2f8600f143432c744b43c04980f	no	15

Warnings:

Information:					
2	Foreign Reference	Translation_of_CN101575408A.pdf	329122 15b1a6d17ef9f6349f2f861ecf3fe5a7b5846094	no	8
Warnings:					
Information:					
3	Foreign Reference	CN102659765A.pdf	2665945 6eac14d10540e4a4babffa40e2eb920534757af5	no	35
Warnings:					
Information:					
4	Foreign Reference	Translation_of_CN102659765A.pdf	531459 c566b4f23bc3405e8c2c47e88b560fe4de468760	no	21
Warnings:					
Information:					
5	Foreign Reference	CN103097340A.pdf	13528080 fb1a189da4085d3a773a00f5c29b40e6090beb62	no	216
Warnings:					
Information:					
6	Foreign Reference	CN103097340A_translation.pdf	13755029 8510829889d3c5e92d7a38e9d5584052e690704b	no	306
Warnings:					
Information:					
7	Foreign Reference	DE3314663A1.pdf	1535453 03977ede25f7cbf94e60450000f01f1a99458a43	no	58
Warnings:					
Information:					
8	Foreign Reference	Translation_of_DE3314663A1.pdf	553182 7d32b4a6a024efd66c28ecae65d945446266d30d6	no	30
Warnings:					
Information:					

9	Foreign Reference	DE3512630A1.pdf	1290751 c74706740f5bef7e2732f88488b6dc1ee245d18e	no	40
Warnings:					
Information:					
10	Foreign Reference	Translation_of_DE3512630A1.pdf	499704 7dfd645269de422069acb1df0c99fa479633a307	no	21
Warnings:					
Information:					
11	Foreign Reference	EP0945446A1.pdf	1380432 28a7f11f09d1a8967fa97f84de872334bb005456	no	50
Warnings:					
Information:					
12	Foreign Reference	JP2004107220A.pdf	1103671 8771f22bd71ce6424963e7e91d79f5cbcb4d673e	no	27
Warnings:					
Information:					
13	Foreign Reference	Translation_of_JP2004107220A.pdf	401270 4b232807df3d4592abb72b71cc4cee38a86f8c64	no	14
Warnings:					
Information:					
14	Foreign Reference	JP2009237115A.pdf	2021334 982bb9059cb2b50f8734adaee8d90d4d5673cd26	no	58
Warnings:					
Information:					
15	Foreign Reference	Translation_of_JP2009237115A.pdf	949914 cc386d15b1f537b860c7c96b8e7cdd577183a05e	no	42
Warnings:					
Information:					

16	Foreign Reference	JP2010079130A.pdf	1815955 47fc8c74aef3238add32e93f7cd8783772a210f8	no	57
Warnings:					
Information:					
17	Foreign Reference	Translation_of_JP2010079130A.pdf	831464 7b5fe2ea280eca6092b5815eb8985c88041d4573	no	36
Warnings:					
Information:					
18	Foreign Reference	JP2010181540A.pdf	1769435 97a8747c442b01dbf6622580d6f2820d1c267155	no	51
Warnings:					
Information:					
19	Foreign Reference	Translation_of_JP2010181540A.pdf	956034 7befceb850d85f10231e0b143acfa0c2283fca15	no	24
Warnings:					
Information:					
20	Foreign Reference	JP4753336B2.pdf	302057 38a07da3dba95e654a858409b15ba2141950ca2e	no	10
Warnings:					
Information:					
21	Foreign Reference	Translation_of_JP4753336B2.pdf	282349 5514b3e037285e75d611247f8683d39b98a782a3	no	8
Warnings:					
Information:					
22	Foreign Reference	WO030016289A1.pdf	2110095 308fddacf0d2ef9ee231105e8bd292b069e89115	no	54
Warnings:					
Information:					

23	Foreign Reference	WO02102313A2.pdf	6922522 a5115b39e5db0956e675800927e99723eb70adac	no	165
Warnings:					
Information:					
24	Foreign Reference	WO2004009562A1.pdf	3103704 63981bc256b5a6622c038368447bac9e931eb9c2	no	63
Warnings:					
Information:					
25	Foreign Reference	WO2004046120A2.pdf	15432189 51aa2d4f7ad4edd65e22caa0d02ac37d28d800d5	no	392
Warnings:					
Information:					
26	Foreign Reference	WO2005035507A2.pdf	7589059 179d4e9b051a30b0eacf17b826fe9cc2a774053a	no	276
Warnings:					
Information:					
27	Foreign Reference	WO2005065691A1.pdf	3816070 4c43c9ea56a45f624094816e2f700d774fbe2093	no	124
Warnings:					
Information:					
28	Foreign Reference	WO2006079791A1.pdf	3056096 127fa1fc1713e5d4c7f6e78bb979a50452fc2eff	no	59
Warnings:					
Information:					
29	Foreign Reference	WO2008070661A1.pdf	2519744 d1a2ea934c086eeb3a87a858e41f4f88de3b5c22	no	65
Warnings:					
Information:					

30	Foreign Reference	WO2008076883A2.pdf	3602101 e3d11b8dd0d6eb4360f687460348d8eea6c93eaa	no	70
Warnings:					
Information:					
31	Foreign Reference	WO2008154026A1.pdf	7524603 96ec16d421aba0f8f30bd66eca2737f6b08c1149	no	223
Warnings:					
Information:					
32	Foreign Reference	WO2009118567A2.pdf	2930451 43fa5cb85038a4e2c9ec4776f8ac789dbda15aca	no	52
Warnings:					
Information:					
33	Foreign Reference	WO2011050210A1.pdf	13578280 4c8fc0ef8541792357f88f9f612d2fbaf4f9978a	no	293
Warnings:					
Information:					
34	Foreign Reference	WO2012074999A1.pdf	8159818 4a25c31d08cb6e779c8e870842b15d3faf1d46ec	no	201
Warnings:					
Information:					
35	Foreign Reference	WO2012171506A1.pdf	9929020 4ada4e83c7748c3e03de98587a03c276071be9b0	no	274
Warnings:					
Information:					
36	Foreign Reference	WO2013102431A1.pdf	9044012 d13454b79e14898e6e85cf83c985bac02e5af683	no	280
Warnings:					
Information:					

37	Foreign Reference	WO2013107291A1.pdf	6888809 f40ef1ef65cd2d63b72380d844586b65f25a2c6c	no	184
Warnings:					
Information:					
38	Foreign Reference	WO2013107405A1.pdf	4708083 3cf4749de62cd42400a635ad31b980b8138 9bede	no	125
Warnings:					
Information:					
39	Foreign Reference	WO2013133367A1.pdf	3883990 1b6c60f853e435167dc376792dd92854f14 2be3c	no	101
Warnings:					
Information:					
40	Non Patent Literature	NPL_-_ANSELL_Interactions_of_artificial_coenzymes.pdf	1013223 9736478bef7ca7520b563e6c4ccde766ecff c053	no	13
Warnings:					
Information:					
41	Non Patent Literature	NPL_-_BHUSHAN_-_Reversed-phase_liquid_chromatographic_resolution_of_diastereomers.pdf	279918 93633c4b18d523d9820d5def0cbabf636c9 642c3	no	8
Warnings:					
Information:					
42	Non Patent Literature	NPL_-_BRAUN_triazine-based_polymers.pdf	1083920 47539323814b08713863cde24d64d0a7d2f 456d2	no	7
Warnings:					
Information:					
43	Non Patent Literature	NPL_-_CHAN_-_Multi-domain_hydrogen-bond_forming_metal_chelates.pdf	307577 d24aa7214890bdffb05b096239353f28da3 5f6b4	no	3
Warnings:					
Information:					

44	Non Patent Literature	NPL_-_CHAPMAN_-_Substituted_aminopyrimidines_protein_kinase_B.pdf	1242078 30e825ca2e042ae9791646ae053566ee608143b3	no	5
Warnings:					
Information:					
45	Non Patent Literature	NPL_-_CHEN_-_Cytotoxicity_hemolysis_and_acute_in_vivo_toxicity.pdf	1044661 b188ab13c219dda2e952a227f96712cd657b9fc5	no	5
Warnings:					
Information:					
46	Non Patent Literature	NPL_-_DANG_IDH_mutations_in_cancer_and_progress_toward_development.pdf	2181150 00083c1af8ad1aef47f1bf945d861dcdbf9f5544	no	10
Warnings:					
Information:					
47	Non Patent Literature	NPL_-_DANG_IDH_mutations_in_glioma.pdf	1710464 eca841f782d078862ee0c208ab54bebbaca63b89	no	11
Warnings:					
Information:					
48	Non Patent Literature	NPL_-_DANG_Isocitrate_dehydrogenase_mutation.pdf	4138675 2bdf8d018cd367579e6cf8cbcbd14b488c61c727	no	31
Warnings:					
Information:					
49	Non Patent Literature	NPL_-_DOHNER_impact_of_genetic_features_on_treatment_decisions_in_aml.pdf	1498213 a834c3883b148c7239677f8a5c96844091562f13	no	7
Warnings:					
Information:					
50	Non Patent Literature	NPL_-_DUANMU_-_Dendron-functionalized_superparamagnetic_nanoparticles.pdf	636709 87a35e53239b6ca617e888e49e5255a24d3e5ea4	no	9
Warnings:					
Information:					
		Total Files Size (in bytes):	177001557		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
15/589,615	05/08/2017	Lenny Dang	AGS-013C2

CONFIRMATION NO. 7017

148106
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

PUBLICATION NOTICE

OC000000095500535

Title:METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

Publication No.US-2017-0325708-A1
Publication Date:11/16/2017

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Public Records Division. The Public Records Division can be reached by telephone at (571) 272-3150 or (800) 972-6382, by facsimile at (571) 273-3250, by mail addressed to the United States Patent and Trademark Office, Public Records Division, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently https://portal.uspto.gov/pair/PublicPair. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	3755322		1973-08-28	Winter et al.	
	2	3867383		1975-02-18	Winter	
	3	5021421		1991-06-04	Hino et al.	
	4	5807876		1998-09-15	Armistead et al.	
	5	5834485		1998-11-10	Dyke et al.	
	6	5965559		1999-10-12	Faull et al.	
	7	5965569		1999-10-12	Camps Garcia et al.	
	8	5984882		1999-11-16	Rosenschein et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	9	6262113		2001-07-17	Widdowson et al.	
	10	6313127		2001-11-06	Waterson et al.	
	11	6399358		2002-06-04	Williams et al.	
	12	6723730		2004-04-20	Bakthavatchalam et al.	
	13	6979675		2005-12-27	Tidmarsh	
	14	7173025		2007-02-06	Stocker et al.	
	15	8133900		2012-03-13	Hood et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020188027	A1	2002-12-12	Robinson et al.	
	2	20030095958	A1	2003-05-22	Bhisetti et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	3	20030109527	A1	2003-06-12	Jin et al.	
	4	20030207882	A1	2003-11-06	Stocker et al.	
	5	20040067234	A1	2004-04-08	Einat et al.	
	6	20040248221	A1	2004-12-09	Stockwell	
	7	20060281122	A1	2006-12-14	Bryant et al.	
	8	20080300208	A1	2008-12-04	Einat et al.	
	9	20090093526	A1	2009-04-09	Miller et al.	
	10	20090163508	A1	2009-06-25	KORI et al.	
	11	20100129350	A1	2010-05-27	Zacharie et al.	
	12	20100273808	A1	2010-10-28	Armitage et al.	
	13	20100331307	A1	2010-12-30	Salituro et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	14	20110086088	A1	2011-04-14	Berry	
	15	20120121515	A1	2012-05-17	Dang et al.	
	16	20120129865	A1	2012-05-24	WANG et al.	
	17	20120164143	A1	2012-06-28	TEELING et al.	
	18	20120202818	A1	2012-08-09	Tao et al.	
	19	20120238576	A1	2012-09-20	Tao et al.	
	20	20120277233	A1	2012-11-01	Tao et al.	
	21	20130035329	A1	2013-02-07	Saunders et al.	
	22	20130109643	A1	2013-05-02	Riggins et al.	
	23	20130184222	A1	2013-07-18	Popovici-Muller et al.	
	24	20130190249	A1	2013-07-25	Lemieux et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	25	20130190287	A1	2013-07-25	Cianchetta et al.	
	26	20140187435	A1	2014-07-03	Dang et al.	
	27	20150018328	A1	2015-01-15	Konteatis et al.	
	28	20150031627	A1	2015-01-29	Lemieux et al.	
	29	20150044716	A1	2015-02-12	Balss et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	101296909	CN	A	2008-10-29	Serono Lab		
	2	0022958	EP	A1	1981-01-28	Bayer Ag		X
	3	0384228	EP	A1	1990-08-29	Dainippon Pharmaceutical Co., Ltd		☐
	4	0385237	EP	A2	1990-09-05	Dainippon Pharmaceutical Co., Ltd		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	5	2735127	FR	A1	1996-12-13	Pf Medicament		☐
	6	11158073	JP		1999-06-15	Takeda Chemical Industries LTD		☐
	7	4099768	JP	B2	2008-06-11			☐
	8	9291034	JP	A	1997-11-11	Yoshitomi Pharmaceuticals Industries, Ltd.		☐
	9	1996030343	WO	A1	1996-10-03	Merck & Co., Inc		☐
	10	1997044322	WO	A1	1997-11-27	Chiroscience Ltd		☐
	11	2001016097	WO	A1	2001-03-08	Sugen, Inc		☐
	12	2001019788	WO	A2	2001-03-22	Cor Therapeutics, Inc		☐
	13	2001019798	WO	A2	2001-03-22	Cor Therapeutics Inc		☐
	14	2001064642	WO	A2	2001-09-07	Cor Therapeutics, Inc		☐
	15	2001064643	WO	A2	2001-09-07	Cor Therapeutics, Inc		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	16	2002100822	WO	A1	2002-12-19	Biovitrum Ab		☐
	17	2004050033	WO	A2	2004-06-17	Arqule, Inc		☐
	18	2004073619	WO	A2	2004-09-02	Smithkline Beecham Corp		☐
	19	2004074438	WO	A2	2004-09-02	Smithkline Beecham Corp		☐
	20	2004089470	WO	A2	2004-10-21	Novo Nordisk As		☐
	21	2005060956	WO	A1	2005-07-07	University Of Maryland, Baltimore		☐
	22	2005120474	WO	A2	2005-12-22	Leuven K U Res & Dev		☐
	23	2006034341	WO	A2	2006-03-30	Xenon Pharmaceuticals Inc		☐
	24	2006038594	WO	A1	2006-04-13	Ono Pharmaceutical Co., Ltd		☐
	25	2006070198	WO	A1	2006-07-06	Astex Therapeutics Ltd		☐
	26	2007003934	WO	A2	2007-01-11	Sterix Ltd		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	27	2007023186	WO	A1	2007-03-01	Applied Research Systems		☐
	28	2008050168	WO	A1	2008-05-02	Ritcher Gedeon Nyrt		☐
	29	2008052190	WO	A2	2008-05-02	Flynn, Gary		☐
	30	2008073670	WO	A2	2008-06-19	Millennium Pharmaceuticals, Inc		☐
	31	2008131547	WO	A1	2008-11-06	Prometic Biosciences Inc		☐
	32	2009013126	WO	A1	2009-01-29	Nerviano Medical Sciences Srl		☐
	33	2009016410	WO	A2	2009-02-05	Astrazeneca Ab		☐
	34	2009126863	WO	A2	2009-10-15	Genentech, Inc		☐
	35	2009150248	WO	A1	2009-12-17	Cytomics Systems		☐
	36	2010007756	WO	A1	2010-01-21	Shionogi & Co., Ltd		☐
	37	2010028099	WO	A1	2010-03-11	Univ Johns Hopkins		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	38	2010105243	WO	A1	2010-09-16	Agios Pharmaceuticals, Inc		☐
	39	2010129596	WO	A1	2010-11-11	Agios Pharmaceuticals, Inc		☐
	40	2010130638	WO	A1	2010-11-18	Evotec Ag		☐
	41	2010144338	WO	A1	2010-12-16	Abraxis Bioscience, Llc		☐
	42	2010144404	WO	A1	2010-12-16	Abraxis Bioscience, Llc		☐
	43	2011002817	WO	A1	2011-01-06	Agios Pharmaceuticals, Inc		☐
	44	2011032169	WO	A2	2011-03-17	Phusis Therapeutics Inc		☐
	45	2011047432	WO	A1	2011-04-28	Fibrotech Therapeutics Pty Ltd		☐
	46	201105210	WO	A1	2011-01-13	Milux Holding Sa		☐
	47	2011072174	WO	A1	2011-06-16	Agios Pharmaceuticals, Inc		☐
	48	2012009678	WO	A1	2012-01-19	Agios Pharmaceuticals, Inc		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	49	2012092442	WO	A1	2012-07-05	Agios Pharmaceuticals, Inc		☐
	50	2012151452	WO	A1	2012-11-08	Agios Pharmaceuticals, Inc		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	AGHILI et al. "Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review", Journal of Neuroncology, 2008. 91:233-236	
	2	BALSS, "Analysis of the IDH1 codon 132 mutation in brain tumors", Acata Neuropathol (2008) volume 116, pages 597-602.	
	3	BENNER et al, "Evolution, language and analogy in functional genomics", Trends in Genetics (2001) volume 17, pages 414-418.	
	4	BLEEKER et al., "IDH1 mutations at residue p.R132 (IDH1 (R132)) occur frequently in high-grade 18-22 gliomas but not in other solid tumors." Hum Muta1., January 2009, Vol 30, No 1, pp 7-11;	
	5	CAIRNS et al. "Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities" Cancer Discovery (2013) Vol 3, Iss 7, pp 730-741	
	6	Cecil Text Book of Medicine, edited by BENNET and PLUM, (1997) 20th edition, Volume 1, pp 1004-1010	
	7	COCCO et al. "Synthesis of Triflouromethylated Pyridinecarbonitriles" Journal of Heterocyclic Chemistry, 1995. Volume 32 pp 543-545	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	8	DANG et al., "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate." Nature, 10 29-32 December 2009, Vol 462, No 7274, pp 739-744.
	9	Dang, Lenny, " Cancer-associated IDH1 mutations produce 2-hydroxyglutarate", Nature, Vol:462,Nr:7274,Page(s):739 - 744, 2009.
	10	DAVIS et al. "Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1" The Journal of Biological Chemistry (2014) vol 289, No 20, pp 13717-13725
	11	DERMER "another Anniversary for the War on Cancer" Bio/Technology (1994) Vol 12, p 320
	12	Docoslis et al., "Characterization of the Distribution, Polymorphism, and Stability of Nimodipine in Its Solid Dispersions in Polyethylene Glycol by Micro-Raman Spectroscopy and Powder X-Ray Diffraction". The AAPS Journal 2007; 9 (3) Article 43, E361-E370.
	13	EP Search Report & Written Opinion for EP 10825706 Dated 03/20/13
	14	European Search Report for Application No. 10751525.6 dated 12/14/2012
	15	Eurpoean Search Report for EP Application No. 11763425.3 dated September 23, 2013
	16	Extended European Search Report for European application no. 16152308.9 dated July 18, 2016
	17	FRESHNEY et al. "Culture of Animal Cells, A Manual of Basic Techniques" Alan R. Liss, Inc. (1983) pp 1-6
	18	Genetics Home Reference. "L2HGDH." accessed at <http://ghr.nlm.nih.gov/gene/L2HGDH> on 4 September 2015

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	19	GOLUB et al. "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring" Science (1999) Vol 286, pp 531-537	
	20	HARTMANN et al. "Type and Frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas" Acta Neuropathologica (2009) 118: 469-474	
	21	HOLMES et al, 750 MHz 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2-hydroxyglutaric aciduria and maple syrup urine disease., Journal of Pharmaceutical and Biomedical Analysis (1997) volume 15, pages 1647-1659	
	22	International Preliminary Report for related application No. PCT/US2010/059778 dated June 12, 2012	
	23	International Preliminary Report on Patentability for International Application No. PCT/CN2012/000841 dated September 10, 2012	
	24	International Preliminary Report on Patentability for International Application No. PCT/CN2012/077096 dated September 17, 2012	
	25	International Preliminary Report on Patentability for PCT/CN2012/000841 dated December 17, 2013	
	26	International Preliminary Report on Patentability for PCT/CN2012/077096 dated December 17, 2013	
	27	International Preliminary Report on Patentability for PCT/US2010/027253 mailed 09/13/11.	
	28	International Preliminary Report on Patentability for PCT/US2010/040486 dated 1/12/12	
	29	International Preliminary Report on Patentability for PCT/US2010/053623 dated April 24, 2012	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	30	International Preliminary Report on Patentability for PCT/US2010/053624 dated 4/7/2011	
	31	International Preliminary Report on Patentability for PCT/US2011/030692 dated October 2, 2012	
	32	International Preliminary Report on Patentability for PCT/US2011/067752 dated April 11, 2013	
	33	International Search Report & Written Opinion for PCT/CN2013/070755 dated April 25, 2013	
	34	International Search Report and Written Opinion for Internatinal Application No. PCT/US2013/064601 dated February 24, 2014	
	35	International Search Report and Written Opinion for International Application No. PCT/US15/020349 dated June 15, 2015	
	36	International Search Report and Written Opinion for International Application No. PCT/US2014/049469 dated January 22, 2015	
	37	International Search Report and Written Opinion for International Application No. PCT/US2015/020346 dated June 18, 2015	
	38	International Search Report dated March 5, 2012 for related international application no. PCT/US2011/067752.	
	39	International Search Report for PCT/2011/030692 dated 7/27/2011	
	40	International Search Report for PCT/CN2012/000841 dated September 27, 2012	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	41	International Search Report for PCT/CN2012/077096 dated 10/4/2012	
	42	International Search Report for PCT/CN2013/000009 dated April 18, 2013	
	43	International Search Report for PCT/CN2013/000068 dated 04/25/13.	
	44	International Search Report for PCT/US10/040486 dated September 1, 2010.	
	45	International Search Report for PCT/US2010/027253 mailed 08/19/10.	
	46	International Search Report for PCT/US2010/059778 dated 03/17/11.	
	47	International Search Report for PCT/US2010/53623 dated January 18, 2011	
	48	International Search Report for PCT/US2010053624 dated 4/7/2011	
	49	International Search Report for PCT/US2011/067752 dated February 22, 2012	
	50	International Search Report for PCT/US2011044254 dated 5/10/2011	

If you wish to add additional non-patent literature document citation information please click the Add button Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2017-10-03
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2012160034	WO	A1	2012-11-29	Bayer Ip Gmbh		
	2	2014015422	WO	A1	2014-01-30	Ontario Inst For Cancer Res		
	3	9728128	WO	A1	1997-08-07	Zeneca Ltd		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	4	9728129	WO	A1	1997-08-07	Zeneca Ltd		
	5	9932463	WO	A1	1999-07-01	Bayer Ag		

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	International Search Report for PCT/US2013/064601 dated February 24, 2014	
	2	JENNINGS et al, Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase, Biochemistry (1997)volume 36, pages 13743-13747	
	3	KIM et al " Ser95, Asn97, and Thr78 are important for the catalytic function of porcine NADP-dependent isocitrate dehydrogenase" Protein Science (2005) 14: pp140-147	
	4	KIM et al. "Identification and Functional Characterization of a Novel, Tissue-specific NAD1-dependent Isocitrate Dehydrogenase b Subunit Isoform" JBC. 24 December 1999, Vol 274 No. 52 pages 36866-36875	
	5	Kranendijk, Martijn, "IDH2 Mutations in Patients with D-2-Hydroxyglutaric Aciduria" Sciences, Vol:330,Page(s):336, 2010.	
	6	KRELL et al., "IDH mutations in tumorigenesis and their potential role as novel therapeutic targets" Future Oncology (2013) Vol 9, Iss 12, pp 1923-1935	
	7	KUSAKABE et al. Chemical Abstracts vol. 152, No. 191956, Abstract for WO2010007756 (2010)	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	8	LIU et al. "Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure - Activity Relationship, and Selective Antitumor Activity" Journal of Medicinal Chemistry (2014) vol 57, pp 8307-8318	
	9	LOU. "IDH1: function follows form." SciBX, 2009, 1-2	
	10	Lutker et al, "Crystal Polymorphism in a Carbamazepine Derivative: Oxcarbazepine". NIH Public Access. J Pharm Sci. 2010 February ; 99(2): 794-803. doi: 10.1002/jps.21873	
	11	MAY et al, How many species are there on earth, Science (1988) volume 241, page 1441	
	12	MCROBBIE et al. "MRI from picture to proton." Cambridge Univ. Press, 2007, 307-308	
	13	PARONIKYAN et al. "Synthesis and biological activity of 3-piperazinylpyrano [3,4-C] pyridines" Armyanskii Khimicheskii Zhurnal (1990) Vol. 43, No. 8, pp 518-523	
	14	PARSONS et al. "An Integrated Genomic Analysis of Human Glioblastoma Multiforme" Science Vol 321 (2008) pp 1807-1812 and Supplemental Data	
	15	POLLARD et al, "Cancer. Puzzling patterns of predisposition." Science. 10 April 2009, Vol 324, 1-5,15-16, 18-22,35-38 No 5924, pp 192-194.	
	16	POPOVICI-MULLER, Janeta et al. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor2-HG in Vivo. ACS Medicinal Chemistry Letters. 17 Sep. 2012 (17. 09. 2012), vol. 3, no. 10, 850-855	
	17	PUBCHEM CID 4078245 [online]; September 13, 2005 [retrieved on February 4, 2012]; retrieved from http://pubchem.ncbi.nim.nih.gov/; 2d-structure	
	18	PUBCHEM CID 4854170 [online]; September 17, 2005 [retrieved on February 4, 2012]; retrieved from http://pubchem.ncbi.nim.nih.gov/; 2d-structure	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	19	Rao et al., "Polymorphism in Drugs and its Significance in Therapeutics". Journal of Scientific & Industrial Research Vol. 46 October 1987 pp 450-455.	
	20	REGISTRY (STN) [online], 2006.08.23 [Retrieved on 2016.01.29] CAS Registration No. 903862-76-0	
	21	REGISTRY (STN) [online], 2006.08.23 [Retrieved on 2016.01.29] CAS Registration No. 903869-26-1	
	22	REGISTRY (STN) [online], 2007.04.13 [Retrieved on 2016.01.29] CAS Registration No. 929819-92-1	
	23	REGISTRY (STN) [online], 2007.04.13 [Retrieved on 2016.01.29] CAS Registration No. 929971-43-7	
	24	REGISTRY (STN) [online], 2009.04.19 [Retrieved on 2016.01.29] CAS Registration No. 1136498-70-8	
	25	REGISTRY (STN) [online], 2009.08.27 [Retrieved on 2016.01.29] CAS Registration No. 1176756-98-1	
	26	REITMAN et al. "Isocitrate Sehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism" Journal of the National Cancer Institute, Vol. 102, No. 13, pp 932-941 (2010).	
	27	ROHLE et al. "An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells" Science, Vol. 340, No. 6132 pp 626-630 (2013)	
	28	SIRKANYAN, S.N. et al "Synthesis of new derivatives of piperazine-substituted pyrano[3,4-c]pyridines. Hayastani Kimiakan Handes 2009, Vol. 62, No 3-4 pp 378-385. English Abstract Only.	
	29	Sonoda, Yukihiko, " Analysis of IDH1 and IDH2 mutations in Japanese glioma patients" Cancer Science, Vol:100,Nr:10,Page(s):1996 - 1998, 2009.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	30	SOSNOVIK et al. "Emerging concepts in molecular MRI." Curr. Op. Biotech., 2007, 18, 4-10	
	31	STN file CA, Registry Number 1023444-33-8, entered STN on May 29, 2008, Chemical Abstracts Index Name "Benzenesulfonamide, 3-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]-N-(4-butylphenyl)-4-methyl-"	
	32	STN File CA, Registry Number 1090629-29-0, entered STN on December 28, 2008, Chemical Abstracts Index Name "Benzenesulfonamide, 3-[[4-[(2,5-dimethoxyphenyl)methyl]-1-piperazinyl]carbonyl]-N-(4-methoxyphenyl)-4-methyl-"	
	33	STN File CA, Registry Number 134538-28-6, entered STN on June 28, 1991, Chemical Abstracts Index Name "1H-Pyrano[3,4-c]pyridine-5-carbonitrile,3,4-dihydro-3,3-dimethyl-6-[4-(1-oxobutyl)-1-piperazinyl]-8-phenyl-", disclosed in Paronikyan et al. Armyanskii Khimicheskii Zhurnal, 1990, Vol 43, No.8	
	34	STN File CA, Registry Number 134538-29-7, entered STN on June 28, 1991, Chemical Abstracts Index Name "1H-Pyrano[3,4-c]pyridine-5-carbonitrile,3,4-dihydro-3,3-dimethyl-6-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-8-phenyl-", disclosed in Paronikyan et al. Armyanskii Khimicheskii Zhurnal, 1990, Vol 43, No.8	
	35	STN File CA, Registry Number 134538-30-0, entered STN on June 28, 1991, Chemical Abstracts Index Name "1H-Pyrano[3,4-c]pyridine-5-carbonitrile,6-(4-benzoyl-1-piperazinyl)-3,4-dihydro-3,3-dimethyl-8-phenyl-", disclosed in Paronikyan et al. Armyanskii Khimicheskii Zhurnal, 1990, Vol 43, No.8	
	36	STN File CA, Registry Number 134538-31-1, entered STN on June 28, 1991, Chemical Abstracts Index Name "1H-Pyrano[3,4-c]pyridine-5-carbonitrile,6-[4-(2-furanylcarbonyl)-1-piperazinyl]-3,4-dihydro-3,3-dimethyl-8-phenyl-", disclosed in Paronikyan et al. Armyanskii Khimicheskii Zhurnal, 1990, Vol 43, No.8	
	37	STN file CA, Registry Number 713505-78-3, entered STN on July 21, 2004, Chemical Abstracts Index Name "1-Piperazinecarboxylic acid, 4-[4-methyl-3-[(phenylamino)sulfonyl]benzoyl]-, ethyl ester"	
	38	STN File CA, Registry Number 847757-57-7, entered STN on April 1, 2005, Chemical Abstracts Index Name "Benzenesulfonamide, 3-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]-N-(4-ethoxyphenyl)-N,4-dimethyl-" or "Piperazine, 1-(1,3-benzodioxol-5-ylmethyl)-4-[5-[[(4-ethoxyphenyl)methylamino]sulfonyl]-2-methylbenzoyl]-"	
	39	STN REGISTRY, L23 ANSWER 2 OF 3 (CAS NUMBER: 1032450-21-7), Database: ASINEX Ltd.,Entered STN: 03 Jul2008 (03. 07. 2008)	
	40	STN Tokyo, Registry Number 1001833-18-6, Entered STN on February 6, 2008, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [(4-methyl-l-piperazinyl)carbonyl]phenyl]–"	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	41	STN Tokyo, Registry Number 1030142-35-8, Entered STN on June 24, 2008, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-[(5-methyl-3-isoxazolyl)methyl]-l-piperazinyl]carbonyl]phenyl]-"
	42	STN Tokyo, Registry Number 1031531-78-8, Entered STN on June 29, 2008 Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, N-4[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]-2,3-dihydro-"
	43	STN Tokyo, Registry Number 1057928-35-4, Entered STN on October 7, 2008, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-pyridinyl)-l-piperazinyl]carbonyl]phenyl]-"
	44	STN Tokyo, Registry Number 1240875-006, entered STN on September 14, 2010, Chemical Abstracts Index Name '1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4-[[4-(2-thiazolyl)-1-piperazinyl]carbonyl]phenyl]-"
	45	STN Tokyo, Registry Number 748791-86-8, Entered STN on September 21, 2004, Chemical Abstracts Index Name '1,4-Benzodioxin-6-sulfonamide, N-[4- [[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]phenyl]-2,3-dihydro-"
	46	STN Tokyo, Registry Number 878469-24-0, Entered STN on March 29, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]phenyl]-"
	47	STN Tokyo, Registry Number 878474-39-6, Entered STN on March 29, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4[(4-phenyl-1-piperazinyl)carbonyl]phenyl]-"
	48	STN Tokyo, Registry Number 878590-33-1, Entered STN on March 30, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4-{[4-(tetrahydro-2-furanyl)methyl]-1-piperazinyl]carbonyl]phenyl]-"
	49	STN Tokyo, Registry Number 878943-66-9 Entered STN on April 2, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 3,4-dihydro-N-[[4-(2-pyrimidinyl)-1-piperazinyl)carbonyl]phenyl]-"
	50	STN Tokyo, Registry Number 878956-06-0, Entered STN on April 2, 2006, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, N-[4- [[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]phenyl]-2,3-dihydro-"

If you wish to add additional non-patent literature document citation information please click the Add button Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2017-10-03
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15589615
Filing Date	2017-05-08
First Named Inventor	Lenny Dang
Art Unit	1797
Examiner Name	C. Hixson
Attorney Docket Number	AGS-013C2

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	1	STN Tokyo, Registry Number 9200679-46-5, Entered STN on February 13, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(4-pyridinyl)-1-piperazinyl]carbonyl]phenyl]-"
	2	STN Tokyo, Registry Number 920822-52-2, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, N-[4- [[4-(4-fluoropheyl)-1-piperazinyl]carbonyl]phenyl] - 2,3dihydro-"
	3	STN Tokyo, Registry Number 920824-56-2, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(3-thienylmethyl)-1-piperazinyl]carbonyl]phenyl]-"
	4	STN Tokyo, Registry Number 920847-34-3, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-methylphenyl)-1-piperazinyl]carbonyl]phenyl]-"
	5	STN Tokyo, Registry Number 920875-39-4, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-hydroxyphenyl)-1-piperazinyl]carbonyl]phenyl]-"
	6	STN Tokyo, Registry Number 920902-88-1, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-thienylmethyl)-l-piperazinyl]carbonyl]phenyl]-"
	7	STN Tokyo, Registry Number 920921-09-1 Entered STN on February 14, 2007, Chemical Abstracts Index Name "2H-1, 5-Benzodioxepin-7-sulfonamide, 3,4-dihydro-N-[4-[[4-(2pyridinyl)-1-piperazinyl]carbonyl]phenyl]-"
	8	STN Tokyo, Registry Number 920924-42-1, Entered STN on February 14, 2007, Chemical Abstracts Index Name "1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[4- [[4-(2-pyridinylmethyl)-1-piperazinyl]carbonyl]phenyl]-"
	9	STN Tokyo, Registry Number 941220-77-5, Entered STN on July 4, 2007, Chemical Abstracts Index Name "2H-1, 5-Benzodioxepin-7-sulfonamide, 3,4-dihydro-N-[4-[(4-methyl-l-piperazinyl)carbonyl]phenyl]-"
	10	STNREGISTRY. L23 ANSWER 1 OF 3 (CAS NUMBER: 1038821-72-5),Database: ChemDB (University of California Irvine), Entered STN: 05 Aug. 2008 (05. 08. 2008)
	11	STRUYS et al, Investigations by mass isotopomer analysis of the formation of D-2-hydroxyglutarate by cultured lymphoblasts from two patients with D-2-hydroxyglutaric aciduria, FEBS letters 92004 volume 557, pages 115-120

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	12	STRUYS et al. "Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria" American Journal of Human Genetics, 2005. 76:358-360
	13	Supplementary European Search Report for EP Application No. 10825707.2 dated June 28, 2013
	14	Supplementary Search Report for EP10794668 Mailed 10/18/12.
	15	Supplimentary European Search Report for EP 10751525 Mailed December 14, 2012.
	16	The radiation fact sheet published by the National Cancer Institute, http://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/radiation-fact-sheet, reviewed June 30, 2010
	17	THOMPSON, "Metabolic Enzymes as Oncogenes or Tumor Suppressors." The New England 18-22 Journal of Medicine, 19 February 2009, Vol 360, No 8, pp 813-815; pg 813, pg 815, col 1; Fig 1.
	18	WANG et al. "A novel ligand N,N?-di(2-pyridyl)-2,4-diamino-6-phenyl-1,3,5-triazine (dpdapt) and its complexes: [Cu (dpdapt)Cl2] and [Cu(dpdapt)(NO3)(H2O)] Â· NO3 Â· H2O" Polyhedron, 2006. Vol 25, Issue 1. pp 195-202
	19	Ward, Patrick S, "The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting [alpha]-Ketoglutarate to 2-Hydroxyglutarate" Cancer cell, Vol:17,Nr:3,Page(s):225 - 234, 2010.
	20	WATANABE et al., "IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas". American Journal of Pathology, April 2009 (published online 26 February (2009), Vol 174, No 4, pp 1149-1153; Abstract, pg 1150, col 1.
	21	Written Opinion for PCT/US2010/027253 mailed 08/19/10.
	22	Written Opinion of International Search Authority for PCT/CN2013/000009 dated April 18, 2013

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

	23	Written Opinion of Search Authority for PCT/US2010/53623 dated January 18, 2011	
	24	Written Opinion of the International Searching Authority for PCT/US2011/067752 dated March 5, 2012	
	25	YAN et al., "IDH1 and IDH2 Mutations in Gliomas." The New England Journal of Medicine, 19 18-22 February 2009, Vol 360, No. 8, pp 765-73.	
	26	ZHAO ET AL: "Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha", SCIENCE, vol. 324, no. 5924, 10 April2009 (2009-04-10), pages 261-265	
	27	ZHENG et al. "Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives" Bioorganic & Medicinal Chemistry (2007) Vol 15, pp 1815-1827	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15589615
	Filing Date	2017-05-08
	First Named Inventor	Lenny Dang
	Art Unit	1797
	Examiner Name	C. Hixson
	Attorney Docket Number	AGS-013C2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ioana Davies/	Date (YYYY-MM-DD)	2017-10-03
Name/Print	Ioana Davies	Registration Number	75,817

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	30549097
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies
Filer Authorized By:	
Attorney Docket Number:	AGS-013C2
Receipt Date:	03-OCT-2017
Filing Date:	08-MAY-2017
Time Stamp:	14:26:15
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	Information_Disclosure_Statement.pdf	21155 e2cc85a52cc6f9c19d85557b238ab30c04e01897	no	2

Warnings:

Information:					
2	Information Disclosure Statement (IDS) Form (SB08)	Information_Disclosure_Statement_Fillable_PDF_1_of_3.pdf	1040096 98bcefcf72a8acca0d53a8d5aeb9e88fa4c6762c	no	17
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Form (SB08)	Information_Disclosure_Statement_Fillable_PDF_2_of_3.pdf	1038565 f440c8d7582393ebdcbf5034b6489f44b936df00	no	9
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
4	Information Disclosure Statement (IDS) Form (SB08)	Information_Disclosure_Statement_Fillable_PDF_3_of_3.pdf	1036939 85643d57981cc941916de7771dc0211ce0597d86	no	6
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
		Total Files Size (in bytes):	3136755		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

<u>New Applications Under 35 U.S.C. 111</u>
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
<u>National Stage of an International Application under 35 U.S.C. 371</u>
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
<u>New International Application Filed with the USPTO as a Receiving Office</u>
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Docket No.: AGS-013C2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Lenny Dang et al.

Application No.: 15/589,615 | Confirmation No.: 7017

Filed: May 8, 2017 | Art Unit: 1797

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Examiner: C. Hixson

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, the attention of the United States Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of the above-identified application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits (37 C.F.R. § 1.97(b)(3)).

In accordance with 37 C.F.R. § 1.98(a)(2)(ii), copies of U.S. patents and U.S. patent application publications are not submitted.

In accordance with 37 C.F.R. § 1.98(d)(1), copies of foreign patents and non-patent literature are not supplied because they were previously cited by or submitted to the Office in prior application numbers 13/939,519 filed July 11, 2013, 13/256,396 filed March 12, 2010 and

relied on in the above-identified application for an earlier effective filing date under 35 U.S.C. § 120.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in this Information Disclosure Statement is, or is considered to be, material to the patentability as defined in 37 C.F.R. § 1.56(b).

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98, and the Examiner is respectfully requested to consider the listed references.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 07-1700, under Order No. AGS-013C2 from which the undersigned is authorized to draw.

Dated: October 3, 2017

Respectfully submitted,

Electronic signature: /Ioana Davies/
Ioana Davies
Registration No.: 75,817
GOODWIN PROCTER LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-3920
Attorney for Applicant

Docket No.: AGS-013C2

DECLARATION FOR PATENT APPLICATION

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, titled **METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS**, or

☒ United States application or PCT International application number **15/589,615** filed on **05/08/2017**.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby state that I have reviewed and understand the contents of the application, including the claims.

I acknowledge the duty to disclose all information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that any willful false statements made in this declaration are punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Lenny Dang — Aug 30, 2017

Inventor's signature — **Date**

Full legal name of original or original joint inventor: **Lenny Dang**

Electronic Acknowledgement Receipt

EFS ID:	30225034
Application Number:	15589615
International Application Number:	
Confirmation Number:	7017
Title of Invention:	METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
First Named Inventor/Applicant Name:	Lenny Dang
Customer Number:	148106
Filer:	Ioana Davies/Jeannie Le
Filer Authorized By:	Ioana Davies
Attorney Docket Number:	AGS-013C2
Receipt Date:	30-AUG-2017
Filing Date:	08-MAY-2017
Time Stamp:	13:47:57
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Oath or Declaration filed	Executed_Declaration_Lenny_Dang.pdf	389133 71ed3cd37cd390de63963d2befa8544ca793c8f0	no	1

Warnings:

Information:	
Total Files Size (in bytes):	389133

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
15/589,615	05/08/2017		2540	AGS-013C2	18	1

CONFIRMATION NO. 7017

UPDATED FILING RECEIPT

148106
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

OC000000093301654

Date Mailed: 08/09/2017

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Lenny Dang, Boston, MA;
Valeria Fantin, Burlingame, CA;
Stefan Gross, Brookline, MA;
Hyun G. Jang, Waltham, MA;
Shengfang Jin, Newton, MA;
Francesco G. Salituro, Marlborough, MA;
Jeffrey O. Saunders, Lincoln, MA;
Shin-San Michael Su, Boston, MA;
Katharine Yen, Wellesley, MA;

Applicant(s)

Lenny Dang, Boston, MA;
Valeria Fantin, Burlingame, CA;
Stefan Gross, Brookline, MA;
Hyun G. Jang, Waltham, MA;
Shengfang Jin, Newton, MA;
Francesco G. Salituro, Marlborough, MA;
Jeffrey O. Saunders, Lincoln, MA;
Shin-San Michael Su, Boston, MA;
Katharine Yen, Wellesley, MA;

Assignment For Published Patent Application

Agios Pharmaceuticals, Inc., Cambridge, MA

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 13/939,519 07/11/2013

which is a CON of 13/256,396 11/29/2011 ABN
which is a 371 of PCT/US10/27253 03/12/2010
which claims benefit of 61/266,929 12/04/2009
and claims benefit of 61/253,820 10/21/2009
and claims benefit of 61/229,689 07/29/2009
and claims benefit of 61/227,649 07/22/2009
and claims benefit of 61/220,543 06/25/2009
and claims benefit of 61/180,609 05/22/2009
and claims benefit of 61/173,518 04/28/2009
and claims benefit of 61/160,664 03/16/2009
and claims benefit of 61/160,253 03/13/2009

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 08/08/2017

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 15/589,615**

Projected Publication Date: 11/16/2017

Non-Publication Request: No

Early Publication Request: No
Title

METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS

Preliminary Class

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
15/589,615	05/08/2017	Lenny Dang	AGS-013C2

CONFIRMATION NO. 7017

148106
GOODWIN PROCTER LLP
PATENT ADMINISTRATOR
100 Northern Avenue
BOSTON, MA 02210

INFORMAL NOTICE

OC000000093301655

Date Mailed: 08/09/2017

INFORMATIONAL NOTICE TO APPLICANT

Applicant is notified that the above-identified application contains the deficiencies noted below. No period for reply is set forth in this notice for correction of these deficiencies. However, if a deficiency relates to the inventor's oath or declaration, the applicant must file an oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each actual inventor no later than the expiration of the time period set in the "Notice of Allowability" to avoid abandonment. See 37 CFR 1.53(f).

The item(s) indicated below are also required and should be submitted with any reply to this notice to avoid further processing delays.

- A properly executed inventor's oath or declaration has not been received for the following inventor(s):
  Lenny Dang

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/ytdemisse/

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 15/589,615

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	280
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	600
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	720
TOTAL CLAIMS (37 CFR 1.16(i))	18 minus 20 =	*			OR	x 80 =	0.00
INDEPENDENT CLAIMS (37 CFR 1.16(h))	1 minus 3 =	*				x 420 =	0.00
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						800
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							0.00
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	2400

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE($)	ADDITIONAL FEE($)		RATE($)	ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

Docket No.: AGS-013C2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Lenny Dang et al.

Application No.: 15/589,615 | Confirmation No.: 7017

Filed: May 8, 2017 | Art Unit: N/A

For: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Examiner: Not Yet Assigned

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice to File Missing Parts of Application, Applicant respectfully submits a Substitute Specification with markings, a Substitute Specification without markings, a Petition for Extension of Time, and Part 2 Copy of Notice.

Please amend the above-identified U.S. patent application specification with the substitute specification, submitted with markings and accompanied by a clean version without markings in compliance with 37 CFR 1.52, 1.121 (b)(3), and 1.125. The Substitute Specification contains no new matter.

Dated: August 7, 2017

Respectfully submitted,

Electronic signature: /Ioana Davies/
Ioana Davies
Registration No.: 75,817
GOODWIN PROCTER LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-3920

92035430

PTO/AIA/22 (03-13)
Approved for use through 7/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)	Docket Number (Optional) AGS-013C2
Application Number 15/589,615-Conf. #7017	Filed May 8, 2017
For METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS	
Art Unit N/A	Examiner Not Yet Assigned

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above-identified application.

The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):

		Fee	Small Entity Fee	Micro Entity Fee	
[X]	One month (37 CFR 1.17(a)(1))	$200	$100	$50	$ 200.00
[ ]	Two months (37 CFR 1.17(a)(2))	$600	$300	$150	$
[ ]	Three months (37 CFR 1.17(a)(3))	$1,400	$700	$350	$
[ ]	Four months (37 CFR 1.17(a)(4))	$2,200	$1,100	$550	$
[ ]	Five months (37 CFR 1.17(a)(5))	$3,000	$1,500	$750	$

[ ] Applicant asserts small entity status. See 37 CFR 1.27.

[ ] Applicant certifies micro entity status. See 37 CFR 1.29.
Form PTO/SB/15A or B or equivalent must either be enclosed or have been submitted previously.

[ ] A check in the amount of the fee is enclosed.

[X] Payment by credit card. Form PTO-2038 is attached.

[ ] The Director has already been authorized to charge fees in this application to a Deposit Account.

[X] The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 07-1700 .

[X] Payment made via EFS-Web.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

I am the

[ ] applicant.

[ ] attorney or agent of record. Registration number _____ .

[X] attorney or agent acting under 37 CFR 1.34. Registration number 75,817 .

/Ioana Davies/ — Signature
August 7, 2017 — Date

Ioana Davies — Typed or printed name
(617) 570-3920 — Telephone Number

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. Submit multiple forms if more than one signature is required, see below*.

[ ] * Total of 1 forms are submitted.

92035794

METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-ELATED DISORDERS

CLAIM OF PRIORITY

This application is a continuation of U.S.S.N. 13/939,519, filed July 11, 2013, which is a continuation of U.S.S.N. 13/256,396, filed November 29, 2011, which is a national stage application under 35 U.S.C. §371 of International Application No. PCT/US2010/027253, filed March 12, 2010, published as International Publication No. WO 2010/105243 on September 16, 2010, which claims priority to U.S.S.N. 61/160,253, filed March 13, 2009; U.S.S.N. 61/160,664, filed March 16, 2009; U.S.S.N. 61/173,518, filed April 28, 2009; U.S.S.N. 61/180,609, filed May 22, 2009; U.S.S.N. 61/220,543, filed June 25, 2009; U.S.S.N. 61/227,649, filed July 22, 2009; U.S.S.N. 61/229,689, filed July 29, 2009; U.S.S.N. 61/253,820, filed October 21, 2009; and U.S.S.N. 61/266,929, filed December 4, 2009, the contents of each of which are incorporated herein by reference.

FIELD OF THE INVENTION

The invention relates to methods and compositions for evaluating and treating cell proliferation-related disorders, *e.g.,* proliferative disorders such as cancer.

BACKGROUND

Isocitrate dehydrogenase, also known as IDH, is an enzyme which participates in the citric acid cycle. It catalyzes the third step of the cycle: the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate or α-KG) and CO_2 while converting NAD+ to NADH. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate (a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. Another isoform of the enzyme catalyzes the same reaction; however this reaction is unrelated to the citric acid cycle, is carried out in the cytosol as well as the mitochondrion and peroxisome, and uses NADP+ as a cofactor instead of NAD+.

SUMMARY OF THE INVENTION

Methods and compositions disclosed herein relate to the role played in disease by neoactive products produced by neoactive mutant enzymes, e.g., mutant metabolic pathway enzymes. The inventors have discovered, *inter alia*, a neoactivity associated with IDH mutants and that the product of the neoactivity can be significantly elevated in cancer cells. Disclosed herein are methods and compositions for treating, and methods of evaluating, subjects having or at risk for a disorder, *e.g.,* a cell proliferation-related disorder characterized by a neoactivity in a metabolic pathway enzyme, e.g., IDH neoactivity. Such disorders include *e.g.,* proliferative disorders such as cancer. The inventors have discovered and disclosed herein novel therapeutic agents for the treatment of disorders, e.g., cancers, characterized by, e.g., by a neoactivity, neoactive protein, neoactive mRNA, or neoactive mutations. In embodiments a therapeutic agent reduces levels of neoactivity or neoactive product or ameliorates an effect of a neoactive product. Methods described herein also allow the identification of a subject, or identification of a treatment for the subject, on the basis of neaoctivity genotype or phenotype. This evaluation can allow for optimal matching of subject with treatment, e.g., where the selection of subject, treatment, or both, is based on an analysis of neoactivity genotype or phenotype. E.g., methods describe herein can allow selection of a treatment regimen comprising administration of a novel compound, e.g., a novel compound disclosed herein, or a known compound, e.g., a known compound not previously recommended for a selected disorder. In embodiments the known compound reduces levels of neoactivity or neoactive product or ameliorates an effect of a neoactive product. Methods described herein can guide and provide a basis for selection and administration of a novel compound or a known compound, or combination of compounds, not previously recommended for subjects having a disorder characterized by a somatic neoactive mutation in a metabolic pathway enzyme. In embodiments the neoactive genotype or phenotype can act as a biomarker the presence of which indicates that a compound, either novel, or previously known, should be administered, to treat a disorder characterized by a somatic neoactive mutation in a metabolic pathway enzyme. Neoactive mutants of IDH1 having a neoactivity that results in the production of 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate and associated disorders are discussed in detail herein. They are exemplary, but not limiting, examples of embodiments of the invention.

While not wishing to be bound by theory it is believed that the balance between the production and elimination of neoactive product, e.g., 2HG, e.g., R-2HG, is important in disease. Neoactive mutants, to varying degrees for varying mutations, increase the level of neoactive product, while other processes, e.g., in the case of 2HG, e.g., R-2HG, enzymatic degradation of 2HG, e.g., by 2HG dehydrogenase, reduce the level of neoative product. An incorrect balance is associated with disease. In embodiments, the net result of a neoactive mutation at IDH1 or IDH2 result in increased levels, in affected cells, of neoactive product, 2HG, e.g., R-2HG,

Accordingly, in one aspect, the invention features, a method of treating a subject having a cell proliferation-related disorder, *e.g.,* a disorder characterized by unwanted cell proliferation, *e.g.,* cancer, or a precancerous disorder. The cell proliferation-related disorder is characterized by a somatic mutation in a metabolic pathway enzyme. The mutation is associated with a neoactivity that results in the production of a neoactivity product. The method comprises: administering to the subject a therapeutically effective amount of a therapeutic agent described herein, e.g., a therapeutic agent that decreases the level of neoactivity product encoded by a selected or mutant somatic allele, e.g., an inhibitor of a neoactivity of the metabolic pathway enzyme (the neoactive enzyme), a therapeutic agent that ameliorates an unwanted affect of the neoactivity product, or a nucleic acid based inhibitor, e.g., a dRNA which targets the neoactive enzyme mRNA,
to thereby treat the subject.

In an embodiment the subject is a subject not having, or not diagnosed as having, 2-hydroxyglutaric aciduria.

In an embodiment the subject has a cell proliferation-related disorder, *e.g.,* a cancer, characterized by the neoactivity of the metabolic pathway enzyme encoded by selected or mutant allele.

In an embodiment the subject has a cell proliferation-related disorder, *e.g.,* a cancer, characterized by the product formed by the neoactivity of the metabolic pathway enzyme encoded by selected or mutant allele.

In one embodiment, the metabolic pathway is selected from a metabolic pathway leading to fatty acid biosynthesis, glycolysis, glutaminolysis, the pentose phosphate shunt, nucleotide biosynthetic pathways, or the fatty acid biosynthetic pathway.

In an embodiment the therapeutic agent is a therapeutic agent described herein.

In an embodiment the method comprises selecting a subject on the basis of having a cancer characterized by the selected or mutant allele, the neoactivity, or an elevated level of neaoctivity product.

In an embodiment the method comprises selecting a subject on the basis of having a cancer characterized by the product formed by the neoactivity of the protein encoded by selected or mutant allele, *e.g.,* by the imaging and/or spectroscopic analysis, *e.g.,* magnetic resonance-based analysis, *e.g.,* MRI (magnetic resonance imaging) and/or MRS (magnetic resonance spectroscopy), to determine the presence, distribution or level of the product of the neoactivity, *e.g.,* in the case of an IDH1 allele described herein, 2-hydroxyglutarate (sometimes referred to herein as 2HG), *e.g.,* R-2-hydroxyglutarate (sometimes referred to herein as R-2HG).

In an embodiment the method comprises confirming or determining, *e.g.,* by direct examination or evaluation of the subject, or sample *e.g.,* tissue, product (e.g., feces, sweat, semen, exhalation, hair or nails), or bodily fluid (*e.g.,* blood (*e.g.,* blood plasma), urine, lymph, or cerebrospinal fluid or other sample sourced disclosed herein) therefrom, (*e.g.,* by DNA sequencing, immuno analysis, or assay for enzymatic activity), or receiving such information about the subject, that the cancer is characterized by the selected or mutant allele.

In an embodiment the method comprises confirming or determining, *e.g.,* by direct examination or evaluation of the subject, the level of neoactivity or the level of the product of the neoactivity, or receiving such information about the subject. In an embodiment the presence, distribution or level of the product of the neoactivity, *e.g.,* in the case of an IDH1 allele described herein, 2HG, *e.g.,* R-2HG, is determined non-invasively, *e.g.,* by imaging methods, *e.g.,* by magnetic resonance-based methods.

In an embodiment the method comprises administering a second anti-cancer agent or therapy to the subject, *e.g.,* surgical removal or administration of a chemotherapeutic.

In another aspect, the invention features, a method of treating a subject having a cell proliferation-related disorder, *e.g.,* a precancerous disorder, or cancer. In an embodiment the subject does not have, or has not been diagnosed as having, 2-hydroxyglutaric aciduria. The cell proliferation-related disorder is characterized by a somatic allele, e.g., a preselected allele, or mutant allele, of an IDH, *e.g.,* IDH1 or IDH2, which encodes a mutant IDH, *e.g.,* IDH1 or IDH2, enzyme having a neoactivity.

In embodiments the neoactivity is alpha hydroxy neoactivity. As used herein, alpha hydroxy neoactivity refers to the ability to convert an alpha ketone to an alpha hydroxy. In embodiments alpha hydroxy neoactivity proceeds with a reductive cofactor, e.g., NADPH or NADH. In embodiments the alpha hydroxyl neoactivity is 2HG neoactivity. 2HG neoactivity, as used herein, refers to the ability to convert alpha ketoglutarate to 2-hydroxyglutarate (sometimes referred to herein as 2HG), *e.g.,* R-2-hydroxyglutarate (sometimes referred to herein as R-2HG). In embodiments 2HG neoactivity proceeds with a reductive cofactor, e.g., NADPH or NADH. In an embodiment a neoactive enzyme, e.g., an alpha hydroxyl, e.g., a 2HG, neoactive enzyme, can act on more than one substrate, e.g., more than one alpha hydroxy substrate.

The method comprises administering to the subject an effective amount of a therapeutic agent of type described herein to thereby treat the subject.

In an embodiment the therapeutic agent: results in lowering the level of a neoactivity product, e.g., an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG.

In an embodiment the method comprises administering a therapeutic agent that lowers neoactivity, e.g., 2HG neoactivity. In an embodiment the method comprises administering an inhibitor of a mutant IDH protein, *e.g.,* a mutant IDH1 or mutant IDH2 protein, having a neoactivity, *e.g.,* alpha hydroxy neoactivity, e.g., 2HG neoactivity.

In an embodiment the therapeutic agent comprises a compound from Table 24a or Table 24b or a compound having the structure of Formula (X) or (Formula (XI) described herein.

In an embodiment the therapeutic agent comprises nucleic acid-based therapeutic agent, e.g., a dsRNA, e.g., a dsRNA described herein.

In an embodiment the the therapeutic agent is an inhibitor, *e.g.,* a polypeptide, peptide, or small molecule (*e.g.,* a molecule of less than 1,000 daltons), or aptomer, that binds to an IDH1 mutant or wildtype subunit and inhibits neoactivity, e.g., by inhibiting formation of a dimer, *e.g.,* a homodimer of mutant IDH1 subunits or a heterodimer of a mutant and a wildype subunit. In an embodiment the inhibitor is a polypeptide. In an embodiment the polypeptide acts as a dominant negative with respect to the neoactivity of the mutant enzyme. The polypeptide can correspond to full length IDH1 or a fragment thereof. The polypeptide need not be indentical with

the corresponding residues of wildtype IDH1, but in embodiments has at least 60, 70, 80, 90 or 95 % homology with wildtype IDH1.

In an embodiment the therapeutic agent decreases the affinity of an IDH, e.g., IDH1 or IDH2 neoactive mutant protein for NADH, NADPH or a divalent metal ion, e.g., Mg^{2+} or Mn^{2+}, or decreases the levels or availability of NADH, NADPH or divalent metal ion, e.g., Mg^{2+} or Mn^{2+}, *e.g.,* by competing for binding to the mutant enzyme. In an embodiment the enzyme is inhibited by replacing Mg^{2+} or Mn^{2+} with Ca^{2+}.

In an embodiment the therapeutic agent is an inhibitor that reduces the level a neoactivity of an IDH, *e.g.,* IDH1 or IDH2, *e.g.,* 2HG neoactivity.

In an embodiment the therapeutic agent is an inhibitor that reduces the level of the product of a mutant having a neoactivity of an IDH, *e.g.,* IDH1 or IDH2 mutant, *e.g.,* it reduces the level of 2HG, *e.g.,* R-2HG.

In an embodiment the therapeutic agent is an inhibitor that:

inhibits, *e.g.,* specifically, a neoactivity of an IDH, *e.g.,* IDH1 or IDH2, *e.g.,* a neoactivity described herein, *e.g.,* 2HG neoactivity; or

inhibits both the wildtype activity and a neoactivity of an IDH, *e.g.,* IDH1 orIDH2, *e.g.,* a neoactivity described herein, e.g, 2HG neoactivity.

In an embodiment the therapeutic agent is an inhibitor that is selected on the basis that it:

inhibits, *e.g.,* specifically, a neoactivity of an IDH, *e.g.,* IDH1 or IDH2, *e.g.,* a neoactivity described herein *e.g.,* 2HG neoactivity; or

inhibits both the wildtype activity and a neoactivity of an IDH1, *e.g.,* IDH1 or IDH2, *e.g.,* a neoactivity described herein, *e.g.,* 2HG neoactivity.

In an embodiment the therapeutic agent is an inhibitor that reduces the amount of a mutant IDH, *e.g.,* IDH1 or IDH2, protein or mRNA.

In an embodiment the therapeutic agent is an inhibitor that interacts directly with, *e.g.,* it binds to, the mutant IDH, *e.g.,* IDH1 or IDH2 mRNA.

In an embodiment the therapeutic agent is an inhibitor that interacts directly with, *e.g.,* it binds to, the mutant IDH, *e.g.,* IDH1 or IDH2, protein.

In an embodiment the therapeutic agent is an inhibitor that reduces the amount of neoactive enzyme activity, *e.g.,* by interacting with, *e.g.,* binding to, mutant IDH, *e.g.,* IDH1 or IDH2, protein. In an embodiment the inhibitor is other than an antibody.

In an embodiment the therapeutic agent is an inhibitor that is a small molecule

and interacts with, *e.g.,* binds, the mutant RNA, *e.g.,* mutant IDH1 or IDH2 mRNA (e.g., mutant IDH1 mRNA).

In an embodiment the therapeutic agent is an inhibitor that interacts directly with, *e.g.,* binds, either the mutant IDH, *e.g.,* IDH1 or IDH2, protein or interacts directly with, *e.g.,* binds, the mutant IDH mRNA, *e.g.,* IDH1 or IDH2 mRNA.

In an embodiment the IDH is IDH1 and the neoactivity is alpha hydroxy neoactivity, e.g., 2HG neoactivity. Mutations in IDH1 associated with 2HG neoactivity include mutations at residue 132, e.g., R132H, R132C, R132S, R132G, R132L, or R132V (e.g., R132H or R132C).

In an embodiment the IDH is IDH2 and the neoactivity of the IDH2 mutant is alpha hydroxy neoactivity, e.g., 2HG neoactivity. Mutations in IDH2 associated with 2HG neoactivity include mutations at residue 172, e.g., R172K, R172M, R172S, R172G, or R172W.

Treatment methods described herein can comprise evaluating a neoactivity genotype or phenotype. Methods of obtaining and analyzing samples, and the in vivo analysis in subjects, described elsewhere herein, e.g., in the section entitled, "Methods of evaluating samples and/or subjects," can be combined with this method.

In an embodiment, prior to or after treatment, the method includes evaluating the growth, size, weight, invasiveness, stage or other phenotype of the cell proliferation-related disorder.

In an embodiment, prior to or after treatment, the method includes evaluating the IDH, e.g., IDH1 or IDH2, alpha hydroxyl neoactivity genotype, e.g., 2HG, genotype, or alpha hydroxy neoactivity phenotype, e.g., 2HG, e.g., R-2HG, phenotype. Evaluating the alpha hydroxyl, e.g., 2HG, genotype can comprise determining if an IDH1 or IDH2 mutation having alpha hydroxy neoactivity, e.g., 2HG neoactivity, is present, e.g., a mutation disclosed herein having alpha hydroxy neoactivity, e.g., 2HG neoactivity. Alpha hydroxy neoactivity phenotype, e.g., 2HG, e.g., R-2HG, phenotype, as used herein, refers to the level of alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, level of alpha hydroxy neoactivity, e.g., 2HG neoactivity, or level of mutant enzyme having alpha hydroxy neoactivity, e.g., 2HG neoactivity (or corresponding mRNA). The evaluation can be by a method described herein.

In an embodiment the subject can be evaluated, before or after treatment, to determine if the cell proliferation-related disorder is characterized by an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment a cancer, *e.g.,* a glioma or brain tumor in a subject, can be analyzed, *e.g.,* by imaging and/or spectroscopic analysis, *e.g.,* magnetic resonance-based analysis, *e.g.,* MRI and/or MRS, *e.g.,* before or after treatment, to determine if it is characterized by presence of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the method comprises evaluating, *e.g.,* by direct examination or evaluation of the subject, or a sample from the subject, or receiving such information about the subject, the IDH, *e.g.,* IDH1 or IDH2, genotype, or an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG phenotype of, the subject, *e.g.,* of a cell, *e.g.,* a cancer cell, characterized by the cell proliferation-related disorder. (As described in more detail elsewhere herein the evaluation can be, *e.g.,* by DNA sequencing, immuno analysis, evaluation of the presence, distribution or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, *e.g.,* from spectroscopic analysis, *e.g.,* magnetic resonance-based analysis, *e.g.,* MRI and/or MRS measurement, sample analysis such as serum or spinal cord fluid analysis, or by analysis of surgical material, *e.g.,* by mass-spectroscopy). In embodiments this information is used to determine or confirm that a proliferation-related disorder, *e.g.,* a cancer, is characterized by an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG. In embodiments this information is used to determine or confirm that a cell proliferation-related disorder, *e.g.,* a cancer, is characterized by an IDH, *e.g.,* IDH1 or IDH2, allele described herein, *e.g.,* an IDH1 allele having a mutation, *e.g.,* a His, Ser, Cys, Gly, Val, Pro or Leu (e.g., His, Ser, Cys, Gly, Val, or Leu at residue 132, more specifically, His or Cys, or an IDH2 allele having a mutation at residue 172, *e.g.,* a K, M, S, G, or W.

In an embodiment, before and/or after treatment has begun, the subject is evaluated or monitored by a method described herein, *e.g.,* the analysis of the presence, distribution, or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, *e.g.,* to select, diagnose or prognose the subject, to select an inhibitor, or to evaluate response to the treatment or progression of disease.

In an embodiment the cell proliferation-related disorder is a tumor of the CNS, *e.g.,* a glioma, a leukemia, *e.g.,* AML or ALL, e.g., B-ALL or T-ALL, prostate cancer, fibrosarcoma, paraganglioma, or myelodysplasia or myelodysplastic syndrome (e.g., B-ALL or T-ALL, prostate cancer, or myelodysplasia or myelodysplastic syndrome) and the evaluation is: evaluation of the presence, distribution, or level of an alpha

hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG; or evaluation of the presence, distribution, or level of a neoactivity, *e.g.,* an alpha hydroxy neoactivity, e.g., 2HG neoactivity, of an IDH1 or IDH2, mutant protein.

In an embodiment the disorder is other than a solid tumor. In an embodiment the disorder is a tumor that, at the time of diagnosis or treatment, does not have a necrotic portion. In an embodiment the disorder is a tumor in which at least 30, 40, 50, 60, 70, 80 or 90% of the tumor cells carry an IHD, e.g., IDH1 or IDH2, mutation having 2HG neoactivity, at the time of diagnosis or treatment.

In an embodiment the cell proliferation-related disorder is a cancer, e.g., a cancer described herein, characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the tumor is characterized by increased levels of an alpha hydroxy neoactivity product, 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type.

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by unwanted (i.e., increased) levels of an alpha hydroxy neoactivity, product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is a tumor of the CNS, *e.g.,* a glioma, *e.g.,* wherein the tumor is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. Gliomas include astrocytic tumors, oligodendroglial tumors, oligoastrocytic tumors, anaplastic astrocytomas, and glioblastomas. In an embodiment the tumor is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type. *E.g.,* in an embodiment, the IDH1 allele encodes an IDH1 having other than an Arg at residue 132. *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu (e.g., His, Ser, Cys, Gly, Val, or Leu), or any residue described in Yan *et al.*, at residue 132, according to the sequence of SEQ ID NO:8 (see also **Fig. 21**). In an embodiment the allele encodes an IDH1 having His at residue 132. In an embodiment the allele encodes an IDH1 having Ser at residue 132.

In an embodiment the IDH1 allele has an A (or any other nucleotide other than C) at nucleotide position 394, or an A (or any other nucleotide other than G) at nucleotide position 395. In an embodiment the allele is a C394A, a C394G, a C394T,

a G395C, a G395T or a G395A mutation; specifically a C394A or a G395A mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having a glioma, wherein the cancer is characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having His, Ser, Cys, Gly, Val, Pro or Leu at residue 132 (SEQ ID NO:8), more specifically His, Ser, Cys, Gly, Val, or Leu; or His or Cys.

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having His, Ser, Cys, Gly, Val, Pro or Leu at residue 132 (SEQ ID NO:8) , more specifically His, Ser, Cys, Gly, Val, or Leu; or His or Cys.

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity, product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the method comprises selecting a subject having a fibrosarcoma or paraganglioma wherein the cancer is characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 (SEQ ID NO:8).

In an embodiment the method comprises selecting a subject having a fibrosarcoma or paraganglioma, on the basis of the cancer being characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 (SEQ ID NO:8).

In an embodiment the method comprises selecting a subject having a fibrosarcoma or paraganglioma, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity, product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is localized or metastatic prostate cancer, *e.g.,* prostate adenocarcinoma, *e.g.,* wherein the cancer is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the cancer is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type.

E.g., in an embodiment, the IDH1 allele encodes an IDH1 having other than an Arg at residue 132. *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Kang *et al*, 2009, Int. J. Cancer, 125: 353-355 at residue 132, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**) (e.g., His, Ser, Cys,

Gly, Val, or Leu). In an embodiment the allele encodes an IDH1 having His or Cys at residue 132.

In an embodiment the IDH1 allele has a T (or any other nucleotide other than C) at nucleotide position 394, or an A (or any other nucleotide other than G) at nucleotide position 395. In an embodiment the allele is a C394T or a G395A mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having prostate cancer, *e.g.,* prostate adenocarcinoma, wherein the cancer is characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having His or Cys at residue 132 (SEQ ID NO:8).

In an embodiment the method comprises selecting a subject having prostate cancer, *e.g.,* prostate adenocarcinoma, on the basis of the cancer being characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having His or Cys at residue 132 (SEQ ID NO:8).

In an embodiment the method comprises selecting a subject having prostate cancer, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is a hematological cancer, *e.g.,* a leukemia, *e.g.,* AML, or ALL, wherein the hematological cancer is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the cancer is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type.

In an embodiment the cell proliferation-related disorder is acute lymphoblastic leukemia (*e.g.,* an adult or pediatric form), *e.g.,* wherein the acute lymphoblastic leukemia (sometimes referred to herein as ALL) is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. The ALL can be, e.g., B-ALL or T-ALL. In an embodiment the cancer is characterized by increased levels of 2 an alpha hydroxy neoactivity product, e.g., HG, e.g., R-2HG, as compared to non-diseased cells of the same type. *E.g.,* in an embodiment, the IDH1 allele is an IDH1 having other than an Arg at residue 132 (SEQ ID NO:8). *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Kang *et a.l*, at residue 132, according to the sequence of SEQ ID

NO:8 (see also **FIG. 21**), more specifically His, Ser, Cys, Gly, Val, or Leu. In an embodiment the allele encodes an IDH1 having Cys at residue 132.

In an embodiment the IDH1 allele has a T (or any other nucleotide other than C) at nucleotide position 394. In an embodiment the allele is a C394T mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 according to the sequence of SEQ ID NO:8.

In an embodiment the method comprises selecting a subject ALL, e.g., B-ALL or T-ALL, on the basis of cancer being characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 (SEQ ID NO:8).

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is acute myelogenous leukemia (*e.g.,* an adult or pediatric form), *e.g.,* wherein the acute myelogenous leukemia (sometimes referred to herein as AML) is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the cancer is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type. *E.g.,* in an embodiment, the IDH1 allele is an IDH1 having other than an Arg at residue 132 (SEQ ID NO:8). *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Kang *et al.*, at residue 132, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**). In an embodiment the allele encodes an IDH1 having Cys, His or Gly at residue 132, more specifically, Cys at residue 132.

In an embodiment the IDH1 allele has a T (or any other nucleotide other than C) at nucleotide position 394. In an embodiment the allele is a C394T mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having acute myelogenous lymphoplastic leukemia (AML) characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys, His, or Gly at residue 132 according to the sequence of SEQ ID NO:8, more specifically, Cys at residue 132.

In an embodiment the method comprises selecting a subject having acute myelogenous lymphoplastic leukemia (AML) on the basis of cancer being characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys, His, or Gly at residue 132 (SEQ ID NO:8), more specifically, Cys at residue 132.

In an embodiment the method comprises selecting a subject having acute myelogenous lymphoplastic leukemia (AML), on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the method further comprises evaluating the subject for the presence of a mutation in the NRAS or NPMc gene.

In an embodiment the cell proliferation-related disorder is myelodysplasia or myelodysplastic syndrome, *e.g.,* wherein the myelodysplasia or myelodysplastic syndrome is characterized by having an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the disorder is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type. *E.g.,* in an embodiment, the IDH1 allele is an IDH1 having other than an Arg at residue 132 (SEQ ID NO:8). *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Kang *et a.l*, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**), more specifically His, Ser, Cys, Gly, Val, or Leu. In an embodiment the allele encodes an IDH1 having Cys at residue 132.

In an embodiment the IDH1 allele has a T (or any other nucleotide other than C) at nucleotide position 394. In an embodiment the allele is a C394T mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys, His, or Gly at residue 132 according to the sequence of SEQ ID NO:8, more specifically, Cys at residue 132.

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome on the basis of cancer being characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys, His, or Gly at residue 132 (SEQ ID NO:8), more specifically, Cys at residue 132.

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome, on the basis of the cancer being

characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is a glioma, characterized by a mutation, or preselected allele, of IDH2 associated with an alpha hydroxy neoactivity, e.g., 2HG neoactivity. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al*., at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), more specifically Lys, Gly, Met, Trp, or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment the method comprises selecting a subject having a glioma, wherein the cancer is characterized by having an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys, Gly, Met, Trp, Thr, or Ser at residue 172 (SEQ ID NO:10), more specifically Lys, Gly, Met, Trp, or Ser; or Lys or Met.

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys, Gly, Met, Trp, Thr, or Ser at residue 172 (SEQ ID NO:10), more specifically Lys, Gly, Met, Trp, or Ser; or Lys or Met.

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is a prostate cancer, *e.g.,* prostate adenocarcinoma, characterized by a mutation, or preselected allele, of IDH2 associated with an alpha hydroxy neoactivity, e.g., 2HG neoactivity. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al*., at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), more specifically Lys, Gly, Met, Trp, or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment the method comprises selecting a subject having a prostate cancer, *e.g.,* prostate adenocarcinoma, wherein the cancer is characterized by having

an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having a prostate cancer, *e.g.,* prostate adenocarcinoma, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having a prostate cancer, *e.g.,* prostate adenocarcinoma, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is ALL, e.g., B-ALL or T-ALL, characterized by a mutation, or preselected allele, of IDH2 associated with an alpha hydroxy neoactivity, e.g., 2HG neoactivity. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al*., at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**). In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, wherein the cancer is characterized by having an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is AML, characterized by a mutation, or preselected allele, of IDH2 associated with an alpha hydroxy neoactivity, e.g., 2HG neoactivity. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al*., at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), more specifically Lys,

Gly, Met, or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172. In an embodiment the allele encodes an IDH2 having Gly at residue 172.

In an embodiment the method comprises selecting a subject having AML, wherein the cancer is characterized by having an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys, Gly or Met at residue 172 (SEQ ID NO:10), more specifically Lys or Met.

In an embodiment the method comprises selecting a subject having AML, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys, Gly, or Met at residue 172 (SEQ ID NO:10), more specifically Lys or Met.

In an embodiment the method comprises selecting a subject having AML, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is myelodysplasia or myelodysplastic syndrome, characterized by a mutation, or preselected allele, of IDH2. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al*., at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), more specifically Lys, Gly, Met, Trp or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172. In an embodiment the allele encodes an IDH2 having Gly at residue 172.

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome,wherein the cancer is characterized by having an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys, Gly, or Met at residue 172 (SEQ ID NO:10), in specific embodiments, Lys or Met.

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys, Gly, or Met at residue 172 (SEQ ID NO:10), in specific embodiments, Lys or Met.

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome, on the basis of the cancer being

characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment a product of the neoactivity is 2HG (*e.g.,* R-2HG) which acts as a metabolite. In another embodiment a product of the neoactivity is 2HG (*e.g.,* R-2HG) which acts as a toxin, *e.g.,* a carcinogen.

In some embodiments, the methods described herein can result in reduced side effects relative to other known methods of treating cancer.

Therapeutic agents and methods of subject evaluation described herein can be combined with other therapeutic mocalities, e.g., with art-known treatments.

In an embodiment the method comprises providing a second treatment, to the subject, *e.g.,* surgical removal, irradiation or administration of a chemotherapeutitc agent, *e.g.,* an administration of an alkylating agent. Administration (or the establishment of therapeutic levels) of the second treatment can: begin prior to the beginning or treatment with (or prior to the establishment of therapeutic levels of) the inhibitor; begin after the beginning or treatment with (or after the establishment of therapeutic levels of) the inhibitor, or can be administered concurrently with the inhibitor, *e.g.,* to achieve therapeiutc levels of both concurrently.

In an embodiment the cell proliferation-related disorder is a CNS tumor, *e.g.,* a glioma, and the second therapy comprises administration of one or more of: radiation; an alkylating agent, e.g., temozolomide, e.g., Temoader®, or BCNU; or an inhibitor of HER1/EGFR tyrosine kinase, e.g., erlotinib, e.g., Tarceva®.

The second therapy, *e.g.,* in the case of glioma, can comprise implantation of BCNU or carmustine in the brain, e.g., implantation of a Gliadel® wafer.

The second therapy, *e.g.,* in the case of glioma, can comprise administration of imatinib, e.g., Gleevec®.

In an embodiment the cell proliferation-related disorder is prostate cancer and the second therapy comprises one or more of: androgen ablation; administration of a microtubule stabilizer, e.g., docetaxol, e.g., Taxotere®; or administration of a topoisomerase II inhibitor, e.g., mitoxantrone.

In an embodiment the cell proliferation-related disorder is ALL, e.g., B-ALL or T-ALL, and the second therapy comprises one or more of:

induction phase treatment comprising the administration of one or more of: a steroid; an inhibitor of microtubule assembly, e.g., vincristine; an agent that reduces

the availability of asparagine, e.g., asparaginase; an anthracycline; or an antimetabolite, e.g., methotrexate, e.g., intrathecal methotrexate, or 6-mercaptopurine;

consolidation phase treatment comprising the administration of one or more of: a drug listed above for the induction phase; an antimetabolite, e.g., a guanine analog, e.g., 6-thioguanine; an alkylating agent , e.g., cyclophosphamide; an anti-metabolite, e.g., AraC or cytarabine; or an inhibitor of topoisomerase I, e.g., etoposide; or

maintenance phase treatment comprising the administration of one or more of the drugs listed above for induction or consolidation phase treatment.

In an embodiment the cell proliferation-related disorder is AML and the second therapy comprises administration of one or more of: an inhibitor of topoisomerase II, e.g., daunorubicin, idarubicin, topotecan or mitoxantrone; an inhibitor of topoisomerase I, e.g., etoposide; or an anti-metabolite, e.g., AraC or cytarabine.

In another aspect, the invention features, a method of evaluating, e.g. diagnosing, a subject, *e.g.,* a subject not having, or not diagnosed as having, 2-hydroxyglutaric aciduria. The method comprises analyzing a parameter related to the neoactivity genotype or phenotype of the subject, e.g., analyzing one or more of:

a) the presence, distribution, or level of a neoactive product, e.g., the product of an alpha hydroxy neoactivity, e.g., 2HG, *e.g.,* R-2HG, e.g., an increased level of product, 2HG, *e.g.,* R-2HG (as used herein, an increased level of a product of an alpha hydroxy neoactivity, e.g., 2HG, *e.g.,* R-2HG, or similar term, e.g., an increased level of neoactive product or neoactivity product, means increased as compared with a reference, e.g., the level seen in an otherwise similar cell lacking the IDH mutation, e.g., IDH1 or IDH2 mutation, or in a tissue or product from a subject noth having the mutation (the terms increased and elevated as refered to the level of a product of alpha hydroxyl neoactivity as used herein, are used interchangably);

b) the presence, distribution, or level of a neoactivity, *e.g.,* alpha hydroxy neoactivity, e.g., 2HG neoactivity, of an IDH1 or IDH2, mutant protein;

c) the presence, distribution, or level of a neoactive mutant protein, e.g., an IDH, *e.g.,* an IDH1 or IDH2, mutant protein which has a neoactivity, e.g., alpha hydroxy neoactivity, *e.g.,* 2HG neoactivity, or a corresponding RNA; or

d) the presence of a selected somatic allele or mutation conferring neoactivity, e.g., an IDH, *e.g.,* IDH1 or IDH2, which encodes a protein with a neoactivity, *e.g.,*

alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* an allele disclosed herein, in cells characterized by a cell proliferation-related disorder from the subject, thereby evaluating the subject.

In an embodiment analyzing comprises performing a procedure, e.g., a test, to provide data or information on one or more of a-d, e.g., performing a method which results in a physical change in a sample, in the subject, or in a device or reagent used in the analysis, or which results in the formation of an image representative of the data. Methods of obtaining and analyzing samples, and the in vivo analysis in subjects, described elsewhere herein, e.g., in the section entitled, "Methods of evaluating samples and/or subjects," can be combined with this method. In another embodiment analyzing comprises receiving data or information from such test from another party. In an embodiment the analyzing comprises receiving data or information from such test from another party and, the method comprises, responsive to that data or information, administering a treatment to the subject.

As described herein, the evaluation can be used in a number of applications, e.g., for diagnosis, prognosis, staging, determination of treatment efficacy, patent selection, or drug selection.

Thus, in an embodiment method further comprises, *e.g.,* responsive to the analysis of one or more of a-d:

diagnosing the subject, *e.g.,* diagnosing the subject as having a cell proliferation-related disorder, *e.g.,* a disorder characterized by unwanted cell proliferation, *e.g.,* cancer, or a precancerous disorder;

staging the subject, *e.g.,* determining the stage of a cell proliferation-related disorder, *e.g.,* a disorder characterized by unwanted cell proliferation, *e.g.,* cancer, or a precancerous disorder;

providing a prognosis for the subject, *e.g.,* providing a prognosis for a cell proliferation-related disorder, *e.g.,* a disorder characterized by unwanted cell proliferation, *e.g.,* cancer, or a precancerous disorder;

determining the efficacy of a treatment, *e.g.,* the efficacy of a chemotherapeutic agent, irradiation or surgery;

determining the efficacy of a treatment with a therapeutic agent, e.g., an inhibitor, described herein;

selecting the subject for a treatment for a cell proliferation-related disorder, *e.g.,* a disorder characterized by unwanted cell proliferation, *e.g.,* cancer, or a

precancerous disorder. The selection can be based on the need for a reduction in neoactivity or on the need for amelioration of a condition associated with or resulting from neoactivity. For example, if it is determined that the subject has a cell proliferation-related disorder, *e.g., e.g.,* cancer, or a precancerous disorder characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, or by a mutant IDH1 or IDH2, having alpha hydroxyl neoactivity, e.g., 2HG, neaoctivity, selecting the subject for treatment with a therapeutic agent described herein, e.g., an inhibitor (*e.g.,* a small molecule or a nucleic acid-based inhibitor) of the neoactivity of that mutant (*e.g.,* conversion of alpha-ketoglutarate to 2HG, *e.g.,* R-2HG);

correlating the analysis with an outcome or a prognosis;

providing a value for an analysis on which the evaluation is based, *e.g.,* the value for a parameter correlated to the presence, distribution, or level of an alpha hydroxyl neoactivity product, e.g., 2HG, *e.g.,* R-2HG;

providing a recommendation for treatment of the subject; or

memorializing a result of, or ouput from, the method, *e.g.,* a measurement made in the course of performing the method, and optionally transmitting the memorialization to a party, *e.g.,* the subject, a healthcare provider, or an entity that pays for the subject's treatment, *e.g.,* a government, insurance company, or other third party payer.

As described herein, the evaluation can provide information on which a number of decisions or treatments can be based.

Thus, in an embodiment the result of the evaluation, *e.g.,* an increased level of an alpha hydroxyl neoactivity product, e.g., 2HG, *e.g.,* R-2HG, the presence of an IDH, *e.g.,* IDH1 or IDH2, neoactivity, *e.g.,* alpha hydroxyl neoactivity, e.g., 2HG neoactivity, the presence of an IDH, *e.g.,* IDH1 or IDH2, mutant protein (or corresponding RNA) which has alpha hydroxyl neoactivity, e.g., 2HG neoactivity, the presence of a mutant allele of IDH, *e.g.,* IDH1 or IDH2, having alpha hydroxyl neoactivity, 2HG neoactivity, *e.g.,* an allele disclosed herein, is indicative of:

a cell proliferation-related disorder, *e.g.,* cancer, *e.g.,* it is indicative of a primary or metastatic lesion;

the stage of a cell proliferation-related disorder;

a prognosis or outcome for a cell proliferation-related disorder, *e.g.,* it is indicative of a less aggressive form of the disorder, *e.g.,* cancer. *E.g.,* in the case of

glioma, presence of an alpha hydroxyl neoactivity product, e.g., 2HG, *e.g.,* R-2HG, can indicate a less aggressive form of the cancer;

the efficacy of a treatment, *e.g.,* the efficacy of a chemotherapeutic agent, irradiation or surgery;

the need of of a therapy disclosed herein, e.g., inhibition a neoactivity of an IDH, *e.g.,* IDH1 or IDH2, neoactive mutant described herein. In an embodiment relatively higher levels (or the presence of the mutant) is correlated with need of inhibition a neoactivity of an IDH, *e.g.,* IDH1 or IDH2, mutant described herein; or

responsiveness to a treatment. The result can be used as a noninvasive biomarker for clinical response. *E.g.,* elevated levels can be predictive on better outcome in glioma patients (*e.g.,* longer life expectancy).

As described herein, the evaluation can provide for the selection of a subject.

Thus, in an embodiment the method comprises, *e.g.,* responsive to the analysis of one or more of a-d, selecting a subject, *e.g.,* for a treatment. The subject can be selected on a basis described herein, e.g., on the basis of:

said subject being at risk for, or having, higher than normal levels of an alpha hydroxy neoactivity product, e.g., 2-hydroxyglurarate (*e.g.,* R-2HG) in cell having a cell proliferation-related disorder, *e.g.,* a leukemia such as AML or ALL, e.g., B-ALL or T-ALL, or a tumor lesion, *e.g.,* a glioma or a prostate tumor;

said subject having a proliferation-related disorder characterized by a selected IDH, *e.g.,* IDH1 or IDH2 allele, *e.g.,* an IDH1 or IDH2 mutation, having alpha hydroxyl neoactivity, e.g., 2HG neoactivity;

said subject having a selected IDH allele, *e.g.,* a selected IDH1 or IDH2 allele; having alpha hydroxyl neoactivity, e.g., 2HG neoactivity;

said subject having a proliferation-related disorder;

said subject being in need of, or being able to benefit from, a therapeutic agent of a type described herein;

said subject being in need of, or being able to benefit from, a compound that inhibits alpha hydroxyl neoactivity, e.g., 2HG neoactivity;

said subject being in need of, or being able to benefit from, a compound that lowers the level of an alpha hydroxyl neoactivity product, e.g., 2HG, e.g., R-2HG.

In an embodiment evaluation comprises selecting the subject, *e.g.,* for treatment with an anti-neoplastic agent, on the establishment of, or determination that, the subject has increased alpha hydroxyl neoactivity product, e.g., 2HG, *e.g.,* R-2HG,

or increased alpha hydroxyl neoactivity, e.g., 2HG neoactivity, or that the subject is in need of inhibition of a neoactivity of an IDH, *e.g.,* IDH1 or IDH2, mutant described herein.

As described herein, the evaluations provided for by methods described herein allow the selection of optimal treatment regimens.

Thus, in an embodiment the method comprises, *e.g.,* responsive to the analysis of one or more of a-d, selecting a treatment for the subject, e.g., selecting a treatment on a basis disclosed herein. The treatment can be the administration of a therapeutic agent disclosed herein. The treatment can be selected on the basis that:

it us useful in treating a disorder charcterized by one or more of alpha hydroxyl neoactivity, e.g., 2HG neoactivity, an IDH1 or IDH2, mutant protein having alpha hydroxyl neoactivity, e.g., 2HG neoactivity (or a corresponding RNA);

it is useful in treating a disorder characterized by a selected somatic allele or mutation of an IDH, *e.g.,* IDH1 or IDH2, which encodes a protein with alpha hydroxyl neoactivity, e.g., 2HG neoactivity, *e.g.,* an allele disclosed herein, in cells characterized by a cell proliferation-related disorder from the subject;

it reduces the level of an alpha hydroxyl neoactivity product, e.g., 2HG, *e.g.,* R-2HG;

it reduces the level of alpha hydroxyl neoactivity, e.g., 2HG neoactivity.

In an embodiment evaluation comprises selecting the subject, *e.g.,* for treatment.

In embodiments the treatment is the administration of a therapeutic agent described herein.

The methods can also include treating a subject, e.g, with a treatment selected in response to, or on the basis of, an evaluation made in the method.

Thus, in an embodiment the method comprises, *e.g.,* responsive to the analysis of one or more of a-d, administerin a treatment to the subject, e.g., the administration of a therapeutic agent of a type described herein.

In an embodiment the therapeutic agent comprises a compound from Table 24a or Table 24b or a compound having the structure of Formula (X) or (XI) described below.

In an embodiment the therapeutic agent comprises nucleic acid, e.g., dsRNA, e.g., a dsRNA described herein.

In an embodiment the the therapeutic agent is an inhibitor, *e.g.,* a polypeptide, peptide, or small molecule (*e.g.,* a molecule of less than 1,000 daltons), or aptomer, that binds to an IDH1 or IDH2 mutant (e.g., an aptomer that binds to an IDH1 mutant) or wildtype subunit and inhibits neoactivity, e.g., by inhibiting formation of a dimer, *e.g.,* a homodimer of mutant IDH1 or IDH2 subunits (e.g., a homodimer of mutant IDH1 subunits) or a heterodimer of a mutant and a wildype subunit. In an embodiment the inhibitor is a polypeptide. In an embodiment the polypeptide acts as a dominant negative with respect to the neoactivity of the mutant enzyme. The polypeptide can correspond to full length IDH1 or IDH2 or a fragment thereof (e.g., the polypeptide correspondes to full length IDH1 or a fragment thereof). The polypeptide need not be indentical with the corresponding residues of wildtype IDH1 or IDH2 (e.g., wildtype IDH1), but in embodiments has at least 60, 70, 80, 90 or 95 % homology with wildtype IDH1 or IDH2 (e.g., wildtype IDH1).

In an embodiment the therapeutic agent decreases the affinity of an IDH, e.g., IDH1 or IDH2 neoactive mutant protein for NADH, NADPH or a divalent metal ion, e.g., Mg^{2+} or Mn^{2+}, or decreases the levels or availability of NADH, NADPH or divalent metal ion, e.g., Mg^{2+} or Mn^{2+}, *e.g.,* by competing for binding to the mutant enzyme. In an embodiment the enzyme is inhibited by replacing Mg^{2+} or Mn^{2+} with Ca^{2+}.

In an embodiment the therapeutic agent is an inhibitor that reduces the level a neoactivity of an IDH, *e.g.,* IDH1 or IDH2, *e.g.,* 2HG neoactivity.

In an embodiment the therapeutic agent is an inhibitor that reduces the level of the product of a mutant having a neoactivity of an IDH, *e.g.,* IDH1 or IDH2 mutant, *e.g.,* it reduces the level of 2HG, *e.g.,* R-2HG.

In an embodiment the therapeutic agent is an inhibitor that:

inhibits, *e.g.,* specifically, a neoactivity of an IDH, *e.g.,* IDH1 or IDH2, *e.g.,* a neoactivity described herein, *e.g.,* 2HG neoactivity; or

inhibits both the wildtype activity and a neoactivity of an IDH, *e.g.,* IDH1 orIDH2, *e.g.,* a neoactivity described herein, e.g, 2HG neoactivity.

In an embodiment the therapeutic agent is an inhibitor that is selected on the basis that it:

inhibits, *e.g.,* specifically, a neoactivity of an IDH, *e.g.,* IDH1 or IDH2, *e.g.,* a neoactivity described herein *e.g.,* 2HG neoactivity; or

inhibits both the wildtype activity and a neoactivity of an IDH1, *e.g.,* IDH1 or IDH2, *e.g.,* a neoactivity described herein, *e.g.,* 2HG neoactivity.

In an embodiment the therapeutic agent is an inhibitor that reduces the amount of a mutant IDH, *e.g.,* IDH1 or IDH2, protein or mRNA.

In an embodiment the therapeutic agent is an inhibitor that interacts directly with, *e.g.,* it binds to, the mutant IDH, *e.g.,* IDH1 or IDH2 mRNA.

In an embodiment the therapeutic agent is an inhibitor that interacts directly with, *e.g.,* it binds to, the mutant IDH, *e.g.,* IDH1 or IDH2, protein.

In an embodiment the therapeutic agent is an inhibitor that reduces the amount of neoactive enzyme activity, *e.g.,* by interacting with, *e.g.,* binding to, mutant IDH, *e.g.,* IDH1 or IDH2, protein. In an embodiment the inhibitor is other than an antibody.

In an embodiment the therapeutic agent is an inhibitor that is a small molecule and interacts with, *e.g.,* binds, the mutant RNA, *e.g.,* mutant IDH1 mRNA.

In an embodiment the therapeutic agent is an inhibitor that interacts directly with, *e.g.,* binds, either the mutant IDH, *e.g.,* IDH1 or IDH2, protein or interacts directly with, *e.g.,* binds, the mutant IDH mRNA, *e.g.,* IDH1 or IDH2 mRNA.

In an embodiment the therapeutic agent is administered.

In an embodiment the treatment: inhibits, *e.g.,* specifically, a neoactivity of IDH1 or IDH2 (e.g., a neoactivity of IDH1) , *e.g.,* a neoactivity described herein; or inhibits both the wildtype and activity and a neoactivity of IDH1 or IDH2 (e.g., a neoactivity of IDH1), *e.g.,* a neoactivity described herein In an embodiment, the subject is subsequently evaluated or monitored by a method described herein, *e.g.,* the analysis of the presence, distribution, or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, *e.g.,* to evaluate response to the treatment or progression of disease.

In an embodiment the treatment is selected on the basis that it: inhibits, *e.g.,* specifically, a neoactivity of IDH1 or IDH2 (e.g., a neoactivity of IDH1), *e.g.,* alpha hydroxy neoactivity, e.g., 2HG neoactivity; or inhibits both the wildtype and activity and a neoactivity of IDH1 or IDH2 (e.g., a neoactivity of IDH1), *e.g.,* a neoactivity described herein.

In an embodiment, the method comprises determining the possibility of a mutation other than a mutation in IDH1 or in IDH2. In embodiments a relatively high level of 2HG, *e.g.,* R-2HG is indicative of another mutation.

In an embodiment, which embodiment includes selecting or administering a treatment for the subject, the subject:

has not yet been treated for the subject the cell proliferation-related disorder and the selected or administered treatment is the initial or first line treatment;

has already been treated for the the cell proliferation-related and the selected or administered treatment results in an alteration of the existing treatment;

has already been treated for the the cell proliferation-related, and the selected treatment results in continuation of the existing treatment; or

has already been treated for the the cell proliferation-related disorder and the selected or administered treatment is different, *e.g.,* as compared to what was administered prior to the evaluation or to what would be administered in the absence of elevated levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment, which embodiment includes selecting or administering a treatment for the subject, the selected or administered treatment can comprise:

a treatment which includes administration of a therapeutic agent at different, *e.g.,* a greater (or lesser) dosage (*e.g.,* different as compared to what was administered prior to the evaluation or to what would be administered in the absence of elevated levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG);

a treatment which includes administration of a therapeutic agent at a different frequency, *e.g.,* more or less frequently, or not at all (*e.g.,* different as compared to what was administered prior to the evaluation or to what would be administered in the absence of elevated levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG); or

a treatment which includes administration of a therapeutic agent in a different therapeutic setting (*e.g.,* adding or deleting a second treatment from the treatment regimen) (*e.g.,* different as compared to what was administered prior to the evaluation or to what would be administered in the absence of elevated levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG).

Methods of evaluating a subject described herein can comprise evaluating a neoactivity genotype or phenotype. Methods of obtaining and analyzing samples, and the in vivo analysis in subjects, described elsewhere herein, e.g., in the section entitled, "Methods of evaluating samples and/or subjects," can be combined with this method.

In an embodiment the method comprises:

subjecting the subject (*e.g.,* a subject not having 2-hydroxyglutaric aciduria) to imaging and/or spectroscopic analysis, *e.g.,* magnetic resonance-based analysis, *e.g.,* MRI and/or MRS *e.g.,*imaging analysis, to provide a determination of the presence, distribution, or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, *e.g.,* as associated with a tumor, *e.g.,* a glioma, in the subject;

optionally storing a parameter related to the determination, *e.g.,* the image or a value related to the image from the imaging analysis, in a tangible medium; and

responsive to the determination, performing one or more of: correlating the determination with outcome or with a prognosis; providing an indication of outcome or prognosis; providing a value for an analysis on which the evaluation is based, *e.g.,* the presence, distribution, or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG; providing a recommendation for treatment of the subject; selecting a course of treatment for the subject, *e.g.,* a course of treatment described herein, *e.g.,* selecting a course of treatment that includes inhibiting a neoactivity of a mutant IDH, *e.g.,* IDH1 or IDH2, allele, *e.g.,* a neoactivity described herein; administering a course of treatment to the subject, *e.g.,* a course of treatment described herein, *e.g.,* a course of treatment that includes inhibiting a neoactivity of a mutant IDH, *e.g.,* IDH1 or IDH2, allele, *e.g.,* a neoactivity described herein; and memorializing memorializing a result of the method or a measurement made in the course of the method, *e.g.,* one or more of the above and/or transmitting memorialization of one or more of the above to a party, *e.g.,* the subject, a healthcare provider, or an entity that pays for the subject's treatment, *e.g.,* a government, insurance company, or other third party payer.

In an embodiment the method comprises confirming or determining, *e.g.,* by direct examination or evaluation of the subject, or sample *e.g.,* tissue or bodily fluid (*e.g.,* blood (*e.g.,* blood plasma), urine, lymph, or cerebrospinal fluid) therefrom, (*e.g.,* by DNA sequencing or immuno analysis or evaluation of the presence, distribution or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG), or receiving such information about the subject, that the subject has a cancer characterized by an IDH, *e.g.,* IDH1 or IDH2, allele described herein, *e.g.,* an IDH1 allele having His, Ser, Cys, Gly, Val, Pro or Leu at residue 132 (SEQ ID NO:8), in specific embodiments, an IDH1 allele having His, Ser, Cys, Gly, Val, or Leu at residue 132 or an IDH1 allele having His or Cys at residue 132; or an IDH2 allele having Lys, Gly, Met, Trp, Thr, or Ser at residue 172 (SEQ ID NO:10).

In an embodiment, prior to or after treatment, the method includes evaluating the growth, size, weight, invasiveness, stage or other phenotype of the cell proliferation-related disorder.

In an embodiment the cell proliferation-related disorder is a tumor of the CNS, *e.g.,* a glioma, a leukemia, *e.g.,* AML or ALL, e.g., B-ALL or T-ALL, prostate cancer, or myelodysplasia or myelodysplastic syndrome and the evaluation is a or b. In an embodiment the method comprises evaluating a sample, e.g., a sample described herein, e.g., a tissue, e.g., a cancer sample, or a bodily fluid, e.g., serum or blood, for increased alpha neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment, a subject is subjected to MRS and the evaluation comprises evaluating the presence or elevated amount of a peak correlated to or corresponding to 2HG, *e.g.,* R-2HG, as determined by magnetic resonance. For example, a subject can be analyzed for the presence and/or strength of a signal at about 2.5 ppm to determine the presence and/or amount of 2HG, *e.g.,* R-2HG in the subject.

In an embodiment the method comprises obtaining a sample from the subject and analyzing the sample, or analyzing the subject, *e.g.,* by imaging the subject and optionally forming a representationof the image on a computer.

In an embodiment the results of the analysis is compared to a reference.

In an embodiment a value for a parameter correlated to the presence, distribution, or level, *e.g.,* of 2HG, *e.g.,* R-2HG, is determined. It can be compared with a reference value, *e.g.,* the value for a reference subject not having abnormal presence, level, or distribution, *e.g.,* a reference subject cell not having a mutation in IDH, *e.g.,* IDH1 or IDH2, having a neoactivity described herein.

In an embodiment the method comprises determing if an IDH, e.g., IDH1 or IDH2, mutant allele that is associated with 2HG neoactivity is present. E.g., in the case of IDH1, the presence of a mutaton at residue 132 associated with 2HG neoactivity can be determined. In the case of IDH2, the presence of a mutaton at residue 172 associated with 2HG neoactivity can be determined. The determination can comprise sequencing a nucleic acid, e.g., genomic DNA or cDNA, from an affected cell, which encodes the relevant amino acid(s). The mutation can be a deletion, insertion, rearrangement, or substitution. The mutation can involve a single nucleotide, e.g., a single substitution, or more than one nucleotide, e.g., a deletion of more than one nucleotides.

In an embodiment the method comprises determining the sequence at position 394 or 395 of the IDH1 gene, or determining the identity of amino acid residue 132 (SEQ ID NO:8) in the IDH1 gene in a cell characterized by the cell proliferation related disorder.

In an embodiment the method comprises determining the amino acid sequence, *e.g.,* by DNA sequenceing, at position 172 of the IDH2 gene in a cell characterized by the cell proliferation related disorder.

In an embodiment a product of the neoactivity is 2-HG, *e.g.,* R-2HG, which acts as a metabolite. In another embodiment a product of the neoactivity is 2HG, *e.g.,* R-2HG, which acts as a toxin, *e.g.,* a carcinogen.

In an embodiment the disorder is other than a solid tumor. In an embodiment the disorder is a tumor that, at the time of diagnosis or treatment, does not have a necrotic portion. In an embodiment the disorder is a tumor in which at least 30, 40, 50, 60, 70, 80 or 90% of the tumor cells carry an IHD, e.g., IDH1 or IDH2, mutation having 2HG neoactivity, at the time of diagnosis or treatment.

In an embodiment the cell proliferation-related disorder is a cancer, e.g., a cancer described herein, characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the tumor is characterized by increased levels of an alpha hydroxy neoactivity product, 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type.

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity, product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is a tumor of the CNS, *e.g.,* a glioma, *e.g.,* wherein the tumor is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. Gliomas include astrocytic tumors, oligodendroglial tumors, oligoastrocytic tumors, anaplastic astrocytomas, and glioblastomas. In an embodiment the tumor is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type. *E.g.,* in an embodiment, the IDH1 allele encodes an IDH1 having other than an Arg at residue 132. *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Yan *et al.*, at residue 132, according to the sequence of SEQ ID NO:8

(see also **Fig. 21**). In an embodiment the allele encodes an IDH1 having His at residue 132. In an embodiment the allele encodes an IDH1 having Ser at residue 132.

In an embodiment the IDH1 allele has an A (or any other nucleotide other than C) at nucleotide position 394, or an A (or any other nucleotide other than G) at nucleotide position 395. In an embodiment the allele is a C394A, a C394G, a C394T, a G395C, a G395T or a G395A mutation, specifically C394A or a G395A mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having a glioma, wherein the cancer is characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having His, Ser, Cys, Gly, Val, Pro or Leu at residue 132 (SEQ ID NO:8) (e.g., His, Ser, Cys, Gly, Val, or Leu; or His or Cys).

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having His, Ser, Cys, Gly, Val, Pro or Leu at residue 132 (SEQ ID NO:8) (e.g., His, Ser, Cys, Gly, Val, or Leu; or His or Cys).

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity, product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment, the cell proliferation disorder is fibrosarcoma or paraganglioma wherein the cancer is characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 (SEQ ID NO:8).

In an embodiment, the cell proliferation disorder is fibrosarcoma or paraganglioma wherein the cancer is characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 (SEQ ID NO:8).

In an embodiment, the cell proliferation disorder is fibrosarcoma or paraganglioma wherein the cancer is characterized by increased levels of an alpha hydroxy neoactivity, product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is localized or metastatic prostate cancer, *e.g.,* prostate adenocarcinoma, *e.g.,* wherein the cancer is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the cancer is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type.

E.g., in an embodiment, the IDH1 allele encodes an IDH1 having other than an Arg at residue 132. *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Kang *et al*, 2009, Int. J. Cancer, 125: 353-355 at residue 132, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**) (e.g., His, Ser, Cys, Gly, Val, or Leu). In an embodiment the allele encodes an IDH1 having His or Cys at residue 132.

In an embodiment the IDH1 allele has a T (or any other nucleotide other than C) at nucleotide position 394, or an A (or any other nucleotide other than G) at nucleotide position 395. In an embodiment the allele is a C394T or a G395A mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having prostate cancer, *e.g.,* prostate adenocarcinoma, wherein the cancer is characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having His or Cys at residue 132 (SEQ ID NO:8).

In an embodiment the method comprises selecting a subject having prostate cancer, *e.g.,* prostate adenocarcinoma, on the basis of the cancer being characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having His or Cys at residue 132 (SEQ ID NO:8).

In an embodiment the method comprises selecting a subject having prostate cancer, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is a hematological cancer, *e.g.,* a leukemia, *e.g.,* AML, or ALL, wherein the hematological cancer is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the cancer is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type. In an embodiment the method comprises evaluating a serum or blood sample for increased alpha neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is acute lymphoblastic leukemia (*e.g.,* an adult or pediatric form), *e.g.,* wherein the acute lymphoblastic leukemia (sometimes referred to herein as ALL) is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. The ALL can be, e.g., B-ALL or T-ALL. In an embodiment the

cancer is characterized by increased levels of 2 an alpha hydroxy neoactivity product, e.g., HG, e.g., R-2HG, as compared to non-diseased cells of the same type. *E.g.,* in an embodiment, the IDH1 allele is an IDH1 having other than an Arg at residue 132 (SEQ ID NO:8). *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Kang *et a.l*, at residue 132, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**) (e.g., His, Ser, Cys, Gly, Val, or Leu). In an embodiment the allele encodes an IDH1 having Cys at residue 132.

In an embodiment the IDH1 allele has a T (or any other nucleotide other than C) at nucleotide position 394. In an embodiment the allele is a C394T mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 according to the sequence of SEQ ID NO:8.

In an embodiment the method comprises selecting a subject ALL, e.g., B-ALL or T-ALL, on the basis of cancer being characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 (SEQ ID NO:8).

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is acute myelogenous leukemia (*e.g.,* an adult or pediatric form), *e.g.,* wherein the acute myelogenous leukemia (sometimes referred to herein as AML) is characterized by an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the cancer is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type. *E.g.,* in an embodiment, the IDH1 allele is an IDH1 having other than an Arg at residue 132 (SEQ ID NO:8). *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Kang *et al.*, at residue 132, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**) (e.g., His, Ser, Cys, Gly, Val or Leu). In an embodiment the allele encodes an IDH1 having Cys, His or Gly at residue 132, specifically, Cys.

In an embodiment the IDH1 allele has a T (or any other nucleotide other than C) at nucleotide position 394. In an embodiment the allele is a C394T mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having acute myelogenous lymphoplastic leukemia (AML) characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys, His or Gly at residue 132 according to the sequence of SEQ ID NO:8, specifically, Cys.

In an embodiment the method comprises selecting a subject having acute myelogenous lymphoplastic leukemia (AML) on the basis of cancer being characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys, His or Gly at residue 132 (SEQ ID NO:8), specifically, Cys.

In an embodiment the method comprises selecting a subject having acute myelogenous lymphoplastic leukemia (AML), on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG. In an embodiment the method comprises evaluating a serum or blood sample for increased alpha neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the method further comprises evaluating the subject for the presence of a mutation in the NRAS or NPMc gene.

In an embodiment the cell proliferation-related disorder is myelodysplasia or myelodysplastic syndrome, *e.g.,* wherein the myelodysplasia or myelodysplastic syndrome is characterized by having an IDH1 somatic mutant having alpha hydroxy neoactivity, e.g., 2HG neoactivity, *e.g.,* a mutant described herein. In an embodiment the disorder is characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, e.g., R-2HG, as compared to non-diseased cells of the same type. *E.g.,* in an embodiment, the IDH1 allele is an IDH1 having other than an Arg at residue 132 (SEQ ID NO:8). *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Kang *et a.l*, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**), specifically, His, Ser, Cys, Gly, Val, or Leu. In an embodiment the allele encodes an IDH1 having Cys at residue 132.

In an embodiment the IDH1 allele has a T (or any other nucleotide other than C) at nucleotide position 394. In an embodiment the allele is a C394T mutation according to the sequence of SEQ ID NO:5.

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome characterized by an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 according to the sequence of SEQ ID NO:8.

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome on the basis of cancer being characterized by having an IDH1 allele described herein, *e.g.,* an IDH1 allele having Cys at residue 132 (SEQ ID NO:8).

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG. In an embodiment the method comprises evaluating a serum or blood sample for increased alpha neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is a glioma, characterized by a mutation, or preselected allele, of IDH2 associated with an alpha hydroxy neoactivity, e.g., 2HG neoactivity. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al*., at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), specifically, Lys, Gly, Met, Trp or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment the method comprises selecting a subject having a glioma, wherein the cancer is characterized by having an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys, Gly, Met, Trp, Thr, or Ser at residue 172 (SEQ ID NO:10), specifically Lys, Gly, Met, Trp, or Ser; or Lys or Met.

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys, Gly, Met, Trp, Thr, or Ser at residue 172 (SEQ ID NO:10), specifically Lys, Gly, Met, Trp, or Ser; or Lys or Met.

In an embodiment the method comprises selecting a subject having a glioma, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is a prostate cancer, *e.g.,* prostate adenocarcinoma, characterized by a mutation, or preselected allele, of IDH2 associated with an alpha hydroxy neoactivity, e.g., 2HG neoactivity. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in

described in Yan *et al*., at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), specifically Lys, Gly, Met, Trp, or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment the method comprises selecting a subject having a prostate cancer, *e.g.,* prostate adenocarcinoma, wherein the cancer is characterized by having an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having a prostate cancer, *e.g.,* prostate adenocarcinoma, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having a prostate cancer, *e.g.,* prostate adenocarcinoma, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is ALL, e.g., B-ALL or T-ALL, characterized by a mutation, or preselected allele, of IDH2 associated with an alpha hydroxy neoactivity, e.g., 2HG neoactivity. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al*., at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), specifically Lys, Gly, Met, Trp, or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, wherein the cancer is characterized by having an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having ALL, e.g., B-ALL or T-ALL, on the basis of the cancer being characterized by increased levels

of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG. In an embodiment the method comprises evaluating a serum or blood sample for increased alpha neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is AML, characterized by a mutation, or preselected allele, of IDH2 associated with an alpha hydroxy neoactivity, e.g., 2HG neoactivity. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al.*, at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), specifically Lys, Gly, Met, Trp, or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment the method comprises selecting a subject having AML, wherein the cancer is characterized by having an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having AML, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having AML, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG. In an embodiment the method comprises evaluating a serum or blood sample for increased alpha neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In an embodiment the cell proliferation-related disorder is myelodysplasia or myelodysplastic syndrome, characterized by a mutation, or preselected allele, of IDH2. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al.*, at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), specifically Lys, Gly, Met, Trp, or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome,wherein the cancer is characterized by having an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome, on the basis of the cancer being characterized by an IDH2 allele described herein, *e.g.,* an IDH2 allele having Lys or Met at residue 172 (SEQ ID NO:10).

In an embodiment the method comprises selecting a subject having myelodysplasia or myelodysplastic syndrome, on the basis of the cancer being characterized by increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG. In an embodiment the method comprises evaluating a serum or blood sample for increased alpha neoactivity product, e.g., 2HG, *e.g.,* R-2HG.

In another aspect the invention features a pharmaceutical composition of an inhibitor (*e.g.,* a small molecule or a nucleic acid-based inhibitor) described herein.

In an embodiment a mutant protein specific reagent, e.g., an antibody that specifically binds an IDH mutant protein, e.g., an antibody that specifically binds an IDH1-R132H mutant protein, can be used to detect neoactive mutant enzyme see, for example, that described by Y.Kato et al., "A monoclonal antibody IMab-1 specifically recognizes $IDH1^{R132H}$, the most common glioma-derived mutation: (Kato, Biochem. Biophys. Res. Commun. (2009), which is hereby incorporated by reference in its entirety.

In another aspect, the invention features, a method of evaluating a candidate compound, *e.g.,* for the ability to inhibit a neoactivity of a mutant enzyme, *e.g.,* for use as an anti-proliferative or anti-cancer agent. In an embodiment the mutant enzyme is an IDH, *e.g.,* an IDH1 or IDH2 mutant, *e.g.,* a mutant described herein. In an embodiment the neaoctivity is alpha hydroxy neoactivity, e.g., 2HG neoactivity. The method comprises:

optionally supplying the candidate compound;

contacting the candidate compound with a mutant enzyme having a neoactivity, or with another enzyme, a referred to herein as a proxy enzyme, having an activity, referred to herein as a proxy activity, which is the same as the neoactivity (or with a cell or cell lysate comprising the same); and

evaluating the ability of the candidate compound to modulate, *e.g.,* inhibit or promote, the neoactivity or the proxy activity,

thereby evaluating the candidate compound.

In an embodiment the mutant enzyme is a mutant IDH1, *e.g.,* an IDH1 mutant described herein, and the neoactivity is an alpha hydroxy neoactivity, e.g., 2HG

neoactivity. Mutations associated with 2HG neoactivity in IDH1 include mutations at residue 132, e.g., R132H, R132C, R132S, R132G, R132L,or R132V, more specifically, R132H or R132C.

In an embodiment the mutant enzyme is a mutant IDH2, *e.g.,* an IDH2 mutant described herein, and the neoactivity is an alpha hydroxy neoactivity, e.g., 2HG neoactivity. Mutations associated with 2HG neoactivity in IDH2 inlcude mutations at residue 172, e.g., R172K, R172M, R172S, R172G, or R172W.

In an embodiment the method includes evaluating the ability of the candidate compound to inhibit the neoactivity or the proxy activity.

In an embodiment the method further comprises evaluating the ability of the candidate compound to inhibit the forward reaction of non-mutant or wild type enzyme activity, *e.g.,* in the case of IDH, *e.g.,* IDH1 or IDH2, the conversion of isocitrate to α-ketoglutarate (or an intermediate thereof, including the reduced hydroxyl intermediate).

In an embodiment, the contacting step comprises contacting the candidate compound with a cell, or a cell lysate thereof, wherein the cell comprises a mutant enzyme having the neoactivity or an enzyme having the activity.

In an embodiment, the cell comprises a mutation, or preselected allele, of a mutant IDH1 gene. *E.g.,* in an embodiment, the IDH1 allele encodes an IDH1 having other than an Arg at residue 132. *E.g.,* the allele can encode His, Ser, Cys, Gly, Val, Pro or Leu, or any other residue described in Yan *et al.*, at residue 132, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**), specifically His, Ser, Cys, Gly, Val, or Leu.

In an embodiment the allele encodes an IDH1 having His at residue 132.

In an embodiment the allele encodes an IDH1 having Ser at residue 132.

In an embodiment the allele is an Arg132His mutation, or an Arg132Ser mutation, according to the sequence of SEQ ID NO:8 (see **FIGs. 2** and **21**).

In an embodiment, the cell comprises a mutation, or preselected allele, of a mutant IDH2 gene. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al.*, at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), specifically, Lys, Gly, Met, Trp, or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment, the cell includes a heterologous copy of a mutant IDH gene, *e.g.,* a mutant IDH1 or IDH2 gene. (Heterologous copy refers to a copy introduced or formed by a genetic engineering manipulation.)

In an embodiment, the cell is transfected (*e.g.,* transiently or stably transfected) or transduced (*e.g.,* transiently or stably transduced) with a nucleic acid sequence encoding an IDH, *e.g.,* IDH1 or IDH2, described herein, *e.g.,* an IDH1 having other than an Arg at residue 132. In an embodiment, the IDH, *e.g.,* IDH1 or IDH2, is epitope-tagged, *e.g.,* myc-tagged.

In an embodiment, the cell, *e.g.,* a cancer cell, is non-mutant or wild type for the IDH, *e.g.,* IDH1 or IDH2, allele. The cell can include a heterologous IDH1 or IDH2 mutant.

In an embodiment, the cell is a cultured cell, *e.g.,* a primary cell, a secondary cell, or a cell line. In an embodiment, the cell is a cancer cell, *e.g.,* a glioma cell (*e.g.,* a glioblastoma cell), a prostate cancer cell, a leukemia cell (*e.g.,* an ALL, e.g., B-ALL or T-ALL, cell or AML cell) or a cell characterized by myelodysplasia or myelodysplastic syndrome. In embodiment, the cell is a 293T cell, a U87MG cell, or an LN-18 cell (*e.g.,* ATCC HTB-14 or CRL-2610).

In an embodiment, the cell is from a subject, *e.g.,* a subject having cancer, *e.g.,* a cancer characterized by an IDH, *e.g.,* IDH1 or IDH2, allele described herein, *e.g.,* an IDH1 allele having His, Ser, Cys, Gly, Val, Pro or Leu at residue 132 (SEQ ID NO:8); specifically His or Cys; or an IDH2 allele having Lys, Gly, Met, Trp, Thr, or Ser at residue 172 (SEQ ID NO:10), specifically Lys, Gly, Met, Trp, or Ser.

In an embodiment, the evaluating step comprises evaluating the presence and/or amount of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, *e.g.,* in the cell lysate or culture medium, *e.g.,* by LC-MS.

In an embodiment, the evaluating step comprises evaluating the presence and/or amount of an alpha hydroxy neoactivity, e.g., 2HG neoactivity, in the cell lysate or culture medium.

In an embodiment, the method further comprises evaluating the presence/amount one or more of TCA metabolite(s), *e.g.,* citrate, α-KG, succinate, fumarate, and/or malate, *e.g.,* by LC-MS, *e.g.,* as a control.

In an embodiment, the method further comprises evaluating the oxidation state of NADPH, *e.g.,* the absorbance at 340 nm, *e.g.,* by spectrophotometer.

In an embodiment, the method further comprises evaluating the ability of the candidate compound to inhibit a second enzymatic activity, *e.g.,* the forward reaction of non-mutant or wild type enzyme activity, *e.g.,* in the case of IDH1 or IDH2 (e.g., IDH1), the conversion of isocitrate to α-ketoglutarate (or an intermediate thereof, including the reduced hydroxyl intermediate).

In an embodiment, the candidate compound is a small molecule, a polypeptide, peptide, a carbohydrate based molecule, or an aptamer (*e.g.,* a nucleic acid aptamer, or a peptide aptamer). The method can be used broadly and can, *e.g.,* be used as one or more of a primary screen, to confirm candidates produced by this or other methods or screens, or generally to guide drug discovery or drug candidate optimization.

In an embodiment, the method comprises evaluating, *e.g.,* confirming, the ability of a candidate compound (*e.g.,* a candidate compound which meets a predetermined level of inhibition in the evaluating step) to inhibit the neoactivity or proxy activity in a second assay.

In an embodiment, the second assay comprises repeating one or more of the contacting and/or evaluating step(s) of the basic method.

In another embodiment, the second assay is different from the first. *E.g.,* where the first assay can use a cell or cell lysate or other non-whole animal model the second assay can use an animal model, *e.g.,* a tumor transplant model, *e.g.,* a mouse having an IDH, *e.g.,* IDH1 or IDH2, mutant cell or tumor transplanted in it. E.g., a U87 cell, or glioma, e.g., glioblastoma, cell, harboring a transfected IDH, e.g., IDH1 or IDH2, neoactive mutant can be implanted as a xenograft and used in an assay. Primary human glioma or AML tumor cells can be grafted into mice to allow propogation of the tumor and used in an assay. A genetically engineered mouse model (GEMM) harboring an IDH1 or IDH2 mutation and/or other mutation, e.g., a p53 null mutation, can also be used in an assay.

In an embodiment the method comprises:

optionally supplying the candidate compound;

contacting the candidate compound with a cell comprising a nucleic acid sequence, *e.g.,* a heterologous sequence, encoding an IDH1 having other than an Arg at residue 132 (*e.g.,* IDH1R132H) or an IDH2 having other than an Arg at residue 172 (specifically an IDH1 having other than an Arg at residue 132); and

evaluating the presence and/or amount of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, in the cell lysate or culture medium, by LC-MS,

thereby evaluating the compound.

In an embodiment the result of the evaluation is compared with a reference, *e.g.,* the level of product, *e.g.,* an alpha hydroxy neoactivity product, e.g., 2HG. *e.g.,* R-2HG, in a control cell, *e.g.,* a cell having inserted therein a wild type or non-mutant copy of IDH1 or IDH2 (e.g., IDH1).

In another aspect, the invention features, a method of evaluating a candidate compound, *e.g.,* for the ability to inhibit an RNA encoding a mutant enzyme having a neoactivity, *e.g.,* for use as an anti-proliferative or anti-cancer agent. In an embodiment the mutant enzyme is an IDH, *e.g.,* an IDH1 or IDH2 mutant, *e.g.,* a mutant described herein. In an embodiment the neaoctivity is alpha hydroxy neoactivity, e.g., 2HG neoactivity. The method comprises:

optionally supplying the candidate compound, *e.g.,* a nucleic acid based inhibitor (*e.g.,* a dsRNA (*e.g.,* siRNA or shRNA), an antisense, or a microRNA);

contacting the candidate compound with an RNA, *e.g.,* an mRNA, which encodes IDH, *e.g.,* an IDH1 or IDH2, *e.g.,* an RNA that encode mutant enzyme having a neoactivity (or with a cell or cell lysate comprising the same); and

evaluating the ability of the candidate compound to inhibit the RNA, thereby evaluating the candidate compound. By inhibit the RNA means, *e.g.,* to cleave or otherwise inactivate the RNA.

In an embodiment the RNA encodes a fusion of all or part of the IDH, *e.g.,* IDH1 or IDH2, wildtype or mutant protein to a second protein, *e.g.,* a reporter protein, *e.g.,* a fluorescent protein, *e.g.,* a green or red fluorescent protein.

In an embodiment the mutant enzyme is a mutant IDH1, *e.g.,* an IDH1 mutant described herein, and the neoactivity is an alpha hydroxy neoactivity, e.g., 2HG neoactivity.

In an embodiment the mutant enzyme is a mutant IDH2, *e.g.,* an IDH2 mutant described herein, and the neoactivity is an alpha hydroxy neoactivity, e.g., 2HG neoactivity.

In an embodiment, the contacting step comprises contacting the candidate compound with a cell, or a cell lysate thereof, wherein the cell comprises RNA encoding IDH, *e.g.,* IDH1 or IDH2, *e.g.,* a mutant IDH, *e.g.,* IDH1 or IDH2, enzyme having the neoactivity.

In an embodiment, the cell comprises a mutation, or preselected allele, of a mutant IDH1 gene. *E.g.,* in an embodiment, the IDH1 allele encodes an IDH1 having

other than an Arg at residue 132. *E.g.,* the allele can encode His, Ser, Cys, Gly, Val, Pro or Leu, or any other residue described in Yan *et al.*, at residue 132, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**), specifically His, Ser, Cys, Gly, Val, or Leu.

In an embodiment the allele encodes an IDH1 having His at residue 132.

In an embodiment the allele encodes an IDH1 having Ser at residue 132.

In an embodiment the allele is an Arg132His mutation, or an Arg132Ser mutation, according to the sequence of SEQ ID NO:8 (see **FIGs. 2** and **21**).

In an embodiment, the cell comprises a mutation, or preselected allele, of a mutant IDH2 gene. *E.g.,* in an embodiment, the IDH2 allele encodes an IDH2 having other than an Arg at residue 172. *E.g.,* the allele encodes Lys, Gly, Met, Trp, Thr, Ser, or any residue described in described in Yan *et al.*, at residue 172, according to the sequence of SEQ ID NO:10(see also **Fig. 22**), specifically Lys, Gly, Met, Trp or Ser. In an embodiment the allele encodes an IDH2 having Lys at residue 172. In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment, the cell includes a heterologous copy of a wildtype or mutant IDH gene, *e.g.,* a wildtype or mutant IDH1 or IDH2 gene. (Heterologous copy refers to a copy introduced or formed by a genetic engineering manipulation.) In an embodiment the heterologous gene comprises a fusion to a reporter protein, *e.g.,* a fluorescent protein, *e.g.,* a green or red fluorescent protein.

In an embodiment, the cell is transfected (*e.g.,* transiently or stably transfected) or transduced (*e.g.,* transiently or stably transduced) with a nucleic acid sequence encoding an IDH, *e.g.,* IDH1 or IDH2, described herein, *e.g.,* an IDH1 having other than an Arg at residue 132 or an IDH2 having other than an Arg at residue 172 (e.g., an IDH1 having other than an Arg at residue 132). In an embodiment, the IDH, *e.g.,* IDH1 or IDH2, is epitope-tagged, *e.g.,* myc-tagged.

In an embodiment, the cell, *e.g.,* a cancer cell, is non-mutant or wild type for the IDH, *e.g.,* IDH1 or IDH2, allele. The cell can include a heterologous IDH1 or IDH2 mutant.

In an embodiment, the cell is a cultured cell, *e.g.,* a primary cell, a secondary cell, or a cell line. In an embodiment, the cell is a cancer cell, *e.g.,* a glioma cell (*e.g.,* a glioblastoma cell), a prostate cancer cell, a leukemia cell (*e.g.,* an ALL, e.g., B-ALL or T-ALL cell or AML cell) or a cell characterized by myelodysplasia or

myelodysplastic syndrome. In embodiment, the cell is a 293T cell, a U87MG cell, or an LN-18 cell (*e.g.,* ATCC HTB-14 or CRL-2610).

In an embodiment, the cell is from a subject, *e.g.,* a subject having cancer, *e.g.,* a cancer characterized by an IDH, *e.g.,* IDH1 or IDH2, allele described herein, *e.g.,* an IDH1 allele having His, Ser, Cys, Gly, Val, Pro or Leu at residue 132 (SEQ ID NO:8); specifically His or Cys. In an embodiment, the cancer is characterized by an IDH2 allele having Lys, Gly, Met, Trp, Thr, or Ser at residue 172 (SEQ ID NO:10), specifically Lys, Gly, Met, Trp, or Ser.

In an embodiment, the method comprises a second assay and the second assay comprises repeating one or more of the contacting and/or evaluating step(s) of the basic method.

In another embodiment, the second assay is different from the first. *E.g.,* where the first assay can use a cell or cell lysate or other non-whole animal model the second assay can use an animal model

In an embodiment the efficacy of the candidate is evaluated by its effect on reporter protein activity.

In another aspect, the invention features, a method of evaluating a candidate compound, *e.g.,* for the ability to inhibit transcription of an RNA encoding a mutant enzyme having a neoactivity, *e.g.,* for use as an anti-proliferative or anti-cancer agent. In an embodiment the mutant enzyme is an IDH, *e.g.,* an IDH1 or IDH2 mutant, *e.g.,* a mutant described herein. In an embodiment the neaoctivity is alpha hydroxy neoactivity, e.g., 2HG neoactivity. The method comprises:

optionally supplying the candidate compound, *e.g.,* a small molecule, polypeptide, peptide, aptomer, a carbohydrate-based molecule or nucleic acid based molecule;

contacting the candidate compound with a system comprising a cell or cell lysate; and

evaluating the ability of the candidate compound to inhibit the translation of IDH, *e.g.,* IDH1 or IDH2, RNA, e.g,

thereby evaluating the candidate compound.

In an embodiment the the system comprises a fusion gene encoding of all or part of the IDH, *e.g.,* IDH1 or IDH2, wildtype or mutant protein to a second protein, *e.g.,* a reporter protein, *e.g.,* a fluorescent protein, *e.g.,* a green or red fluorescent protein.

In an embodiment the mutant enzyme is a mutant IDH1, *e.g.,* an IDH1 mutant described herein, and the neoactivity is alpha hydroxy neoactivity, e.g., 2HG neoactivity.

In an embodiment the mutant enzyme is a mutant IDH2, *e.g.,* an IDH2 mutant described herein, and the neoactivity is alpha hydroxy neoactivity, e.g., 2HG neoactivity.

In an embodiment, the system includes a heterologous copy of a wildtype or mutant IDH gene, *e.g.,* a wildtype or mutant IDH1 or IDH2 gene. (Heterologous copy refers to a copy introduced or formed by a genetic engineering manipulation.) In an embodiment the heterologous gene comprises a fusion to a reporter protein, *e.g.,* a fluorescent protein, *e.g.,* a green or red fluorescent protein.

In an embodiment the cell, *e.g.,* a cancer cell, is non-mutant or wild type for the IDH, *e.g.,* IDH1 or IDH2, allele. The cell can include a heterologous IDH1 or IDH2 mutant.

In an embodiment, the cell is a cultured cell, *e.g.,* a primary cell, a secondary cell, or a cell line. In an embodiment, the cell is a cancer cell, *e.g.,* a glioma cell (*e.g.,* a glioblastoma cell), a prostate cancer cell, a leukemia cell (*e.g.,* an ALL, e.g., B-ALL or T-ALL, cell or AML cell) or a cell characterized by myelodysplasia or myelodysplastic syndrome. In embodiment, the cell is a 293T cell, a U87MG cell, or an LN-18 cell (*e.g.,* ATCC HTB-14 or CRL-2610).

In an embodiment, the cell is from a subject, *e.g.,* a subject having cancer, *e.g.,* a cancer characterized by an IDH, *e.g.,* IDH1 or IDH2, allele described herein, *e.g.,* an IDH1 allele having His, Ser, Cys, Gly, Val, Pro or Leu at residue 132 (SEQ ID NO:8); specifically His, Ser, Cys, Gly, Val, or Leu. In an embodiment, the cancer is characterized an IDH2 allele having Lys, Gly, Met, Trp, Thr, or Ser at residue 172 (SEQ ID NO:10).

In an embodiment, the method comprises a second assay and the second assay comprises comprises repeating the method.

In another embodiment, the second assay is different from the first. *E.g.,* where the first assay can use a cell or cell lysate or other non-whole animal model the second assay can use an animal model.

In an embodiment the efficacy of the candidate is evaluated by its effect on reporter protein activity.

In another aspect, the invention features, a method of evaluating a candidate compound, e.g., a therapeutic agent, or inhibitor, described herein in an animal model. The candidate compound can be, *e.g.,* a small molecule, polypeptide, peptide, aptomer, a carbohydrate-based molecule or nucleic acid based molecule. The method comprises, contacting the candidate with the animal model and evaluating the animal model.

In an embodiment evaluating comprises;

determining an effect of the compound on the general health of the animal;

determining an effect of the compound on the weight of the animal;

determining an effect of the compound on liver function, e.g, on a liver enzyme;

determining an effect of the compound on the cardiovascular system of the animal;

determining an effect of the compound on neurofunction, *e.g.,* on neuromuscular control or response;

determining an effect tof the compound on eating or drinking;

determining the distribution of the compound in the animal;

determining the persistence of the compound in the animal or in a tissue or oragn of the animal, *e.g.,* determining plasma half-life; or

determining an effect of the compound on a selected cell in the animal;

determining an effect of the compound on the growth, size, weight, invasiveness or other phenotype of a tumor, *e.g.,* an endogenous tumor or a tumor arising from introduction of cells from the same or a different species.

In an embodiment the animal is a non-human primate, *e.g.,* a cynomolgus monkey or chimpanzee.

In an embodiment the animal is a rodent, *e.g.,* a rat or mouse.

In an embodiment the animal is a large animal, *e.g.,* a dog or pig, other than a non-human primate.

In an embodiment the evaluation is memorialized and optionally transmetted to another party.

In one aspect, the invention provides, a method of evaluating or processing a therapeutic agent, *e.g.,* a therapeutic agent referred to herein, *e.g.,* a therapeutic agent that results in a lowering of the level of a product of an IDH, *e.g.,* IDH1 or IDH2, mutant having a neoactivity. In an embodiment the neoactivity is an alpha hydroxy

neoactivity, e.g., 2HG neoactivity, and the level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, is lowered.

The method includes:

providing, *e.g.,* by testing a sample, a value (*e.g.,* a test value) for a parameter related to a property of the therapeutic agent, *e.g.,* the ability to inhibit the conversion of alpha ketoglutarate to 2 hydroxyglutarate (i.e., 2HG), *e.g.,* R-2 hydroxyglutarate (i.e., R-2HG), and,

optionally, providing a determination of whether the value determined for the parameter meets a preselected criterion, *e.g.,* is present, or is present within a preselected range,

thereby evaluating or processing the therapeutic agent.

In an embodiment the therapeutic agent is approved for use in humans by a government agency, *e.g.,* the FDA.

In an embodiment the parameter is correlated to the ability to inhibit 2HG neoactivity, and, *e.g.,* the therapeutic agent is an inhibitor which binds to IDH1 or IDH2 protein and reduces an alpha hydroxy neoactivity, e.g., 2HG neoactivity.

In an embodiment the parameter is correlated to the level of mutant IDH, *e.g.,* IDH1 or IDH2, protein, and, *e.g.,* the therapeutic agent is an inhibitor which reduces the level of IDH1 or IDH2 mutant protein.

In an embodiment the parameter is correlated to the level of an RNA that encodes a mutant IDH, *e.g.,* IDH1 or IDH2, protein, and, *e.g.,* the therapeutic agent reduces the level of RNA, *e.g.,* mRNA, that encodes IDH1 or IDH2 mutant protein.

In an embodiment the method includes contacting the therapeutic agent with a mutant IDH, *e.g.,* IDH1 or IDH2, protein (or corresponding RNA).

In an embodiment, the method includes providing a comparison of the value determined for a parameter with a reference value or values, to thereby evaluate the therapeutic agent. In an embodiment, the comparison includes determining if a test value determined for the therapeutic agent has a preselected relationship with the reference value, *e.g.,* determining if it meets the reference value**.** The value need not be a numerical value but, *e.g.,* can be merely an indication of whether an activity is present.

In an embodiment the method includes determining if a test value is equal to or greater than a reference value, if it is less than or equal to a reference value, or if it falls within a range (either inclusive or exclusive of one or both endpoints). In an

embodiment, the test value, or an indication of whether the preselected criterion is met, can be memorialized, *e.g.,* in a computer readable record.

In an embodiment, a decision or step is taken, *e.g.,* a sample containing the therapeutic agent, or a batch of the therapeutic agent, is classified, selected, accepted or discarded, released or withheld, processed into a drug product, shipped, moved to a different location, formulated, labeled, packaged, contacted with, or put into, a container, *e.g.,* a gas or liquid tight container, released into commerce, or sold or offered for sale, or a record made or altered to reflect the determination, depending on whether the preselected criterion is met. *E.g.,* based on the result of the determination or whether an activity is present, or upon comparison to a reference standard, the batch from which the sample is taken can be processed, *e.g.,* as just described.

The evaluation of the presence or level of activity can show if the therapeutic agent meets a reference standard.

In an embodiment, methods and compositions disclosed herein are useful from a process standpoint, *e.g.,* to monitor or ensure batch-to-batch consistency or quality, or to evaluate a sample with regard to a reference, *e.g.,* a preselected value.

In an embodiment, the method can be used to determine if a test batch of a therapeutic agent can be expected to have one or more of the properties. Such properties can include a property listed on the product insert of a therapeutic agent, a property appearing in a compendium, *e.g.,* the US Pharmacopea, or a property required by a regulatory agency, *e.g.,* the FDA, for commercial use.

In an embodiment the method includes testing the therapeutic agent for its effect on the wildtype activity of an IDH, *e.g.,* IDH1 or IDH2, protein, and providing a determination of whether the value determined meets a preselected criterion, *e.g.,* is present, or is present within a preselected range.

In an embodiment the method includes:

contacting a therapeutic agent that is an inhibitor of IDH1 an alpha hydroxy neoactivity, e.g., 2HG neoactivity, with an IDH1 mutant having an alpha hydroxy neoactivity, e.g., 2HG neoactivity,

determining a value related to the inhibition of an alpha hydroxy neoactivity, e.g., 2HG neoactivity, and

comparing the value determined with a reference value, *e.g.,* a range of values, for the inhibition of an alpha hydroxy neoactivity, e.g., 2HG neoactivity. In an embodiment the reference value is an FDA required value, *e.g.,* a release criteria.

In an embodiment the method includes:

contacting a therapeutic agent that is an inhibitor of mRNA which encodes a mutant IDH1 having an alpha hydroxy neoactivity, e.g., 2HG neoactivity, with an mRNA that encodes an IDH1 mutant having an alpha hydroxy neoactivity, e.g., 2HG neoactivity,

determining a value related to the inhibition of the mRNA, and,

comparing the value determined with a reference value, *e.g.,* a range of values for inhibition of the mRNA. In an embodiment the reference value is an FDA required value, *e.g.,* a release criteria.

In one aspect, the invention features a method of evaluating a sample of a therapeutic agent, *e.g.,* a therapeutic agent referred to herein, that includes receiving data with regard to an activity of the therapeutic agent; providing a record which includes said data and optionally includes an identifier for a batch of therapeutic agent; submitting said record to a decision-maker, *e.g.,* a government agency, *e.g.,* the FDA; optionally, receiving a communication from said decision maker; optionally, deciding whether to release market the batch of therapeutic agent based on the communication from the decision maker. In one embodiment, the method further includes releasing, or other wise processing, *e.g.,* as described herein, the sample.

In another aspect, the invention features, a method of selecting a payment class for treatment with a therapeutic agent described herein, *e.g.,* an inhibitor of IDH, *e.g.,* IDH1 or IDH2, neoactivity, for a subject having a cell proliferation-related disorder. The method includes:

providing (*e.g.,* receiving) an evaluation of whether the subject is positive for increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, or neoactivity, *e.g.,* an alpha hydroxy neoactivity, e.g., 2HG neoactivity, a mutant IDH1 or IDH2 having neoactivity, *e.g.,* an alpha hydroxy neoactivity, e.g., 2HG neoactivity, (or a corresponding RNA), or a mutant IDH, *e.g.,* IDH1 or IDH2, somatic gene, *e.g.,* a mutant described herein, and

performing at least one of (1) if the subject is positive selecting a first payment class, and (2) if the subject is a not positive selecting a second payment class.

In an embodiment the selection is memorialized, *e.g.,* in a medical records system.

In an embodiment the method includes evaluation of whether the subject is positive for increased levels of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, or neoactivity, *e.g.,* an alpha hydroxy neoactivity, e.g., 2HG neoactivity.

In an embodiment the method includes requesting the evaluation.

In an embodiment the evaluation is performed on the subject by a method described herein.

In an embodiment, the method comprises communicating the selection to another party, *e.g.,* by computer, compact disc, telephone, facsimile, email, or letter.

In an embodiment, the method comprises making or authorizing payment for said treatment.

In an embodiment, payment is by a first party to a second party. In some embodiments, the first party is other than the subject. In some embodiments, the first party is selected from a third party payor, an insurance company, employer, employer sponsored health plan, HMO, or governmental entity. In some embodiments, the second party is selected from the subject, a healthcare provider, a treating physician, an HMO, a hospital, a governmental entity, or an entity which sells or supplies the drug. In some embodiments, the first party is an insurance company and the second party is selected from the subject, a healthcare provider, a treating physician, an HMO, a hospital, a governmental entity, or an entity which sells or supplies the drug. In some embodiments, the first party is a governmental entity and the second party is selected from the subject, a healthcare provider, a treating physician, an HMO, a hospital, an insurance company, or an entity which sells or supplies the drug.

As used herein, a cell proliferation-related disorder is a disorder characterized by unwanted cell proliferation or by a predisposition to lead to unwanted cell proliferation (sometimes referred to as a precancerous disorder). Examples of disorders characterized by unwanted cell proliferation include cancers, *e.g.,* tumors of the CNS, *e.g.,* a glioma. Gliomas include astrocytic tumors, oligodendroglial tumors, oligoastrocytic tumors, anaplastic astrocytomas, and glioblastomas. Other examples include hematological cancers, *e.g.,* a leukemia, *e.g.,* AML (*e.g.,* an adult or pediatric form) or ALL, e.g., B-ALL or T-ALL (*e.g.,* an adult or pediatric form), localized or metastatic prostate cancer, *e.g.,* prostate adenocarcinoma, fibrosarcoma, and paraganglioma; specificallya leukemia, *e.g.,* AML (*e.g.,* an adult or pediatric form) or ALL, e.g., B-ALL or T-ALL (*e.g.,* an adult or pediatric form), localized or metastatic prostate cancer, *e.g.,* prostate adenocarcinoma. Examples of disorders characterized

by a predisposition to lead to unwanted cell proliferation include myelodysplasia or myelodysplastic syndrome, which are a diverse collection of hematological conditions marked by ineffective production (or dysplasia) of myeloid blood cells and risk of transformation to AML.

As used herein, specifically inhibits a neoactivity (and similar language), means the neoactivity of the mutant enzyme is inhibted to a significantly greater degree than is the wildtype enzyme activity. By way of example, "specifically inhibits the 2HG neoactivity of mutant IDH1 (or IDH2)" means the 2HG neoactivity is inhibited to a significantly greater degree than is the forward reaction (the conversion of isocitrate to alpha ketoglutarate) of wildtype IDH1 (or IDH2) activity. In embodiments the neactivity is inhibited at least 2, 5, 10, or 100 fold more than the wildtype activity. In embodiments an inhibitor that is specfic for the 2HG neaoctivity of IDH, e.g., IDH1 or IDH2, will also inhibit another dehydrogenase, e.g., malate dehydrogenase. In other embodiments the specific inhibitor does inhibit other dehydrogenases, e.g., malate dehydrogenase.

As used herein, a cell proliferation-related disorder, *e.g.,* a cancer, characterized by a mutation or allele, means a cell proliferation-related disorder having a substantial number of cells which carry that mutation or allele. In an embodiment at least 10, 25, 50, 75, 90, 95 or 99% of the cell proliferation-related disorder cells, *e.g.,* the cells of a cancer, or a representative, average or typical sample of cancer cells, *e.g.,* from a tumor or from affected blood cells, carry at least one copy of the mutation or allele. A cell proliferation-related disorder, characterized by a mutant IDH, *e.g.,* a mutant IDH1 or mutant IDH2, having 2HG neoactivity is exemplary. In an embodiment the mutation or allele is present as a heterozygote at the indicated frequencies.

As used herein, a "SNP" is a DNA sequence variation occurring when a single nucleotide (A, T, C, or G) in the genome (or other shared sequence) differs between members of a species (or between paired chromosomes in an individual).

As used herein, a subject can be a human or non-human subject. Non-human subjects include non-human primates, rodents, *e.g.,* mice or rats, or other non-human animals.

The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and the drawings, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts DNA sequence verification of pET41a-IDH1 and alignment against published IDH1 CDS. The sequence of IDH1 (CDS) corresponds to SEQ ID NO:5. The sequence of pET41a-IDH1 corresponds to SEQ ID NO:6, and the "consensus" sequence corresponds to SEQ ID NO:7.

FIG. 2 depicts DNA sequence verification of R132S and R132H mutants according to the SEQ ID NO:8. The amino acid sequence of IDH1 (SEQ ID NO:8) is provided in FIG. 21.

FIG. 3 depicts separation of wild type IDH1 protein on Ni-Sepharose column.

FIG. 4 depicts protein analysis of wild type IDH1 on SDS gel pre and post Ni column fractionation. T: total protein; I: insoluble fractions; S: soluble fraction; L: sample for loading on Ni-column. The numbers in the figure indicates the fraction numbers. Fractions #17 ~ #27 were collected for further purification.

FIG. 5A depicts separation of wild type IDH1 protein through SEC column S-200.

FIG. 5B depicts protein analysis of wild type IDH1 on SDS gel pre and post S-200 column fractionation. M: molecular weight marker; Ni: nickel column fraction prior to S-200; S200: fraction from SEC column.

FIG. 6 depicts separation of mutant R132S protein on Ni-Sepharose column.

FIG. 7 depicts protein analysis of mutant R132S on SDS gel pre and post Ni column fractionation. M: protein marker (KDa): 116, 66.2, 45, 35, 25, 18.4, 14.4; T: total cell protein; So: soluble fraction; In: insoluble fraction; Ft: flow through. #3-#7 indicate the corresponding eluted fraction numbers.

FIG. 8A depicts separation of mutant R132S protein through SEC column S-200.

FIG. 8B depicts protein analysis of mutant R132S on SDS gel post S-200 column fractionation. M: molecular weight marker; R132S: fraction from SEC column.

FIG. 9 depicts separation of mutant R132H protein on Ni-Sepharose column.

FIG. 10 depicts protein analysis of mutant R132H on SDS gel pre and post Ni column fractionation. M: protein marker (KDa): 116, 66.2, 45, 35, 25, 18.4, 14.4; T: total cell protein; So: soluble fraction; In: insoluble fraction; Ft: flow through; #5-#10 indicate the corresponding eluted fraction numbers; Ni: sample from Ni-Sepharose column, pool #5-#10 together.

FIG. 11A depicts separation of mutant R132H protein through SEC column S-200.

FIG. 11B depicts protein analysis of mutant R132H on SDS gel post S-200 column fractionation. M: molecular weight marker; R132H: fraction from SEC column.

FIG. 12A depicts Michaelis-Menten plot of IDH1 wild-type in the oxidative decarboxylation of ioscitrate to α-ketoglutarate.

FIG. 12B depicts Michaelis-Menten plot of R132H mutant enzyme in the oxidative decarboxylation of ioscitrate to α-ketoglutarate.

FIG. 12C depicts Michaelis-Menten plot of R132S mutant enzyme in the oxidative decarboxylation of ioscitrate to α-ketoglutarate.

FIG. 13A depicts α-KG inhibition of IDH1 wild-type.

FIG. 13B depicts α-KG inhibition of R132H mutant enzyme.

FIG. 13C depicts α-KG inhibition of R132S mutant enzyme.

FIG. 14 depicts IDH1 wt, R132H, and R132S in the conversion α-ketoglutarate to 2-hydroxyglutarate.

FIG. 15A depicts Substrate-Concentration velocity plot for R132H mutant enzyme.

FIG. 15B depicts Substrate-Concentration velocity plot for R132S mutant enzyme.

FIG. 16 depicts IDH1 wt, R132H, and R132S in the conversion α-ketoglutarate to 2-hydroxyglutarate with NADH.

FIG. 17A depicts oxalomalate inhibition to IDH1 wt.

FIG. 17B depicts oxalomalate inhibition to R132H.

FIG. 17C depicts oxalomalate inhibition to R132S.

FIG. 18A depicts LC-MS/MS analysis of the control reaction.

FIG. 18B depicts LC-MS/MS analysis of the reaction containing enzyme.

FIG. 18C depicts LC-MS/MS analysis of the spiked control reaction.

FIG. 19 depicts LC-MS/MS analysis of alpha-hydroxyglutarate.

FIG. 20 depicts LC-MS/MS analysis showing that R132H consumes α-KG to produce 2-hydroxyglutaric acid.

FIG. 21 depicts the amino acid sequence of IDH1 (SEQ ID NO:13) as described in GenBank Accession No. NP_005887.2 (GI No. 28178825) (record dated May 10, 2009).

FIG. 21A is the cDNA sequence of IDH1 as presented at GenBank Accession No. NM_005896.2 (Record dated May 10, 2009; GI No. 28178824) (SEQ ID NO:8).

FIG. 21B depicts the mRNA sequence of IDH1 as described in GenBank Accession No. NM_005896.2 (Record dated May 10, 2009; GI No. 28178824) (SEQ ID NO:9).

FIG. 22 is the amino acid sequence of IDH2 as presented at GenBank Accession No. NM_002168.2 (Record dated August 16, 2009; GI28178831) (SEQ ID NO:10).

FIG. 22A is the cDNA sequence of IDH2 as presented at GenBank Accession No. NM_002168 (Record dated August 16, 2009; GI28178831) (SEQ ID NO:11).

FIG. 22B is the mRNA sequence of IDH2 as presented at GenBank Accession No. NM_002168.2 (Record dated August 16, 2009; GI28178831) (SEQ ID NO:12).

FIG. 23 depicts the progress of forward reactions (isocitrate to α-KG) for the mutant enzyme R132H and R132S.

FIG. 24A depicts LC-MS/MS analysis of derivitized 2-HG racemic mixture.

FIG. 24B depicts LC-MS/MS analysis of derivitized R-2HG standard.

FIG. 24C depicts LC-MS/MS analysis of a coinjection of derivitized 2-HG racemate and R-2-HG standard.

FIG. 24D depicts LC-MS/MS analysis of the deriviatized neoactivity reaction product.

FIG. 24E depicts LC-MS/MS analysis of a coinjection of the neoactivty enzyme reaction product and the R-2-HG standard.

FIG. 24F depicts LC-MS/MS analysis of a coinjection of the neoactivity enzyme reaction product and the 2-HG racemic mixture.

FIG. 25 depicts the inhibitory effect of 2-HG derived from the reduction of α-KG by ICDH1 R132H on the wild-type ICDH1 catalytic oxidative decarboxylation of isocitrate to α-KG.

FIG. 26A depicts levels of 2-HG in CRL-2610 cell lines expressing wildtype or IDH-1 R132H mutant protein.

FIG. 26B depicts levels of 2-HG in HTB-14 cell lines expressing wildtype or IDH-1 R132H mutant protein.

FIG. 27 depicts human IDH1 genomic DNA: intron/2nd exon sequence.

FIG. 28 depicts concentrations of 2HG in human malignant gliomas containing R132 mutations in IDH1. Human glioma samples obtained by surgical resection were snap frozen, genotyped to stratify as wild-type (WT) (N=10) or carrying an R132 mutant allele (Mutant) (n=12) and metabolites extracted for LC-MS analysis. Among the 12 mutant tumors, 10 carried a R132H mutation, one an R132S mutation, and one an R132G mutation. Each symbol represents the amount of the listed metabolite found in each tumor sample. Red lines indicate the group sample means. The difference in 2HG observed between WT and R132 mutant IDH1 mutant tumors was statistically significant by Student's t-test ($p<0.0001$). There were no statistically significant

differences in αKG, malate, fumarate, succinate, or isocitrate levels between the WT and R132 mutant IDH1 tumors.

FIG. 29A depicts the structural analysis of R132H mutant IDH1. On left is shown an overlay structure of R132H mutant IDH1 and WT IDH1 in the 'closed' conformation. On the right is shown an overlay structure of WT IDH1 in the 'open' conformation with mutant IDH1 for comparison.

FIG. 29B depicts the close-up structural comparison of the R132H IDH1 (left) and wild-type (WT) IDH1 (right) active-site containing both αKG and NADPH. In addition to changes at residue 132, the position of the catalytic residues Tyr 139 and Lys 212 are different and αKG is oriented differently relative to NADPH for catalytic hydride transfer in the WT versus R132H mutant enzymes.

FIG. 30A depicts the enzymatic properties of IDH1 R132H mutants when ecombinant human wild-type (WT) and R132H mutant (R132H) IDH1 enzymes were assessed for oxidative decarboxylation of isocitrate to αKG with $NADP^+$ as cofactor. Different concentrations of enzyme were used to generate the curves.

FIG. 30B depicts the enxymatic properties of IDH R132 mutants when WT and R132H mutant IDH1 enzymes were assessed for reduction of αKG with NADPH as cofactor. Different concentrations of enzyme were used to generate the curves.

FIG. 30C depicts kinetic parameters of oxidative and reductive reactions as measured for WT and R132H IDH1 enzymes are shown. K_m and k_{cat} values for the reductive activity of the WT enzyme were unable to be determined as no measurable enzyme activity was detectable at any substrate concentration.

FIG. 31A depicts the LC-MS/MS analysis identifying 2HG as the reductive reaction product of recombinant human R132H mutant IDH1.

FIG. 31B depicts the diacetyl-L-tartaric anhydride derivatization and LC-MS/MS analysis of the chirality of 2HG produced by R132H mutant IDH1. Normalized LC-MS/MS signal for the reductive reaction (rxn) product alone, an R(-)-2HG standard alone, and the two together (Rxn + R(-)-2HG) are shown as is the signal for a racemic mixture of R(-) and S(+) forms (2HG Racemate) alone or with the reaction products (Rxn + Racemate).

FIG. 32A depicts SDS-PAGE and Western blot analyses of C-terminal affinity-purification tagged IDH1 R132S protein used for crystallization.

FIG. 32B depicts the chromatogram of FPLC analysis of the IDH1 R132S protein sample.

FIG. 33 depicts crystals obtained from a protein solution contained 5 mM NADP, 5 mM isocitrate, 10 mM Ca2+. Precipitant solution contained 100 mM MES (pH 6.0) and 20% PEG 6000 using a hanging drop method of crystallization.

FIG. 34 depicts crystal obtained from a protein solution contained 5 mM NADP, 5 mM α-ketoglutarate, 10 mM Ca2+. Precipitant contained 100 mM MES (pH 6.5) and 12% PEG 20000.

FIG. 35 is a bar graph depicting elevated NADPH reductive catalysis activity in IDH2-R172K mutant enzyme as compared to wildtype IDH2.

FIGs. 36A-C are graphs depicting the following: **(A)** Extracts from IDH1/2 wt (n=10), and IDH1/2 mutant (n=16) patient leukemia cells obtained at presentation and relapse, and IDH1 R132 mutant leukemia cells grown in culture for 14 days (n=14) analyzed by LC-MS to measure levels of 2-HG; and **(B)** 2-HG measured in serum of patients with IDH1 wt or IDH1 R132 mutant leukemia. In **(A)** and **(B)**, each point represents an individual patient sample. Diamonds represent wildtype, circles represent IDH1 mutants, and triangles represent IDH2 mutants. Horizontal bars indicate the mean. (*) indicates a statistically significant difference relative to wild-type patient cells ($p<0.05$). **(C)** depicts *In vitro* growth curves of IDH1 R132 mutant and IDH1 wild-type AML cells.

FIG. 37 is a graph depicting the results of extracts from leukemia cells of AML patients carrying an IDH1/2 mutant (n=16) or wild-type (n=10) allele obtained at initial presentation and relapse assayed by LC-MS for levels of a-KG, succinate, malate, and fumarate. Each point represents an individual patient sample. Open circles represent wild-types, closed circles represent IDH1 mutants, and triangles represent IDH2 mutants. Horizontal bars represent the mean. There were no statistically significant differences between the wild-type and IDH1/2 mutant AML samples.

FIG. 38 depicts graphical representations of LC-MS analysis of *in vitro* reactions using recombinant IDH1 R132C and IDH2 R172K confirming that 2-HG and not isocitrate is the end product of the mutant enzyme reactions.

FIGs. 39A and B depict **(A)** the wild-type IDH1 enzyme catalysis of the oxidative decarboxylation of isocitrate to alpha-ketoglutarate with the concomitant reduction of NADP to NADPH; and **(B)** the IDH1 R132C mutant reduction of alpha-ketoglutarate

to 2-hydroxyglutarate while oxidizing NADPH to NADP. These are referred to as the "forward" and "partial reverse" reactions, respectively.

DETAILED DESCRIPTION

The inventors have discovered that certain mutated forms of an enzyme (*e.g.,* IDH1 or IDH2) have a gain of function, referred to herein as a neoactivity, which can be targeted in the treatment of a cell proliferation-related disorder, *e.g.,* a proliferative disorder such as cancer. For example, in the case of a metabolic pathway enzyme, a gain of function or neoactivity can serve as a target for treatment of cancer. Described herein are methods and compositions for the treatment of a cell proliferation-related disorder, *e.g.,* a proliferative disorder such as cancer. The methods include, *e.g.,* treating a subject having a glioma or brain tumor characterized by a preselected IDH1 allele, *e.g.,* an allele having A at position 394, such as a C394A, a C394G, a C394T, a G395C, a G395T or a G395A mutation, (*e.g.,* a C394A mutant) or an A at position 395 (*e.g.,* a G395A mutant) according to the sequence of SEQ ID NO:5, that encodes an IDH1 having His, Ser, Cys, Gly, Val, Pro or Leu at position 132 (e.g., His); or a preselected IDH2 allelle that encodes an IDH2 having Lys, Gly, Met, Trp, Thr, or Ser at position 172 and having a neoactivity disclosed herein, by administering to the subject a therapeutically effective amount of an inhibitor of IDH1 or IDH2 (e.g., IDH1), *e.g.,* a small molecule or nucleic acid. The nucleic acid based inhibitor is, for example, a dsRNA, *e.g.,* a dsRNA that comprises the primary sequences of the sense strand and antisense strands of **Tables 7-14**. The dsRNA is composed of two separate strands, or a single strand folded to form a hairpin structure (*e.g.,* a short hairpin RNA (shRNA)). In some embodiments, the nucleic acid based inhibitor is an antisense nucleic acid, such as an antisense having a sequence that overlaps, or includes, an antisense sequence provided in **Tables 7-14**.

Neoactivity of an enzyme

Neoactivity, as used herein, means an activity that arises as a result of a mutation, *e.g.,* a point mutation, *e.g.,* a substitution, *e.g.,* in the active site of an enzyme. In an embodiment the neoactivity is substantially absent from wild type or non-mutant enzyme. This is sometimes referred to herein as a first degree neoactivity. An example of a first degree neoactivity is a "gain of function" wherein the mutant enzyme gains a new catalytic activity. In an embodiment the neoactivity is present in wild type or non-mutant enzyme but at a level which is less than 10, 5, 1, 0.1, 0.01 or

0.001 % of what is seen in the mutant enzyme. This is sometimes referred to herein as a second degree neoactivity. An example of a second degree neoactivity is a "gain of function" wherein the mutant enzyme has an increase, for example, a 5 fold increase in the rate of a catalytic activity possessed by the enzyme when lacking the mutation.

In some embodiments, a non-mutant form the enzyme, *e.g.,* a wild type form, converts substance A (*e.g.,* isocitrate) to substance B (*e.g.,* α-ketoglutarate), and the neoactivity converts substance B (*e.g.,* α-ketoglutarate) to substance C, sometimes referred to as the neoactivity product (*e.g.,* 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate). In some embodiments, the enzyme is in a metabolic pathway, *e.g.,* a metabolic pathway leading to fatty acid biosynthesis, glycolysis, glutaminolysis, the pentose phosphate shunt, the nucleotide biosynthetic pathway, or the fatty acid biosynthetic pathway, *e.g.,* IDH1 or IDH2.

In some embodiments, a non-mutant form the enzyme, *e.g.,* a wild type form, converts substance A to substance B, and the neoactivity converts substance B to substance A. In some embodiments, the enzyme is in a metabolic pathway, *e.g.,* a metabolic pathway leading to fatty acid biosynthesis, glycolysis, glutaminolysis, the pentose phosphate shunt, the nucleotide biosynthetic pathway, or the fatty acid biosynthetic pathway.

Isocitrate Dehydrogenases

Isocitrate dehydrogenases (IDHs) catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate (*i.e.*, α-ketoglutarate). These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP(+)-dependent isozyme is a homodimer.

IDH1 (isocitrate dehydrogenase 1 (NADP+), cytosolic) is also known as IDH; IDP; IDCD; IDPC or PICD. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for

intraperoxisomal reductions, such as the conversion of 2, 4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production.

The human IDH1 gene encodes a protein of 414 amino acids. The nucleotide and amino acid sequences for human IDH1 can be found as GenBank entries NM_005896.2 and NP_005887.2 respectively. The nucleotide and amino acid sequences for IDH1 are also described in, *e.g.,* Nekrutenko *et al.*, Mol. Biol. Evol. 15:1674-1684(1998); Geisbrecht *et al.*, J. Biol. Chem. 274:30527-30533(1999); Wiemann *et al.*, Genome Res. 11:422-435(2001); The MGC Project Team, Genome Res. 14:2121-2127(2004); Lubec *et al.*, Submitted (DEC-2008) to UniProtKB; Kullmann *et al.*, Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases; and Sjoeblom *et al.*, Science 314:268-274(2006).

IDH2 (isocitrate dehydrogenase 2 (NADP+), mitochondrial) is also known as IDH; IDP; IDHM; IDPM; ICD-M; or mNADP-IDH. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the mitochondria. It plays a role in intermediary metabolism and energy production. This protein may tightly associate or interact with the pyruvate dehydrogenase complex. Human IDH2 gene encodes a protein of 452 amino acids. The nucleotide and amino acid sequences for IDH2 can be found as GenBank entries NM_002168.2 and NP_002159.2 respectively. The nucleotide and amino acid sequence for human IDH2 are also described in, *e.g.,* Huh *et al.*, Submitted (NOV-1992) to the EMBL/GenBank/DDBJ databases; and The MGC Project Team, Genome Res. 14:2121-2127(2004).

Non-mutant, *e.g.,* wild type, IDH1 catalyzes the oxidative decarboxylation of ioscitrate to α-ketoglutarate thereby reducing NAD^+ ($NADP^+$) to NADP (NADPH), *e.g.,* in the forward reaction:

Isocitrate + NAD^+ ($NADP^+$) → α-KG + CO_2 + NADH (NADPH) + H^+

In some embodiments, the neoactivity of a mutant IDH1 can have the ability to convert α-ketoglutarate to 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate:

α-KG + NADH (NADPH) + H^+ → 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate + NAD^+ ($NADP^+$).

In some embodiments, the neoactivity can be the reduction of pyruvate or malate to the corresponding α-hydroxyl compounds.

In some embodiments, the neoactivity of a mutant IDH1 can arise from a mutant IDH1 having a His, Ser, Cys, Gly, Val, Pro or Leu, or any other mutations described in Yan *et al.*, at residue 132 (e.g., His, Ser, Cys, Gly, Val or Leu; or His, Ser, Cys or Lys). In some embodiments, the neoactivity of a mutant IDH2 can arise from a mutant IDH2 having a Lys, Gly, Met, Trp, Thr, or Ser (e.g., Lys, Gly, Met, Trp, or Ser; or Gly, Met or Lys), or any other mutations described in Yan H *et al.*, at residue 172. Exemplary mutations include the following: R132H, R132C, R132S, R132G, R132L, and R132V.

In some embodiments, the mutant IDH1 and/or IDH2 (*e.g.,* a mutant IDH1 and/or IDH2 having a neoactivity described herein) could lead to an increased level of 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate in a subject. The accumulation of 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate in a subject, *e.g.,* in the brain of a subject, can be harmful. For example, in some embodiments, elevated levels of 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate can lead to and/or be predictive of cancer in a subject such as a cancer of the central nervous system, *e.g.,* brain tumor, *e.g.,* glioma, *e.g.,* glioblastoma multiforme (GBM). Accordingly, in some embodiments, a method described herein includes administering to a subject an inhibitor of the neoactivity.

Detection of 2-hydroxyglutarate

2-hydroxyglutarate can be detected, *e.g.,* by LC/MS. To detect secreted 2-hydroxyglutarate in culture media, 500 μL aliquots of conditioned media can be collected, mixed 80:20 with methanol, and centrifuged at 3,000 rpm for 20 minutes at 4 degrees Celsius. The resulting supernatant can be collected and stored at -80 degrees Celsius prior to LC-MS/MS to assess 2-hydroxyglutarate levels. To measure whole-cell associated metabolites, media can be aspirated and cells can be harvested, *e.g.,* at a non-confluent density. A variety of different liquid chromatography (LC) separation methods can be used. Each method can be coupled by negative electrospray ionization (ESI, -3.0 kV) to triple-quadrupole mass spectrometers operating in multiple reaction monitoring (MRM) mode, with MS parameters optimized on infused metabolite standard solutions. Metabolites can be separated by reversed phase chromatography using 10 mM tributyl-amine as an ion pairing agent in the aqueous mobile phase, according to a variant of a previously reported method (Luo *et al. J Chromatogr A* 1147, 153-64, 2007). One method allows resolution of

TCA metabolites: t = 0, 50% B; t = 5, 95% B; t= 7, 95% B; t= 8, 0% B, where B refers to an organic mobile phase of 100% methanol. Another method is specific for 2-hydroxyglutarate, running a fast linear gradient from 50% -95% B (buffers as defined above) over 5 minutes. A Synergi Hydro-RP, 100mm × 2 mm, 2.1 µm particle size (Phenomonex) can be used as the column, as described above. Metabolites can be quantified by comparison of peak areas with pure metabolite standards at known concentration. Metabolite flux studies from ^{13}C-glutamine can be performed as described, *e.g.,* in Munger *et al.* Nat Biotechnol 26, 1179-86, 2008.

In an embodiment 2HG, e.g., R-2HG, is evaluated and the analyte on which the determination is based is 2HG, e.g., R-2HG. In an embodiment the analyte on which the determination is based is a derivative of 2HG, *e.g.,* R-2HG, formed in process of performing the analytic method. By way of example such a derivative can be a derivative formed in MS analysis. Derivatives can include a salt adduct, *e.g.,* a Na adduct, a hydration variant, or a hydration variant which is also a salt adduct, e.g., a Na adduct, e.g., as formed in MS analysis. Exemplary 2HG derivatives include dehydrated derivatives such as the compounds provided below or a salt adduct thereof:



,


,


and


.

Methods of evaluating samples and/or subjects

This section provides methods of obtaining and analyzing samples and of analyzing subjects.

Embodiments of the method comprise evaluation of one or more parameters related to IDH, e.g., IDH1 or IDH2, an alpha hydroxy neoactivity, e.g., 2HG neoactivity, e.g., to evaluate the IDH1 or IDH2 2HG neoactivity genotype or phenotype. The evaluation can be performed, e.g., to select, diagnose or prognose the subject, to select a therapeutic agent, e.g., an inhibitor, or to evaluate response to the treatment or progression of disease. In an embodiment the evaluation, which can be performed before and/or after treatment has begun, is based, at least in part, on analysis of a tumor sample, cancer cell sample, or precancerous cell sample, from the subject. *E.g.,* a sample from the patient can be analyzed for the presence or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, by evaluating a parameter correlated to the presence or level of an alpha hydroxy neoactivity product,

e.g., 2HG, *e.g.,* R-2HG. An alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, in the sample can be determined by a chromatographic method, *e.g.,* by LC-MS analysis. It can also be determined by contact with a specific binding agent, *e.g.,* an antibody, which binds the alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, and allows detection. In an embodiment the sample is analyzed for the level of neoactivity, *e.g.,* an alpha hydroxy neoactivity, e.g., 2HG neoactivity. In an embodment the sample is analysed for the presence of a mutant IDH, *e.g.,* IDH1 or IDH2, protein having an alpha hydroxy neoactivity, e.g., 2HG neoactivity (or a corresponding RNA). E.g., a mutant protein specific reagent, e.g., an antibody that specifically binds an IDH mutant protein, e.g., an antibody that specifically binds an IDH1-R132H mutant protein or an IDH2-R172 mutant protein (e.g., an IDH1-R132H mutant protein), can be used to detect neoactive mutant enzymeIn an embodiment a nucleic acid from the sample is sequenced to determine if a selected allele or mutation of IDH1 or IDH2 disclosed herein is present. In an embodiment the analysis is other than directly determining the presence of a mutant IDH, *e.g.,* IDH1 or IDH2, protein (or corresponding RNA) or sequencing of an IDH, *e.g.,* IDH1 or IDH2 gene. In an embodiment the analysis is other than directly determining, e.g., it is other than sequencing genomic DNA or cDNA, the presence of a mutation at residue 132 of IDH1 and/or a mutation at residue 172 of IDH2. *E.g.,* the analysis can be the detection of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, or the measurement of the mutation's an alpha hydroxy neoactivity, e.g., 2HG neoactivity. In an embodiment the sample is removed from the patient and analyzed. In an embodiment the evaluation can include one or more of performing the analysis of the sample, requesting analysis of the sample, requesting results from analysis of the sample, or receiving the results from analysis of the sample. (Generally herein, analysis can include one or both of performing the underlying method or receiving data from another who has performed the underlying method.)

In an embodiment the evaluation, which can be performed before and/or after treatment has begun, is based, at least in part, on analysis of a tissue (e.g., a tissue other than a tumor sample), or bodily fluid, or bodily product. Exemplary tissues include lymph node, skin, hair follicles and nails. Exemplary bodily fluids include blood, plasma, urine, lymph, tears, sweat, saliva, semen, and cerebrospinal fluid. Exemplary bodily products include exhaled breath. *E.g.,* the tissue, fluid or product can be analyzed for the presence or level of an alpha hydroxy neoactivity product, e.g.,

2HG, *e.g.,* R-2HG, by evaluating a parameter correlated to the presence or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG. An alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, in the sample can be determined by a chromatographic method, *e.g.,* by LC-MS analysis. It can also be determend by contact with a specific binding agent, *e.g.,* an antibody, which binds the alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, and allows detection. In embodiments where sufficient levels are present, the tissue, fluid or product can be analyzed for the level of neoactivity, *e.g.,* an alpha hydroxy neoactivity, e.g., the 2HG neoactivity. In an embodment the sample is analysed for the presence of a mutant IDH, *e.g.,* IDH1 or IDH2, protein having an alpha hydroxy neoactivity, e.g., 2HG neoactivity (or a corresponding RNA). E.g., a mutant protein specific reagent, e.g., an antibody that specifically binds an IDH mutant protein, e.g., an antibody that specifically binds an IDH1-R132H mutant protein or an IDH2-R172 mutant protein (e.g., an IDH1-R132H mutant protein), can be used to detect neoactive mutant enzyme. In an embodiment a nucleic acid from the sample is sequenced to determine if a selected allele or mutation of IDH1 or IDH2 disclosed herein is present. In an embodiment the analysis is other than directly determining the presence of a mutant IDH, *e.g.,* IDH1 or IDH2, protein (or corresponding RNA) or sequencing of an IDH, *e.g.,* IDH1 or IDH2 gene. *E.g.,* the analysis can be the detection of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, or the measurement of 2HG neoactivity. In an embodiment the tissue, fluid or product is removed from the patient and analyzed. In an embodiment the evaluation can include one or more of performing the analysis of the tissue, fluid or product, requesting analysis of the tissue, fluid or product, requesting results from analysis of the tissue, fluid or product, or receiving the results from analysis of the tissue, fluid or product.

In an embodiment the evaluation, which can be performed before and/or after treatment has begun, is based, at least in part, on alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, imaging of the subject. In embodiments magnetic resonance methods are is used to evaluate the presence, distribution, or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, in the subject. In an embodiment the subject is subjected to imaging and/or spectroscopic analysis, *e.g.,* magnetic resonance-based analysis, *e.g.,* MRI and/or MRS *e.g.,*analysis, and optionally an image corresponding to the presence, distribution, or level of an alpha hydroxy neoactivity product, e.g., 2HG, *e.g.,* R-2HG, or of the tumor, is formed. Optionally

the image or a value related to the image is stored in a tangible medium and/or transmitted to a second site. In an embodiment the evaluation can include one or more of performing imaging analysis, requesting imaging analysis, requesting results from imaging analysis, or receiving the results from imaging analysis.

Methods of treating a proliferative disorder

Described herein are methods of treating a cell proliferation-related disorder, *e.g.,* a cancer, *e.g.,* a glioma, *e.g.,* by inhibiting a neoactivity of a mutant enzyme, *e.g.,* an enzyme in a metabolic pathway, *e.g.,* a metabolic pathway leading to fatty acid biosynthesis, glycolysis, glutaminolysis, the pentose phosphate shunt, the nucleotide biosynthetic pathway, or the fatty acid biosynthetic pathway, *e.g.,* IDH1 or IDH2. The cancer can be characterized by the presence of a neoactivity, such as a gain of function in one or more mutant enzymes (*e.g.,* an enzyme in the metabolic pathway, *e.g.,* a metabolic pathway leading to fatty acid biosynthesis, glycolysis, glutaminolysis, the pentose phosphate shunt, the nucleotide biosynthetic pathway, or the fatty acid biosynthetic pathway *e.g.,* IDH1 or IDH2). In some embodiments, the gain of function is the conversion of α-ketoglurarate to 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate.

Compounds for the treatment of cancer

A candidate compound can be evaluated for modulation (*e.g.,* inhibition) of neoactivity, for example, using an assay described herein. A candidate compound can also be evaluated for modulation (*e.g.,* inhibition) of wild type or non-mutant activity. For example, the formation of a product or by-product of any activity (*e.g.,* enzymatic activity) can be assayed, thus evaluating a candidate compound. In some embodiments, the activity (*e.g.,* wild type/non-mutant or neoactivity) can be evaluated by measuring one or more readouts from an enzymatic assay. For example, the change in nature and/or amount of substrate and/or product can be measured, *e.g.,* using methods such as fluorescent or radiolabeled substrates. Exemplary substrates and/or products include α-ketoglutarate, CO_2, NADP, NADPH, NAD, NADH, and 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate. In some embodiments, the rate of reaction of the enzyme can also be evaluated as can the nature and/or amount of a product of the enzymatic reaction. In addition to the measurement of potential enzymatic activities, activity (*e.g.,* wild type/non-mutant or neoactivity) can be

detected by the quenching of protein fluorescence upon binding of a potential substrate, cofactor, or enzymatic activity modulator to the enzyme.

In one embodiment, assay progress can be monitored by changes in the OD340 or fluorescence of the NAD or NADP cofactor. In another embodiment, the reaction progress can be coupled to a secondary enzyme assay system in continuous mode or endpoint mode for increasing the dynamic range of the assay. For example, an endpoint assay can be performed by adding to the reaction an excess of diaphorase and rezasarin. Diaphorase consumes the remaining NADPH or NADH while producing resorufin from rezasarin. Resorufin is a highly fluorescent product which can be measured by fluorescence at Ex544 Em590. This not only terminates the reaction but also generates an easily detectable signal with greater quantum yield than the fluorescence of the cofactor.

A continuous assay can be implemented through coupling a product of the primary reaction to a secondary enzyme reaction that yields detectable results of greater dynamic range or more convenient detection mode. For example, inclusion in the reaction mix of aldehyde dehydrogenase (ALDH), which is an NADP+ dependent enzyme, and 6-methoxy-2-napthaldehye, a chromogenic substrate for ALDH, will result in the production of the fluorescent product 6-methoxy-2-napthoate (Ex310 Em 360) at a rate dependent on the production of NADP+ by isocitrate dehydrogenase. The inclusion of a coupling enzyme such as aldehyde dehydrogenase has the additional benefit of allowing screening of neoactivity irrespective of whether NADP+ or NAD+ is produced, since this enzyme is capable of utilizing both. Additionally, since the NADPH or NADH cofactor required for the "reverse" assay is regenerated, a coupled enzyme system which cycles the cofactor back to the IDH enzyme has the further advantage of permitting continuous assays to be conducted at cofactor concentrations much below Km for the purpose of enhancing the detection of competitive inhibitors of cofactor binding.

In yet a third embodiment of an activity (*e.g.,* wild type/non-mutant or neoactivity) screen, one or a number of IDH substrates, cofactors, or products can be isotopically labeled with radioactive or "heavy" elements at defined atoms for the purpose of following specific substrates or atoms of substrates through the chemical reaction. For example, the alpha carbon of a-KG, isocitrate, or 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate may be ^{14}C or ^{13}C. Amount, rate, identity and structure of

products formed can be analyzed by means known to those of skill in the art, for example mass spectroscopy or radiometric HPLC.

Compounds that inhibit a neoactivity, *e.g.,* a neoactivity described herein, can include, *e.g.,* small molecule, nucleic acid, protein and antibody.

Exemplary small molecules include, *e.g*, small molecules that bind to enzymes and decrease their activity, *e.g.,* a neoactivity described herein. The binding of an inhibitor can stop a substrate from entering the enzyme's active site and/or hinder the enzyme from catalyzing its reaction. Inhibitor binding is either reversible or irreversible. Irreversible inhibitors usually react with the enzyme and change it chemically. These inhibitors can modify key amino acid residues needed for enzymatic activity. In contrast, reversible inhibitors bind non-covalently and different types of inhibition are produced depending on whether these inhibitors bind the enzyme, the enzyme-substrate complex, or both.

In some embodiments, the small molecule is oxalomalate, oxalofumarate, or oxalosuccinate.

In some embodiments, the small molecule is a compound of formula (X), or a compound as listed in **Table 24a**. The compound of formula (X) is provided below:



Formula (X)

wherein X is C_1-C_6 alkylene (*e.g.,* methylene), C(O), or C(O)C_1-C_6 alkylene; wherein X is optionally substituted;

R^1 is halo (*e.g.,* fluoro), C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxyl, C_1-C_6 alkoxy, cyano, nitro, amino, alkylamino, dialkylamino, amido, -C(O)OH, or C(O)OC_1-C_6alkyl; and

m is 0, 1, 2, or 3.

In some embodiments, the compound is a compound of formula (XI) or a pharmaceutically acceptable salt thereof or a compound listed in Table 24b



(XI)

wherein:

W, X, Y and Z are each independently selected from CH or N;

B and B^1 are independently selected from hydrogen, alkyl or when taken together with the carbon to which they are attached form a carbonyl group;

Q is C=O or SO_2;

D and D^1 are independently selected from a bond, oxygen or NR^c;

A is optionally substituted aryl or optionally substituted heteroaryl;

R^1 is independently selected from alkyl, acyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, cycloalkylalkyl, aralkyl, and heteroaralkyl; each of which may be optionally substituted with 0-3 occurrences of R^d;

each R^3 is independently selected from halo, haloalkyl, alkyl and $-OR^a$;

each R^a is independently selected from alkyl, and haloalkyl;

each R^b is independently alkyl;

each R^c is independently selected from hydrogen, alkyl and alkenyl;

each R^d is independently selected from halo, haloalkyl, alkyl, nitro, cyano, and $–OR^a$, or two R^d taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;

n is 0, 1, or 2;

h is 0, 1, 2; and

g is 0, 1 or 2.

In some embodiments, the small molecule is a selective inhibitor of the neoactivity (*e.g.,* relative to the wild type activity).

Nucleic acids can be used to inhibit a neoactivity, *e.g.,* a neoactivity described herein, *e.g.,* by decreasing the expression of the enzyme. Exemplary nucleic acids include, *e.g.,* siRNA, shRNA, antisense RNA, aptamer and ribozyme. Art-known methods can be used to select inhibitory molecules, *e.g.,* siRNA molecules, for a particular gene sequence.

Proteins can also be used to inhibit a neoactivity, *e.g.,* a neoactivity described herein, by directly or indirectly binding to the enzyme and/or substrate, or competing binding to the enzyme and/or substrate. Exemplary proteins include, *e.g.,* soluble receptors, peptides and antibodies. Exemplary antibodies include, *e.g.,* whole antibody or a fragment thereof that retains its ability to bind to the enzyme or substrate.

Exemplary candidate compounds, which can be tested for inhibitin of a neoactivity described herein (*e.g.,* a neoactivity associated with mutant IDH1), are

described in the following references, each of which are incorporated herein by reference: Bioorganic & Medicinal Chemistry (2008), 16(7), 3580-3586; Free Radical Biology & Medicine (2007), 42(1), 44-51; KR 2005036293 A; Applied and Environmental Microbiology (2005), 71(9), 5465-5475; KR 2002095553 A; U.S. Pat. Appl. US 2004067234 A1; PCT Int. Appl. (2002), WO 2002033063 A1; Journal of Organic Chemistry (1996), 61(14), 4527-4531; Biochimica et Biophysica Acta, Enzymology (1976), 452(2), 302-9; Journal of Biological Chemistry (1975), 250(16), 6351-4; Bollettino - Societa Italiana di Biologia Sperimentale (1972), 48(23), 1031-5; Journal of Biological Chemistry (1969), 244(20), 5709-12.

Isomers

Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, atropic, stereoisomer, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; α- and β-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms").

In one embodiment, a compound described herein, *e.g.,* an inhibitor of a neoactivity or 2-HG is an enantiomerically enriched isomer of a stereoisomer described herein. For example, the compound has an enantiomeric excess of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. Enantiomer, when used herein, refers to either of a pair of chemical compounds whose molecular structures have a mirror-image relationship to each other.

In one embodiment, a preparation of a compound disclosed herein is enriched for an isomer of the compound having a selected stereochemistry, *e.g.,* R or S, corresponding to a selected stereocenter, *e.g.,* the 2-position of 2-hydroxyglutaric acid. 2HG can be purchased from commercial sources or can be prepared using methods known in the art, for example, as described in Org. Syn. Coll vol., 7, P-99, 1990. For example, the compound has a purity corresponding to a compound having a selected stereochemistry of a selected stereocenter of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

In one embodiment, a composition described herein includes a preparation of a compound disclosed herein that is enriched for a structure or structures having a selected stereochemistry, *e.g.,* R or S, at a selected stereocenter, *e.g.,* the 2-position of 2-hydroxyglutaric acid. Exemplary R/S configurations can be those provided in an example described herein.

An "enriched preparation," as used herein, is enriched for a selected stereoconfiguration of one, two, three or more selected stereocenters within the subject compound. Exemplary selected stereocenters and exemplary stereoconfigurations thereof can be selected from those provided herein, *e.g.,* in an example described herein. By enriched is meant at least 60%, *e.g.,* of the molecules of compound in the preparation have a selected stereochemistry of a selected stereocenter. In an embodiment it is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. Enriched refers to the level of a subject molecule(s) and does not connote a process limitation unless specified.

Note that, except as discussed below for tautomeric forms, specifically excluded from the term "isomers," as used herein, are structural (or constitutional) isomers (*i.e.*, isomers which differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, -OCH3, is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH2OH. Similarly, a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl. However, a reference to a class of structures may well include structurally isomeric forms falling within that class (*e.g.,* C1-7alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).

The above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.



Note that specifically included in the term "isomer" are compounds with one or more isotopic substitutions. For example, H may be in any isotopic form, including 1H, 2H (D), and 3H (T); C may be in any isotopic form, including 12C, 13C, and 14C; O may be in any isotopic form, including 16O and 18O; and the like. Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof. Methods for the preparation (*e.g.,* asymmetric synthesis) and separation (*e.g.,* fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.

Salts

It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the active compound, for example, a pharmaceutically-acceptable salt. Examples of pharmaceutically acceptable salts are discussed in Berge *et al*., 1977, "Pharmaceutically Acceptable Salts." J. Pharm. ScL. Vol. 66, pp. 1-19.

For example, if the compound is anionic, or has a functional group which may be anionic (*e.g.,* -COOH may be -COO"), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na+ and K+, alkaline earth cations such as Ca2+ and Mg2+, and other cations such as Al+3. Examples of suitable organic cations include, but are not limited to, ammonium ion (*i.e*., NH4+) and substituted ammonium ions (*e.g.,* NH3R+, NH2R2+, NHR3+, NR4+). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH3)4+.

If the compound is cationic, or has a functional group that may be cationic (*e.g.,* -NH2 may • be -NH3+), then a salt may be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.

Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.

Unless otherwise specified, a reference to a particular compound also includes salt forms thereof.

Chemically Protected Forms

It may be convenient or desirable to prepare, purify, and/or handle the active compound in a chemically protected form. The term "chemically protected form" is used herein in the conventional chemical sense and pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions under specified conditions (*e.g.,* pH, temperature, radiation, solvent, and the like). In practice, well known chemical methods are employed to reversibly render unreactive a functional group, which otherwise would be reactive, under specified conditions. In a chemically protected form, one or more reactive functional groups are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group). By protecting a reactive functional group, reactions involving other unprotected reactive functional groups can be performed, without affecting the protected group; the protecting group may be removed, usually in a subsequent step, without substantially affecting the remainder of the molecule. See, for example, Protective Groups in Organic Synthesis (T. Green and P. Wuts; 3rd Edition; John Wiley and Sons, 1999). Unless otherwise specified, a reference to a particular compound also includes chemically protected forms thereof.

A wide variety of such "protecting," "blocking," or "masking" methods are widely used and well known in organic synthesis. For example, a compound which has two nonequivalent reactive functional groups, both of which would be reactive under specified conditions, may be derivatized to render one of the functional groups

"protected," and therefore unreactive, under the specified conditions; so protected, the compound may be used as a reactant which has effectively only one reactive functional group. After the desired reaction (involving the other functional group) is complete, the protected group may be "deprotected" to return it to its original functionality.

For example, a hydroxy group may be protected as an ether (-OR) or an ester (-OC(=O)R), for example, as: a t-butyl ether; a benzyl, benzhydryl (diphenylmethyl), or trityl (triphenylmethyl) ether; a trimethylsilyl or t-butyldimethylsilyl ether; or an acetyl ester (-OC(=O)CH3, -OAc).

For example, an aldehyde or ketone group may be protected as an acetal (R-CH(OR)2) or ketal (R2C(OR)2), respectively, in which the carbonyl group (>C=O) is converted to a diether (>C(OR)2), by reaction with, for example, a primary alcohol. The aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.

For example, an amine group may be protected, for example, as an amide (-NRCO-R) or a urethane (-NRCO-OR), for example, as: a methyl amide (-NHCO-CH3); a benzyloxy amide (-NHCO-OCH2C6H5, -NH-Cbz); as a t-butoxy amide (-NHCO-OC(CH3)3, -NH-Boc); a 2-biphenyl-2-propoxy amide (-NHCO-OC(CH3)2C6H4C6H5, -NH-Bpoc), as a 9- fluorenylmethoxy amide (-NH-Fmoc), as a 6-nitroveratryloxy amide (-NH-Nvoc), as a 2-trimethylsilylethyloxy amide (-NH-Teoc), as a 2,2,2-trichloroethyloxy amide (-NH-Troc), as an allyloxy amide (-NH-Alloc), as a 2(-phenylsulphonyl)ethyloxy amide (-NH-Psec); or, in suitable cases (*e.g.,* cyclic amines), as a nitroxide radical (>N-O«).

For example, a carboxylic acid group may be protected as an ester for example, as: an C^alkyl ester (*e.g.,* a methyl ester; a t-butyl ester); a Cvrhaloalkyl ester (*e.g.,* a C1-7trihaloalkyl ester); a triC1-7alkylsilyl-Ci.7alkyl ester; or a C5.2oaryl-C1-7alkyl ester (*e.g.,* a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide.

For example, a thiol group may be protected as a thioether (-SR), for example, as: a benzyl thioether; an acetamidomethyl ether (-S-CH2NHC(=O)CH3).

Nucleic acid based inhibitors

Nucleic acid-based inhibitors for inhibition IDH, *e.g.,* IDH1, can be, *e.g.,* double stranded RNA (dsRNA) that function, *e.g.,* by an RNA interference (RNAi

mechanism), an antisense RNA, or a microRNA (miRNA). In an embodiment the nucleic-acid based inhibitor binds to the target mRNA and inhibits the production of protein therefrom, *e.g.,*. by cleavage of the targent mRNA.

Double stranded RNA (dsRNA)

A nucleic acid based inhibitor useful for decreasing IDH1 or IDH2 mutant function is, *e.g.,* a dsRNA, such as a dsRNA that acts by an RNAi mechanism. RNAi refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs). dsRNAs as used herein are understood to include siRNAs. Typically, inhibition of IDH, *e.g.,* IDH1,by dsRNAs does not trigger the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

dsRNAs targeting an IDH,*e.g.,* IDH1,enzyme, *e.g.,* a wildtype or mutant IDH1, can be unmodified or chemically modified. The dsRNA can be chemically synthesized, expressed from a vector or enzymatically synthesized. The invention also features various chemically modified synthetic dsRNA molecules capable of modulating IDH1 gene expression or activity in cells by RNA interference (RNAi). The use of chemically modified dsRNA improves various properties of native dsRNA molecules, such as through increased resistance to nuclease degradation *in vivo* and/or through improved cellular uptake.

The dsRNAs targeting nucleic acid can be composed of two separate RNAs, or of one RNA strand, which is folded to form a hairpin structure. Hairpin dsRNAs are typically referred to as shRNAs.

An shRNA that targets IDH, *e.g.,* a mutant or wildtype IDH1 gene can be expressed from a vector, *e.g.,* viral vector, such as a lentiviral or adenoviral vector. In certain embodiments, a suitable dsRNA for inhibiting expression of an IDH1 gene will be identified by screening an siRNA library, such as an adenoviral or lentiviral siRNA library.

In an embodiment, a dsRNA that targets IDH, *e.g.,* IDH1, is about 15 to about 30 base pairs in length (*e.g.,* about 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) basepairs in length. In another embodiment, the dsRNA includes overhanging ends of about 1 to about 3 (*e.g.,* about 1, 2, or 3) nucleotides. By "overhang" is meant that 3'-end of one strand of the dsRNA extends beyond the 5'-end of the other strand,

or vice versa. The dsRNA can have an overhang on one or both ends of the dsRNA molecule. In some embodiments, the single-stranded overhang is located at the 3'-terminal end of the antisense strand, or, alternatively, at the 3‘-terminal end of the sense strand. In some embodiments, the overhang is a TT or UU dinucleotide overhang, *e.g.,* a TT or UU dinucleotide overhang. For example, in an embodiment, the dsRNA includes a 21-nucleotide antisense strand, a 19 base pair duplex region, and a 3'-terminal dinucleotide. In yet another embodiment, a dsRNA includes a duplex nucleic acid where both ends are blunt, or alternatively, where one of the ends is blunt.

In an embodiment, the dsRNA includes a first and a second strand, each strand is about 18 to about 28 nucleotides in length, *e.g.,* about 19 to about 23 nucleotides in length, the first strand of the dsRNA includes a nucleotide sequence having sufficient complementarity to the IDH, *e.g.,* IDH1, RNA for the dsRNA to direct cleavage of the IDH, *e.g.,* IDH1, mRNA via RNA interference, and the second strand of the dsRNA includes a nucleotide sequence that is complementary to the first strand.

In an embodiment, a dsRNA targeting an IDH, *e.g.,* IDH1, gene can target wildtype and mutant forms of the gene, or can target different allelic isoforms of the same gene. For example, the dsRNA will target a sequence that is identical in two or more of the different isoforms. In an embodiment, the dsRNA targets an IDH1 having G at position 395 or C at position 394 (*e.g.,* a wildtype IDH1 RNA) and an IDH1 having A at position 395 or A at position 394, such as a C394A, a C394G, a C394T, a G395C, a G395T or a G395A mutation, (*e.g.,* an IDH1 RNA carrying a G395A and/or a C394A mutation) (**FIG. 2**).

In an embodiment, a dsRNA will preferentially or specifically target a mutant IDH RNA, or a particular IDH polymorphism. In some embodiments, the IDH has a mutation at position 394 or 395 such as a C394A, a C394G, a C394T, a G395C, a G395T or a G395A mutation. For example, in an embodiment, the dsRNA targets an IDH1 RNA carrying an A at position 395, *e.g.,* G395A, and in another embodiment, the dsRNA targets an IDH1 RNA carrying an A at position 394, *e.g.,* C394A mutation.

In an embodiment, a dsRNA targeting an IDH RNA includes one or more chemical modifications. Non-limiting examples of such chemical modifications include without limitation phosphorothioate internucleotide linkages, 2'-deoxyribonucleotides, 2'-O-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, “universal base” nucleotides, “acyclic” nucleotides, 5-C-methyl nucleotides, and

terminal glyceryl and/or inverted deoxy abasic residue incorporation. Such chemical modifications have been shown to preserve RNAi activity in cells while at the same time, dramatically increasing the serum stability of these compounds. Furthermore, one or more phosphorothioate substitutions are well-tolerated and have been shown to confer substantial increases in serum stability for modified dsRNA constructs.

In an embodiment, a dsRNA targeting an IDH, *e.g.,* IDH1, RNA includes modified nucleotides while maintaining the ability to mediate RNAi. The modified nucleotides can be used to improve *in vitro* or *in vivo* characteristics such as stability, activity, and/or bioavailability. For example, the dsRNA can include modified nucleotides as a percentage of the total number of nucleotides present in the molecule. As such, the dsRNA can generally include about 5% to about 100% modified nucleotides (*e.g.,* about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% modified nucleotides).

In some embodiments, the dsRNA targeting IDH, *e.g.,* IDH1, is about 21 nucleotides long. In another embodiment, the dsRNA does not contain any ribonucleotides, and in another embodiment, the dsRNA includes one or more ribonucleotides. In an embodiment, each strand of the dsRNA molecule independently includes about 15 to about 30 (*e.g.,* about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) nucleotides, wherein each strand includes about 15 to about 30 (*e.g.,* about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) nucleotides that are complementary to the nucleotides of the other strand. In an embodiment, one of the strands of the dsRNA includes a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof of the IDH1 or IDH2 gene, and the second strand of the dsRNA includes a nucleotide sequence substantially similar to the nucleotide sequence of the IDH1 or IDH2 gene or a portion thereof.

In an embodiment, the dsRNA targeting IDH1 or IDH2 includes an antisense region having a nucleotide sequence that is complementary to a nucleotide sequence of the IDH1 or IDH2 gene or a portion thereof, and a sense region having a nucleotide sequence substantially similar to the nucleotide sequence of the IDH1 or IDH2 gene or a portion thereof. In an embodiment, the antisense region and the sense region independently include about 15 to about 30 (*e.g.,* about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) nucleotides, where the antisense region includes

about 15 to about 30 (*e.g.,* about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) nucleotides that are complementary to nucleotides of the sense region.

As used herein, the term "dsRNA" is meant to include nucleic acid molecules that are capable of mediating sequence specific RNAi, such as short interfering RNA (siRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. In addition, as used herein, the term "RNAi" is meant to include sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetics.

Nucleic acid-based IDH inhibitors

In an embodiment the inhibitor is a nucleic acid-based inhibitor, such as a double stranded RNA (dsRNA) or antisense RNA that targets a mutant IDH, *e.g.,* mutant IDH1or IDH2.

In one embodiment, the nucleic acid based inhibitor, e.g., a dsRNA or antisense molecule, decreases or inhibits expression of an IDH1 having other than an Arg, e.g., having a His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Yan *et al.*, N. Eng. J. Med. 360:765-73, at residue 132, according to the sequence of SEQ ID NO:8 (see also **FIG. 21**). In one embodiment, the nucleic acid based inhibitor decreases or inhibits expression of an IDH1 enzyme having His at residue 132

In an embodiment the nucleic acid-based inhibitor is a dsRNA that targets an mRNA that encodes an IDH1 allele described herein, *e.g.,* an IDH1 allele having other than an Arg at residue 132. *E.g.,* the allele encodes His, Ser, Cys, Gly, Val, Pro or Leu, or any residue described in Yan *et al.*, at residue 132, according to the sequence of SEQ ID NO:8 (see also **Fig. 21**).

In an embodiment the allele encodes an IDH1 having His at residue 132.

In an embodiment the allele encodes an IDH1 having Ser at residue 132.

In an embodiment, the nucleic acid-based inhibitor is a dsRNA that targets IDH1, *e.g.,* an IDH1 having an A or a T (or a nucleotide other than C) at nucleotide position 394 or an A (or a nucleotide other than G) at nucleotide position 395, *e.g.,* a mutant allele carrying a C394T mutation or a G395A mutation according to the IDH1 sequence of SEQ ID NO:8 (see also Fig 21A).

In an embodiment, the dsRNA targets an IDH1 having other than C, *e.g.,* a T or an A, at nucleotide position 394 or and other than G, *e.g.,* an A, at 395 (*e.g.,* a mutant) and an IDH1 having a C at nucleotide position 394 or a G at nucleotide position 395 (*e.g.,* a wildtype), *e.g.,* by targeting a region of the IDH1 mRNA that is identical between the wildtype and mutant transcripts. In yet another embodiment, the dsRNA targets a particular mutant or polymorphism (such as a single nucleotide polymorphism (SNP)), but not a wildtype allele. In this case, the nucleic acid based inhibitor, *e.g.,* a dsRNA, targets the region of the IDH1 containing the mutation.

In some embodiments, the nucleic acid based inhibitor, *e.g.,* a dsRNA preferentially or specifically inhibits the product of a mutant IDH1 as compared to the product of a wildtype IDH1. In some embodiments, the IDH has a mutation at position 394 or 395 such as a C394A, a C394G, a C394T, a G395C, a G395T or a G395A mutation. For example, in one embodiment, a dsRNA targets a region of an IDH1 mRNA that carries the mutation (*e.g.,* a C394A of C394T or a G395A mutation according to SEQ ID NO:5).

In one embodiment, the nucleic acid-based inhibitor is a dsRNA including a sense strand and an antisense strand having a primary sequence presented in **Tables 7- 14**. In another embodiment, the nucleic acid based inhibitor is an antisense oligonucleotide that includes all or a part of an antisense primary sequence presented in **Tables 7- 14** or which targets the same or substantially the same region as does a dsRNA from **Tables 7- 14**.

In one embodiment, the nucleic acid based inhibitor decreases or inhibits expression of an IDH2 having Lys, Gly, Met, Trp, Thr, Ser, or any residue described in Yan *et al.*, at residue 172, according to the amino acid sequence of SEQ ID NO:10 (see also **FIG. 22**). In one embodiment, the nucleic acid based inhibitor decreases or inhibits expression of an IDH2 enzyme having Lys at residue 172.

In an embodiment the nucleic acid-based inhibitor is a dsRNA that targets an mRNA that encodes an IDH2 allele described herein, *e.g.,* an IDH2 allele having other than an Arg at residue 172. *E.g.,* the allele can have Lys, Gly, Met, Trp, Thr, Ser, or any residue described in Yan *et al.*, at residue 172, according to the sequence of SEQ ID NO:10 (see also **Fig. 22**).

In an embodiment the allele encodes an IDH2 having Lys at residue 172.

In an embodiment the allele encodes an IDH2 having Met at residue 172.

In an embodiment, the nucleic acid-based inhibitor is a dsRNA that targets IDH2, *e.g.,* an IDH2 having a G or a T (or a nucleotide other than A or C) at nucleotide position 514 or an A or T or C (or a nucleotide other than G) at nucleotide position 515, *e.g.,* a mutant allele carrying a A514G mutation or a G515T or a G515A mutation according to the IDH2 sequence of SEQ ID NO:10 (**Fig. 22A**). In one embodiment, the nucleic acid-based inhibitor is a dsRNA that targets IDH2, *e.g.,* an IDH2 having a C or a T (or a nucleotide other than G or A) at nucleotide position 516 according to the IDH2 sequence of SEQ ID NO:10.

In an embodiment, the nucleic acid-based inhibitor is a dsRNA that targets IDH2, *e.g.,* an IDH2 having a G at nucleotide position 514 or a T at nucleotide position 515 or an A at position 515, according to the IDH2 sequence of SEQ ID NO:10.

In an embodiment, the dsRNA targets an IDH2 having other than A, *e.g.,* a G or a T, at nucleotide position 514, or other than G, *e.g.,* an A or C or T at position 515 (*e.g.,* a mutant), or other than G, *e.g.,* C or T, and an IDH2 having an A at nucleotide position 514 or a G at nucleotide position 515 or a G at position 516 (*e.g.,* a wildtype), *e.g.,* by targeting a region of the IDH2 mRNA that is identical between the wildtype and mutant transcripts. In yet another embodiment, the dsRNA targets a particular mutant or polymorphism (such as a single nucleotide polymorphism (SNP)), but not a wildtype allele. In this case, the nucleic acid based inhibitor, *e.g.,* a dsRNA, targets the region of the IDH2 containing the mutation.

In some embodiments, the nucleic acid based inhibitor, *e.g.,* a dsRNA, preferentially or specifically inhibits the product of a mutant IDH2 as compared to the product of a wildtype IDH2. For example, in one embodiment, a dsRNA targets a region of an IDH2 mRNA that carries the mutation (*e.g.,* an A514G or G515T or a G515U mutation according to SEQ ID NO:10).

In one embodiment, the nucleic acid-based inhibitor is a dsRNA including a sense strand and an antisense strand having a primary sequence presented in **Tables 15-23**. In another embodiment, the nucleic acid based inhibitor is an antisense oligonucleotide that includes all or a part of an antisense primary sequence presented in **Tables 15-23** or which targets the same or substantially the same region as does a dsRNA from **Tables 15-23**.

In an embodiment, the nucleic acid based inhibitor is delivered to the brain, *e.g.,* directly to the brain, *e.g.,* by intrathecal or intraventricular delivery. The nucleic

acid based inhibitor can also be delivered from an inplantable device. In an embodiment, the nucleic acid-based inhibitor is delivered by infusion using, *e.g.,* a catheter, and optionally, a pump.

Antisense

Suitable nucleic acid based inhibitors include antisense nucleic acids. While not being bound by theory it is believed that antisense inhibition is typically based upon hydrogen bonding-based hybridization of oligonucleotide strands or segments such that at least one strand or segment is cleaved, degraded, or otherwise rendered inoperable.

An antisense agent can bind IDH1 or IDH2 DNA. In embodiments it inhibits replication and transcription. While not being bound by theory it is believed that an antisense agent can also function to inhibit target RNA translocation, *e.g.,* to a site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more RNA species, and catalytic activity or complex formation involving the RNA.

An antisense agents can have a chemical modification described above as being suitable for dsRNA.

Antisense agents can include, for example, from about 8 to about 80 nucleobases (*i.e.*, from about 8 to about 80 nucleotides), *e.g.,* about 8 to about 50 nucleobases, or about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression. Anti-sense compounds can include a stretch of at least eight consecutive nucleobases that are complementary to a sequence in the target gene. An oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, *i.e.*, under physiological conditions in the case of *in vivo* assays or therapeutic treatment or, in the case of *in vitro* assays, under conditions in which the assays are conducted.

Hybridization of antisense oligonucleotides with mRNA (*e.g.,* an mRNA encoding IDH1 or IDH2) can interfere with one or more of the normal functions of mRNA. While not being bound by theory it is believed that athe functions of mRNA to be interfered with include all key functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in by the RNA. Binding of specific protein(s) to the RNA may also be interfered with by antisense oligonucleotide hybridization to the RNA.

Exemplary antisense compounds include DNA or RNA sequences that specifically hybridize to the target nucleic acid, *e.g.,* the mRNA encoding IDH1 or IDH2. The complementary region can extend for between about 8 to about 80 nucleobases. The compounds can include one or more modified nucleobases. Modified nucleobases may include, *e.g.,* 5-substituted pyrimidines such as 5-iodouracil, 5-iodocytosine, and C5-propynyl pyrimidines such as C5-propynylcytosine and C5-propynyluracil. Other suitable modified nucleobases include N^4-(C_1-C_{12}) alkylaminocytosines and N^4,N^4-(C_1-C_{12}) dialkylaminocytosines. Modified nucleobases may also include 7-substituted-5-aza-7-deazapurines and 7-substituted-7-deazapurines such as, for example, 7-iodo-7-deazapurines, 7-cyano-7-deazapurines, 7-aminocarbonyl-7-deazapurines. Examples of these include 6-amino-7-iodo-7-deazapurines, 6-amino-7-cyano-7-deazapurines, 6-amino-7-aminocarbonyl-7-deazapurines, 2-amino-6-hydroxy-7-iodo-7-deazapurines, 2-amino-6-hydroxy-7-cyano-7-deazapurines, and 2-amino-6-hydroxy-7-aminocarbonyl-7-deazapurines. Furthermore, N^6-(C_1-C_{12}) alkylaminopurines and N^6,N^6-(C_1-C_{12}) dialkylaminopurines, including N^6-methylaminoadenine and N^6,N^6-dimethylaminoadenine, are also suitable modified nucleobases. Similarly, other 6-substituted purines including, for example, 6-thioguanine may constitute appropriate modified nucleobases. Other suitable nucleobases include 2-thiouracil, 8-bromoadenine, 8-bromoguanine, 2-fluoroadenine, and 2-fluoroguanine. Derivatives of any of the aforementioned modified nucleobases are also appropriate. Substituents of any of the preceding compounds may include C_1-C_{30} alkyl, C_2-C_{30} alkenyl, C_2-C_{30} alkynyl, aryl, aralkyl, heteroaryl, halo, amino, amido, nitro, thio, sulfonyl, carboxyl, alkoxy, alkylcarbonyl, alkoxycarbonyl, and the like.

MicroRNA

In some embodiments, the nucleic acid-based inhibitor suitable for targeting IDH, *e.g.,* IDH1, is a microRNA (miRNA). A miRNA is a single stranded RNA that regulates the expression of target mRNAs either by mRNA cleavage, translational repression/inhibition or heterochromatic silencing. The miRNA is 18 to 25 nucleotides, typically 21 to 23 nucleotides in length. In some embodiments, the miRNA includes chemical modifications, such as one or more modifications described herein.

In some embodiments, a nucleic acid based inhibitor targeting IDH has partial complementarity (*i.e.*, less than 100% complementarity) with the target IDH, *e.g.,* IDH1 or IDH2, mRNA. For example, partial complementarity can include various mismatches or non-base paired nucleotides (*e.g.,* 1, 2, 3, 4, 5 or more mismatches or non-based paired nucleotides, such as nucleotide bulges), which can result in bulges, loops, or overhangs that result between the antisense strand or antisense region of the nucleic acid-based inhibitor and the corresponding target nucleic acid molecule.

The nucleic acid-based inhibitors described herein, *e.g.,* antisense nucleic acid described herein, can be incorporated into a gene construct to be used as a part of a gene therapy protocol to deliver nucleic acids that can be used to express and produce agents within cells. Expression constructs of such components may be administered in any biologically-effective carrier, *e.g.,* any formulation or composition capable of effectively delivering the component gene to cells *in vivo*. Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, lentivirus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (*e.g.,* antibody conjugated) polylysine conjugates, gramacidin S, artificial viral envelopes or other such intracellular earners, as well as direct injection of the gene construct or $CaPO_4$ precipitation carried out *in vivo*.

In an embodiment, *in vivo* introduction of nucleic acid into a cell includes use of a viral vector containing nucleic acid, *e.g.,* a cDNA. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, *e.g.,* by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.

Retroviral vectors and adeno-associated virus vectors can be used as a recombinant gene delivery system for the transfer of exogenous genes *in vivo* particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. *et al.* (eds.) Greene Publishing Associates (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE, and pEM which are known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include Crip, Cre, 2, and Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, *in vitro* and/or *in vivo* (see, for example, Eglitis *et al.* (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson *et al.* (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano *et al.* (1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber *et al.* (1991) Proc. Natl. Acad. Sci. USA 88:8039-8043; Ferry *et al.* (1991) Proc. Natl. Acad. Sci. USA 88:8377-8381; Chowdhury *et al.* (1991) Science 254:1802-1805; van Beusechem *et al.* (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay *et al.* (1992) Human Gene Therapy 3:641-647; Dai *et al.* (1992) Proc. Natl. Acad. Sci. USA 89:10892-10895; Hwu *et al.* (1993) J. Immunol. 150:4104-4115; U.S. Pat. Nos. 4,868,116 and 4,980,286; PCT Pub. Nos. WO 89/07136, WO 89/02468, WO 89/05345, and WO 92/07573).

Another viral gene delivery system utilizes adenovirus-derived vectors. See, for example, Berkner *et al.* (1988) BioTechniques 6:616; Rosenfeld *et al.* (1991) Science 252:431-434; and Rosenfeld *et al.* (1992) Cell 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 d1324 or other strains of adenovirus (*e.g.,* Ad2, Ad3, Ad7 etc.) are known to those skilled in the art.

Yet another viral vector system useful for delivery of the subject gene is the adeno-associated virus (AAV). See, for example, Flotte *et al.* (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356; Samulski *et al.* (1989) J. Virol. 63:3822-3828; and McLaughlin *et al.* (1989) J. Virol. 62:1963-1973.

Pharmaceutical compositions

The compositions delineated herein include the compounds delineated herein, as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of disease or disease symptoms, including those described herein.

The term "pharmaceutically acceptable carrier or adjuvant" refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.

Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.

The pharmaceutical compositions containing inhibitors of IDH, *e.g.,* IDH1, may be administered directly to the central nervous system, such as into the cerebrospinal fluid or into the brain. Delivery can be, for example, in a bolus or by continuous pump infusion. In certain embodiments, delivery is by intrathecal delivery or by intraventricular injection directly into the brain. A catheter and, optionally, a pump can be used for delivery. The inhibitors can be delivered in and released from an implantable device, *e.g.,* a device that is implanted in association with surgical

removal of tumor tissue. *E.g.,* for delivery to the brain, the delivery can be analogous to that with Gliadel, a biopolymer wafer designed to deliver carmustine directly into the surgical cavity created when a brain tumor is resected. The Gliadel wafer slowly dissolves and delivers carmustine.

The therapeutics disclosed herein, *e.g.,* nucleic acid based inhibitors, *e.g.* siRNAs can be administered directly to the CNS, *e.g.,* the brain, *e.g.,* using a pump and/or catheter system. In one embodiment, the pump is implanted under the skin. In an embodiment and a catheter attached to a pump is inserted into the CNS, *e.g.,* into the brain or spine. In one embodiment, the pump (such as the IsoMed Drug Pump from Medtronic) delivers dosing, *e.g*, constant dosing, of a nucleic acid based inhibitor. In an embodiment, the pump is programmable to administer variable or constant doses at predetermined time intervals. For example, the IsoMed Drug pump from Medtronic (or a similar device) can be used to administer a constant supply of the inhibitor, or the SynchroMedII Drug Pump (or a similar device) can be used to administer a variable dosing regime.

Methods and devices described in US patents 7,044,932, 6,620,151, 6,283949, and 6,685,452 can be used in methods described herein.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents

that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

Topical administration of the pharmaceutical compositions of this invention is useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active

components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.

The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

The compounds described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.02 to about 100 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated

effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound.

Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.

Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

Kits

A compound described herein can be provided in a kit.

In an embodiment the kit includes (a) a compound described herein, *e.g.,* a composition that includes a compound described herein (wherein, *e.g.,* the compound can be an inhibitor described herein), and, optionally (b) informational material. The informational material can be descriptive, instructional, marketing or other material that relates to the methods described herein and/or the use of a compound described herein for the methods described herein.

In an embodiment the kit provides materials for evaluating a subject. The evaluation can be, *e.g.,*for: identifying a subject having unwanted levels (e.g., higher than present in normal or wildtype cells) of any of 2HG, 2HG neoactivity, or mutant

IDH1 or IDH2 protien having 2HG neoactivity (or corresponding RNA), or having a somatic mutation in IDH1 or IDH2 characterized by 2HG neoactivity; diagnosing, prognosing, or staging, a subject, *e.g.,* on the basis of having increased levels of 2HG, 2HG neoactivity, or mutant IDH1 or IDH2 protien having 2HG neoactivity (or corresponding RNA), or having a somatic mutation in IDH1 or IDH2 characterized by 2HG neoactivity; selecting a treatment for, or evaluating the efficacy of, a treatment, *e.g.,* on the basis of the subject having increased levels of 2HG, 2HG neoactivity, or mutant IDH1 or IDH2 protien having 2HG neoactivity (or corresponding RNA), or having a somatic mutation in IDH1 or IDH2 characterized by 2HG neoactivity. The kit can include one or more reagent useful in the evaluation, *e.g.,* reagents mentioned elsewhere herein. A detection reagent, *e.g.,* an antibody or other specific bindng reagent can be included. Standards or reference samples, *e.g.,* a positive or negative control standard can be included. *E.g.,* if the evaluation is based on the presence of 2HG the kit can include a reagent, e.g, a positive or negative control standards for an assay, *e.g.,* a LC-MS assay.

If the evaluation is based on the presence of 2HG neoactivity, the kit can include a reagent, *e.g.,* one or more of those mentioned elsewhere herein, for assaying 2HG neoactivity. If the evaluation is based on sequencing, the kit can include primers or other matierials useful for sequencing the relevant nucleic acids for identifying an IHD, e.g., IDH1 or IDH2, neoactive mutant. E.g., the kit can contain a reagent that provides for interrogation of the indentity, i.e., sequencing of, residue 132 of IDH1 to determine if a neoactive mutant is present. The kit can include nucleic acids, e.g., an oligomer, e.g., primers, which allow sequencing of of the nucleotides that encode residue 132 of IDH1. In an embodiment the kit includes a nucleic acid whose hybridization, or ability to be amplified, is dependent on the indentity of residue 132 of IDH1. In other embodiments the kit includes a reagent, e.g., an antibody or other specific binding molecule that can identify the presence of a neoactive mutant, *e.g.*, a protein encoded by a neoactive mutant at 132 of IDH1. As described below, a kit can also include buffers, solvents, and information related to the evaluation.

In one embodiment, the informational material can include information about production of the compound, molecular weight of the compound, concentration, date of expiration, batch or production site information, and so forth. In one embodiment, the informational material relates to methods for administering the compound.

In one embodiment, the informational material can include instructions to administer a compound described herein in a suitable manner to perform the methods described herein, *e.g.,* in a suitable dose, dosage form, or mode of administration (*e.g.,* a dose, dosage form, or mode of administration described herein). In another embodiment, the informational material can include instructions to administer a compound described herein to a suitable subject, *e.g.,* a human, *e.g.,* a human having or at risk for a disorder described herein.

The informational material of the kits is not limited in its form. In many cases, the informational material, *e.g.,* instructions, is provided in printed matter, *e.g.,* a printed text, drawing, and/or photograph, *e.g.,* a label or printed sheet. However, the informational material can also be provided in other formats, such as Braille, computer readable material, video recording, or audio recording. In another embodiment, the informational material of the kit is contact information, *e.g.,* a physical address, email address, website, or telephone number, where a user of the kit can obtain substantive information about a compound described herein and/or its use in the methods described herein. Of course, the informational material can also be provided in any combination of formats.

In addition to a compound described herein, the composition of the kit can include other ingredients, such as a solvent or buffer, a stabilizer, a preservative, a flavoring agent (*e.g.,* a bitter antagonist or a sweetener), a fragrance or other cosmetic ingredient, and/or a second agent for treating a condition or disorder described herein. Alternatively, the other ingredients can be included in the kit, but in different compositions or containers than a compound described herein. In such embodiments, the kit can include instructions for admixing a compound described herein and the other ingredients, or for using a compound described herein together with the other ingredients.

A compound described herein can be provided in any form, *e.g.,* liquid, dried or lyophilized form. It is preferred that a compound described herein be substantially pure and/or sterile. When a compound described herein is provided in a liquid solution, the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being preferred. When a compound described herein is provided as a dried form, reconstitution generally is by the addition of a suitable solvent. The solvent, *e.g.,* sterile water or buffer, can optionally be provided in the kit.

The kit can include one or more containers for the composition containing a compound described herein. In some embodiments, the kit contains separate containers, dividers or compartments for the composition and informational material. For example, the composition can be contained in a bottle, vial, or syringe, and the informational material can be contained in a plastic sleeve or packet. In other embodiments, the separate elements of the kit are contained within a single, undivided container. For example, the composition is contained in a bottle, vial or syringe that has attached thereto the informational material in the form of a label. In some embodiments, the kit includes a plurality (*e.g.,* a pack) of individual containers, each containing one or more unit dosage forms (*e.g.,* a dosage form described herein) of a compound described herein. For example, the kit includes a plurality of syringes, ampules, foil packets, or blister packs, each containing a single unit dose of a compound described herein. The containers of the kits can be air tight, waterproof (*e.g.,* impermeable to changes in moisture or evaporation), and/or light-tight.

The kit optionally includes a device suitable for administration of the composition, *e.g.,* a syringe, inhalant, pipette, forceps, measured spoon, dropper (*e.g.,* eye dropper), swab (*e.g.,* a cotton swab or wooden swab), or any such delivery device. In an embodiment, the device is a medical implant device, *e.g.,* packaged for surgical insertion.

Combination therapies

In some embodiments, a compound or composition described herein, is administered together with an additional cancer treatment. Exemplary cancer treatments include, for example: surgery, chemotherapy, targeted therapies such as antibody therapies, immunotherapy, and hormonal therapy. Examples of each of these treatments are provided below.

Chemotherapy

In some embodiments, a compound or composition described herein, is administered with a chemotherapy. Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells. "Chemotherapy" usually refers to cytotoxic drugs which affect rapidly dividing cells in general, in contrast with targeted therapy. Chemotherapy drugs interfere with cell division in various possible ways, *e.g.,* with the duplication of DNA or the separation of newly formed chromosomes. Most forms of chemotherapy targ*et al*l rapidly dividing cells and are not specific for cancer cells,

although some degree of specificity may come from the inability of many cancer cells to repair DNA damage, while normal cells generally can.

Examples of chemotherapeutic agents used in cancer therapy include, for example, antimetabolites (*e.g.,* folic acid, purine, and pyrimidine derivatives) and alkylating agents (*e.g.,* nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazines, triazenes, aziridines, spindle poison, cytotoxic agents, toposimerase inhibitors and others). Exemplary agents include Aclarubicin, Actinomycin, Alitretinon, Altretamine, Aminopterin, Aminolevulinic acid, Amrubicin, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase, Atrasentan, Belotecan, Bexarotene, endamustine, Bleomycin, Bortezomib, Busulfan, Camptothecin, Capecitabine, Carboplatin, Carboquone, Carmofur, Carmustine, Celecoxib, Chlorambucil, Chlormethine, Cisplatin, Cladribine, Clofarabine, Crisantaspase, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Decitabine, Demecolcine, Docetaxel, Doxorubicin, Efaproxiral, Elesclomol, Elsamitrucin, Enocitabine, Epirubicin, Estramustine, Etoglucid, Etoposide, Floxuridine, Fludarabine, Fluorouracil (5FU), Fotemustine, Gemcitabine, Gliadel implants, Hydroxycarbamide, Hydroxyurea, Idarubicin, Ifosfamide, Irinotecan, Irofulven, Ixabepilone, Larotaxel, Leucovorin, Liposomal doxorubicin, Liposomal daunorubicin, Lonidamine, Lomustine, Lucanthone, Mannosulfan, Masoprocol, Melphalan, Mercaptopurine, Mesna, Methotrexate, Methyl aminolevulinate, Mitobronitol, Mitoguazone, Mitotane, Mitomycin, Mitoxantrone, Nedaplatin, Nimustine, Oblimersen, Omacetaxine, Ortataxel, Oxaliplatin, Paclitaxel, Pegaspargase, Pemetrexed, Pentostatin, Pirarubicin, Pixantrone, Plicamycin, Porfimer sodium, Prednimustine, Procarbazine, Raltitrexed, Ranimustine, Rubitecan, Sapacitabine, Semustine, Sitimagene ceradenovec, Strataplatin, Streptozocin, Talaporfin, Tegafur-uracil, Temoporfin, Temozolomide, Teniposide, Tesetaxel, Testolactone, Tetranitrate, Thiotepa, Tiazofurine, Tioguanine, Tipifarnib, Topotecan, Trabectedin, Triaziquone, Triethylenemelamine, Triplatin, Tretinoin, Treosulfan, Trofosfamide, Uramustine, Valrubicin, Verteporfin, Vinblastine, Vincristine, Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zorubicin, and other cytostatic or cytotoxic agents described herein.

Because some drugs work better together than alone, two or more drugs are often given at the same time. Often, two or more chemotherapy agents are used as combination chemotherapy. In some embodiments, the chemotherapy agents

(including combination chemotherapy) can be used in combination with a compound described herein, *e.g.,* phenformin.

Targeted therapy

In some embodiments, a compound or composition described herein, is administered with a targeted therapy. Targeted therapy constitutes the use of agents specific for the deregulated proteins of cancer cells. Small molecule targeted therapy drugs are generally inhibitors of enzymatic domains on mutated, overexpressed, or otherwise critical proteins within the cancer cell. Prominent examples are the tyrosine kinase inhibitors such as Axitinib, Bosutinib, Cediranib, desatinib, erlotinib, imatinib, gefitinib, lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, and Vandetanib, and also cyclin-depdendent kinase inhibitors such as Alvocidib and Seliciclib. Monoclonal antibody therapy is another strategy in which the therapeutic agent is an antibody which specifically binds to a protein on the surface of the cancer cells. Examples include the anti-HER2/neu antibody trastuzumab (HERCEPTIN®) typically used in breast cancer, and the anti-CD20 antibody rituximab and Tositumomab typically used in a variety of B-cell malignancies. Other exemplary antibodies include Cetuximab, Panitumumab, Trastuzumab, Alemtuzumab, Bevacizumab, Edrecolomab, and Gemtuzumab. Exemplary fusion proteins include Aflibercept and Denileukin diftitox. In some embodiments, the targeted therapy can be used in combination with a compound described herein, *e.g.,* a biguanide such as metformin or phenformin, preferably phenformin.

Targeted therapy can also involve small peptides as "homing devices" which can bind to cell surface receptors or affected extracellular matrix surrounding the tumor. Radionuclides which are attached to these peptides (*e.g.,* RGDs) eventually kill the cancer cell if the nuclide decays in the vicinity of the cell. An example of such therapy includes BEXXAR®.

Immunotherapy

In some embodiments, a compound or composition described herein, is administered with an immunotherapy. Cancer immunotherapy refers to a diverse set of therapeutic strategies designed to induce the patient's own immune system to fight the tumor. Contemporary methods for generating an immune response against tumors include intravesicular BCG immunotherapy for superficial bladder cancer, and use of interferons and other cytokines to induce an immune response in renal cell carcinoma and melanoma patients.

Allogeneic hematopoietic stem cell transplantation can be considered a form of immunotherapy, since the donor's immune cells will often attack the tumor in a graft-versus-tumor effect. In some embodiments, the immunotherapy agents can be used in combination with a compound or composition described herein.

Hormonal therapy

In some embodiments, a compound or composition described herein, is administered with a hormonal therapy. The growth of some cancers can be inhibited by providing or blocking certain hormones. Common examples of hormone-sensitive tumors include certain types of breast and prostate cancers. Removing or blocking estrogen or testosterone is often an important additional treatment. In certain cancers, administration of hormone agonists, such as progestogens may be therapeutically beneficial. In some embodiments, the hormonal therapy agents can be used in combination with a compound or a composition described herein.

In some embodiments, a compound or composition described herein, is administered together with an additional cancer treatment (*e.g.,* surgical removal), in treating cancer in nervous system, *e.g.,* cancer in central nervous system, *e.g.,* brain tumor, *e.g.,* glioma, *e.g.,* glioblastoma multiforme (GBM).

Several studies have suggested that more than 25% of glioblastoma patients obtain a significant survival benefit from adjuvant chemotherapy. Meta-analyses have suggested that adjuvant chemotherapy results in a 6-10% increase in 1-year survival rate.

Temozolomide is an orally active alkylating agent that is used for persons newly diagnosed with glioblastoma multiforme. It was approved by the United States Food and Drug Administration (FDA) in March 2005. Studies have shown that the drug was well tolerated and provided a survival benefit. Adjuvant and concomitant temozolomide with radiation was associated with significant improvements in median progression-free survival over radiation alone (6.9 vs 5 mo), overall survival (14.6 vs 12.1 mo), and the likelihood of being alive in 2 years (26% vs 10%).

Nitrosoureas: BCNU (carmustine)-polymer wafers (Gliadel) were approved by the FDA in 2002. Though Gliadel wafers are used by some for initial treatment, they have shown only a modest increase in median survival over placebo (13.8 vs. 11.6 months) in the largest such phase III trial, and are associated with increased rates of CSF leak and increased intracranial pressure secondary to edema and mass effect.

MGMT is a DNA repair enzyme that contributes to temozolomide resistance. Methylation of the MGMT promoter, found in approximately 45% of glioblastoma multiformes, results in an epigenetic silencing of the gene, decreasing the tumor cell's capacity for DNA repair and increasing susceptibility to temozolomide.

When patients with and without MGMT promoter methylation were treated with temozolomide, the groups had median survivals of 21.7 versus 12.7 months, and 2-year survival rates of 46% versus 13.8%, respectively.

Though temozolomide is currently a first-line agent in the treatment of glioblastoma multiforme, unfavorable MGMT methylation status could help select patients appropriate for future therapeutic investigations.

O6-benzylguanine and other inhibitors of MGMT as well as RNA interference-mediated silencing of MGMT offer promising avenues to increase the effectiveness of temozolomide and other alkylating antineoplastics, and such agents are under active study.

Carmustine (BCNU) and cis -platinum (cisplatin) have been the primary chemotherapeutic agents used against malignant gliomas. All agents in use have no greater than a 30-40% response rate, and most fall into the range of 10-20%.

Data from the University of California at San Francisco indicate that, for the treatment of glioblastomas, surgery followed by radiation therapy leads to 1-, 3-, and 5-year survival rates of 44%, 6%, and 0%, respectively. By comparison, surgery followed by radiation and chemotherapy using nitrosourea-based regimens resulted in 1-, 3-, and 5-year survival rates of 46%, 18%, and 18%, respectively.

A major hindrance to the use of chemotherapeutic agents for brain tumors is the fact that the blood-brain barrier (BBB) effectively excludes many agents from the CNS. For this reason, novel methods of intracranial drug delivery are being developed to deliver higher concentrations of chemotherapeutic agents to the tumor cells while avoiding the adverse systemic effects of these medications.

Pressure-driven infusion of chemotherapeutic agents through an intracranial catheter, also known as convection-enhanced delivery (CED), has the advantage of delivering drugs along a pressure gradient rather than by simple diffusion. CED has shown promising results in animal models with agents including BCNU and topotecan.

Initial attempts investigated the delivery of chemotherapeutic agents via an intraarterial route rather than intravenously. Unfortunately, no survival advantage was observed.

Chemotherapy for recurrent glioblastoma multiforme provides modest, if any, benefit, and several classes of agents are used. Carmustine wafers increased 6-month survival from 36% to 56% over placebo in one randomized study of 222 patients, though there was a significant association between the treatment group and serious intracranial infections.

Genotyping of brain tumors may have applications in stratifying patients for clinical trials of various novel therapies.

The anti-angiogenic agent bevacizumab, when used with irinotecan improved 6-month survival in recurrent glioma patients to 46% compared with 21% in patients treated with temozolomide. This bevacizumab and irinotecan combination for recurrent glioblastoma multiforme has been shown to improve survival over bevacizumab alone. Anti-angiogenic agents also decrease peritumoral edema, potentially reducing the necessary corticosteroid dose.

Some glioblastomas responds to gefitinib or erlotinib (tyrosine kinase inhibitors). The simultaneous presence in glioblastoma cells of mutant EGFR (EGFRviii) and PTEN was associated with responsiveness to tyrosine kinase inhibitors, whereas increased p-akt predicts a decreased effect. Other targets include PDGFR, VEGFR, mTOR, farnesyltransferase, and PI3K.

Other possible therapy modalities include imatinib, gene therapy, peptide and dendritic cell vaccines, synthetic chlorotoxins, and radiolabeled drugs and antibodies.

Patient selection/monitoring

Described herein are methods of treating a cell proliferation-related disorder, *e.g.,* cancer, in a subject and methods of identifying a subject for a treatment described herein. Also described herein are methods of predicting a subject who is at risk of developing cancer (*e.g.,* a cancer associate with a mutation in an enzyme (*e.g.,* an enzyme in the metabolic pathway such as IDH1 and/or IDH2)). The cancer is generally characterized by the presence of a neoactivity, such as a gain of function in one or more mutant enzymes (*e.g.,* an enzyme in the metabolic pathway leading to fatty acid biosynthesis, glycolysis, glutaminolysis, the pentose phosphate shunt, the nucleotide biosynthetic pathway, or the fatty acid biosynthetic pathway, *e.g.,* IDH1 or

IDH2). The subject can be selected on the basis of the subject having a mutant gene having a neoactivity, *e.g.,* a neoactivity described herein. As used herein, "select" means selecting in whole or part on said basis.

In some embodiments, a subject is selected for treatment with a compound described herein based on a determination that the subject has a mutant enzyme described herein (*e.g.,* an enzyme in the metabolic pathway, *e.g.,* a metabolic pathway leading to fatty acid biosynthesis, glycolysis, glutaminolysis, the pentose phosphate shunt, the nucleotide biosynthetic pathway, or the fatty acid biosynthetic pathway, *e.g.,* IDH1 or IDH2). In some embodiments, the mutant enzyme has a neoactivity and the patient is selected on that basis. The neoactivity of the enzyme can be identified, for example, by evaluating the subject or sample (*e.g.,* tissue or bodily fluid) therefrom, for the presence or amount of a substrate, cofactor and/or product of the enzyme. The presence and/or amount of substrate, cofactor and/or product can correspond to the wild-type/non-mutant activity or can correspond to the neoactivity of the enzyme. Exemplary bodily fluid that can be used to identifty (*e.g.,* evaluate) the neoactivity of the enzyme include amniotic fluid surrounding a fetus, aqueous humour, blood (*e.g.,* blood plasma), Cerebrospinal fluid, cerumen, chyme, Cowper's fluid, female ejaculate, interstitial fluid, lymph, breast milk, mucus (*e.g.,* nasal drainage or phlegm), pleural fluid, pus, saliva, sebum, semen, serum, sweat, tears, urine, vaginal secretion, or vomit.

In some embodiments, a subject can be evaluated for neoactivity of an enzyme using magnetic resonance. For example, where the mutant enzyme is IDH1 or IDH2 and the neoactivity is conversion of α-ketoglutarate to 2-hydroxyglutarate, the subject can be evaluated for the presence of and/or an elevated amount of 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate relative to the amount of 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate present in a subject who does not have a mutation in IDH1 or IDH2 having the above neoactivity. In some embodiments, neoactivity of IDH1 or IDH2 can be determined by the presence or elevated amount of a peak corresponding to 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate as determined by magnetic resonance. For example, a subject can be evaluated for the presence and/or strength of a signal at about 2.5 ppm to determine the presence and/or amount of 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate in the subject. This can be correlated to and/or predictive of a neoactivity described herein for the mutant enzyme IDH. Similarly, the presence,

strength and/or absence of a signal at about 2.5 ppm could be predictive of a response to treatment and thereby used as a noninvasive biomarker for clinical response.

Neoactivity of a mutant enzyme such as IDH can also be evaluated using other techniques known to one skilled in the art. For example, the presence or amount of a labeled substrate, cofactor, and/or reaction product can be measured such as a ^{13}C or ^{14}C labeled substrate, cofactor, and/or reaction product. The neoactivity can be evaluated by evaluating the forward reaction of the wild-type/non mutant enzyme (such as the oxidative decarboxylation of ioscitrate to α-ketoglutarate in a mutant IDH1 or IDH2 enzyme, specifically a mutant IDH1 enzyme) and/or the reaction corresponding to the neoactivity (*e.g.,* the conversion of α-ketoglutarate to 2-hydroxyglutarate, *e.g.,* R-2-hydroxyglutarate in a mutant IDH1 or IDH2 enzyme, specifically a mutant IDH1 enzyme).

Disorders

The IDH-related methods disclosed herein, *e.g.,* methods of evaluating or treating subjects, are directed to subjects having a cell proliferation-related disorder characterized by an IDH mutant, *e.g.,* an IDH1 or IDH2, mutant having neoactivity, *e.g.,* 2HG neoactivity. Examples of some of the disorders below have been shown to be characterized by an IDH1 or IDH2 mutation. Others can be analyzed, *e.g.,* by sequencing cell samples to determine the presence of a somatic mutation at amino acid 132 of IDH1 or at amino acid 172 of IDH2. Without being bound by theory it is expected that a portion of the tumors of given type of cancer will have an IDH, e.g., IDH1 or IDH2, mutant having 2HG neoactivity.

The disclosed methods are useful in evaluating or treating proliferative disorders, *e.g.* evaluating or treating solid tumors, soft tissue tumors, and metastases thereof wherein the solid tumor, soft tissue tumor or metastases thereof is a cancer described herein. Exemplary solid tumors include malignancies (*e.g.,* sarcomas, adenocarcinomas, and carcinomas) of the various organ systems, such as those of brain, lung, breast, lymphoid, gastrointestinal (*e.g.,* colon), and genitourinary (*e.g.,* renal, urothelial, or testicular tumors) tracts, pharynx, prostate, and ovary. Exemplary adenocarcinomas include colorectal cancers, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, and cancer of the small intestine. The disclosed methods are also useful in evaluating or treating non-solid cancers.

The methods described herein can be used with any cancer, for example those described by the National Cancer Institute. A cancer can be evaluated to determine whether it is using a method described herein. Exemplary cancers described by the National Cancer Institute include: Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Childhood; Acute Myeloid Leukemia, Adult; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; AIDS-Related Lymphoma; AIDS-Related Malignancies; Anal Cancer; Astrocytoma, Childhood Cerebellar; Astrocytoma, Childhood Cerebral; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bladder Cancer, Childhood; Bone Cancer, Osteosarcoma/Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Cerebellar Astrocytoma, Childhood; Brain Tumor, Cerebral Astrocytoma/Malignant Glioma, Childhood; Brain Tumor, Ependymoma, Childhood; Brain Tumor, Medulloblastoma, Childhood; Brain Tumor, Supratentorial Primitive Neuroectodermal Tumors, Childhood; Brain Tumor, Visual Pathway and Hypothalamic Glioma, Childhood; Brain Tumor, Childhood (Other); Breast Cancer; Breast Cancer and Pregnancy; Breast Cancer, Childhood; Breast Cancer, Male; Bronchial Adenomas/Carcinoids, Childhood; Carcinoid Tumor, Childhood; Carcinoid Tumor, Gastrointestinal; Carcinoma, Adrenocortical; Carcinoma, Islet Cell; Carcinoma of Unknown Primaiy; Central Nervous System Lymphoma, Primary; Cerebellar Astrocytoma, Childhood; Cerebral Astrocytoma/Malignant Glioma, Childhood; Cervical Cancer; Childhood Cancers; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Clear Cell Sarcoma of Tendon Sheaths; Colon Cancer; Colorectal Cancer, Childhood; Cutaneous T-CeIl Lymphoma; Endometrial Cancer; Ependymoma, Childhood; Epithelial Cancer, Ovarian; Esophageal Cancer; Esophageal Cancer, Childhood; Ewing's Family of Tumors; Extracranial Germ Cell Tumor, Childhood; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumor; Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma, Childhood Brain Stem; Glioma, Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer, Adult (Primary); Hepatocellular (Liver) Cancer, Childhood (Primary); Hodgkin's

Lymphoma, Adult; Hodgkin's Lymphoma, Childhood; Hodgkin's Lymphoma During Pregnancy; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma, Childhood; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi's Sarcoma; Kidney Cancer; Laryngeal Cancer; Laryngeal Cancer, Childhood; Leukemia, Acute Lymphoblastic, Adult; Leukemia, Acute Lymphoblastic, Childhood; Leukemia, Acute Myeloid, Adult; Leukemia, Acute Myeloid, Childhood; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer, Adult (Primary); Liver Cancer, Childhood (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoblastic Leukemia, Adult Acute; Lymphoblastic Leukemia, Childhood Acute; Lymphocytic Leukemia, Chronic; Lymphoma, AIDS- Related; Lymphoma, Central Nervous System (Primary); Lymphoma, Cutaneous T-CeIl; Lymphoma, Hodgkin's, Adult; Lymphoma, Hodgkin's, Childhood; Lymphoma, Hodgkin's During Pregnancy; Lymphoma, Non-Hodgkin's, Adult; Lymphoma, Non- Hodgkin's, Childhood; Lymphoma, Non-Hodgkin's During Pregnancy; Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom's; Male Breast Cancer; Malignant Mesothelioma, Adult; Malignant Mesothelioma, Childhood; Malignant Thymoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular; Merkel Cell Carcinoma; Mesothelioma, Malignant; Metastatic Squamous Neck Cancer with Occult Primary; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Nasopharyngeal Cancer, Childhood; Neuroblastoma; Non-Hodgkin's Lymphoma, Adult; Non-Hodgkin's Lymphoma, Childhood; Non-Hodgkin's Lymphoma During Pregnancy; Non-Small Cell Lung Cancer; Oral Cancer, Childhood; Oral Cavity and Lip Cancer; Oropharyngeal Cancer; Osteosarcoma/Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer, Childhood; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Childhood; Pancreatic Cancer, Islet Cell; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pheochromocytoma; Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Pregnancy and Breast Cancer; Pregnancy and Hodgkin's

Lymphoma; Pregnancy and Non-Hodgkin's Lymphoma; Primary Central Nervous System Lymphoma; Primary Liver Cancer, Adult; Primary Liver Cancer, Childhood; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Cell Cancer, Childhood; Renal Pelvis and Ureter, Transitional Cell Cancer; Retinoblastoma; Rhabdomyosarcoma, Childhood; Salivary Gland Cancer; Salivary Gland Cancer, Childhood; Sarcoma, Ewing's Family of Tumors; Sarcoma, Kaposi's; Sarcoma (Osteosarcoma)/Malignant Fibrous Histiocytoma of Bone; Sarcoma, Rhabdomyosarcoma, Childhood; Sarcoma, Soft Tissue, Adult; Sarcoma, Soft Tissue, Childhood; Sezary Syndrome; Skin Cancer; Skin Cancer, Childhood; Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma, Adult; Soft Tissue Sarcoma, Childhood; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Stomach (Gastric) Cancer, Childhood; Supratentorial Primitive Neuroectodermal Tumors, Childhood; T- CeIl Lymphoma, Cutaneous; Testicular Cancer; Thymoma, Childhood; Thymoma, Malignant; Thyroid Cancer; Thyroid Cancer, Childhood; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Unknown Primary Site, Cancer of, Childhood; Unusual Cancers of Childhood; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Sarcoma; Vaginal Cancer; Visual Pathway and Hypothalamic Glioma, Childhood; Vulvar Cancer; Waldenstrom's Macro globulinemia; and Wilms' Tumor. Metastases of the aforementioned cancers can also be treated or prevented in accordance with the methods described herein.

The methods described herein are useful in treating cancer in nervous system, *e.g.,* brain tumor, *e.g.,* glioma, *e.g.,* glioblastoma multiforme (GBM), *e.g.,* by inhibiting a neoactivity of a mutant enzyme, *e.g.,* an enzyme in a metabolic pathway, *e.g.,* a metabolic pathway leading to fatty acid biosynthesis, glycolysis, glutaminolysis, the pentose phosphate shunt, the nucleotide biosynthetic pathway, or the fatty acid biosynthetic pathway, *e.g.,* IDH1 or IDH2.

Gliomas, a type of brain tumors, can be classified as grade I to grade IV on the basis of histopathological and clinical criteria established by the World Health Organization (WHO). WHO grade I gliomas are often considered benign. Gliomas of WHO grade II or III are invasive, progress to higher-grade lesions. WHO grade IV tumors (glioblastomas) are the most invasive form. Exemplary brain tumors include, *e.g.,* astrocytic tumor (*e.g.,* pilocytic astrocytoma, subependymal giant-cell

astrocytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, anaplastic astrocytoma, astrocytoma, giant cell glioblastoma, glioblastoma, secondary glioblastoma, primary adult glioblastoma, and primary pediatric glioblastoma); oligodendroglial tumor (*e.g.,* oligodendroglioma, and anaplastic oligodendroglioma); oligoastrocytic tumor (*e.g.,* oligoastrocytoma, and anaplastic oligoastrocytoma); ependymoma (*e.g.,* myxopapillary ependymoma, and anaplastic ependymoma); medulloblastoma; primitive neuroectodermal tumor, schwannoma, meningioma, meatypical meningioma, anaplastic meningioma; and pituitary adenoma. Exemplary cancers are described in Acta Neuropathol (2008) 116:597–602 and N Engl J Med. 2009 Feb 19;360(8):765-73, the contents of which are each incorporated herein by reference.

In embodiments the disorder is glioblastoma.

In an embodiment the disorder is prostate cancer, e.g., stage T1 (*e.g.,* T1a, T1b and T1c), T2 (*e.g.,* T2a, T2b and T2c), T3 (*e.g.,* T3a and T3b) and T4, on the TNM staging system. In embodiments the prostate cancer is grade G1, G2, G3 or G4 (where a higher number indicates greater difference from normal tissue).. Types of prostate cancer include, *e.g.,* prostate adenocarcinoma, small cell carcinoma, squamous carcinoma, sarcomas, and transitional cell carcinoma.

Methods and compositions of the inventin can be combined with art-known treatment. Art-known treatment for prostate cancer can include, *e.g.,* active surveillance, surgery (*e.g.,* radical prostatectomy, transurethral resection of the prostate, orchiectomy, and cryosurgegry), radiation therapy including brachytherapy (prostate brachytherapy) and external beam radiation therapy, High-Intensity Focused Ultrasound (HIFU), chemotherapy, cryosurgery, hormonal therapy (*e.g.,* antiandrogens (*e.g.,* flutamide, bicalutamide, nilutamide and cyproterone acetate, ketoconazole, aminoglutethimide), GnRH antagonists (*e.g.,* Abarelix)), or a combination thereof.

All references described herein are expressly incorporated herein by reference.

EXAMPLES

Example 1 IDH1 cloning, mutagenesis, expression and purification

1. Wild type IDH1 was cloned into pET41a, creating His8 tag at C-terminus.

The IDH1 gene coding region (cDNA) was purchased from Invitrogen in pENTR221 vector (www.invitrogen.com, Cat#B-068487_Ultimate_ORF). Oligo

nucleotides were designed to PCR out the coding region of IDH1 with NdeI at the 5' end and XhoI at the 3'. (IDH1-f: TAATCATATGTCCAAAAAAATCAGT (SEQ ID NO:1), IDH1-r: TAATCTCGAGTGAAAGTTTGGCCTGAGCTAGTT (SEQ ID NO:2)). The PCR product is cloned into the NdeI/XhoI cleaved pET41a vector. NdeI/XhoI cleavage of the vector pET41a releases the GST portion of the plasmid, and creating a C-terminal His8 tag (SEQ ID NO:3) without the N-terminal GST fusion. The original stop codon of IDH1 is change to serine, so the junction sequence in final IDH1 protein is: Ser-Leu-Glu-His-His-His-His-His-His-His-His-Stop (SEQ ID NO:4).

The C-terminal His tag strategy instead of N-terminal His tag strategy was chosen, because C-terminal tag might not negatively impact IDH1 protein folding or activity. See, *e.g.,* Xu X *et al*, J Biol Chem. 2004 Aug 6; 279(32):33946-57.

The sequence for pET41a-IDH1 plasmid is confirmed by DNA sequencing. **FIG. 1** shows detailed sequence verification of pET41a-IDH1and alignment against published IDH1 CDS below.

2. IDH1 site directed mutagenesis to create the IDHr132s and IDHr132h mutants.

Site directed mutagenesis was performed to convert R132 to S or H, DNA sequencing confirmed that G395 is mutated to A (creating Arg→His mutation in the IDH1 protein), and C394 is mutated to A (creating Arg→Ser in the IDH1 protein). Detailed method for site directed mutagenesis is described in the user manual for QuikChange® MultiSite-Directed Mutagenesis Kit (Stratagene, cat# 200531). **FIG. 2** shows DNA sequence verification of such mutations. Highlighted nucleotides were successfully changed in the mutagenesis: G395→A mutation allows amino acid Arg132→His; C394→A mutation allows amino acid Arg132→Ser.

3. IDH1 protein expression and purification.

IDHwt, IDHR132S, and IDHR132H proteins were expressed in the *E. coli* strain Rosetta and purified according to the detailed procedure below. Active IDH1 proteins are in dimer form, and SEC column fraction/peak that correspond to the dimer form were collected for enzymology analysis and cross comparison of catalytic activities of these proteins.

A. Cell culturing:

Cells were grown in LB (20 μg/ml Kanamycin) at 37°C with shaking until OD600 reaches 0.6. The temperature was changed to 18°C and protein was induced by adding IPTG to final concentration of 1 mM. Cells were collected 12-16 hours after IPTG induction.

B. Buffer system:

Lysis buffer: 20mM Tris, pH7.4, 0.1% Triton X-100, 500 mM NaCl, 1 mM PMSF, 5 mM β-mercaptoethanol, 10 % glycerol.

Ni-Column Buffer A: 20 mM Tris, pH7.4, 500mM NaCl, 5 mM β-mercaptoethanol, 10% glycerol.

Ni-column Buffer B: 20 mM Tris, pH7.4, 500 mM NaCl, 5 mM β-mercaptoethanol , 500 mM Imidazole, 10% glycerol

Gel filtration Buffer C: 200 mM NaCl, 50 mM Tris 7.5, 5 mM β-mercaptoethanol, 2 mM $MnSO_4$, 10% glycerol.

C. Protein purification procedure

1. Cell pellet were resuspended in the lysis buffer (1gram cell/5-10 ml buffer).
2. Cells were broken by passing the cell through Microfludizer with at a pressure of 15,000 psi for 3 times.
3. Soluble protein was collected from supernatant after centrifugation at 20,000g (Beckman Avanti J-26XP) for 30 min at 4°C.
4. 5-10 ml of Ni-column was equilibrated by Buffer A until the A280 value reached baseline. The supernatant was loaded onto a 5-ml Ni-Sepharose column (2 ml/min). The column was washed by 10-20 CV of washing buffer (90 % buffer A+10 % buffer B) until A280 reach the baseline (2 ml/min).
5. The protein was eluted by liner gradient of 10-100% buffer B (20 CV) with the flow rate of 2 ml/min and the sample fractions were collected as 2 ml/tube.
6. The samples were analyzed on SDS-PAGE gel.
7. The samples were collected and dialyzed against 200x Gel filtration buffer for 2 times (1 hour and > 4 hours).
8. The samples were concentrated to 10 ml.
9. 200 ml of S-200 Gel-filtration column was equilibrated by buffer C until the A280 value reached baseline. The samples were loaded onto Gel filtration column (0.5 ml/min).

10. The column was washed by 10 CV of buffer C, collect fractions as 2-4 ml/tube.
11. The samples were analyzed on SDS-PAGE gel and protein concentration was determined.

D. Protein purification results

The results for purification of wild type IDH1 are shown in **FIGs. 3, 4, 5A** and **5B**.

The results for purification of mutant IDH1R132S are shown in **FIGs. 6, 7, 8A** and **8B**.

The results for purification of wild type IDH1R132H are shown in **FIGs. 9, 10, 11A** and **11B**.

EXAMPLE 2 ENZYMOLOGY ANALYSIS OF IDH1 WILD TYPE AND MUTANTS

1. Analysis of IDH1 wild-type and mutants R132H and R132S in the oxidative decarboxylation of isocitrate to α-Ketoglutarate (α-KG).

A. Methods

To determine the catalytic efficiency of enzymes in the oxidative decarboxylation of isocitrate to α-Ketoglutarate (α-KG) direction, reactions were performed to determine Vmax and Km for isocitrate. In these reactions, the substrate was varied while the cofactor was held constant at 500 uM. All reactions were performed in 150 mM NaCl, 20 mM Tris-Cl, pH 7.5, 10% glycerol, and 0.03% (w/v) BSA). Reaction progress was followed by spectroscopy at 340 nM monitoring the change in oxidation state of the cofactor. Sufficient enzyme was added to give a linear change in absorbance for 10 minutes.

B. ICDH1 R132H and ICDH1 R132S are impaired for conversion of isocitrate to α-KG.

Michaelis-Menten plots for the relationship of isocitrate concentration to reaction velocity are presented in **FIGs. 12A-12C**. Kinetic parameters are summarized in the **Table 1**. All data was fit to the Hill equation by least-squares regression analysis.

Table 1

Enzyme	Vmax (umol/min/mg)	Km (uM)	Hill Constant	Vmax/Km	Relative Catalytic Efficiency
Wt	30.5	56.8	1.8	0.537	100%
R132H	0.605	171.7	0.6	0.0035	0.35%
R132S	95	>1e6	0.479	<9.5e7	<.001%

Both mutant enzymes display a reduced Hill coefficient and an increase in Km for isocitrate, suggesting a loss of co-operativity in substrate binding and/or reduced affinity for substrate. R132H enzyme also displays a reduced Vmax, suggestive of a lower kcat. R132S displays an increase in Vmax, suggesting an increase in kcat, although this comes at the expense of a 20,000 fold increase in Km so that the overall effect on catalytic efficiency is a great decrease as compared to the wild-type enzyme. The relative catalytic efficiency, described as Vmax/Km, is dramatically lower for the mutants as compared to wild-type. The *in vivo* effect of these mutations would be to decrease the flux conversion of isocitrate to α-KG.

C. The ICDH1 R132H and R132S mutants display reduced product inhibition in the oxidative decarboxylation of isocitrate to α-Ketoglutarate (α-KG).

A well-known regulatory mechanism for control of metabolic enzymes is feedback inhibition, in which the product of the reaction acts as a negative regulator for the generating enzyme. To examine whether the R132S or R132H mutants maintain this regulatory mechanism, the Ki for α-KG in the oxidative decarboxylation of ioscitrate to α-ketoglutarate was determined. Data is presented in **FIGs. 13A-13C** and summarized in **Table 2**. In all cases, α-KG acts as a competitive inhibitor of the isocitrate substrate. However, R132H and R132S display a 20-fold and 13-fold increase in sensitivity to feedback inhibition as compared to the wild-type enzyme.

Table 2

Enzyme	Ki (uM)
Wt	612.2
R132H	28.6
R132S	45.3

D. The effect of $MnCl_2$ in oxidative decarboxylation of isocitrate to α-Ketoglutarate (α-KG).

$MnCl_2$ can be substituted with $MgCl_2$ to examine if there is any difference in oxidative decarboxylation of isocitrate to α-Ketoglutarate (α-KG).

E. The effect of R132 mutations on the inhibitory effect of oxalomalate on IDH1

The purpose of this example is to examine the susceptibility of IDH1R132S and IDH1R132H in oxidative decarboxylation of isocitrate to α-Ketoglutarate (α-KG) to the known IDH1 inhibitor oxalomalate. Experiments were performed to examine if R132 mutations circumvent the inhibition by oxalomalate.

Final concentrations: Tris 7.5 20 mM, NaCl 150 mM, $MnCl_2$ 2 mM, Glycerol 10%, BSA 0.03%, NADP 0.5 mM, IDH1 wt 1.5 ug/ml, IDH1R132S 30 ug/ml, IDH1R132H 60 ug/ml, DL-isocitrate (5 – 650 uM). The results are summarized in **FIG. 17** and Table 3. The R132S mutation displays approximately a two-fold increase in susceptibility to inhibition by oxalomalate, while the R132H mutation is essentially unaffected. In all three cases, the same fully competitive mode of inhibition with regards to isocitrate was observed.

Table 3

Enzyme	Oxalomalate Ki (uM)
wt	955.4
R132S	510
R132H	950.8

F. Forward reactions (isocitrate to α-KG) of mutant enzyme do not go to completion.

Forward reactions containing ICDH1 R132S or ICDH1 R132H were assembled and reaction progress monitored by an increase in the OD340 of the reduced NADPH cofactor. It was observed (**FIG. 23**), that these reactions proceed in the forward direction for a period of time and then reverse direction and oxidize the cofactor reduced in the early stages of the reaction, essentially to the starting concentration present at the initiation of the experiment. Addition of further isocitrate re-initiated the forward reaction for a period of time, but again did not induce the reaction to proceed to completion. Rather, the system returned to initial concentrations of NADPH. This experiment suggested that the mutant enzymes were performing a reverse reaction other than the conversion of α-KG to isocitrate.

2. Analysis of IDH1 wild-type and mutants R132H and R132S in the reduction of α-Ketoglutarate (α-KG).

A. Methods

To determine the catalytic efficiency of enzymes in the reduction of α-Ketoglutarate (α-KG), reactions were performed to determine Vmax and Km for α-KG. In these reactions, substrate was varied while the cofactor was held constant at 500 uM. All reactions were performed in 50 mM potassium phosphate buffer, pH 6.5, 10% glycerol, 0.03% (w/v) BSA, 5 mM $MgCl_2$, and 40 mM sodium hydrocarbonate. Reaction progress was followed by spectroscopy at 340 nM monitoring the change in oxidation state of the cofactor. Sufficient enzyme was added to give a linear change in absorbance for 10 minutes.

B. The R132H and R132S mutant enzymes, but not the wild-type enzyme, support the reduction of α-KG.

To test the ability of the mutant and wild-type enzymes to perform the reduction of α-KG, 40 ug/ml of enzyme was incubated under the conditions for the reduction of α-Ketoglutarate (α-KG) as described above. Results are presented in **FIG. 14**. The wild-type enzyme was unable to consume NADPH, while R132S and R132H reduced α-KG and consumed NADPH.

C. The reduction of α-KG by the R132H and R132S mutants occurs *in vitro* at physiologically relevant concentrations of α-KG.

To determine the kinetic parameters of the reduction of α-KG performed by the mutant enzymes, a substrate titration experiment was performed, as presented in **FIGs. 15A-15B**. R132H maintained the Hill-type substrate interaction as seen in the oxidative decarboxylation of isocitrate, but displayed positive substrate co-operative binding. R132S showed a conversion to Michaelis-Menten kinetics with the addition of uncompetitive substrate inhibition, as compared to wild-type enzyme in the oxidative decarboxylation of isocitrate. The enzymatic parameters of the mutant enzyme are presented in **Table 4**. Since the wild-type enzyme did not consume measurable NADPH in the experiment described above, a full kinetic workup was not performed.

Table 4

Enzyme	Vmax (umol/min/mg)	Km (mM)	Hill Constant	Ki (mM)	Vmax/Km
R132H	1.3	0.965	1.8		1.35
R132S	2.7	0.181	0.479	24.6	14.92

The relative catalytic efficiency of reduction of α-KG is approximately ten-fold higher in the R132S mutant than in the R132H mutant. The biological consequence is that the rate of metabolic flux should be greater in cells expressing R132S as compared to R132H.

D. Analysis of IDH1 wild-type and mutants R132H and R132S in the reduction of alpha-ketoglutarate with NADH.

In order to evaluate the ability of the mutant enzymes to utilize NADH in the reduction of alpha-ketoglutarate, the following experiment was conducted. Final concentrations: NaHCO3 40mM, MgCl2 5mM, Glycerol 10%, K2HPO4 50mM, BSA 0.03%, NADH 0.5mM, IDH1wt 5ug/ml, R132S 30ug/ml, R132H 60ug/ml, alpha-Ketoglutarate 5mM.

The results are shown in **FIG. 16** and **Table 5**. The R132S mutant demonstrated the ability to utilize NADH while the wild type and R132H show no measurable consumption of NADH in the presence of alpha-ketoglutarate.

Table 5: Consumption of NADH by R132S in the presence of alpha-ketoglutarate

	R132S		Mean	SD
Rate (ΔA/sec)	0.001117	0.001088	0.001103	2.05E-05
Umol/min/mg	0.718328	0.699678	**0.709003**	0.013187

Summary

To understand how R132 mutations alter the enzymatic properties of IDH1, wild-type and R132H mutant IDH1 proteins were produced and purified from *E. coli*. When $NADP^+$-dependent oxidative decarboxylation of isocitrate was measured using purified wild-type or R132H mutant IDH1 protein, it was confirmed that R132H mutation impairs the ability of IDH1 to catalyze this reaction (Yan, H. et al. N Engl J Med 360, 765-73 (2009); Zhao, S. et al. Science 324, 261-5 (2009)), as evident by the loss in binding affinity for both isocitrate and $MgCl_2$ along with a 1000-fold decrease

in catalytic turnover (**FIGs. 30A** and **30C**). In contrast, when NADPH-dependent reduction of αKG was assessed using either wild-type or R132H mutant IDH1 protein, only R132H mutant could catalyze this reaction at a measurable rate (**FIGs. 30** and **30C**). Part of this increased rate of αKG reduction results from an increase in binding affinity for both the cofactor NADPH and substrate αKG in the R132H mutant IDH1 (**FIG. 30C**). Taken together, these data demonstrate that while the R132H mutation leads to a loss of enzymatic function for oxidative decarboxylation of isocitrate, this mutation also results in a gain of enzyme function for the NADPH-dependent reduction of αKG.

2: Analysis of mutant IDH1

The R132H mutant does not result in the conversion of α-KG to isocitrate.

Using standard experimental methods, an API2000 mass spectrometer was configured for optimal detection of α-KG and isocitrate (Table 6). MRM transitions were selected and tuned such that each analyte was monitored by a unique transition. Then, an enzymatic reaction containing 1 mM α-KG, 1 mM NADPH, and ICDH1 R132H were assembled and run to completion as judged by the decrease to baseline of the optical absorbance at 340 nM. A control reaction was performed in parallel from which the enzyme was omitted. Reactions were quenched 1:1 with methanol, extracted, and subjected to analysis by LC-MS/MS.

FIG. 18A presents the control reaction indicating that aKG was not consumed in the absence of enzyme, and no detectable isocitrate was present. **FIG. 18B** presents the reaction containing R132H enzyme, in which the α-KG has been consumed, but no isocitrate was detected. **FIG. 18C** presents a second analysis of the reaction containing enzyme in which isocitrate has been spiked to a final concentration of 1 mM, demonstrating that had α-KG been converted to isocitrate at any appreciable concentration greater than 0.01%, the configured analytical system would have been capable of detecting its presence in the reaction containing enzyme. The conclusion from this experiment is that while α-KG was consumed by R132H, isocitrate was not produced. This experiment indicates that one neoactivity of the R132H mutant is the reduction of α-KG to a compound other than isocitrate.

Table 6. Instrument settings for MRM detection of compounds

Compound	Q1	Q3	DP	FP	EP	CEP	CE	CXP
α-KG	144.975	100.6	-6	-220	-10	-16	-10	-22
isocitrate	191.235	110.9	-11	-230	-4.5	-14	-16	-24
a-hydroxyglutarate	147.085	128.7	-11	-280	-10	-22	-12	-24

The R132H mutant reduces α-KG to 2-hydroxyglutaric acid.

Using standard experimental methods, an API2000 mass spectrometer was configured for optimal detection 2-hydroxyglutarate (**Table 6** and **FIG. 19**). The reaction products of the control and enzyme-containing reactions from above were investigated for the presence of 2-hydroxyglutaric acid, **FIG. 20**. In the control reaction, no 2-hydroxyglutaric acid was detected, while in reaction containing R132H, 2-hydroxyglutaric acid was detected. This data confirms that one neoactivity of the R132H mutant is the reduction of α-KG to 2-hydroxyglutaric acid.

To determine whether R132H mutant protein directly produced 2HG from αKG, the product of the mutant IDH1 reaction was examined using negative ion mode triple quadrupole electrospray LC-MS. These experiments confirmed that 2HG was the direct product of NADPH-dependent αKG reduction by the purified R132H mutant protein through comparison with a known metabolite standards (**FIG. 31A**). Conversion of αKG to isocitrate was not observed.

One can determine the enantiomeric specificity of the reaction product through derivitazation with DATAN (diacetyl-L-tartaric acid) and comparing the retention time to that of known R and S standards. This method is described in Struys *et al.* Clin Chem 50:1391-1395(2004). The stereo-specific production of either the R or S enantomer of alpha-hydroxyglutaric acid by ICDH1 R132H may modify the biological activity of other enzymes present in the cell. The racemic production may also occur.

For example, one can measure the inhibitory effect of alpha-hydroxyglutaric acid on the enzymatic activity of enzymes which utilize α-KG as a substrate. In one embodiment, alpha-hydroxyglutaric acid may be a substrate- or product- analogue inhibitor of wild-type ICDH1. In another embodiment alpha-hydroxyglutaric acid may be a substrate- or product- analogue inhibitor of HIF1 prolyl hydroxylase. In the former case, inhibition of wild type ICDH1 by the enzymatic product of R132H will reduce the circulating levels of aKG in the cell. In the latter case, inhibition of HIF1

prolyl hydroxylase will result in the stabilization of HIF1 and an induction of the hypoxic response cohort of cellular responses.

ICDH R132H reduces aKG to the R-enantiomer of 2-hydroxyglutarate.

There are two possible enantiomers of the ICDHR132H reductive reaction product, converting alpha-ketoglutarate to 2-hydroxyglutarate, with the chiral center being located at the alpha-carbon position. Exemplary products are depicted below.



R-2-hydroxyglutarate



S-2-hydroxyglutarate

These are referred to by those with knowledge in the art as the R (or pro-R) and S (or pro-S) enantiomers, respectively. In order to determine which form or both is produced as a result of the ICDH1 neoactivity described above, the relative amount of each chiral form in the reaction product was determined in the procedure described below.

Reduction of α-KG to 2-HG was performed by ICDHR132H in the presence of NADPH as described above, and the reaction progress was monitored by a change in extinction coefficient of the nucleotide cofactor at 340 nM; once the reaction was judged to be complete, the reaction was extracted with methanol and dried down completely in a stream of nitrogen gas. In parallel, samples of chirally pure R-2-HG and a racemic mixture of R- and S-2-HG (produced by a purely chemical reduction of α-KG to 2-HG) were resuspended in ddH_2O, similarly extracted with methanol, and dried.

The reaction products or chiral standards were then resuspended in a solution of dichloromethane:acetic acid (4:1) containing 50 g/L DATAN and heated to 75°C for 30 minutes to promote the derivitization of 2-HG in the scheme described below:



After cooling to room temperature, the derivitization reactions were dried to completion and resuspended in ddH_2O for analysis on an LC-MS/MS system. Analysis of reaction products and chiral standards was performed on an API2000 LC-MS/MS system using a 2 x 150 mM C18 column with an isocratic flow of 200 µl/min of 90:10 (ammonium formate, pH 3.6:methanol) and monitoring the retention times of the 2-HG-DATAN complex using XIC and the diagnostic MRM transition of 363/147 in the negative ion mode.

It should be noted that retention times in the experiments described below are approximate and accurate to within +/- 1 minute; the highly reproducible peak seen at 4 minutes is an artefact of a column switching valve whose presence has no result on the conclusions drawn from the experiment.

Injection of the racemic mixture gave two peaks of equal area at retention times of 8 and 10 minutes (**FIG. 24A**), while injection of the R-2-HG standard resulted in a major peak of >95% area at 10 minutes and a minor peak <5% area at 8 minutes (**FIG. 24B**); indicating that the R-2-HG standard is approximately 95% R and 5% S. Thus, this method allows us to separate the R and S-2-HG chiral forms and to determine the relative amounts of each in a given sample. Coinjection of the racemic mixture and the R-2-HG standard resulted in two peaks at 8 and 10 minutes, with a larger peak at 10 minutes resulting from the addition of surplus pro-R-form (the standard) to a previously equal mixture of R- and S-2-HG (**FIG. 24C**). These experiments allow us to assign the 8 minute peak to the S-2-HG form and the 10 minute peak to the R-2-HG form.

Injection of the derivatized neoactivity enzyme reaction product alone yields a single peak at 10 minutes, suggesting that the neoactivity reaction product is chirally pure R-2-HG (**FIG. 24D**). Coinjection of the neoactivity reaction product with the R-

2-HG standard results in a major peak of >95% area at 10 minutes (**FIG. 24E**) and a single minor peak of <5% area at 8 minutes (previously observed in injection of the R-2-HG standard alone) confirming the chirality of the neoactivity product as R. Coinjection of a racemic mixture and the neoactivity reaction product (**FIG. 24F**) results in a 60% area peak at 10 minutes and a 40% area peak at 8 minutes; this deviation from the previously symmetrical peak areas observed in the racemate sample being due to the excess presence of R-2-HG form contributed by the addition of the neoactivity reaction product.

These experiments allow us to conclude that the ICDH1 neoactivity is a highly specific chiral reduction of α-KG to R-2-HG.

Enzyme properties of other IDH1 mutations

To determine whether the altered enzyme properties resulting from R132H mutation were shared by other R132 mutations found in human gliomas, recombinant R132C, R132L and R132S mutant IDH1 proteins were generated and the enzymatic properties assessed. Similar to R132H mutant protein, R132C, R132L, and R132S mutations all result in a gain-of-function for NADPH-dependent reduction of αKG (data not shown). Thus, in addition to impaired oxidative decarboxylation of isocitrate, one common feature shared among the IDH1 mutations found in human gliomas is the ability to catalyze direct NADPH-dependent reduction of αKG.

Identification of 2-HG production in glioblastoma cell lines containing the IDH-1 R132H mutant protein.

Generation of genetic engineered glioblastoma cell lines expressing wildtype or mutant IDH-1 protein. A carboxy-terminal Myc-DDK-tagged open reading frame (ORF) clone of human isocitrate dehydrogenase 1 (IDH1; Ref. ID: NM_005896) cloned in vector pCMV6 was obtained from commercial vendor Origen Inc. Vector pCMV6 contains both kanamycin and neomycin resistance cassettes for selection in both bacterial and mammalian cell systems. Standard molecular biology mutagenesis techniques were utilized to alter the DNA sequence at base pair 364 of the ORF to introduce base pair change from guanine to adenine resulting in a change in the amino acid code at position 132 from argentine (wt) to histidine (mutant; or R132H). Specific DNA sequence alteration was confirmed by standard methods for

DNA sequence analysis. Parental vector pCMV6 (no insert), pCMV6-wt IDH1 or pCMV6-R132H were transfected into immortalized human glioblastoma cell lines ATCC® CRL-2610 (LN-18) or HTB-14 (U-87) in standard growth medium (DMEM; Dulbecco's modified Eagles Medium containing 10 % fetal bovine serum). Approximately 24 hrs after transfection, the cell cultures were transitioned to DMEM containing G418 sodium salt at concentrations of either 750 ug/ml (CRL-2610) or 500 ug/ml (HTB-14) to select those cells in culture that expressed the integrated DNA cassette expressing both the neomycin selectable marker and the ORF for human wild type or R132H. Pooled populations of G418 resistant cells were generated and expression of either wild type IDH1 or R132 IDH1 was confirmed by standard Western blot analysis of cell lysates using commercial antibodies recognizing either human IDH1 antigen or the engineered carboxy-terminal MYC-DDK expression tag. These stable clonal pools were then utilized for metaobolite preparation and analysis.

Procedure for metabolite preparation and analysis. Glioblastoma cell lines (CRL-2610 and HTB-14) expressing wildtype or mutant IDH-1 protein were grown using standard mammalian tissue culture techniques on DMEM media containing 10% FCS, 25 mM glucose, 4 mM glutamine, and G418 antibiotic (CRL-2610 at 750 ug/mL; HTB-14 at 500 ug/mL) to insure ongoing selection to preserve the transfected mutant expression sequences. In preparation for metabolite extraction experiments, cells were passaged into 10 cm round culture dishes at a density of $1x10^6$ cells. Approximately 12 hours prior to metabolite extraction, the culture media was changed (8 mL per plate) to DMEM containing 10% dialyzed FCS (10,000 mwco), 5 mM glucose, 4 mM glutamine, and G-418 antibiotic as before; the dialyzed FCS removes multiple small molecules form the culture media and enables cell culture-specific assessment of metabolite levels. The media was again changed 2 horrs prior to metabolite extraction. Metabolite extraction was accomplished by quickly aspirating the media from the culture dishes in a sterile hood, immediately placing the dishes in a tray containing dry ice to cool them to -80°C, and as quickly as possible, adding 2.6 mL of 80% MeOH/20% water, pre-chilled to -80°C in a dry-ice/acetone bath. These chilled, methanol extracted cells were then physically separated from the culture dish by scraping with a sterile polyethylene cell lifter (Corning #3008), brought into suspension and transferred to a 15 mL conical vial, then chilled to -20°C. An additional 1.0 mL of 80% MeOH/20% water was applied to the chilled culture dish

and the cell lifting procedure repeated, to give a final extraction volume of 3.6 mL. The extracts were centrifuged at 20,000 x g for 30 minutes to sediment the cell debris, and 3.0 mL of the supernatants was transferred to a screw-cap freezer vial and stored at -80°C until ready for analysis.

In preparation for analysis, the extracts were removed from the freezer and dried on a nitrogen blower to remove methanol. The 100% aqueous samples were analyzed by LCMS as follows. The extract (10 µL) was injected onto a reverse-phase HPLC column (Synergi 150mm x 2 mm, Phenomenex Inc.) and eluted using a linear gradient of LCMS-grade methanol (Buffer B) in Aq. 10 mM tributylamine , 15 mM Acetic acid (Buffer A), running from 3% Buffer B to 95% Buffer B over 45 minutes at 200 µL/min. Eluted metabolite ions were detected using a triple-quadrapole mass spectrometer, tuned to detect in negative mode with multiple-reaction-monitoring mode transition set (MRM's) according to the molecular weights and fragmentation patterns for 38 known central metabolites, including 2-hydroxyglutarate (MRM parameters were optimized by prior infusion of known compound standards). Data was processed using Analyst Software (Applied Biosystems, Inc.) and metabolite signal intensities were converted into absolute concentrations using signal build-up curves from injected mixtures of metabolite standards at known concentrations. Final metabolite concentrations were reported as mean of at least three replicates, +/- standard deviation.

Results. Analyses reveal significantly higher levels of 2-HG in cells that express the IDH-1 R132H mutant protein. As shown in **FIG. 26A**, levels of 2-HG in CRL-2610 cell lines expressing the IDH-1 R132H mutant protein are approximately 28-fold higher than identical lines expressing the wild-type protein. Similarly, levels of 2-HG in HTB-14 cell lines expressing the IDH-1 R132H mutant protein are approximately 38-fold higher than identical lines expressing the wild-type protein, as shown in **FIG. 26B**.

Evaluation of 2-hydroxyglutarate (2-HG) production in human glioblastoma tumors containing mutations in isocitrate dehydrogenase 1 (IDH1) at amino acid 132.

Heterozygous somatic mutations at nucleotide position 395 (amino acid codon 132) in the transcript encoding isocitrate dehydrogenase 1(IDH1) can occur in brain tumors.

***Tissue source*:** Human brain tumors were obtained during surgical resection, flash frozen in liquid nitrogen and stored at -80°C. Clinical classification of the tissue as gliomas was performed using standard clinical pathology categorization and grading.

Genomic sequence analysis to identify brain tumor samples containing either wild type isocitrate dehydrogenase (IDH1) or mutations altering amino acid 132. Genomic DNA was isolated from 50-100 mgs of brain tumor tissue using standard methods. A polymerase chain reaction (PCR) procedure was then performed on the isolated genomic DNA to amplify a 295 base pair fragment of the genomic DNA that contains both intron and 2nd exon sequences of human IDH1 (**FIG. 27**). In **FIG. 27**, intron sequence is shown in lower case font; 2nd exon IDH1 DNA sequence is shown in upper case font; forward (5') and reverse (3') primer sequences are shown in underlined font; guanine nucleotide mutated in a subset of human glioma tumors is shown in bold underlined font.

The amplified DNA fragment was then sequenced using standard protocols and sequence alignments were performed to classify the sequences as either wild type or mutant at the guanine nucleotide at base pair 170 of the amplified PCR fragment. Tumors were identified that contained genomic DNA having either two copies of guanine (wild type) or a mixed or monoalellic combination of one IDH1 allele containing guanine and the other an adenine (mutant) sequence at base pair 170 of the amplified product (**Table 15**). The nucleotide change results in a change at amino acid position 132 of human IDH1 protein from arginine (wild type) to histidine (mutant) as has been previously reported.

Table 15. Sequence variance at base pair 170 of the amplified genomic DNA from human glioma samples.

Sample ID	Base 170	IDH1 Amino Acid 132	Genotype
1102	G	arginine	wild type
1822	A	histidine	mutant
496	G	arginine	wild type
1874	A	histidine	mutant
816	A	histidine	mutant
534	G	arginine	wild type
AP-1	A	histidine	mutant
AP-2	A	histidine	mutant

Procedure for metabolite preparation and analysis. Metabolite extraction was accomplished by adding a 10 X volume (m/v ratio) of -80 C methanol:water mix (80%:20%) to the brain tissue (approximately 100mgs) followed by 30 s homogenization at 4 C. These chilled, methanol extracted homogenized tissues were then centrifuged at 14,000 rpm for 30 minutes to sediment the cellular and tissue debris and the cleared tissue supernatants were transferred to a screw-cap freezer vial and stored at -80℃. For analysis, a 2X volume of tributylamine (10 mM) acetic acid (10 mM) pH 5.5 was added to the samples and analyzed by LCMS as follows. Sample extracts were filtered using a Millex-FG 0.20 micron disk and 10 µL were injected onto a reverse-phase HPLC column (Synergi 150mm x 2 mm, Phenomenex Inc.) and eluted using a linear gradient LCMS-grade methanol (50%) with 10 mM tributylamine and 10 mM acetic acid) ramping to 80 % methanol:10 mM tributylamine: 10 mM acetic acid over 6 minutes at 200 µL/min. Eluted metabolite ions were detected using a triple-quadrapole mass spectrometer, tuned to detect in negative mode with multiple-reaction-monitoring mode transition set (MRM's) according to the molecular weights and fragmentation patterns for 8 known central metabolites, including 2-hydroxyglutarate (MRM parameters were optimized by prior infusion of known compound standards). Data was processed using Analyst Software (Applied Biosystems, Inc.) and metabolite signal intensities were obtained by standard peak integration methods.

Results. Analyses revealed dramatically higher levels of 2-HG in cells tumor samples that express the IDH-1 R132H mutant protein. Data is summarized in **Table 16** and **FIG. 28**.

Table 16

Sample ID	Primary Specimen Diagnosis	Grade	Tumor Cells in Tumor Foci (%)	Geno-type	Nucleo-tide change	Codon	2HG (□mole/g)	□KG (□mole/g)	Malate (□mole/g)	Fumarate (□mole/g)	Succinate (□mole/g)	Isocitrate (□mole/g)
1	Glioblastoma, residual/recurrent	WHO grade IV	n/a	wild type	wild type	R132	0.18	0.161	1.182	0.923	1.075	0.041
2	Glioblastoma	WHO grade IV	n/a	wild type	wild type	R132	0.16	0.079	1.708	1.186	3.156	0.100
3	Glioblastoma	WHO grade IV	n/a	wild type	wild type	R132	0.13	0.028	0.140	0.170	0.891	0.017
4	Oligoastrocytoma	WHO grade II	n/a	wild type	wild type	R132	0.21	0.016	0.553	1.061	1.731	0.089
5	Glioblastoma	WHO grade IV	n/a	mutant	G364A	R132H	16.97	0.085	1.091	0.807	1.357	0.058
6	Glioblastoma	WHO grade IV	n/a	mutant	G364A	R132H	19.42	0.023	0.462	0.590	1.966	0.073
7	Glioblastoma	WHO grade IV	n/a	mutant	G364A	R132H	31.56	0.068	0.758	0.503	2.019	0.093
8	Oligodendroglioma, anaplastic	WHO grade III	75	mutant	G364A	R132H	12.49	0.033	0.556	0.439	0.507	0.091
9	Oligodendroglioma, anaplastic	WHO grade III	90	mutant	G364A	R132H	4.59	0.029	1.377	1.060	1.077	0.574
10	Oligoastrocytoma	WHO grade II	n/a	mutant	G364A	R132H	6.80	0.038	0.403	0.503	1.561	0.065
11	Glioblastoma	WHO grade IV	n/a	wild type	wild type	R132	0.686	0.686	0.686	0.686	0.686	0.007
12	Glioblastoma	WHO grade IV	n/a	mutant	G364A	R132H	18.791	18.791	18.791	18.791	18.791	0.031
13	Glioblastoma	WHO grade IV	n/a	mutant	G364A	R132H	4.59	0.029	1.377	1.060	1.077	0.043
14	Glioblastoma	WHO grade IV	n/a	wild type	wild type	R132	0.199	0.046	0.180	0.170	0.221	0.014
15	Glioblastoma	WHO grade IV	n/a	mutant	C363G	R132G	13.827	0.030	0.905	0.599	1.335	0.046
16	Glioblastoma	WHO grade IV	n/a	mutant	G364A	R132H	28.364	0.068	0.535	0.488	2.105	0.054
17	Glioblastoma	WHO grade IV	n/a	mutant	C363A	R132S	9.364	0.029	1.038	0.693	2.151	0.121
18	Glioblastoma	WHO grade IV	n/a	wild type	wild type	R132	0.540	0.031	0.468	0.608	1.490	0.102
19	Glioma, malignant, astrocytoma	WHO grade IV	80	mutant	G364A	R132H	19.000	0.050	0.654	0.391	2.197	0.171
20	Oligodendroglioma	WHO grade III	80	wild type	wild type	R132	0.045	0.037	1.576	0.998	1.420	0.018
21	Glioma, malignant, astrocytoma	WHO grade	95	wild type	wild type	R132	0.064	0.034	0.711	0.710	2.105	0.165

		IV										
22	Glioblastoma	WHO grade IV	70	wild type	wild type	R132	0.171	0.041	2.066	1.323	0.027	0.072

To determine if 2HG production is characteristic of tumors harboring mutations in IDH1, metabolites were extracted from human malignant gliomas that were either wild-type or mutant for IDH1. It has been suggested that αKG levels are decreased in cells transfected with mutant IDH1 (Zhao, S. et al. Science 324, 261-5 (2009)). The average αKG level from 12 tumor samples harboring various R132 mutations was slightly less than the average αKG level observed in 10 tumors which are wild-type for IDH1. This difference in αKG was not statistically significant, and a range of αKG levels was observed in both wild-type and mutant tumors. In contrast, increased 2HG levels were found in all tumors that contained an R132 IDH1 mutation. All R132 mutant IDH1 tumors examined had between 5 and 35 μmol of 2HG per gram of tumor, while tumors with wild-type IDH1 had over 100 fold less 2HG. This increase in 2HG in R132 mutant tumors was statistically significant ($p<0.0001$). It was confirmed that (R)-2HG was the isomer present in tumor samples (data not shown). Together these data establish that the novel enzymatic activity associated with R132 mutations in IDH1 results in the production of 2HG in human brain tumors that harbor these mutations.

2HG is known to accumulate in the inherited metabolic disorder 2-hydroxyglutaric aciduria. This disease is caused by deficiency in the enzyme 2-hydroxyglutarate dehydrogenase, which converts 2HG to αKG (Struys, E. A. et al. Am J Hum Genet 76, 358-60 (2005)). Patients with 2-hydroxyglutarate dehydrogenase deficiencies accumulate 2HG in the brain as assessed by MRI and CSF analysis, develop leukoencephalopathy, and have an increased risk of developing brain tumors (Aghili, M., Zahedi, F. & Rafiee, J Neurooncol 91, 233-6 (2009); Kolker, S., Mayatepek, E. & Hoffmann, G. F. Neuropediatrics 33, 225-31 (2002); Wajner, M., Latini, A., Wyse, A. T. & Dutra-Filho, C. S. J Inherit Metab Dis 27, 427-48 (2004)). Furthermore, elevated brain levels of 2HG result in increased ROS levels (Kolker, S. et al. Eur J Neurosci 16, 21-8 (2002); Latini, A. et al. Eur J Neurosci 17, 2017-22 (2003)), potentially contributing to an increased risk of cancer. The ability of 2HG to act as an NMDA receptor agonist may contribute to this effect (Kolker, S. et al. Eur J

Neurosci 16, 21-8 (2002)). 2HG may also be toxic to cells by competitively inhibiting glutamate and/or αKG utilizing enzymes. These include transaminases which allow utilization of glutamate nitrogen for amino and nucleic acid biosynthesis, and αKG-dependent prolyl hydroxylases such as those which regulate Hif1α levels. Alterations in Hif1α have been reported to result from mutant IDH1 protein expression (Zhao, S. et al. Science 324, 261-5 (2009)). Regardless of mechanism, it appears likely that the gain-of-function ability of cells to produce 2HG as a result of R132 mutations in IDH1 contributes to tumorigenesis. Patients with 2-hydroxyglutarate dehydrogenase deficiency have a high risk of CNS malignancy (Aghili, M., Zahedi, F. & Rafiee, E. J Neurooncol 91, 233-6 (2009)). The ability of mutant IDH1 to directly act on αKG may explain the prevalence of IDH1 mutations in tumors from CNS tissue, which are unique in their high level of glutamate uptake and its ready conversion to αKG in the cytosol (Tsacopoulos, M. J Physiol Paris 96, 283-8 (2002)), thereby providing high levels of substrate for 2HG production. The apparent co-dominance of the activity of mutant IDH1 with that of the wild-type enzyme is consistent with the genetics of the disease, in which only a single copy of the gene is mutated. As discussed above, the wild-type IDH1 could directly provide NADPH and αKG to the mutant enzyme. These data also demonstrate that mutation of R132 to histidine, serine, cysteine, glycine or leucine share a common ability to catalyze the NADPH-dependent conversion of αKG to 2HG. These findings help clarify why mutations at other amino acid residues of IDH1, including other residues essential for catalytic activity, are not found. Finally, these findings have clinical implications in that they suggest that 2HG production will identify patients with IDH1 mutant brain tumors. This will be important for prognosis as patients with IDH1 mutations live longer than patients with gliomas characterized by other mutations (Parsons, D. W. et al. Science 321, 1807-12 (2008)). In addition, patients with lower grade gliomas may benefit by the therapeutic inhibition of 2HG production. Inhibition of 2HG production by mutant IDH1 might slow or halt conversion of lower grade glioma into lethal secondary glioblastoma, changing the course of the disease.

The reaction product of ICDH1 R132H reduction of α-KG inhibits the oxidative decarboxylation of isocitrate by wild-type ICDH1.

A reaction containing the wild-type ICDH1, NADP, and α-KG was assembled (under conditions as described above) to which was added in a titration series either (R)-2-hydroxyglutarate or the reaction product of the ICDH1 R1321H mutant reduction of α-KG to 2-hydroxyglutarate. The reaction product 2-HG was shown to inhibit the oxidative decarboxylation of isocitrate by the wild-type ICDH1, while the (R)-2-hydroxyglutarate did not show any effect on the rate of the reaction. Since there are only two possible chiral products of the ICDH1 R132H mutant reduction of α-KG to 2-HG, and the (R)-2-HG did not show inhibition in this assay, it follows that the product of the mutant reaction is the (S)-2-HG form. This experiment is presented in **FIG. 25**.

To determine the chirality of the 2HG produced, the products of the R132H reaction was derivatized with diacetyl-L-tartaric anhydride, which allowed separating the (S) and (R) enantiomers of 2HG by simple reverse-phase LC and detecting the products by tandem mass spectrometry (Struys, E. A., Jansen, E. E., Verhoeven, N. M. & Jakobs, C. Clin Chem 50, 1391-5 (2004)) (**FIG. 31B**). The peaks corresponding to the (S) and (R) isomers of 2HG were confirmed using racemic and R(-)-2HG standards. The reaction product from R132H co-eluted with R(-)-2HG peak, demonstrating that the R(-) stereoisomer is the product produced from αKG by R132H mutant IDH1.

The observation that the reaction product of the mutant enzyme is capable of inhibiting a metabolic reaction known to occur in cells suggests that this reaction product might also inhibit other reactions which utilize α-KG, isocitrate, or citrate as substrates or produce them as products in vivo or in vitro.

EXAMPLE 3 METABOLOMICS ANALYSIS OF IDH1 WILD TYPE AND MUTANTS

Metabolomics research can provide mechanistic basis for why R132 mutations confer survival advantage for GBM patients carrying such mutations.

1. Metabolomics of GBM tumor cell lines: wild type vs R132 mutants

Cell lines with R132 mutations can be identified and profiled. Experiments can be performed in proximal metabolite pool with a broad scope of metabolites.

2. Oxalomalate treatment of GBM cell lines

Oxalomalate is a competitive inhibitor of IDH1. Change of NADPH (metabolomics) when IDH1 is inhibited by a small molecule can be examined.

3. Metabolomics of primary GBM tumors: wild type vs R132 mutations

Primary tumors with R132 mutations can be identified. Experiments can be performed in proximal metabolite pool with a broad scope of metabolites.

4. Detection of 2-hydroxyglutarate in cells that overexpress IDH1 132 mutants

Overexpression of an IDH1 132 mutant in cells may cause an elevated level of 2-hydroxyglutarate and/or a reduced level of alpha-ketoglutarate. One can perform a metabolomic experiment to demonstrate the consequence of this mutation on the cellular metabolite pool.

EXAMPLE 4 EVALUATION OF IDH1 AS A CANCER TARGET

shRNAmir inducible knockdown can be performed to examine the cellular phenotype and metabolomics profiles. HTS grade IDH1 enzymes are available. The IDH mutations described herein can be used for patient selection.

EXAMPLE 5 siRNAs

IDH1

Exemplary siRNAs are presented in the following tables. Art-known methods can be used to select other siRNAs. siRNAs can be evaluated, *e.g.,* by determining the ability of an siRNA to silence an IDH, *e.g.,* IDH1, *e.g.,* in an *in vitro* system, *e.g.,* in cultured cells, *e.g.,* HeLa cells or cultured glioma cells. siRNAs known in the art for silencing the target can also be used, see, *e.g., Silencing of cytosolic NADP+ dependent isoccitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward stauropine*, Lee *et al.*, 2009, Free Radical Research, 43: 165-173.

The siRNAs in **Table 7** (with the exception of entry 1356) were generated using the siRNA selection tool available on the worldwide web at jura.wi.mit.edu/bioc/siRNAext/. (Yuan *et al.* Nucl. Acids. Res. 2004 32:W130-W134.) Other selection tools can be used as well. Entry 1356 was adapted from *Silencing of cytosolic NADP+ dependent isoccitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward stauropine*, Lee *et al.*, 2009, Free Radical Research, 43: 165-173.

The siRNAs in Tables 7, 8, 9, 10, 11, 12, 13 and 14 represent candidates spanning the IDH1 mRNA at nucleotide positions 628 and 629 according to the sequence at GenBank Accession No. NM_005896.2 (SEQ ID NO:9, FIG. 22).

The RNAs in the tables can be modified, *e.g.,* as described herein. Modifications include chemical modifications to enhance properties, *e.g.,* resistance to degradation, or the use of overhangs. For example, either one or both of the sense and antisense strands in the tables can include an additional dinucleotide at the 3' end, *e.g.,* TT, UU, dTdT.

Table 7. siRNAs targeting wildtype IDH1

Position on mRNA (FIG. 21B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
13	GGUUUCUGCAGAGUCUACU	14	AGUAGACUCUGCAGAAACC	15
118	CUCUUCGCCAGCAUAUCAU	16	AUGAUAUGCUGGCGAAGAG	17
140	GGCAGGCGAUAAACUACAU	18	AUGUAGUUUAUCGCCUGCC	19
145	GCGAUAAACUACAUUCAGU	20	ACUGAAUGUAGUUUAUCGC	21
199	GAAAUCUAUUCACUGUCAA	22	UUGACAGUGAAUAGAUUUC	23
257	GUUCUGUGGUAGAGAUGCA	24	UGCAUCUCUACCACAGAAC	25
272	GCAAGGAGAUGAAAUGACA	26	UGUCAUUUCAUCUCCUUGC	27
277	GGAGAUGAAAUGACACGAA	28	UUCGUGUCAUUUCAUCUCC	29
278	GAGAUGAAAUGACACGAAU	30	AUUCGUGUCAUUUCAUCUC	31
280	GAUGAAAUGACACGAAUCA	32	UGAUUCGUGUCAUUUCAUC	33
292	CGAAUCAUUUGGGAAUUGA	34	UCAAUUCCCAAAUGAUUCG	35
302	GGGAAUUGAUUAAAGAGAA	36	UUCUCUUUAAUCAAUUCCC	37
332	CCUACGUGGAAUUGGAUCU	38	AGAUCCAAUUCCACGUAGG	39
333	CUACGUGGAAUUGGAUCUA	40	UAGAUCCAAUUCCACGUAG	41
345	GGAUCUACAUAGCUAUGAU	42	AUCAUAGCUAUGUAGAUCC	43
356	GCUAUGAUUUAGGCAUAGA	44	UCUAUGCCUAAAUCAUAGC	45
408	GGAUGCUGCAGAAGCUAUA	46	UAUAGCUUCUGCAGCAUCC	47
416	CAGAAGCUAUAAAGAAGCA	48	UGCUUCUUUAUAGCUUCUG	49
418	GAAGCUAUAAAGAAGCAUA	50	UAUGCUUCUUUAUAGCUUC	51
432	GCAUAAUGUUGGCGUCAAA	52	UUUGACGCCAACAUUAUGC	53
467	CUGAUGAGAAGAGGGUUGA	54	UCAACCCUCUUCUCAUCAG	55
481	GUUGAGGAGUUCAAGUUGA	56	UCAACUUGAACUCCUCAAC	57
487	GAGUUCAAGUUGAAACAAA	58	UUUGUUUCAACUUGAACUC	59
495	GUUGAAACAAAUGUGGAAA	60	UUUCCACAUUUGUUUCAAC	61
502	CAAAUGUGGAAAUCACCAA	62	UUGGUGAUUUCCACAUUUG	63
517	CCAAAUGGCACCAUACGAA	64	UUCGUAUGGUGCCAUUUGG	65
528	CAUACGAAAUAUUCUGGG	66	ACCCAGAAUAUUUCGUAU	67

	U		G	
560	GAGAAGCCAUUAUCUGCAA	68	UUGCAGAUAAUGGCUUCUC	69
614	CUAUCAUCAUAGGUCGUCA	70	UGACGACCUAUGAUGAUAG	71
618	CAUCAUAGGUCGUCAUGCU	72	AGCAUGACGACCUAUGAUG	73
621	CAUAGGUCGUCAUGCUUAU	74	AUAAGCAUGACGACCUAUG	75
691	GAGAUAACCUACACACCAA	76	UUGGUGUGUAGGUUAUCUC	77
735	CCUGGUACAUAACUUUGAA	78	UUCAAAGUUAUGUACCAGG	79
747	CUUUGAAGAAGGUGGUGGU	80	ACCACCACCUUCUUCAAAG	81
775	GGGAUGUAUAAUCAAGAUA	82	UAUCUUGAUUAUACAUCCC	83
811	GCACACAGUUCCUUCCAAA	84	UUUGGAAGGAACUGUGUGC	85
818	GUUCCUUCCAAAUGGCUCU	86	AGAGCCAUUUGGAAGGAAC	87
844	GGUUGGCCUUUGUAUCUGA	88	UCAGAUACAAAGGCCAACC	89
851	CUUUGUAUCUGAGCACCAA	90	UUGGUGCUCAGAUACAAAG	91
882	GAAGAAAUAUGAUGGGCGU	92	ACGCCCAUCAUAUUUCUUC	93
942	GUCCCAGUUUGAAGCUCAA	94	UUGAGCUUCAAACUGGGAC	95
968	GGUAUGAGCAUAGGCUCAU	96	AUGAGCCUAUGCUCAUACC	97
998	GGCCCAAGCUAUGAAAUCA	98	UGAUUUCAUAGCUUGGGCC	99
1001	CCCAAGCUAUGAAAUCAGA	100	UCUGAUUUCAUAGCUUGGG	101
1127	CAGAUGGCAAGACAGUAGA	102	UCUACUGUCUUGCCAUCUG	103
1133	GCAAGACAGUAGAAGCAGA	104	UCUGCUUCUACUGUCUUGC	105
1184	GCAUGUACCAGAAAGGACA	106	UGUCCUUUCUGGUACAUGC	107
1214	CCAAUCCCAUUGCUUCCAU	108	AUGGAAGCAAUGGGAUUGG	109
1257	CCACAGAGCAAAGCUUGAU	110	AUCAAGCUUUGCUCUGUGG	111
1258	CACAGAGCAAAGCUUGAUA	112	UAUCAAGCUUUGCUCUGUG	113
1262	GAGCAAAGCUUGAUAACAA	114	UUGUUAUCAAGCUUUGCUC	115
1285	GAGCUUGCCUUCUUUGCAA	116	UUGCAAAGAAGGCAAGCUC	117
1296	CUUUGCAAAUGCUUUGGAA	118	UUCCAAAGCAUUUGCAAAG	119
1301	CAAAUGCUUUGGAAGAAGU	120	ACUUCUUCCAAAGCAUUUG	121
1307	CUUUGGAAGAAGUCUCUAU	122	AUAGAGACUUCUUCCAAAG	123
1312	GAAGAAGUCUCUAUUGAGA	124	UCUCAAUAGAGACUUCUUC	125

1315	GAAGUCUCUAUUGAGACAA	126	UUGUCUCAAUAGAGACUUC	127
1356	GGACUUGGCUGCUUGCAUU	128	AAUGCAAGCAGCCAAGUCC	129
1359	CUUGGCUGCUUGCAUUAAA	130	UUUAAUGCAAGCAGCCAAG	131
1371	CAUUAAAGGUUUACCCAAU	132	AUUGGGUAAACCUUUAAUG	133
1385	CCAAUGUGCAACGUUCUGA	134	UCAGAACGUUGCACAUUGG	135
1390	GUGCAACGUUCUGACUACU	136	AGUAGUCAGAACGUUGCAC	137
1396	CGUUCUGACUACUUGAAUA	138	UAUUCAAGUAGUCAGAACG	139
1415	CAUUUGAGUUCAUGGAUAA	140	UUAUCCAUGAACUCAAAUG	141
1422	GUUCAUGGAUAAACUUGGA	142	UCCAAGUUUAUCCAUGAAC	143
1425	CAUGGAUAAACUUGGAGAA	144	UUCUCCAAGUUUAUCCAUG	145
1455	CAAACUAGCUCAGGCCAAA	146	UUUGGCCUGAGCUAGUUUG	147
1487	CCUGAGCUAAGAAGGAUAA	148	UUAUCCUUCUUAGCUCAGG	149
1493	CUAAGAAGGAUAAUUGUCU	150	AGACAAUUAUCCUUCUUAG	151
1544	CUGUGUUACACUCAAGGAU	152	AUCCUUGAGUGUAACACAG	153
1546	GUGUUACACUCAAGGAUAA	154	UUAUCCUUGAGUGUAACAC	155
1552	CACUCAAGGAUAAAGGCAA	156	UUGCCUUUAUCCUUGAGUG	157
1581	GUAAUUUGUUUAGAAGCCA	158	UGGCUUCUAAACAAAUUAC	159
1646	GUUAUUGCCACCUUUGUGA	160	UCACAAAGGUGGCAAUAAC	161
1711	CAGCCUAGGAAUUCGGUUA	162	UAACCGAAUUCCUAGGCUG	163
1713	GCCUAGGAAUUCGGUUAGU	164	ACUAACCGAAUUCCUAGGC	165
1714	CCUAGGAAUUCGGUUAGUA	166	UACUAACCGAAUUCCUAGG	167
1718	GGAAUUCGGUUAGUACUCA	168	UGAGUACUAACCGAAUUCC	169
1719	GAAUUCGGUUAGUACUCAU	170	AUGAGUACUAACCGAAUUC	171
1725	GGUUAGUACUCAUUUGUAU	172	AUACAAAUGAGUACUAACC	173
1730	GUACUCAUUUGUAUUCACU	174	AGUGAAUACAAAUGAGUAC	175
1804	GGUAAAUGAUAGCCACAGU	176	ACUGUGGCUAUCAUUUACC	177
1805	GUAAAUGAUAGCCACAGUA	178	UACUGUGGCUAUCAUUUAC	179
1816	CCACAGUAUUGCUCCCUAA	180	UUAGGGAGCAAUACUGUGG	181
1892	GGGAAGUUCUGGUGUCAUA	182	UAUGACACCAGAACUUCCC	183
1897	GUUCUGGUGUCAUAGAUA	184	AUAUCUAUGACACCAGAA	185

	U		C	
1934	GCUGUGCAUUAAACUUGCA	186	UGCAAGUUUAAUGCACAGC	187
1937	GUGCAUUAAACUUGCACAU	188	AUGUGCAAGUUUAAUGCAC	189
1939	GCAUUAAACUUGCACAUGA	190	UCAUGUGCAAGUUUAAUGC	191
1953	CAUGACUGGAACGAAGUAU	192	AUACUUCGUUCCAGUCAUG	193
1960	GGAACGAAGUAUGAGUGCA	194	UGCACUCAUACUUCGUUCC	195
1961	GAACGAAGUAUGAGUGCAA	196	UUGCACUCAUACUUCGUUC	197
1972	GAGUGCAACUCAAAUGUGU	198	ACACAUUUGAGUUGCACUC	199
1976	GCAACUCAAAUGUGUUGAA	200	UUCAACACAUUUGAGUUGC	201
1982	CAAAUGUGUUGAAGAUACU	202	AGUAUCUUCAACACAUUUG	203
1987	GUGUUGAAGAUACUGCAGU	204	ACUGCAGUAUCUUCAACAC	205
1989	GUUGAAGAUACUGCAGUCA	206	UGACUGCAGUAUCUUCAAC	207
2020	CCUUGCUGAAUGUUUCCAA	208	UUGGAAACAUUCAGCAAGG	209
2021	CUUGCUGAAUGUUUCCAAU	210	AUUGGAAACAUUCAGCAAG	211
2024	GCUGAAUGUUUCCAAUAGA	212	UCUAUUGGAAACAUUCAGC	213
2035	CCAAUAGACUAAAUACUGU	214	ACAGUAUUUAGUCUAUUGG	215
2067	GAGUUUGGAAUCCGGAAUA	216	UAUUCCGGAUUCCAAACUC	217
2073	GGAAUCCGGAAUAAAUACU	218	AGUAUUUAUUCCGGAUUCC	219
2074	GAAUCCGGAAUAAAUACUA	220	UAGUAUUUAUUCCGGAUUC	221
2080	GGAAUAAAUACUACCUGGA	222	UCCAGGUAGUAUUUAUUCC	223
2133	GGCCUGGCCUGAAUAUUAU	224	AUAAUAUUCAGGCCAGGCC	225
2134	GCCUGAAUAUUAUACUACU	226	AGUAGUAUAAUAUUCAGGC	227
2136	CUGGCCUGAAUAUUAUACU	228	AGUAUAAUAUUCAGGCCAG	229
2166	CAUAUUUCAUCCAAGUGCA	230	UGCACUUGGAUGAAAUAUG	231
2180	GUGCAAUAAUGUAAGCUGA	232	UCAGCUUACAUUAUUGCAC	233
2182	GCAAUAAUGUAAGCUGAAU	234	AUUCAGCUUACAUUAUUGC	235
2272	CACUAUCUUAUCUUCUCCU	236	AGGAGAAGAUAAGAUAGUG	237
2283	CUUCUCCUGAACUGUUGAU	238	AUCAACAGUUCAGGAGAAG	239

Table 8. siRNAs targeting wildtype IDH1

Position on mRNA (FIG. 21B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
611	AACCUAUCAUCAUAGGUCG	240	CGACCUAUGAUGAUAGGUU	241
612	ACCUAUCAUCAUAGGUCGU	242	ACGACCUAUGAUGAUAGGU	243
613	CCUAUCAUCAUAGGUCGUC	244	GACGACCUAUGAUGAUAGG	245
614	CUAUCAUCAUAGGUCGUCA	246	UGACGACCUAUGAUGAUAG	247
615	UAUCAUCAUAGGUCGUCAU	248	AUGACGACCUAUGAUGAUA	249
616	AUCAUCAUAGGUCGUCAUG	250	CAUGACGACCUAUGAUGAU	251
617	UCAUCAUAGGUCGUCAUGC	252	GCAUGACGACCUAUGAUGA	253
618	CAUCAUAGGUCGUCAUGCU	254	AGCAUGACGACCUAUGAUG	255
619	AUCAUAGGUCGUCAUGCUU	256	AAGCAUGACGACCUAUGAU	257
620	UCAUAGGUCGUCAUGCUUA	258	UAAGCAUGACGACCUAUGA	259
621	CAUAGGUCGUCAUGCUUAU	260	AUAAGCAUGACGACCUAUG	261
622	AUAGGUCGUCAUGCUUAUG	262	CAUAAGCAUGACGACCUAU	263
623	UAGGUCGUCAUGCUUAUGG	264	CCAUAAGCAUGACGACCUA	265
624	AGGUCGUCAUGCUUAUGGG	266	CCCAUAAGCAUGACGACCU	267
625	GGUCGUCAUGCUUAUGGGG	268	CCCCAUAAGCAUGACGACC	269
626	GUCGUCAUGCUUAUGGGGA	270	UCCCAUAAGCAUGACGACC	271
627	UCGUCAUGCUUAUGGGGAU	272	AUCCCAUAAGCAUGACGAC	273

Table 9. siRNAs targeting G395A mutant IDH1 (SEQ ID NO:5) (equivalent to G629A of SEQ ID NO:9 (FIG. 21B))

Position on mRNA (FIG. 21B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
611	AACCUAUCAUCAUAGGUCA	274	UGACCUAUGAUGAUAGGUU	275
612	ACCUAUCAUCAUAGGUCAU	276	AUGACCUAUGAUGAUAGGU	277
613	CCUAUCAUCAUAGGUCAUC	278	GAUGACCUAUGAUGAUAGG	279
614	CUAUCAUCAUAGGUCAUCA	280	UGAUGACCUAUGAUGAUAG	281
615	UAUCAUCAUAGGUCAUCAU	282	AUGAUGACCUAUGAUGAUA	283

616	AUCAUCAUAGGUCAUCAUG	284	CAUGAUGACCUAUGAUGAU	285
617	UCAUCAUAGGUCAUCAUGC	286	GCAUGAUGACCUAUGAUGA	287
618	CAUCAUAGGUCAUCAUGCU	288	AGCAUGAUGACCUAUGAUG	289
619	AUCAUAGGUCAUCAUGCUU	290	AAGCAUGAUGACCUAUGAU	291
620	UCAUAGGUCAUCAUGCUUA	292	UAAGCAUGAUGACCUAUGA	293
621	CAUAGGUCAUCAUGCUUAU	294	AUAAGCAUGAUGACCUAUG	295
622	AUAGGUCAUCAUGCUUAUG	296	CAUAAGCAUGAUGACCUAU	297
623	UAGGUCAUCAUGCUUAUGG	298	CCAUAAGCAUGAUGACCUA	299
624	AGGUCAUCAUGCUUAUGGG	300	CCCAUAAGCAUGAUGACCU	301
625	GGUCAUCAUGCUUAUGGGG	302	CCCCAUAAGCAUGAUGACC	303
626	GUCAUCAUGCUUAUGGGGA	304	UCCCCAUAAGCAUGAUGAC	305
627	UCAUCAUGCUUAUGGGGAU	306	AUCCCCAUAAGCAUGAUGA	307

Table 10. siRNAs targeting C394A mutant IDH1 (SEQ ID NO:5) (equivalent to C628A of SEQ ID NO:9 (FIG. 21B)) (Arg132Ser (SEQ ID NO:8))

Position on mRNA (FIG. 21B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
611	AACCUAUCAUCAUAGGUAG	308	CUACCUAUGAUGAUAGGUU	309
612	ACCUAUCAUCAUAGGUAGU	310	ACUACCUAUGAUGAUAGGU	311
613	CCUAUCAUCAUAGGUAGUC	312	GACUACCUAUGAUGAUAGG	313
614	CUAUCAUCAUAGGUAGUCA	314	UGACUACCUAUGAUGAUAG	315
615	UAUCAUCAUAGGUAGUCAU	316	AUGACUACCUAUGAUGAUA	317
616	AUCAUCAUAGGUAGUCAUG	318	CAUGACUACCUAUGAUGAU	319
617	UCAUCAUAGGUAGUCAUGC	320	GCAUGACUACCUAUGAUGA	321
618	CAUCAUAGGUAGUCAUGCU	322	AGCAUGACUACCUAUGAUG	323
619	AUCAUAGGUAGUCAUGCUU	324	AAGCAUGACUACCUAUGAU	325
620	UCAUAGGUAGUCAUGCUUA	326	UAAGCAUGACUACCUAUGA	327
621	CAUAGGUAGUCAUGCUUAU	328	AUAAGCAUGACUACCUAUG	329
622	AUAGGUAGUCAUGCUUAUG	330	CAUAAGCAUGACUACCUAU	331
623	UAGGUAGUCAUGCUUAUGG	332	CCAUAAGCAUGACUACCUA	333
624	AGGUAGUCAUGCUUAUGGG	334	CCCAUAAGCAUGACUACCU	335
625	GGUAGUCAUGCUUAUGGGG	336	CCCCAUAAGCAUGACUACC	337
626	GUAGUCAUGCUUAUGGGGA	338	UCCCCAUAAGCAUGACUAC	339
627	UAGUCAUGCUUAUGGGGAU	340	AUCCCCAUAAGCAUGACUA	341

Table 11. siRNAs targeting C394U mutant IDH1 (SEQ ID NO:5) (equivalent to C628U of SEQ ID NO:9 (FIG. 21B)) (Arg132Cys (SEQ ID NO:8))

Position on mRNA (FIG. 21B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
611	AACCUAUCAUCAUAGGUUG	342	CAACCUAUGAUGAUAGGUU	343
612	ACCUAUCAUCAUAGGUUGU	344	ACAACCUAUGAUGAUAGGU	345
613	CCUAUCAUCAUAGGUUGUC	346	GACAACCUAUGAUGAUAGG	347
614	CUAUCAUCAUAGGUUGUCA	348	UGACAACCUAUGAUGAUAG	349
615	UAUCAUCAUAGGUUGUCAU	350	AUGACAACCUAUGAUGAUA	351
616	AUCAUCAUAGGUUGUCAUG	352	CAUGACAACCUAUGAUGAU	353
617	UCAUCAUAGGUUGUCAUGC	354	GCAUGACAACCUAUGAUGA	355
618	CAUCAUAGGUUGUCAUGCU	356	AGCAUGACAACCUAUGAUG	357
619	AUCAUAGGUUGUCAUGCUU	358	AAGCAUGACAACCUAUGAU	359
620	UCAUAGGUUGUCAUGCUUA	360	UAAGCAUGACAACCUAUGA	361
621	CAUAGGUUGUCAUGCUUAU	362	AUAAGCAUGACAACCUAUG	363
622	AUAGGUUGUCAUGCUUAUG	364	CAUAAGCAUGACAACCUAU	365
623	UAGGUUGUCAUGCUUAUGG	366	CCAUAAGCAUGACAACCUA	367
624	AGGUUGUCAUGCUUAUGGG	368	CCCAUAAGCAUGACAACCU	369
625	GGUUGUCAUGCUUAUGGGG	370	CCCCAUAAGCAUGACAACC	371
626	GUUGUCAUGCUUAUGGGGA	372	UCCCCAUAAGCAUGACAAC	373
627	UUGUCAUGCUUAUGGGGAU	374	AUCCCCAUAAGCAUGACAA	375

Table 12. siRNAs targeting C394G mutant IDH1 (SEQ ID NO:5) (equivalent to C628G of SEQ ID NO:9 (FIG. 21B)) (Arg132Gly (SEQ ID NO:8))

Position on mRNA (FIG. 21B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
611	AACCUAUCAUCAUAGGUGG	376	CCACCUAUGAUGAUAGGUU	377
612	ACCUAUCAUCAUAGGUGGU	378	ACCACCUAUGAUGAUAGGU	379
613	CCUAUCAUCAUAGGUGGUC	380	GACCACCUAUGAUGAUAGG	381
614	CUAUCAUCAUAGGUGGUCA	382	UGACCACCUAUGAUGAUAG	383
615	UAUCAUCAUAGGUGGUCAU	384	AUGACCACCUAUGAUGAUA	385
616	AUCAUCAUAGGUGGUCAUG	386	CAUGACCACCUAUGAUGAU	387
617	UCAUCAUAGGUGGUCAUGC	388	GCAUGACCACCUAUGAUGA	389
618	CAUCAUAGGUGGUCAUGCU	390	AGCAUGACCACCUAUGAUG	391
619	AUCAUAGGUGGUCAUGCU	392	AAGCAUGACCACCUAUGA	393

	U		U	
620	UCAUAGGUGGUCAUGCUU A	394	UAAGCAUGACCACCUAUG A	395
621	CAUAGGUGGUCAUGCUUA U	396	AUAAGCAUGACCACCUAU G	397
622	AUAGGUGGUCAUGCUUAU G	398	CAUAAGCAUGACCACCUA U	399
623	UAGGUGGUCAUGCUUAUG G	400	CCAUAAGCAUGACCACCU A	401
624	AGGUUGUCAUGCUUAUGG G	402	CCCAUAAGCAUGACCACC U	403
625	GGUUGUCAUGCUUAUGGG G	404	CCCCAUAAGCAUGACCAC C	405
626	GUUGUCAUGCUUAUGGGG A	406	UCCCCAUAAGCAUGACCA C	407
627	UUGUCAUGCUUAUGGGGA U	408	AUCCCCAUAAGCAUGACC A	409

Table 13. siRNAs targeting G395C mutant IDH1 (SEQ ID NO:5) (equivalent to G629C of SEQ ID NO:9 (FIG. 21B)) (Arg132Pro (SEQ ID NO:8))

Position on mRNA (FIG. 21B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
611	AACCUAUCAUCAUAGGUC G	410	CGACCUAUGAUGAUAGGU U	411
612	ACCUAUCAUCAUAGGUCG U	412	ACGACCUAUGAUGAUAGG U	413
613	CCUAUCAUCAUAGGUCGU C	414	GACGACCUAUGAUGAUAG G	415
614	CUAUCAUCAUAGGUCGUC A	416	UGACGACCUAUGAUGAUA G	417
615	UAUCAUCAUAGGUCGUCA U	418	AUGACGACCUAUGAUGAU A	419
616	AUCAUCAUAGGUCGUCAU G	420	CAUGACGACCUAUGAUGA U	421
617	UCAUCAUAGGUCGUCAUG C	422	GCAUGACGACCUAUGAUG A	423
618	CAUCAUAGGUCGUCAUGC U	424	AGCAUGACGACCUAUGAU G	425
619	AUCAUAGGUCGUCAUGCU U	426	AAGCAUGACGACCUAUGA U	427
620	UCAUAGGUCGUCAUGCUU A	428	UAAGCAUGACGACCUAUG A	429
621	CAUAGGUCGUCAUGCUUA U	430	AUAAGCAUGACGACCUAU G	431
622	AUAGGUCGUCAUGCUUAU G	432	CAUAAGCAUGACGACCUA U	433
623	UAGGUCGUCAUGCUUAUG G	434	CCAUAAGCAUGACGACCU A	435
624	AGGUCGUCAUGCUUAUGG G	436	CCCAUAAGCAUGACGACC U	437
625	GGUCGUCAUGCUUAUGGG G	438	CCCCAUAAGCAUGACGAC C	439

626	GUCGUCAUGCUUAUGGGGA	440	UCCCCAUAAGCAUGACGAC	441
627	UCGUCAUGCUUAUGGGGAU	442	AUCCCCAUAAGCAUGACGA	443

Table 14. siRNAs targeting G395U mutant IDH1 (SEQ ID NO:5) (equivalent to G629U of SEQ ID NO:9 (FIG. 21B)) (Arg132Leu (SEQ ID NO:8))

Position on mRNA (FIG. 21B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
611	AACCUAUCAUCAUAGGUCU	444	AGACCUAUGAUGAUAGGUU	445
612	ACCUAUCAUCAUAGGUCUU	446	AAGACCUAUGAUGAUAGGU	447
613	CCUAUCAUCAUAGGUCUUC	448	GAAGACCUAUGAUGAUAGG	449
614	CUAUCAUCAUAGGUCUUCA	450	UGAAGACCUAUGAUGAUAG	451
615	UAUCAUCAUAGGUCUUCAU	452	AUGAAGACCUAUGAUGAUA	453
616	AUCAUCAUAGGUCUUCAUG	454	CAUGAAGACCUAUGAUGAU	455
617	UCAUCAUAGGUCUUCAUGC	456	GCAUGAAGACCUAUGAUGA	457
618	CAUCAUAGGUCUUCAUGCU	458	AGCAUGAAGACCUAUGAUG	459
619	AUCAUAGGUCUUCAUGCUU	460	AAGCAUGAAGACCUAUGAU	461
620	UCAUAGGUCUUCAUGCUUA	462	UAAGCAUGAAGACCUAUGA	463
621	CAUAGGUCUUCAUGCUUAU	464	AUAAGCAUGAAGACCUAUG	465
622	AUAGGUCUUCAUGCUUAUG	466	CAUAAGCAUGAAGACCUAU	467
623	UAGGUCUUCAUGCUUAUGG	468	CCAUAAGCAUGAAGACCUA	469
624	AGGUCUUCAUGCUUAUGGG	470	CCCAUAAGCAUGAAGACCU	471
625	GGUCUUCAUGCUUAUGGGG	472	CCCCAUAAGCAUGAAGACC	473
626	GUCUUCAUGCUUAUGGGGA	474	UCCCCAUAAGCAUGAAGAC	475
627	UCUUCAUGCUUAUGGGGAU	476	AUCCCCAUAAGCAUGAAGA	477

IDH2

Exemplary siRNAs are presented in the following tables. Art-known methods can be used to select other siRNAs. siRNAs can be evaluated, *e.g.,* by determining the ability of an siRNA to silence an *e.g.,*IDH2, *e.g.,* in an *in vitro* system, *e.g.,* in cultured cells, *e.g.,* HeLa cells or cultured glioma cells. *e.g.,*

The siRNAs in **Table 15** were generated using the siRNA selection tool available on the worldwide web at jura.wi.mit.edu/bioc/siRNAext/. (Yuan *et al*. Nucl. Acids. Res. 2004 32:W130-W134.) Other selection tools can be used as well. Entry 1356 was adapted from *Silencing of cytosolic NADP+ dependent isoccitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward stauropine*, Lee *et al*., 2009, Free Radical Research, 43: 165-173.

The siRNAs in Tables **16-23** represent candidates spanning the IDH2 mRNA at nucleotide positions 600, 601, and 602 according to the mRNA sequence presented at GenBank Accession No. NM_002168.2 (Record dated August 16, 2009; GI28178831) (SEQ ID NO12, **FIG. 22B**; equivalent to nucleotide positions 514, 515, and 516 of the cDNA sequence represented by SEQ ID NO:11, **FIG. Fig. 22A**).

The RNAs in the tables can be modified, *e.g.,* as described herein. Modifications include chemical modifications to enhance properties, *e.g.,* resistance to degradation, or the use of overhangs. For example, either one or both of the sense and antisense strands in the tables can include an additional dinucleotide at the 3' end, *e.g.,* TT, UU, dTdT.

Table 15. siRNAs targeting wildtype IDH2

Position on mRNA (FIG. 22B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
250	GUGAUGAGAUGACCCGUAU	478	AUACGGGUCAUCUCAUCAC	479
252	GAUGAGAUGACCCGUAUUA	480	UAAUACGGGUCAUCUCAUC	481
264	CGUAUUAUCUGGCAGUUCA	482	UGAACUGCCAGAUAAUACG	483
274	GGCAGUUCAUCAAGGAGAA	484	UUCUCCUUGAUGAACUGCC	485
451	GUGUGGAAGAGUUCAAGCU	486	AGCUUGAACUCUUCCACAC	487
453	GUGGAAGAGUUCAAGCUGA	488	UCAGCUUGAACUCUUCCAC	489
456	GAAGAGUUCAAGCUGAAGA	490	UCUUCAGCUUGAACUCUUC	491
795	CAGUAUGCCAUCCAGAAGA	492	UCUUCUGGAUGGCAUACUG	493
822	CUGUACAUGAGCACCAAGA	494	UCUUGGUGCUCAUGUACAG	495
832	GCACCAAGAACACCAUACU	496	AGUAUGGUGUUCUUGGUGC	497
844	CCAUACUGAAAGCCUACGA	498	UCGUAGGCUUUCAGUAUGG	499
845	CAUACUGAAAGCCUACGAU	500	AUCGUAGGCUUUCAGUAUG	501
868	GUUUCAAGGACAUCUUCCA	502	UGGAAGAUGUCCUUGAAAC	503
913	CCGACUUCGACAAGAAUAA	504	UUAUUCUUGUCGAAGUCGG	505
915	GACUUCGACAAGAAUAAGA	506	UCUUAUUCUUGUCGAAGUC	507
921	GACAAGAAUAAGAUCUGGU	508	ACCAGAUCUUAUUCUUGUC	509
949	GGCUCAUUGAUGACAUGGU	510	ACCAUGUCAUCAAUGAGCC	511
1009	GCAAGAACUAUGACGGAGA	512	UCUCCGUCAUAGUUCUUGC	513
1010	CAAGAACUAUGACGGAGAU	514	AUCUCCGUCAUAGUUCUUG	515
1024	GAGAUGUGCAGUCAGACAU	516	AUGUCUGACUGCACAUCUC	517
1096	CUGAUGGGAAGACGAUUGA	518	UCAAUCGUCUUCCCAUCAG	519
1354	GCAAUGUGAAGCUGAACGA	520	UCGUUCAGCUUCACAUUGC	521
1668	CUGUAAUUUAUAUUGCCCU	522	AGGGCAAUAUAAAUUACAG	523
1694	CAUGGUGCCAUAUUUAGCU	524	AGCUAAAUAUGGCACCAUG	525
1697	GGUGCCAUAUUUAGCUACU	526	AGUAGCUAAAUAUGGCACC	527
1698	GUGCCAUAUUUAGCUACUA	528	UAGUAGCUAAAUAUGGCAC	529
1700	GCCAUAUUUAGCUACUAAA	530	UUUAGUAGCUAAAUAUGGC	531

Table 16. siRNAs targeting wildtype IDH2

Position on mRNA (FIG. 22B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
584	GCCCAUCACCAUUGGCAGG	532	CCUGCCAAUGGUGAUGGGC	533
585	CCCAUCACCAUUGGCAGGC	534	GCCUGCCAAUGGUGAUGGG	535
586	CCAUCACCAUUGGCAGGCA	536	UGCCUGCCAAUGGUGAUGG	537
587	CAUCACCAUUGGCAGGCAC	538	GUGCCUGCCAAUGGUGAUG	539
588	AUCACCAUUGGCAGGCACG	540	CGUGCCUGCCAAUGGUGAU	541
589	UCACCAUUGGCAGGCACGC	542	GCGUGCCUGCCAAUGGUGA	543
590	CACCAUUGGCAGGCACGCC	544	GGCGUGCCUGCCAAUGGUG	545
591	ACCAUUGGCAGGCACGCCC	546	GGGCGUGCCUGCCAAUGGU	547
592	CCAUUGGCAGGCACGCCCA	548	UGGGCGUGCCUGCCAAUGG	549
593	CAUUGGCAGGCACGCCCAU	550	AUGGGCGUGCCUGCCAAUG	551
594	AUUGGCAGGCACGCCCAUG	552	CAUGGGCGUGCCUGCCAAU	553
595	UUGGCAGGCACGCCCAUGG	554	CCAUGGGCGUGCCUGCCAA	555
596	UGGCAGGCACGCCCAUGGC	556	GCCAUGGGCGUGCCUGCCA	557
597	GGCAGGCACGCCCAUGGCG	558	CGCCAUGGGCGUGCCUGCC	559
598	GCAGGCACGCCCAUGGCGA	560	UCGCCAUGGGCGUGCCUGC	561
599	CAGGCACGCCCAUGGCGAC	562	GUCGCCAUGGGCGUGCCUG	563
600	AGGCACGCCCAUGGCGACC	564	GGUCGCCAUGGGCGUGCCU	565

Table 17. siRNAs targeting A514G mutant IDH2 (equivalent to A600G of SEQ ID NO:12, **(FIG. 22B)**

Position on mRNA (FIG. 22B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
584	GCCCAUCACCAUUGGCGGG	566	CCCGCCAAUGGUGAUGGGC	567
585	CCCAUCACCAUUGGCGGGC	568	GCCCGCCAAUGGUGAUGGG	569
586	CCAUCACCAUUGGCGGGCA	570	UGCCCGCCAAUGGUGAUGG	571
587	CAUCACCAUUGGCGGGCAC	572	GUGCCCGCCAAUGGUGAUG	573
588	AUCACCAUUGGCGGGCACG	574	CGUGCCCGCCAAUGGUGAU	575
589	UCACCAUUGGCGGGCACGC	576	GCGUGCCCGCCAAUGGUGA	577
590	CACCAUUGGCGGGCACGCC	578	GGCGUGCCCGCCAAUGGUG	579
591	ACCAUUGGCGGGCACGCCC	580	GGGCGUGCCCGCCAAUGGU	581
592	CCAUUGGCGGGCACGCCCA	582	UGGGCGUGCCCGCCAAUGG	583
593	CAUUGGCGGGCACGCCCAU	584	AUGGGCGUGCCCGCCAAUG	585
594	AUUGGCGGGCACGCCCAUG	586	CAUGGGCGUGCCCGCCAAU	587
595	UUGGCGGGCACGCCCAUGG	588	CCAUGGGCGUGCCCGCCAA	589
596	UGGCGGGCACGCCCAUGGC	590	GCCAUGGGCGUGCCCGCCA	591
597	GGCGGGCACGCCCAUGGCG	592	CGCCAUGGGCGUGCCCGCC	593
598	GCGGGCACGCCCAUGGCGA	594	UCGCCAUGGGCGUGCCCGC	595
599	CGGGCACGCCCAUGGCGAC	596	GUCGCCAUGGGCGUGCCCG	597
600	GGGCACGCCCAUGGCGACC	598	GGUCGCCAUGGGCGUGCCC	599

Table 18. siRNAs targeting A514U mutant IDH2 (equivalent to A600U of SEQ ID NO:12, **(FIG. 22B)**

Position on mRNA (FIG. 22B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
584	GCCCAUCACCAUUGGCUGG	600	CCAGCCAAUGGUGAUGGGC	601
585	CCCAUCACCAUUGGCUGGC	602	GCCAGCCAAUGGUGAUGGG	603
586	CCAUCACCAUUGGCUGGCA	604	UGCCAGCCAAUGGUGAUGG	605
587	CAUCACCAUUGGCUGGCAC	606	GUGCCAGCCAAUGGUGAUG	607
588	AUCACCAUUGGCUGGCACG	608	CGUGCCAGCCAAUGGUGAU	609
589	UCACCAUUGGCUGGCACGC	610	GCGUGCCAGCCAAUGGUGA	611
590	CACCAUUGGCUGGCACGCC	612	GGCGUGCCAGCCAAUGGUG	613
591	ACCAUUGGCUGGCACGCCC	614	GGGCGUGCCAGCCAAUGGU	615
592	CCAUUGGCUGGCACGCCCA	616	UGGGCGUGCCAGCCAAUGG	617
593	CAUUGGCUGGCACGCCCAU	618	AUGGGCGUGCCAGCCAAUG	619
594	AUUGGCUGGCACGCCCAUG	620	CAUGGGCGUGCCAGCCAAU	621
595	UUGGCUGGCACGCCCAUGG	622	CCAUGGGCGUGCCAGCCAA	623
596	UGGCUGGCACGCCCAUGGC	624	GCCAUGGGCGUGCCAGCCA	625
597	GGCUGGCACGCCCAUGGCG	626	CGCCAUGGGCGUGCCAGCC	627
598	GCUGGCACGCCCAUGGCGA	628	UCGCCAUGGGCGUGCCAGC	629
599	CUGGCACGCCCAUGGCGAC	630	GUCGCCAUGGGCGUGCCAG	631
600	UGGCACGCCCAUGGCGACC	632	GGUCGCCAUGGGCGUGCCA	633

Table 19. siRNAs targeting G515A mutant IDH2 (equivalent to G601A of SEQ ID NO:12, **(FIG. 22B)**

Position on mRNA (FIG. 22B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
584	GCCCAUCACCAUUGGCAAG	634	CUUGCCAAUGGUGAUGGGC	635
585	CCCAUCACCAUUGGCAAGC	636	GCUUGCCAAUGGUGAUGGG	637
586	CCAUCACCAUUGGCAAGCA	638	UGCUUGCCAAUGGUGAUGG	639
587	CAUCACCAUUGGCAAGCAC	640	GUGCUUGCCAAUGGUGAUG	641
588	AUCACCAUUGGCAAGCACG	642	CGUGCUUGCCAAUGGUGAU	643
589	UCACCAUUGGCAAGCACGC	644	GCGUGCUUGCCAAUGGUGA	645
590	CACCAUUGGCAAGCACGCC	646	GGCGUGCUUGCCAAUGGUG	647
591	ACCAUUGGCAAGCACGCCC	648	GGGCGUGCUUGCCAAUGGU	649
592	CCAUUGGCAAGCACGCCCA	650	UGGGCGUGCUUGCCAAUGG	651
593	CAUUGGCAAGCACGCCCAU	652	AUGGGCGUGCUUGCCAAUG	653
594	AUUGGCAAGCACGCCCAUG	654	CAUGGGCGUGCUUGCCAAU	655
595	UUGGCAAGCACGCCCAUGG	656	CCAUGGGCGUGCUUGCCAA	657
596	UGGCAAGCACGCCCAUGGC	658	GCCAUGGGCGUGCUUGCCA	659
597	GGCAAGCACGCCCAUGGCG	660	CGCCAUGGGCGUGCUUGCC	661
598	GCAAGCACGCCCAUGGCGA	662	UCGCCAUGGGCGUGCUUGC	663
599	CAAGCACGCCCAUGGCGAC	664	GUCGCCAUGGGCGUGCUUG	665
600	AAGCACGCCCAUGGCGACC	666	GGUCGCCAUGGGCGUGCUU	667

Table 20. siRNAs targeting G515C mutant IDH2 (equivalent to G601C of SEQ ID NO:12, **(FIG. 22B)**

Position on mRNA (FIG. 22B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
584	GCCCAUCACCAUUGGCACG	668	CGUGCCAAUGGUGAUGGGC	669
585	CCCAUCACCAUUGGCACGC	670	GCGUGCCAAUGGUGAUGGG	671
586	CCAUCACCAUUGGCACGCA	672	UGCGUGCCAAUGGUGAUGG	673
587	CAUCACCAUUGGCACGCAC	674	GUGCGUGCCAAUGGUGAUG	675
588	AUCACCAUUGGCACGCACG	676	CGUGCGUGCCAAUGGUGAU	677
589	UCACCAUUGGCACGCACGC	678	GCGUGCGUGCCAAUGGUGA	679
590	CACCAUUGGCACGCACGCC	680	GGCGUGCGUGCCAAUGGUG	681
591	ACCAUUGGCACGCACGCCC	682	GGGCGUGCGUGCCAAUGGU	683
592	CCAUUGGCACGCACGCCCA	684	UGGGCGUGCGUGCCAAUGG	685
593	CAUUGGCACGCACGCCCAU	686	AUGGGCGUGCGUGCCAAUG	687
594	AUUGGCACGCACGCCCAUG	688	CAUGGGCGUGCGUGCCAAU	689
595	UUGGCACGCACGCCCAUGG	690	CCAUGGGCGUGCGUGCCAA	691
596	UGGCACGCACGCCCAUGGC	692	GCCAUGGGCGUGCGUGCCA	693
597	GGCACGCACGCCCAUGGCG	694	CGCCAUGGGCGUGCGUGCC	695
598	GCACGCACGCCCAUGGCGA	696	UCGCCAUGGGCGUGCGUGC	697
599	CACGCACGCCCAUGGCGAC	698	GUCGCCAUGGGCGUGCGUG	699
600	ACGCACGCCCAUGGCGACC	700	GGUCGCCAUGGGCGUGCGU	701

Table 21. siRNAs targeting G515U mutant IDH2 (equivalent to G601U of SEQ ID NO:12, **(FIG. 22B)**

Position on mRNA (FIG. 22B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
584	GCCCAUCACCAUUGGCAUG	702	CAUGCCAAUGGUGAUGGGC	703
585	CCCAUCACCAUUGGCAUGC	704	GCAUGCCAAUGGUGAUGGG	705
586	CCAUCACCAUUGGCAUGCA	706	UGCAUGCCAAUGGUGAUGG	707
587	CAUCACCAUUGGCAUGCAC	708	GUGCAUGCCAAUGGUGAUG	709
588	AUCACCAUUGGCAUGCACG	710	CGUGCAUGCCAAUGGUGAU	711
589	UCACCAUUGGCAUGCACGC	712	GCGUGCAUGCCAAUGGUGA	713
590	CACCAUUGGCAUGCACGCC	714	GGCGUGCAUGCCAAUGGUG	715
591	ACCAUUGGCAUGCACGCCC	716	GGGCGUGCAUGCCAAUGGU	717
592	CCAUUGGCAUGCACGCCCA	718	UGGGCGUGCAUGCCAAUGG	719
593	CAUUGGCAUGCACGCCCAU	720	AUGGGCGUGCAUGCCAAUG	721
594	AUUGGCAUGCACGCCCAUG	722	CAUGGGCGUGCAUGCCAAU	723
595	UUGGCAUGCACGCCCAUGG	724	CCAUGGGCGUGCAUGCCAA	725
596	UGGCAUGCACGCCCAUGGC	726	GCCAUGGGCGUGCAUGCCA	727
597	GGCAUGCACGCCCAUGGCG	728	CGCCAUGGGCGUGCAUGCC	729
598	GCAUGCACGCCCAUGGCGA	730	UCGCCAUGGGCGUGCAUGC	731
599	CAUGCACGCCCAUGGCGAC	732	GUCGCCAUGGGCGUGCAUG	733
600	AUGCACGCCCAUGGCGACC	734	GGUCGCCAUGGGCGUGCAU	735

Table 22. siRNAs targeting G516C mutant IDH2 (equivalent to G602C of SEQ ID NO:12, **(FIG. 22B)**

Position on mRNA (FIG. 22B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
584	GCCCAUCACCAUUGGCAGC	736	GCUGCCAAUGGUGAUGGGC	737
585	CCCAUCACCAUUGGCAGCC	738	GGCUGCCAAUGGUGAUGGG	739
586	CCAUCACCAUUGGCAGCCA	740	UGGCUGCCAAUGGUGAUGG	741
587	CAUCACCAUUGGCAGCCAC	742	GUGGCUGCCAAUGGUGAUG	743
588	AUCACCAUUGGCAGCCACG	744	CGUGGCUGCCAAUGGUGAU	745
589	UCACCAUUGGCAGCCACGC	746	GCGUGGCUGCCAAUGGUGA	747
590	CACCAUUGGCAGCCACGCC	748	GGCGUGGCUGCCAAUGGUG	749
591	ACCAUUGGCAGCCACGCCC	750	GGGCGUGGCUGCCAAUGGU	751
592	CCAUUGGCAGCCACGCCCA	752	UGGGCGUGGCUGCCAAUGG	753
593	CAUUGGCAGCCACGCCCAU	754	AUGGGCGUGGCUGCCAAUG	755
594	AUUGGCAGCCACGCCCAUG	756	CAUGGGCGUGGCUGCCAAU	757
595	UUGGCAGCCACGCCCAUGG	758	CCAUGGGCGUGGCUGCCAA	759
596	UGGCAGCCACGCCCAUGGC	760	GCCAUGGGCGUGGCUGCCA	761
597	GGCAGCCACGCCCAUGGCG	762	CGCCAUGGGCGUGGCUGCC	763
598	GCAGCCACGCCCAUGGCGA	764	UCGCCAUGGGCGUGGCUGC	765
599	CAGCCACGCCCAUGGCGAC	766	GUCGCCAUGGGCGUGGCUG	767
600	AGCCACGCCCAUGGCGACC	768	GGUCGCCAUGGGCGUGGCU	769

Table 23. siRNAs targeting G516U mutant IDH2 (equivalent to G602U of SEQ ID NO:12, **(FIG. 22B)**

Position on mRNA (FIG. 22B)	sense (5' to 3')	SEQ ID NO:	antisense (5' to 3')	SEQ ID NO:
584	GCCCAUCACCAUUGGCAGU	770	ACUGCCAAUGGUGAUGGGC	771
585	CCCAUCACCAUUGGCAGUC	772	GACUGCCAAUGGUGAUGGG	773
586	CCAUCACCAUUGGCAGUCA	774	UGACUGCCAAUGGUGAUGG	775
587	CAUCACCAUUGGCAGUCAC	776	GUGACUGCCAAUGGUGAUG	777
588	AUCACCAUUGGCAGUCACG	778	CGUGACUGCCAAUGGUGAU	779
589	UCACCAUUGGCAGUCACGC	780	GCGUGACUGCCAAUGGUGA	781
590	CACCAUUGGCAGUCACGCC	782	GGCGUGACUGCCAAUGGUG	783
591	ACCAUUGGCAGUCACGCCC	784	GGGCGUGACUGCCAAUGGU	785
592	CCAUUGGCAGUCACGCCCA	786	UGGGCGUGACUGCCAAUGG	787
593	CAUUGGCAGUCACGCCCAU	788	AUGGGCGUGACUGCCAAUG	789
594	AUUGGCAGUCACGCCCAUG	790	CAUGGGCGUGACUGCCAAU	791
595	UUGGCAGUCACGCCCAUGG	792	CCAUGGGCGUGACUGCCAA	793
596	UGGCAGUCACGCCCAUGGC	794	GCCAUGGGCGUGACUGCCA	795
597	GGCAGUCACGCCCAUGGCG	796	CGCCAUGGGCGUGACUGCC	797
598	GCAGUCACGCCCAUGGCGA	798	UCGCCAUGGGCGUGACUGC	799
599	CAGUCACGCCCAUGGCGAC	800	GUCGCCAUGGGCGUGACUG	801
600	AGUCACGCCCAUGGCGACC	802	GGUCGCCAUGGGCGUGACU	803

EXAMPLE 6 STRUCTURAL ANALYSIS OF R132H MUTANT IDH1

To define how R132 mutations alter the enzymatic properties of IDH1, the crystal structure of R132H mutant IDH1 bound to αKG, NADPH, and Ca^{2+} was solved at 2.1 Å resolution.

The overall quaternary structure of the homodimeric R132H mutant enzyme adopts the same closed catalytically competent conformation (shown as a monomer in **FIG. 29A**) that has been previously described for the wild-type enzyme (Xu, X. et al. J Biol Chem 279, 33946-57 (2004)). NADPH is positioned as expected for hydride transfer to αKG in an orientation that would produce R(-)-2HG, consistent with our chiral determination of the 2HG product.

Two important features were noted by the change of R132 to histidine: the effect on catalytic conformation equilibrium and the reorganization of the active-site. Locating atop a β-sheet in the relatively rigid small domain, R132 acts as a gate-keeper residue and appears to orchestrate the hinge movement between the open and closed conformations. The guanidinium moiety of R132 swings from the open to the closed conformation with a distance of nearly 8 Å. Substitution of histidine for arginine is likely to change the equilibrium in favor of the closed conformation that forms the catalytic cleft for cofactor and substrate to bind efficiently, which partly explains the high-affinity for NADPH exhibited by the R132H mutant enzyme. This feature may be advantageous for the NADPH-dependent reduction of αKG to R(-)-2HG in an environment where NADPH concentrations are low. Secondly, closer examination of the catalytic pocket of the mutant IDH1 structure in comparison to the wild-type enzyme showed not only the expected loss of key salt-bridge interactions between the guanidinium of R132 and the α/β carboxylates of isocitrate, as well as changes in the network that coordinates the metal ion, but also an unexpected reorganization of the active-site. Mutation to histidine resulted in a significant shift in position of the highly conserved residues Y139 from the A subunit and K212' from the B subunit (**FIG. 29B**), both of which are thought to be critical for catalysis of this enzyme family (Aktas, D. F. & Cook, P. F. Biochemistry 48, 3565-77 (2009)). In particular, the hydroxyl moiety of Y139 now occupies the space of the β-carboxylate of isocitrate. In addition, a significant repositioning of αKG compared to isocitrate where the distal carboxylate of αKG now points upward to make new contacts with N96 and S94 was observed. Overall, this single R132 mutation results in formation of a distinct active site compared to wild-type IDH1.

EXAMPLE 7 MATERIALS AND METHODS

Summary

R132H, R132C, R132L and R132S mutations were introduced into human IDH1 by standard molecular biology techniques. 293T and the human glioblastoma cell lines U87MG and LN-18 were cultured in DMEM, 10% fetal bovine serum. Cells were transfected and selected using standard techniques. Protein expression levels were determined by Western blot analysis using IDHc antibody (Santa Cruz Biotechnology), IDH1 antibody (proteintech), MYC tag antibody (Cell Signaling